
<html lang="en"     class="pb-page"  data-request-id="4b66cd83-1582-4a47-a283-f18f08096115"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.7b00839;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2017.60.issue-17;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity" /></meta><meta name="dc.Creator" content="Adam  Bucki" /></meta><meta name="dc.Creator" content="Monika  Marcinkowska" /></meta><meta name="dc.Creator" content="Joanna  Śniecikowska" /></meta><meta name="dc.Creator" content="Krzysztof  Więckowski" /></meta><meta name="dc.Creator" content="Maciej  Pawłowski" /></meta><meta name="dc.Creator" content="Monika  Głuch-Lutwin" /></meta><meta name="dc.Creator" content="Anna  Gryboś" /></meta><meta name="dc.Creator" content="Agata  Siwek" /></meta><meta name="dc.Creator" content="Karolina  Pytka" /></meta><meta name="dc.Creator" content="Magdalena  Jastrzębska-Więsek" /></meta><meta name="dc.Creator" content="Anna  Partyka" /></meta><meta name="dc.Creator" content="Anna  Wesołowska" /></meta><meta name="dc.Creator" content="Paweł  Mierzejewski" /></meta><meta name="dc.Creator" content="Marcin  Kołaczkowski" /></meta><meta name="dc.Description" content="The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label...." /></meta><meta name="Description" content="The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label...." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 18, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00839" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00839" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00839" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00839" /></link>
        
    
    

<title>Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00839" /></meta><meta property="og:title" content="Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0007.jpeg" /></meta><meta property="og:description" content="The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label. Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well-tolerated and effective therapy of BPSD. We designed and synthesized multifunctional ligands characterized in vitro as high-affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT. Moreover, the molecules activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel. Compound 16 (N-{2-[4-(5-chloro-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide) exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice. Most importantly, 16 showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine. The molecule outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychological) symptoms of dementia." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00839"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00839">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00839&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00839&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00839&amp;href=/doi/10.1021/acs.jmedchem.7b00839" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7483-7501</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00834" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00860" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1<i>H</i>-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Adam++Bucki">Adam Bucki</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-0451-9814" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Monika++Marcinkowska">Monika Marcinkowska</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-4948-6617" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joanna++%C5%9Aniecikowska">Joanna Śniecikowska</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Krzysztof++Wi%C4%99ckowski">Krzysztof Więckowski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maciej++Paw%C5%82owski">Maciej Pawłowski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Monika++G%C5%82uch-Lutwin">Monika Głuch-Lutwin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Grybo%C5%9B">Anna Gryboś</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Agata++Siwek">Agata Siwek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karolina++Pytka">Karolina Pytka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Magdalena++Jastrz%C4%99bska-Wi%C4%99sek">Magdalena Jastrzębska-Więsek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Partyka">Anna Partyka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Weso%C5%82owska">Anna Wesołowska</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pawe%C5%82++Mierzejewski">Paweł Mierzejewski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marcin++Ko%C5%82aczkowski">Marcin Kołaczkowski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Institute of Psychiatry and Neurology, 9 Sobieskiego Street, 02-957 Warsaw, Poland</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Adamed Ltd., Pieńków 149, 05-152 Czosnów, Poland</span></div><div class="corresp-info"><strong>*</strong>Phone: (48)126205460. Fax: (48)126205458. E-mail: <a href="/cdn-cgi/l/email-protection#600104010d4e0215030b0920150a4e0504154e100c"><span class="__cf_email__" data-cfemail="94f5f0f5f9baf6e1f7fffdd4e1febaf1f0e1bae4f8">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00839&amp;href=/doi/10.1021%2Facs.jmedchem.7b00839" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7483–7501</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 1, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 June 2017</li><li><span class="item_label"><b>Published</b> online</span>18 August 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 September 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00839" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00839</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7483%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAdam%2BBucki%252C%2BMonika%2BMarcinkowska%252C%2BJoanna%2B%25C5%259Aniecikowska%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D17%26contentID%3Dacs.jmedchem.7b00839%26title%3DNovel%2B3-%25281%252C2%252C3%252C6-Tetrahydropyridin-4-yl%2529-1H-indole-Based%2BMultifunctional%2BLigands%2Bwith%2BAntipsychotic-Like%252C%2BMood-Modulating%252C%2Band%2BProcognitive%2BActivity%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7501%26publicationDate%3DSeptember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00839"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1112</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00839" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;Bucki&quot;},{&quot;first_name&quot;:&quot;Monika&quot;,&quot;last_name&quot;:&quot;Marcinkowska&quot;},{&quot;first_name&quot;:&quot;Joanna&quot;,&quot;last_name&quot;:&quot;Śniecikowska&quot;},{&quot;first_name&quot;:&quot;Krzysztof&quot;,&quot;last_name&quot;:&quot;Więckowski&quot;},{&quot;first_name&quot;:&quot;Maciej&quot;,&quot;last_name&quot;:&quot;Pawłowski&quot;},{&quot;first_name&quot;:&quot;Monika&quot;,&quot;last_name&quot;:&quot;Głuch-Lutwin&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Gryboś&quot;},{&quot;first_name&quot;:&quot;Agata&quot;,&quot;last_name&quot;:&quot;Siwek&quot;},{&quot;first_name&quot;:&quot;Karolina&quot;,&quot;last_name&quot;:&quot;Pytka&quot;},{&quot;first_name&quot;:&quot;Magdalena&quot;,&quot;last_name&quot;:&quot;Jastrzębska-Więsek&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Partyka&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Wesołowska&quot;},{&quot;first_name&quot;:&quot;Paweł&quot;,&quot;last_name&quot;:&quot;Mierzejewski&quot;},{&quot;first_name&quot;:&quot;Marcin&quot;,&quot;last_name&quot;:&quot;Kołaczkowski&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;7483-7501&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00839&quot;},&quot;abstract&quot;:&quot;The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label. Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well-tolerated and effective therapy of BPSD. We designed and synthesized multifunctional ligands characterized in vitro as high-affinity partial agonists of D2R, antagonists of 5-HT6R, and blockers of SERT. Moreover, the molecules activated 5-HT1AR and blocked 5-HT7R while having no relevant affinity for off-target M1R and hERG channel. Compound 16 (N-{2-[4-(5-chloro-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide) exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice. Most importantly, 16 showed memory-enhancing properties and it ameliorated memory deficits induced by&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00839&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00839" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00839&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00839" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00839&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00839" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00839&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00839&amp;href=/doi/10.1021/acs.jmedchem.7b00839" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00839" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00839" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00839%26sid%3Dliteratum%253Aachs%26pmid%3D28763213%26genre%3Darticle%26aulast%3DBucki%26date%3D2017%26atitle%3DNovel%2B3-%25281%252C2%252C3%252C6-Tetrahydropyridin-4-yl%2529-1H-indole-Based%2BMultifunctional%2BLigands%2Bwith%2BAntipsychotic-Like%252C%2BMood-Modulating%252C%2Band%2BProcognitive%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D17%26spage%3D7483%26epage%3D7501%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (6)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292461" title="Neurophysiology">Neurophysiology</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/jmcmar.2017.60.issue-17/20170914/jmcmar.2017.60.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00839&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The most troublesome aspects of behavioral and psychological symptoms of dementia (BPSD) are nowadays addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label. Considering their modest effectiveness in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet need for well-tolerated and effective therapy of BPSD. We designed and synthesized multifunctional ligands characterized in vitro as high-affinity partial agonists of D<sub>2</sub>R, antagonists of 5-HT<sub>6</sub>R, and blockers of SERT. Moreover, the molecules activated 5-HT<sub>1A</sub>R and blocked 5-HT<sub>7</sub>R while having no relevant affinity for off-target M<sub>1</sub>R and hERG channel. Compound <b>16</b> (<i>N</i>-{2-[4-(5-chloro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide) exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like activity, not eliciting motor impairments in mice. Most importantly, <b>16</b> showed memory-enhancing properties and it ameliorated memory deficits induced by scopolamine. The molecule outperformed most important comparators in selected tests, indicating its potential in the treatment of both cognitive and noncognitive (behavioral and psychological) symptoms of dementia.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08422" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08422" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Dementia refers to cognitive issues such as memory loss and thinking inability of variable pathophysiology, the most common being Alzheimer’s disease (AD) and vascular dementia.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Regardless of their origin, in 90% of patients, cognitive decline is complicated by combinations of behavioral and psychological symptoms of dementia (BPSD), such as agitation, restlessness, aggression, depression, anxiety, and psychosis. BPSD, also called neuropsychiatric symptoms (NPS),<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> pose severe problems to patients, their families, and caregivers, in many cases more unbearable than the core cognitive decline.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> The most troublesome noncognitive aspects are addressed by antidepressant,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> anxiolytic,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and antipsychotic drugs<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> often administered off-label.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> Furthermore, antipsychotics have modest effectiveness in the treatment of agitation, aggression, and psychosis associated with dementia and increase risk of cerebrovascular adverse events, cognitive deterioration, and mortality.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> Consequently, there is still a need for considerably more research on well-tolerated and effective therapy of BPSD.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">In the past years, the “one-target, one-drug” paradigm has been dominant in the drug discovery processes. This approach relies on finding a single compound that acts on a particular molecular target.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> For instance, so-called cognitive enhancers, frequently used in the treatment of memory and learning deficits mostly in dementia, act by inhibiting a single target, namely the enzyme acetylcholinesterase and thus increase both the level and duration of action of the neurotransmitter acetylcholine.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> They improve or delay cognitive decline and reduce behavioral changes, particularly apathy, depression, and aberrant motor behavior, being inefficient in the remaining symptoms though.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> Consequently, to improve the pharmacotherapy of BPSD, atypical antipsychotics are often used in the combination with other drugs such as antidepressants (SSRIs)<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> or anxiolytics (benzodiazepines).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> As a result, patients receive a pharmacological cocktail made up of several single drugs with potentially different and mutually intertwined bioavailability, pharmacokinetics, and metabolism as well as multiplied side effects.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> Moreover, diversified dosing regimen in polypharmacy might be confusing and often cause drug–drug interactions, particularly in the case of elderly patients with coexisting diseases.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a></div><div class="NLM_p">Literature data suggests that it is possible to overcome those limitations by designing a multifunctional molecule which simultaneously modulates several targets and therefore being beneficial in the treatment of various psychiatric diseases.<a onclick="showRef(event, 'ref14 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref14 ref19 ref20 ref21">(14, 19-21)</a> In our search for a versatile molecule addressing the most common neuropsychiatric symptoms typical for dementia, we have recognized molecules that had been proven effective in the given single symptoms to inspire design of multiple ligands.</div><div class="NLM_p">Atypical antipsychotics have been extensively used to treat dementia patients, and the selected ones have been reported to improve neuropsychiatric symptoms. The American Psychiatric Association even recommended the use of antipsychotic medications, although only in emergency settings for the treatment of agitation or psychosis when symptoms are severe and dangerous.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> One of them, that was positively rated in terms of efficacy in the treatment of agitation, anxiety, and depression as well as safety and tolerance in Alzheimer’s disease patients, is aripiprazole.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23-25)</a> A molecular target that has gained our considerable attention is therefore dopamine D<sub>2</sub> receptor, particularly effects of its partial activation. Aripiprazol, an atypical antipsychotic touted as a dopamine system stabilizer that acts primarily as D<sub>2</sub> receptor partial agonist, possess also antidepressant and anxiolytic activity, which might result from its substantial affinity for serotonin 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptors, as well as dopamine D<sub>3</sub> receptors.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Furthermore, dopamine D<sub>2</sub> receptor partial agonists demonstrated synergic mood modulating activity when administered together with selective serotonin reuptake inhibitors (SSRIs) in late-life depression.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a></div><div class="NLM_p">Serotonin transporter (SERT) inhibition itself is an attractive target for designing a molecule of therapeutic value in neuropsychiatric symptoms. Besides the clinically proven efficacy of SSRIs in major depressive disorder and other affective disorders, their favorable safety profile has been proven in dementia patients. Moreover, SSRIs show ability to reduce psychotic episodes and behavioral disturbances in patients with dementia and also depression.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a></div><div class="NLM_p">An example of single drug acting on multiple targets worth considering in the context of BPSD is vortioxetine, a serotonin modulator and stimulator approved for the treatment of major depressive disorder.<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31-33)</a> Its antidepressant and additional anxiolytic effect result from the concomitant inhibition of SERT and modulation of a wide range of serotonergic receptors, such as 5-HT<sub>1A</sub> (agonist), 5-HT<sub>1B</sub> (partial agonist) as well as 5-HT<sub>1D</sub>, 5-HT<sub>3</sub>, and 5-HT<sub>7</sub> (antagonist).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> It should be highlighted that the unique mechanism of action of vortioxetine, comparing to the currently available SSRIs, has largely contributed to the improvement of therapy of treatment-resistant patients.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Another multifunctional ligand combining activity toward serotonin receptors and its transporter is lumateperone, a phase III investigational atypical antipsychotic capable of reducing negative symptoms of schizophrenia. It acts as a 5-HT<sub>2A</sub> receptor antagonist and D<sub>2</sub> receptor partial agonist, having also SERT inhibitory properties.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Interestingly none of the aforementioned drugs significantly influence 5-HT<sub>6</sub> receptors.</div><div class="NLM_p">Degenerative changes in the CNS of dementia patients result in dysregulation of serotonergic system, which is in turn a source of cognitive dysfunction.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> A potential novel therapy of BPSD should include the effect on cognition. Undisputedly, cognitive functions mustn’t be disturbed to a greater extent in dementia patients.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Given that the blockade of 5-HT<sub>6</sub> receptors induces acetylcholine release, it became reasonable to consider that 5-HT<sub>6</sub> receptor antagonism could be a promising approach for improving cognitive abilities. A large amount of scientific data describes the research on 5-HT<sub>6</sub> receptor ligands as effective procognitive agents in preclinical studies.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39-41)</a> Two antagonists, intepirdine and idalopirdine, have been successfully evaluated in phase II clinical trials, which revealed their potential as drug candidates for the symptomatic treatment of AD.<a onclick="showRef(event, 'ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45">(42-45)</a></div><div class="NLM_p last">The aforementioned facts have encouraged us to design multitarget ligands that will be able to precisely modulate the activity of several monoaminergic receptors and serotonin transporter, expecting that this multifunctional profile will contribute positively to the therapeutic potential in dementia patients. We have identified D<sub>2</sub> and 5HT<sub>6</sub> receptors as well as SERT as crucial molecular targets in the development of new potential anti-BPSD agents because drugs acting via these targets proved to be effective in the treatment of psychotic symptoms and mood disorders in patients with dementia. The pharmacological profile of the newly designed molecules is presumed to be improved compared to aripiprazole and enhanced with procognitive activity. Herein we present computer-aided design, synthesis, and in vitro activity characterization of a series of arylsulfonamide-based derivatives as multimodal agents. The most promising molecule of the whole series was further characterized in extended pharmacological studies.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design</h3><div class="NLM_p">In the course of discovery of novel designed multiple ligands (DML) targeting behavioral and psychological symptoms of dementia (BPSD), we have previously described a series of arylsulfonamide-based hybrid molecules.<a onclick="showRef(event, 'ref38 ref46'); return false;" href="javascript:void(0);" class="ref ref38 ref46">(38, 46)</a> As a result of those studies, substantially supported by molecular modeling, we designed and pharmacologically characterized a group of compounds being the 5-HT<sub>6</sub>/5-HT<sub>7</sub>/5-HT<sub>2A</sub> and D<sub>2</sub> receptor antagonists that displayed pronounced antipsychotic activity in the absence of cognitive or motor impairment. The design of these compounds was inspired by investigation into the binding mode of 5-HT<sub>7</sub> receptor antagonists.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> On the basis of this, we constructed a series of multifunctional ligands by combining the 5-HT<sub>7</sub> receptor blocking arylsulfonamide moiety, preferred by the 5-HT<sub>6</sub> receptor as well, with the 3-(piperidin-4-yl)-1,2-benzoxazole or 3-(piperazin-4-yl)-1,2-benzothiazole fragments responsible for the antagonism of the 5-HT<sub>2A</sub> and D<sub>2</sub> receptors.<a onclick="showRef(event, 'ref38 ref48'); return false;" href="javascript:void(0);" class="ref ref38 ref48">(38, 48)</a></div><div class="NLM_p">In the present study, we followed the same logic, but instead of the above-mentioned arylamine fragments we used the appropriately substituted 3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole (THPI), a fragment that had previously been proven to introduce SERT inhibition (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A,B and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf" class="ext-link">Figures S1, S2</a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> This in turn might have implemented additional antidepressant activity besides the expected antipsychotic effect from the D<sub>2</sub> receptors (partial agonism) and procognitive effect resulting from antagonism of the 5-HT<sub>6</sub> receptors. Such a pharmacological profile would have enhanced the favorable activity, not causing excessive sedation or EPS resulting from D<sub>2</sub> receptor blockade. The initially constructed hybrid molecule (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>C, compound <b>14</b>) was docked to the homology models of the main therapeutic targets, affinity for which we intended to incorporate in the novel multimodal ligands. Complementarity of interactions between the prototype compound and the active sites of 5-HT<sub>6</sub>, D<sub>2</sub> as well as 5-HT<sub>1<i>A</i>/7</sub> receptors, which was the main assumption of the design rationale, was therefore verified. The putative binding modes in the given receptor sites provided the basis to assess probability of binding to the given biological targets (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>D, for details see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf" class="ext-link">Figures S3–S5</a>). The binding patterns of the prototype hybrid in complexes with the examined targets were encouraging enough to proceed with analysis of its potential interactions with the main antitargets. These included the M<sub>1</sub> cholinergic receptor and the hERG potassium channel, blockade of which could lead to adverse effects such as memory disruption or cardiac arrhythmia, respectively. As expected, on the basis of the experiences with the previously described arylsulfonamide-based hybrids sharing the same general structure,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> also in the case of the 3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole derivatives the relevant affinity for both the antitargets occurred to be unlikely due to excessive volume of the molecule or lack of interaction complementarity (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>E, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf" class="ext-link">Figure S6</a>). Subsequently, a first series of 18 hybrid molecules, varying in the substitution of the 3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole moiety, length of the alkyl linker as well as structure of the arylsulfonamide portion, was designed and synthesized (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Having early in vitro results pointing out superior activity of the derivatives containing 5-chloro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole moiety, a further 18 modifications preserving the latter fragment were proposed in the structure optimization stage (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The presented project resulted in 36 original compounds (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>F) which were scheduled for in-depth pharmacological characterization.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of multifunctional ligands. Proposed binding mode of the prototype compound <b>14</b>, the arylsulfonamide fragment of which mimics interactions of (1<i>R</i>)-3,<i>N</i>-dimethyl-<i>N</i>-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide (SB-258719)<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> in the 5-HT<sub>7</sub> receptor site (A) and the 3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole moiety is responsible for SERT blocking properties (B). Structure of compound <b>14</b> (C) proved to satisfy steric and electrostatic requirements in docking studies to the homology models of the 5-HT<sub>6</sub>, 5-HT<sub>1A</sub>, and D<sub>2</sub> receptors (D). Furthermore, the molecule was incompatible with structural representations of hERG channel and M<sub>1</sub> receptor (E). The design stage resulted in a series of 36 multiple ligands characterized by potentially high affinity for the desirable biological targets and low risk of binding to the off-targets (F). Amino acid residues engaged in ligand binding (within 4 Å from the ligand atoms) are displayed as sticks, whereas those forming H-bonds (dotted yellow lines), π–π stacking (dotted blue lines), or cation−π (dotted green lines) are represented as thick sticks. M<sub>1</sub> receptor structure displayed with antagonist tiotropium because docking of <b>14</b> resulted in no valid poses (E). For the sake of clarity, extracellular loop 2 (ECL2) of the given GPCRs was hidden (A,D). The detailed complexes are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf" class="ext-link">Figures S1–S6</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00839&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis</h3><div class="NLM_p">The synthesis of the designed molecules <b>13</b>–<b>48</b> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. In the first step, the appropriately substituted 3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>1</b>–<b>3</b> was reacted with the corresponding 2-(bromoalkyl)-1<i>H</i>-isoindoline-1,3(2<i>H</i>)-dione in the presence of potassium carbonate and a catalytic amount of potassium iodide in acetonitryle at 70 °C to give key intermediates <b>4</b>–<b>12</b>. In the next step, deprotection of phthalimides <b>4</b>–<b>12</b> with 40% solution of methylamine afforded free amines, which were reacted immediately with diverse commercially available sulfonyl chlorides to provide the final sulfonamides <b>13</b>–<b>48</b>. The reaction was carried out in tetrahydrofuran in the presence of 1 M KOH solution. The structures of the final molecules are presented in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Final Compounds <b>13</b>–<b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00839&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, Kl, CH<sub>3</sub>CN, 70 °C, 12 h; (b) 40% aq MeNH<sub>2</sub>, 50 °C, 4 h; (c) THF drv, 1 M KOH solution, rt, 12 h.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Structure–Activity Relationships</h3><div class="NLM_p last">All the synthesized compounds were subjected for in vitro radioligand binding assays to determine affinity for the serotonin 5-HT<sub>6</sub>, 5-HT<sub>7</sub>, 5-HT<sub>1A</sub>, dopamine D<sub>2</sub> receptors, and SERT.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Series I</h3><div class="NLM_p">First, potent SERT-binding capabilities of the molecules containing the 3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole fragment was proven. This conclusion is true for both 5-F (<i>K</i><sub>i</sub> range 1.7 ± 0.9 to 8.5 ± 0.9 nM) and 5-Cl derivatives (2.7 ± 0.8 to 6.2 ± 2.2 nM). On the other hand, the 2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-5-chloro-1<i>H</i>-indoles displayed considerably lower affinity for the transporter (<i>K</i><sub>i</sub> between 12 ± 4.6 and 40 ± 7.1 nM). The aromatic ring at the opposite end of the molecule proved to play a secondary role in binding to this target. Compounds containing 2-naphthalene, particularly those with a possibly short (2-unit) linker, performed slightly better than those having 3-methylphenyl, which in turn preferred a longer (4-unit) alkyl chain.</div><div class="NLM_p">Analysis of the affinity for the serotonin and dopamine receptors revealed poor performance of the 2-methyl-indole derivatives (<i>K</i><sub>i</sub> range 99 ± 5.6 to 610 ± 42 nM). This result was more surprising in that the analysis of the molecular surface of the given receptor models pointed to the possibility of introducing small alkyl group in position 2 of indole ring. Nevertheless, further development of methylated analogues was abandoned. Of the remaining combinations, the 3-(1,2,3,6-tetrahydropyridin-4-yl)-5-chloro-1<i>H</i>-indoles displayed far better affinity for the tested serotonin receptors (<i>K</i><sub>i</sub> ≥ 0.6 ± 0.2 nM) than fluorine analogues (<i>K</i><sub>i</sub> ≥ 10 ± 1.6 nM), still maintaining reasonable activity toward dopamine receptor (<i>K</i><sub>i</sub> ≥ 2.5 ± 0.8 nM vs <i>K</i><sub>i</sub> ≥ 0.3 ± 0.1 nM, respectively). In this group, compound <b>16</b> was characterized by the most favorable in vitro profile, having one-digit nanomolar affinity for all the desired molecular targets (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The structure of this compound reflected preliminary requirements for potent DMLs of assumed activity: single-ring arylsulfonamide and short ethylene spacer were privileged in the binding sites of the receptors of interest. To explore in-depth the allowed chemical space around the most promising 3-(1,2,3,6-tetrahydropyridin-4-yl)-5-chloro-1<i>H</i>-indole fragment, pharmacological characterization of a new series was performed.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure and Receptor Binding Profile of Compounds <b>13</b>–<b>30</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0003.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0004.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Data expressed as the mean ± SEM of three independent experiments carried out in duplicate. Affinities of reference compounds are as follows: 5-HT<sub>6</sub>R <i>K</i><sub>i</sub> = 1.0 ± 0.1 nM and 5-HT<sub>7</sub>R <i>K</i><sub>i</sub> = 1.0 ± 0.1 nM (methiothepin), 5-HT<sub>1A</sub>R <i>K</i><sub>i</sub> = 1.3 ± 0.1 nM (serotonin), D<sub>2</sub>R <i>K</i><sub>i</sub> = 1.4 ± 0.4 nM (haloperidol), SERT <i>K</i><sub>i</sub> = 1.0 nM (imipramine).</p></div></div><div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Series II</h3><div class="NLM_p">In the follow-up series of the 3-(1,2,3,6-tetrahydropyridin-4-yl)-5-chloro-1<i>H</i>-indoles, the arylsulfonamide moiety and linker length were differentiated to optimize in vitro binding properties in the given chemical space. In the case of the 5-HT<sub>6</sub> receptor affinity, superior properties were observed for derivatives possessing 2-unit linkers and 1-ring aryl ring. Among them, <i>m</i>-CH<sub>3</sub> derivative from series I subsided only the one containing <i>m</i>-OH (compound <b>40</b> of top <i>K</i><sub>i</sub> = 3.5 ± 0.6 nM). There are few examples of 3-unit spacer derivatives having moderate affinity, always inferior to those possessing shorter ones. The compounds having 4-unit spacer were able to compete only when coupled to the more extensive lipophilic rings (preferably 2-naphthyl, compound <b>27</b> of series I, <i>K</i><sub>i</sub> = 100 ± 7 nM). Similar relationships were observed for the 5-HT<sub>7</sub> receptor, noting that propylene-linker derivatives had a slightly higher affinity than ethylene-based analogues (again preferred were <i>m</i>-CH<sub>3</sub>– and <i>m</i>-OH-phenyl, <i>K</i><sub>i</sub> = 0.6 ± 0.2 and 1.0 ± 0.3 nM, respectively) and definitely higher than those of butylene linker (<i>K</i><sub>i</sub> over 61 ± 9.3 nM).</div><div class="NLM_p">The relationships for the D<sub>2</sub> receptor were reversed, favoring compounds with longer (3–4 unit) linkers. Nevertheless, there were also examples of excellent binders within ethylene spacer derivatives (e.g., <i>m</i>-CH<sub>3</sub>– and <i>m</i>-OH-phenyl, <i>K</i><sub>i</sub> = 3.3 ± 1.2 and 1.5 ± 0.6 nM, respectively).</div><div class="NLM_p">Analysis of the 5-HT<sub>1A</sub> and SERT affinity suggested that there’s no certain linker length preferred. The compounds displayed very high affinities of usually one-digit nanomolar value, no matter which arylsulfonamide fragment was applied (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure and Receptor Binding Profile of Compounds <b>31</b>–<b>48</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0005.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0006.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Data expressed as the mean ± SEM of three independent experiments carried out in duplicate. Affinities of reference compounds are as follows: 5-HT<sub>6</sub>R <i>K</i><sub>i</sub> = 1.0 ± 0.1 nM and 5-HT<sub>7</sub>R <i>K</i><sub>i</sub> = 1.0 ± 0.1 nM (methiothepin), 5-HT<sub>1A</sub>R <i>K</i><sub>i</sub> = 1.3 ± 0.1 nM (serotonin), D<sub>2</sub>R <i>K</i><sub>i</sub> = 1.4 ± 0.4 nM (haloperidol), SERT <i>K</i><sub>i</sub> = 1.0 nM (imipramine).</p></div></div><div></div></div><div class="NLM_p">The novel ligands proved to have a wide safety window, showing an estimated affinity for the main antitargets of over 1 μM. The values were lower than 6.7% and 25.1% inhibition of control specific binding at the concentration of 1.0 × 10<sup>–6</sup> M for M<sub>1</sub> and hERG, respectively (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Screening for adverse targets was carried out for the most promising compounds of highest affinity for the main targets.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antitarget Activity Data for the Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">% activity at 1.0 × 10<sup>–6</sup> M</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">M<sub>1</sub>R<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center">3.2</td><td class="colsep0 rowsep0" align="char" char=".">25.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">0.7</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="char" char=".">19.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="center">0.0</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="center">6.2</td><td class="colsep0 rowsep0" align="char" char=".">11.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="center">6.7</td><td class="colsep0 rowsep0" align="char" char=".">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="center">3.7</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="center">0.0</td><td class="colsep0 rowsep0" align="char" char=".">10.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="center">6.4</td><td class="colsep0 rowsep0" align="char" char=".">12.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">% inhibition of control specific binding at the concentration of 1.0 × 10<sup>–6</sup> M.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">% inhibition of hERG-mediated potassium currents at the concentration of 1.0 × 10<sup>–6</sup> M. Assays carried out in duplicate (<i>n</i> = 2). nd, not determined. Affinity of reference pirenzepine for M<sub>1</sub>R <i>K</i><sub>i</sub> = 20 nM and inhibition of hERG with E-4031, 96% at the concentration of 1.0 × 10<sup>–6</sup> M.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vitro Functional Activity</h3><div class="NLM_p">Compounds of outstanding affinity were tested in functional in vitro assays toward the receptors of interest to pick up molecule of possibly most suitable pharmacological profile. Furthermore, serotonin (5-HT) uptake reduction was determined. According to design assumptions, to exert the desirable pharmacological action, a molecule should act as a partial agonist at the D<sub>2</sub> receptor (antipsychotic/antidepressant action resembling aripiprazole) and as antagonist at the 5-HT<sub>6</sub> receptor (procognitive effect). Moreover, a molecule is supposed to efficiently block 5-HT uptake (antidepressant activity) and show agonistic properties for the 5-HT<sub>1A</sub> receptor (anxiolytic effect), while the 5-HT<sub>7</sub> receptors should be antagonized. The tested compounds proved to be efficient DMLs, which displayed partial agonist activity for the D<sub>2</sub> receptor in the vast majority (up to 42% of agonist effect) and presented a prominent antagonist effect at the 5-HT<sub>6</sub> receptor (92% inhibition of control response). The 5-HT uptake functional assay showed robust SERT inhibiting activity (IC<sub>50</sub> ≤ 17 ± 1.7 nM). Additionally, the compounds demonstrated pronounced antagonist efficacy at the 5-HT<sub>7</sub> receptor (even 91% inhibition of control agonist response) and were almost full agonists of the 5-HT<sub>1A</sub> receptor, reaching 100% of agonist control response (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Functional Data for the Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">D<sub>2</sub>R</th><th class="rowsep1 colsep0" colspan="2" align="center">5-HT<sub>6</sub>R</th><th class="rowsep1 colsep0" colspan="2" align="center">5-HT<sub>7</sub>R</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">5-HT<sub>1A</sub>R</th><th class="rowsep1 colsep0" align="center">5-HT uptake</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">%AGO<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">%ANT<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">%AGO<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">%ANT<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">%AGO<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">%ANT<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">%AGO<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">%ANT<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> [nM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">106</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">92</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">36</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">–6</td><td class="colsep0 rowsep0" align="center">17 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">–1</td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="char" char=".">102</td><td class="colsep0 rowsep0" align="char" char=".">–37</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">–34</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">–6</td><td class="colsep0 rowsep0" align="center">10 ± 2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">63</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">57</td><td class="colsep0 rowsep0" align="center">11 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">86</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">91</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">–8</td><td class="colsep0 rowsep0" align="center">16 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">76</td><td class="colsep0 rowsep0" align="center">–2</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="char" char=".">–22</td><td class="colsep0 rowsep0" align="center">12 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">7</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">16</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">–33</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">18</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="char" char=".">–13</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ARI</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">40</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">43</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="center">nd</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Percent activity of agonist control response at 1.0 × 10<sup>–6</sup> M.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Percent inhibition of control agonist response at 1.0 × 10<sup>–6</sup> M. Assay carried out in duplicate (<i>n</i> = 2). ARI, aripiprazole; nd, not determined. 5-HT uptake for the reference imipramine IC<sub>50</sub> = 61 nM.</p></div></div></div><div class="NLM_p last">Compound <b>16</b> demonstrated the highest agonist response toward the D<sub>2</sub> receptor (42% in the concentration of 1.0 × 10<sup>–6</sup> M), and thus functional profile of activity in multiple concentrations was determined to verify its performance indicated in screening tests. The studies confirmed a partial agonist function of compound <b>16</b> in the D<sub>2</sub> receptor (EC<sub>50</sub> = 56 ± 9.3 nM; <i>E</i><sub>max</sub> = 56 ± 2.9%; <i>K</i><sub>b</sub> = 2.1 ± 0.042 nM) as well as robust antagonist effect in the 5-HT<sub>6</sub> receptor (<i>K</i><sub>B</sub> = 5.6 ± 3.2 nM). Moreover, the functional 5-HT uptake assay resulted in favorable IC<sub>50</sub> = 17 ± 1.7 nM. The above data satisfied the expected design criteria, and together with other advantageous pharmacological data, authorized its choice as a lead compound for in vivo behavioral studies. For safety reasons, concentration–response curve of hERG binding of compound <b>16</b> was evaluated in three independent experiments as well, resulting in IC<sub>50</sub> > 1 μM each time.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo Pharmacology</h3><div class="NLM_p">A set of behavioral tests were selected to challenge pharmacological effects of compound <b>16</b> against reference compounds. The compound was tested in mice for antipsychotic-like activity in the MK-801-induced hyperlocomotion test, anxiolytic-like effect in the four-plate test, and antidepressant-like capabilities in the forced swim test. Possible procognitive activity was assessed in the step-through passive avoidance task. Moreover, its potential adverse effects, i.e., the risk of causing catalepsy and sedation, were tested in the bar test and the spontaneous locomotor activity test, respectively (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50, 51)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Characterization of Compound <b>16</b> in Behavioral in Vivo Pharmacological Tests in Comparison to Reference Drugs<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">test procedures</th><th class="colsep0 rowsep0" align="center">compd <b>16</b></th><th class="colsep0 rowsep0" align="center">aripiprazole</th><th class="colsep0 rowsep0" align="center">diazepam</th><th class="colsep0 rowsep0" align="center">imipramine</th><th class="colsep0 rowsep0" align="center">ditalopram</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1. Catalepsy (bar test) ED<sub>50</sub> [mg/kg] (dose range [mg/kg])</td><td class="colsep0 rowsep0" align="center">>100 (10–100)</td><td class="colsep0 rowsep0" align="center">1.881 (1–10)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2. Spontaneous locomotor activity MSD [mg/kg] (dose range [mg/kg])</td><td class="colsep0 rowsep0" align="center">>10 (0.625–10)</td><td class="colsep0 rowsep0" align="center">1.0 (0.5–5)</td><td class="colsep0 rowsep0" align="center">2.5 (1.25–5)</td><td class="colsep0 rowsep0" align="center">>30 (10–30)</td><td class="colsep0 rowsep0" align="center">>10 (2.5–10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3. MK-801-induced hyperlocomotion MED [mg/kg] (dose range [mg/kg])</td><td class="colsep0 rowsep0" align="center">1.25 (1–10)</td><td class="colsep0 rowsep0" align="center">0.5 (0.125–0.5)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4. Four-plate test MED [mg/kg] (dose range [mg/kg])</td><td class="colsep0 rowsep0" align="center">0.625 (0.3125–10)</td><td class="colsep0 rowsep0" align="center">>0.5 (0.06–0.5)</td><td class="colsep0 rowsep0" align="center">1.25 (0.625–5)</td><td class="colsep0 rowsep0" align="center">30 (10–30)</td><td class="colsep0 rowsep0" align="center">5 (2.5–40)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5. Forced swim test MED [mg/kg] (dose range [mg/kg])</td><td class="colsep0 rowsep0" align="center">1.25 (0.3125–5)</td><td class="colsep0 rowsep0" align="center">>0.5 (0.01–0.5)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">10 (5–20)</td><td class="colsep0 rowsep0" align="center">2.5 (1.25–5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6. Passive avoidance (PA) MED [mg/kg] (dose range [mg/kg])</td><td class="colsep0 rowsep0" align="center">0.3125 (0.15–0.625)</td><td class="colsep0 rowsep0" align="center">>2.0 (0.25–2)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7. Scopolamine effect reversal in PA MED [mg/kg] (dose range [mg/kg])</td><td class="colsep0 rowsep0" align="center">0.3125 (0.15–0.625)</td><td class="colsep0 rowsep0" align="center">>2.0 (0.25–2)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup>a</sup><p class="last">Tests carried out on CD-1 mice (tests 1, 3, 6, and 7) and Swiss albino mice (tests 2, 4, 5) after intraperitoneal (ip) administration. ED<sub>50</sub>, median effective dose; MED, minimum effective dose; MSD, minimum sedative dose.</p></div></div></div><div class="NLM_p">The main goal of the in vivo studies was to obtain an animal level proof-of-concept for the multimodal ligand activity in direct comparison to the reference compounds. Because all of the results for the reference drugs were previously obtained after intraperitoneal (ip) administration, we chose the same route of administration for the innovative compounds. Indeed, while testing the compounds by oral administration would provide an additional information, notably by suggesting favorable bioavailability, some potential confounds may prevent clear conclusions to be drawn. For example, the effects of the parent compound might be interfered by the effects of its metabolites (first pass effect), which would be undesired at this proof-of-concept level. Considering the above, at this stage, we chose the ip administration for the innovative compounds in all the in vivo studies.</div><div class="NLM_p">Compound <b>16</b> displayed antipsychotic-like activity, significantly reversing MK-801-induced hyperactivity at minimum effective dose (MED) 1.25 mg/kg. Moreover, in contrast to aripiprazole, it was also found to be active in classic models of antidepressant- and anxiolytic-like activity in the similar dose range (0.625–1.25 mg/kg). In fact, compound <b>16</b> was even more potent than the standard antidepressants imipramine and citalopram as well as the anxiolytic drug diazepam. It should be noted that, while being active in models of psychosis and mood deficits, compound <b>16</b> did not elicit catalepsy (ED<sub>50</sub> > 100 mg/kg) nor did it inhibit spontaneous locomotor activity (up to 10 mg/kg). Both the features related to motor impairments beneficially differentiated its activity profile from aripiprazole, which elicited sedation and catalepsy in the same experimental paradigm, presenting modest dose separation from the antipsychotic-like activity. Considering the rather benign safety profile of aripiprazole in clinic, it testifies for a particular safety of compound <b>16</b> in this respect.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a></div><div class="NLM_p last">The effect of compound <b>16</b> on learning and memory was evaluated in the step-through passive avoidance test (a hippocampus-dependent memory task). It was shown that compound <b>16</b> administered at 0.3125 mg/kg displayed memory-enhancing properties in naïve mice, as it significantly increased the latency time in the retention but not the acquisition trial. Moreover, the same dose of the compound <b>16</b> ameliorated memory deficits induced by the anticholinergic agent scopolamine, which is of particular importance in the view of the cholinergic deficit in dementia patients. It is worth noting that the reference antipsychotic aripiprazole did not improve memory or ameliorate memory deficits caused by scopolamine. Similarly, our previous experiments demonstrated that the antidepressant fluoxetine (a selective serotonin reuptake inhibitor; 5–20 mg/kg) was also inactive in this test.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Those results are even more significant, considering that most of the antipsychotic drugs elicit cognitive deficits in passive avoidance paradigm.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Our previous efforts to develop designed multiple ligands with antipsychotic activity resulted in potent molecules with benign effect on cognition, however, not able to reverse the cholinergic deficits.<a onclick="showRef(event, 'ref38 ref46'); return false;" href="javascript:void(0);" class="ref ref38 ref46">(38, 46)</a> This work constitutes therefore a step forward in search for novel candidates for treatment of both noncognitive and cognitive symptoms associated with dementia.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54823" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54823" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In search for new possibilities of dealing with symptoms of dementia, we designed multifunctional ligands of promising pharmacological activity, which address the main bothersome aspects: cognitive deficits, as well as noncognitive symptoms, e.g., psychosis, depression, and anxiety. Their therapeutic-like activity resulted from the unique structural features incorporated within the hybrid molecule, combining scaffolds of the 3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole (THPI) and (4-methylpiperidin-1-yl)propyl]benzenesulfonamide. Such a combination of pharmacophore fragments allowed for specific interactions in nanomolar range with essentially matched biological targets, resulting in an adequate functional activity. These included partial agonist efficacy at the D<sub>2</sub> dopamine receptor, which was supposed to exert antipsychotic/antidepressant effect resembling the one of aripiprazole, combined with antagonism of the 5-HT<sub>6</sub> serotonin receptor, responsible for procognitive effect (vide intepirdine) and blockade of serotonin transporter, bringing antidepressant activity characteristic for SSRIs, e.g., escitalopram. The 5-HT<sub>1A</sub> receptors were considered secondary targets able to mediate anxiolytic effect upon their activation (like in the case of buspiron). Ultimately, the 5-HT<sub>7</sub> receptors blockade have been anticipated to strengthen antidepressant effect. Along with optimizing affinity for the relevant receptor/transporter proteins, avoiding binding to antitargets (the M<sub>1</sub> muscarinic receptor and hERG channel) was a major concern in order to unmask cholinomimetic action from the 5-HT<sub>6</sub> receptors and avoid adverse cardiac effects, respectively.</div><div class="NLM_p last">The compound selected upon in vitro testing cascade, <i>N</i>-{2-[4-(5-chloro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide (<b>16</b>), proved to have a broad spectrum of antipsychotic-, antidepressant-, and anxiolytic-like activity in mice. Importantly, in the active dose range, it did not elicit catalepsy nor inhibit spontaneous locomotor activity, both features related to potential motor impairments. Most interestingly, it was shown that compound <b>16</b> possessed memory-enhancing properties in naïve mice as well as it ameliorated memory disruption induced by cholinergic deficit. In the given experimental paradigm, compound <b>16</b> outperformed the most significant comparators, including aripiprazole. The overall effectiveness and expected safety margin implies therapeutic-like potential of the presented THPI derivatives and warrants their further evaluation as potential symptomatic treatment of dementia.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52777" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52777" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Molecular Modeling</h3><div class="NLM_p">Computer-aided ligand design consisted in ligand–receptor complex analysis resulting from docking to the previously developed homology models or refined crystal structures of the D<sub>2</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>6</sub>, and 5-HT<sub>7</sub> receptors as well as SERT. Protein optimization stage, common for all the evaluated structures, was based on induced-fit docking (IFD) from Schrödinger. General procedure for building ligand-optimized models of high predictive value has been characterized previously.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Models of SERT and M<sub>1</sub> receptor were derived from crystal structures, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I73">5I73</a><a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CXV">5CXV</a>,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> respectively. Structure refinement stage using Protein Preparation Wizard was followed by docking (IFD) a reference inhibitor, s-citalopram to the SERT model, and antagonist, tiotropium in the case of the M<sub>1</sub> receptor. Selection of the best complex was based on scoring function and visual analysis of binding mode. Protein models optimized that way served as grid for docking studies. The homology model of the hERG potassium channel and its induced fit structure applied for docking studies were acquired from <a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a>.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p last">For each of the remaining receptor types, the most appropriate structural template for homology modeling was chosen based on sequence identity and other structural characteristics, e.g., common construction of loops forming a binding site. hhsearch tool via GeneSilico Metaserver<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> was applied for sequence identity prediction. A template that got the highest score and sequence identity index of all the crystal structures accessible (at the time of the given model preparation) was taken for homology modeling. Thus, the human 5-HT<sub>7</sub> receptor model was built using β<sub>2</sub>-adrenergic receptor (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RH1">2RH1</a>),<a onclick="showRef(event, 'ref38 ref59'); return false;" href="javascript:void(0);" class="ref ref38 ref59">(38, 59)</a> the D<sub>2</sub> receptor model was constructed on the D<sub>3</sub> receptor structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>),<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60, 61)</a> while the 5-HT<sub>6</sub> receptor model was based on the relatively novel 5-HT<sub>1B</sub> crystal structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR">4IAR</a>,<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62, 63)</a> similarly to the model of 5-HT<sub>1A</sub> receptor, which is presented for the first time herein. The alignment of amino acid sequences (UniProt Data Base ID: <a href="https://P08908" class="ext-link">P08908</a>) of the 5-HT<sub>1A</sub> and 5-HT<sub>2B</sub> receptors was implemented from the hhsearch model, which established the overall amino acid sequence identity for 38%. Crude homology model was obtained via SwissModel platform.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The artificial fragments replacing the third intracellular loop (ICL3) in the protein crystal structure were removed and short loops were created by joining Arg217 and Thr346. Then it was validated by processing in Protein Preparation Wizard. Ligand-based optimization of the binding site, which was performed using IFD protocol, as well as crossdocking-based (Glide XP) validation, were carried out using various chemical classes of high affinity 5-HT<sub>1A</sub>R ligands. The described procedure resulted in a variety of conformational models that served as molecular targets in docking studies. The binding mode of compound <b>2</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a> in the design section and <a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf" class="ext-link">Figure S4</a> in the Supporting Information) was presented in a model optimized using structure of agonist befiradol (3-chloro-4-fluorophenyl-[4-fluoro-4-([(5-methylpyridin-2-yl)methylamino]methyl)piperidin-1-yl]methanone.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Ligand structures were optimized using LigPrep tool. Glide XP flexible docking procedure was carried out using OPLS3 force field and default parameters. H-bond constraint, as well as centroid of a grid box for docking to 5-HT<sub>6</sub> receptor were located on Asp3.32. Glide, induced fit docking, LigPrep, and Protein Preparation Wizard were implemented in the Small-Molecule Drug Discovery Suite (Schrödinger, Inc.), which was licensed for Jagiellonian University Medical College.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Chemistry Information</h4><div class="NLM_p last">Unless otherwise indicated, all the starting materials were obtained from commercial suppliers and were used without further purification. Analytical thin-layer chromatography (TLC) was performed on Merck Kieselgel 60 F<sub>254</sub> (0.25 mm) precoated aluminum sheets (Merck, Darmstadt, Germany). Visualization was performed with a 254 nm UV lamp. Column chromatography was performed using silica gel (particle size 0.063–0.200 mm; 70–230 mesh ATM) purchased from Merck. The UPLC-MS or UPLC-MS/MS analyzes were run on UPLC-MS/MS system comprising Waters ACQUITY UPLC (Waters Corporation, Milford, MA, USA) coupled with a Waters TQD mass spectrometer (electrospray ionization mode ESI with tandem quadrupole). Chromatographic separations were carried out using the Acquity UPLC BEH (bridged ethyl hybrid) C<sub>18</sub> column: 2.1 mm × 100 mm and 1.7 μm particle size. The column was maintained at 40 °C and eluted under gradient conditions using 95% to 0% of eluent A over 10 min, at a flow rate of 0.3 mL/min. Eluent A, water/formic acid (0.1%, v/v); eluent B, acetonitrile/formic acid (0.1%, v/v). A total of 10 μL of each sample were injected, and chromatograms were recorded using a Waters eλ PDA detector. The spectra were analyzed in the range of 200–700 nm with 1.2 nm resolution and at a sampling rate of 20 points/s. MS detection settings of Waters TQD mass spectrometer were as follows: source temperature 150 °C, desolvation temperature 350 °C, desolvation gas flow rate 600 L/h, cone gas flow 100 L/h, capillary potential 3.00 kV, and cone potential 20 V. Nitrogen was used for both nebulizing and drying. The data were obtained in a scan mode ranging from 50 to 1000 <i>m</i>/<i>z</i> at 0.5 s intervals; 8 scans were summed up to obtain the final spectrum. Collision activated dissociation (CAD) analyzes were carried out with the energy of 20 eV, and all the fragmentations were observed in the source. Consequently, the ion spectra were obtained in the range from 50 to 500 <i>m</i>/<i>z</i>. MassLynx V 4.1 software (Waters) was used for data acquisition. Standard solutions (1 mg/mL) of each compound were prepared in a mixture comprising analytical grade acetonitrile/water (1/1, v/v). The UPLC/MS purity of all the test compounds and key intermediates was determined to be >95%. <sup>1</sup>H NMR, <sup>13</sup>C NMR, and <sup>19</sup>F NMR spectra were obtained in a Varian Mercury spectrometer (Varian Inc., Palo Alto, CA, USA) in CDCl<sub>3,</sub> CD<sub>3</sub>OD, DMSO, or acetone operating at 300 MHz (<sup>1</sup>H NMR), 75 MHz (<sup>13</sup>C NMR), and 282 MHz (<sup>19</sup>F NMR). Chemical shifts are reported in terms of δ values (ppm) relative to TMS δ = 0 (<sup>1</sup>H) as internal standard. The <i>J</i> values are expressed in hertz. Signal multiplicities are represented by the following abbreviations: s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublets), dt (doublet of triplets), dtd (doublet of triplet of doublets), t (triplet), td (triplet of doublets), tdd (triplet of doublet of doublets), q (quartet), quin (quintet), m (multiplet). Melting points (mp) were determined with a Büchi melting point B-540 apparatus using open glass capillaries and are uncorrected.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthetic Procedures</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedure for the Synthesis of Phthalimide Derivatives <b>4</b>–<b>12</b></h4><div class="NLM_p">A mixture of 11.1 mmol (1.1 equiv) of appropriate tetrahydropyridinindole derivative <b>1</b>–<b>3</b> and 10 mmol (1 equiv) of appropriate 2-(bromoalkyl)-1<i>H</i>-isoindoline-1,3(2<i>H</i>)-dione, 20 mmol (2 equiv) of potassium carbonate, a catalytic amount of potassium iodide and 25 mL of CH<sub>3</sub>CN was stirred at 70 °C for 12 h. After that time, the solid was filtered and the solvent was evaporated under the reduced pressure. Next, the reaction mixture was purified by column chromatography over silica gel using chloroform/methanol 98:2 as eluent.</div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> 2-{2-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (<b>4</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>1</b> (11.1 mmol, 1.1 equiv, 2.38 g) and 2-(2-bromoethyl)-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (10 mmol, 1 equiv, 2.52 g). Yield 70%, yellowish solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.19 (br s, 1 H), 7.72–7.90 (m, 4 H), 7.47 (dd, <i>J</i> = 2.30, 10.80 Hz, 1 H), 7.42 (d, <i>J</i> = 2.31 Hz, 1 H), 7.33 (dd, <i>J</i> = 4.74, 8.85 Hz, 1 H), 6.92 (dt, <i>J</i> = 2.44, 9.04 Hz, 1 H), 6.00 (br s, 1 H), 3.75 (t, <i>J</i> = 6.28 Hz, 2 H), 3.14 (br s, 2 H), 2.56–2.73 (m, 4 H), 2.41 (br s, 2 H). LC-MS (ESI) calcd for C<sub>23</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>2</sub> 390.16 [M + H<sup>+</sup>], found 390.32 [M + H<sup>+</sup>].</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 2-{3-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]propyl}-2,3-dihydro-1-<i>H</i>-isoindole-1,3-dione (<b>5</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>1</b> (11.1 mmol, 1.1 equiv, 2.38 g), 2-(3-bromopropyl)-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (10 mmol, 1 equiv, 2.68 g). Yield 61%, yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.50 (br s, 1 H), 7.75–7.89 (m, 2 H), 7.58–7.67 (m, 2 H), 7.42 (dd, <i>J</i> = 2.18, 10.39 Hz, 1 H), 7.22–7.32 (m, 1 H), 7.11 (s, 1 H), 6.92 (dt, <i>J</i> = 2.31, 8.98 Hz, 1 H), 5.99 (br s, 1 H), 3.81 (t, <i>J</i> = 6.92 Hz, 2 H), 3.20 (br s, 2 H), 2.68–2.78 (m, 2 H), 2.62 (t, <i>J</i> = 7.18 Hz, 2 H), 2.48 (br s, 2 H), 2.00 (t, <i>J</i> = 7.05 Hz, 2 H). LC-MS (ESI) calcd for C<sub>24</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>2</sub> 404.18 [M + H<sup>+</sup>], found 404.34 [M + H<sup>+</sup>].</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 2-{4-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]butyl}-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (<b>6</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>1</b> (11.1 mmol, 1.1 equiv, 2.38 g), 2-(4-bromobutyl)-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (10 mmol, 1 equiv, 2.82 g). Yield 64%, yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.72 (br s, 1 H), 7.78–7.89 (m, 2 H), 7.64–7.75 (m, 2 H), 7.45 (dd, <i>J</i> = 2.18, 10.39 Hz, 1 H), 7.25–7.34 (m, 1 H), 7.07–7.18 (m, 1 H), 6.91 (dt, <i>J</i> = 2.31, 8.98 Hz, 1 H), 6.03 (br s, 1 H), 3.74 (t, <i>J</i> = 6.67 Hz, 2 H), 3.30 (br s, 2 H), 2.81 (d, <i>J</i> = 11.28 Hz, 2 H), 2.50–2.70 (m, 4 H), 1.60–1.85 (m, 4 H). LC-MS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>2</sub> 418.19 [M + H<sup>+</sup>], found 418.37 [M + H<sup>+</sup>].</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 2-(2-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)isoindoline-1,3-dione (<b>7</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-chloro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>2</b> (11.1 mmol, 1.1 equiv, 2.56 g) and 2-(2-bromoethyl)isoindoline-1,3-dione (10 mmol, 1 equiv, 2.52 g). Yield 65%, yellowish solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.28 (br s, 1 H), 7.87–7.77 (m, 4 H), 7.73 (d, <i>J</i> = 2.1 Hz, 1 H), 7.42 (d, <i>J</i> = 2.6 Hz, 1 H), 7.38–7.32 (m, 1 H), 7.07 (dd, <i>J</i> = 2.1, 8.5 Hz, 1 H), 6.02 (s, 1 H), 3.76 (t, <i>J</i> = 6.4 Hz, 2 H), 3.15 (d, <i>J</i> = 2.8 Hz, 2 H), 2.72–2.60 (m, 4 H), 2.41 (m, 2 H). LC-MS (ESI) calcd for C<sub>23</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>2</sub> 406.12 [M + H<sup>+</sup>], found 406.33 [M + H<sup>+</sup>].</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 2-(3-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)isoindoline-1,3-dione (<b>8</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-chloro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>2</b> (11.1 mmol, 1.1 equiv, 2.56 g) and 2-(3-bromopropyl)isoindoline-1,3-dione (10 mmol, 1 equiv, 2.68 g). Yield 81%, yellowish solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.27 (br s, 1 H), 7.86–7.77 (m, 2 H), 7.75–7.66 (m, 3 H), 7.40–7.32 (m, 2 H), 7.08 (dd, <i>J</i> = 2.1, 8.5 Hz, 1 H), 5.96 (s, 1 H), 3.65 (t, <i>J</i> = 6.9 Hz, 2 H), 3.02 (d, <i>J</i> = 2.8 Hz, 2 H), 2.59–2.49 (m, 2 H), 2.42 (t, <i>J</i> = 6.7 Hz, 2 H), 2.36 (br s, 2 H), 1.80 (quin, <i>J</i> = 6.9 Hz, 2 H). LC-MS (ESI) calcd for C<sub>24</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>2</sub> 420.14 [M + H<sup>+</sup>], found 420.32 [M + H<sup>+</sup>].</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 2-(4-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)isoindoline-1,3-dione (<b>9</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-chloro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>2</b> (11.1 mmol, 1.1 equiv, 2.56 g) and 2-(4-bromobutyl)isoindoline-1,3-dione (10 mmol, 1 equiv, 2.82 g). Yield 65%, yellowish solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.29 (br s, 1 H), 7.88–7.78 (m, 4 H), 7.74 (d, <i>J</i> = 2.1 Hz, 1 H), 7.45–7.33 (m, 2 H), 7.08 (dd, <i>J</i> = 2.1, 8.7 Hz, 1 H), 6.02 (br s, 1 H), 3.59 (t, <i>J</i> = 6.9 Hz, 2 H), 3.04 (d, <i>J</i> = 2.8 Hz, 2 H), 2.60–2.52 (m, 2 H), 2.46–2.33 (m, 4 H), 1.70–1.56 (m, 2 H), 1.54–1.41 (m, 2 H). LC-MS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub> 434.16 [M + H<sup>+</sup>], found 434.39 [M + H<sup>+</sup>].</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 2-{2-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (<b>10</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>3</b> (5.5 mmol, 1.1 equiv, 1.357 g) and 2-(2-bromoethyl)-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (5 mmol, 1 equiv, 1.270 g). Yield 40%, yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.99 (br s, 1H), 7.82 (dd, <i>J</i> = 2.95, 5.51 Hz, 2H), 7.68 (dd, <i>J</i> = 3.08, 5.64 Hz, 2H), 7.45 (d, <i>J</i> = 1.80 Hz, 1H), 7.09–7.17 (m, 1H), 6.98–7.06 (m, 1H), 5.66 (br s, 1H), 3.93 (t, <i>J</i> = 6.80 Hz, 2H), 3.30 (d, <i>J</i> = 2.82 Hz, 2H), 2.77–2.89 (m, 4H), 2.50 (d, <i>J</i> = 1.54 Hz, 2H), 2.36 (s, 3H). LC-MS (ESI) calcd for C<sub>24</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>2</sub> 420.15 [M + H<sup>+</sup>], found 420.37 [M + H<sup>+</sup>].</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 2-{3-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]propyl}-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (<b>11</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>3</b> (5.5 mmol, 1.1 equiv, 1.357 g) and 2-(3-bromopropyl)-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (5 mmol, 1 equiv, 1.341 g). Yield 67%, yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.79–7.90 (m, 3H), 7.69 (dd, <i>J</i> = 3.08, 5.39 Hz, 2H), 7.43 (d, <i>J</i> = 1.54 Hz, 1H), 7.08–7.20 (m, 1H), 6.98–7.07 (m, 1H), 5.62 (br s, 1H), 3.82 (t, <i>J</i> = 6.92 Hz, 2H), 3.16 (d, <i>J</i> = 2.82 Hz, 2H), 2.64–2.74 (m, 2H), 2.59 (t, <i>J</i> = 7.18 Hz, 2H), 2.44 (d, <i>J</i> = 1.54 Hz, 2H), 2.37 (s, 3H), 1.98 (quin, <i>J</i> = 7.05 Hz, 2H). LC-MS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub> 434.16 [M + H<sup>+</sup>], found 434.39 [M + H<sup>+</sup>].</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 2-{4-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]butyl}-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (<b>12</b>)</h5><div class="NLM_p last">The title compound was prepared starting from 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole <b>3</b> (5.5 mmol, 1.1 equiv, 1.357 g) and 2-(4-bromobutyl)-2,3-dihydro-1<i>H</i>-isoindole-1,3-dione (5 mmol, 1 equiv, 1.411 g). Yield 67%, yellowish solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.93 (br s, 1H), 7.80–7.87 (m, 2H), 7.65–7.75 (m, 2H), 7.51 (d, <i>J</i> = 1.54 Hz, 1H), 7.11–7.18 (m, 1H), 6.98–7.07 (m, 1H), 5.67 (br s, 1H), 3.75 (t, <i>J</i> = 7.05 Hz, 2H), 3.18 (d, <i>J</i> = 2.82 Hz, 2H), 2.64–2.80 (m, 2H), 2.46–2.58 (m, 4H), 2.40 (s, 3H), 1.56–1.83 (m, 4H). LC-MS (ESI) calcd for C<sub>26</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub> 448.18 [M + H<sup>+</sup>], found 448.35 [M + H<sup>+</sup>].</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Procedure for the Synthesis of Intermediate Amines</h4><div class="NLM_p last">The appropriate alkyltetrahydropyridine derivative <b>4</b>–<b>12</b> (5 mmol, 1 equiv) was dissolved in 40% aqueous solution of MeNH<sub>2</sub> (50 mL), and the resulting reaction mixture was stirred at 50 °C for 4 h. Next, the reaction mixture was cooled to the room temperature and a solution of 10% KOH (25 mL) was added and the resulted mixture was stirred for additional 1 h. After that time, the reaction mixture was refrigerated overnight and the obtained oil was rinsed with water and dried in vacuum. The resulted intermediate was used directly to the next step without further purification.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> General Procedure for the Preparation of Sulfonamide Derivatives (<b>13</b>–<b>48</b>)</h4><div class="NLM_p">To a solution of appropriate intermediate (0.5 mmol, 1 equiv) in 5 mL of THF dry, appropriate sulfonyl chloride (0.5 mmol, 1 equiv), 1 M KOH solution (0.5 mmol, 0.5 mL) was added. The resulted reaction mixture was stirred for 12 h at room temperature. After that time, THF was evaporated and EtOAc (10 mL) and water (10 mL) were added, the organic layer was separated and dried over sodium sulfate, and the crude mixture was purified by column chromatography over silica gel using chloroform/methanol 98:2 as eluent.</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> <i>N</i>-{2-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide (<b>13</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.130 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 63%, yellowish solid, mp 118–122 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.45 (br s, 1 H), 7.64–7.75 (m, 2 H), 7.47 (dd, <i>J</i> = 2.31, 10.26 Hz, 1 H), 7.36–7.43 (m, 2 H), 7.26–7.32 (m, <i>J</i> = 4.62 Hz, 1 H), 7.17 (s, 1 H), 6.93 (dt, <i>J</i> = 2.31, 8.98 Hz, 1 H), 5.97 (br s, 1 H), 3.07 (t, <i>J</i> = 5.77 Hz, 2 H), 2.98 (d, <i>J</i> = 2.56 Hz, 2 H), 2.49–2.61 (m, 4 H), 2.34–2.49 (m, 5 H), NH (sulfonamide) proton not detected. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 158.1 (d, <i>J</i> = 234.42 Hz), 139.4, 139.3, 133.4, 133.3, 129.5, 128.9, 127.4, 125.3 (d, <i>J</i> = 9.95 Hz), 124.2, 123.0, 118.3, 117.7 (d, <i>J</i> = 4.98 Hz), 111.9 (d, <i>J</i> = 9.95 Hz), 110.5 (d, <i>J</i> = 25.99 Hz), 105.6 (d, <i>J</i> = 24.33 Hz), 55.6, 52.3, 49.7, 39.6, 28.8, 21.3. LC-MS (ESI) calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>2</sub>S 414.16 [M + H<sup>+</sup>], found 414.38 [M + H<sup>+</sup>].</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> <i>N</i>-{3-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]propyl}-3-methylbenzene-1-sulfonamide (<b>14</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.137 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 57%, yellowish solid, mp 120–122 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.38–8.53 (m, 1 H), 7.59–7.72 (m, 2 H), 7.46–7.56 (m, 1 H), 7.27–7.41 (m, 3 H), 7.18 (s, 1 H), 6.94 (d, <i>J</i> = 2.05 Hz, 1 H), 6.05 (br s, 1 H), 3.04–3.18 (m, 4 H), 2.65–2.73 (m, 2 H), 2.49–2.62 (m, 4 H), 2.39 (s, 3 H), 1.73 (t, <i>J</i> = 5.64 Hz, 2 H), NH (sulfonamide) proton not detected. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 158.1 (d, <i>J</i> = 236.63 Hz), 139.8, 139.1, 133.3, 133.1, 129.8, 128.8, 127.2, 125.2 (d, <i>J</i> = 9.40 Hz), 124.0, 123.31, 117.8, 117.5 (d, <i>J</i> = 4.42 Hz), 112.0 (d, <i>J</i> = 9.95 Hz), 110.4 (d, <i>J</i> = 26.54 Hz), 105.5 (d, <i>J</i> = 24.88 Hz), 57.6, 53.4, 49.6, 44.2, 28.5, 24.4, 21.3. LC-MS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>2</sub>S 428.18 [M + H<sup>+</sup>], found 428.34 [M + H<sup>+</sup>].</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> <i>N</i>-{4-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]butyl}-2-methylbenzene-1-sulfonamide (<b>15</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.144 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 43%, yellowish solid, mp 117–120 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.20 (br s, 1 H), 7.64 (t, <i>J</i> = 5.64 Hz, 1 H), 7.53–7.60 (m, 2 H), 7.50 (dd, <i>J</i> = 2.31, 10.77 Hz, 1 H), 7.39–7.45 (m, 3 H), 7.35 (dd, <i>J</i> = 4.87, 8.98 Hz, 1 H), 6.93 (dt, <i>J</i> = 2.31, 9.10 Hz, 1 H), 6.02 (br s, 1 H), 3.02 (br s, 2 H), 2.75 (d, <i>J</i> = 5.39 Hz, 2 H), 2.54 (d, <i>J</i> = 5.13 Hz, 2 H), 2.45 (br s, 2 H), 2.35 (s, 3 H), 2.23–2.32 (m, 2 H), 1.32–1.49 (m, 4 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 157.2 (d, <i>J</i> = 231.10 Hz), 140.5, 138.8, 133.5, 133.4, 132.8, 129.2, 128.9, 126.66, 124.6 (d, <i>J</i> = 11.06 Hz), 123.6, 117.7, 116.1 (d, <i>J</i> = 4.42 Hz), 112.6 (d, <i>J</i> = 9.95 Hz), 109.3 (d, <i>J</i> = 25.43 Hz), 104.8 (d, <i>J</i> = 24.33 Hz), 57.3, 52.6, 50.0, 42.5, 28.4, 27.1, 23.6, 20.8. LC-MS (ESI) calcd for C<sub>24</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>2</sub>S 442.20 [M + H<sup>+</sup>], found 442.44 [M + H<sup>+</sup>].</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> <i>N</i>-(2-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)-3-methylbenzenesulfonamide (<b>16</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.131 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 38%, yellowish solid, mp 127–130 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.29 (br s, 1 H), 7.74 (d, <i>J</i> = 1.8 Hz, 1 H), 7.64–7.58 (m, 2 H), 7.49–7.45 (m, 1 H), 7.44–7.40 (m, 3 H), 7.37 (d, <i>J</i> = 9.0 Hz, 1 H), 7.08 (dd, <i>J</i> = 2.1, 8.5 Hz, 1 H), 5.99 (br s, 1 H), 3.02 (d, <i>J</i> = 2.3 Hz, 2 H), 2.91 (t, <i>J</i> = 6.7 Hz, 2 H), 2.57–2.50 (m, 2 H), 2.42 (t, <i>J</i> = 6.7 Hz, 4 H), 2.37 (s, 3 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 141.0, 139.3, 135.8, 133.3, 129.5, 127.2, 126.1, 124.9, 124.4, 124.1, 121.6, 119.5, 118.6, 116.2, 113.7, 57.3, 52.9, 50.4, 40.8, 28.8, 21.3. LC-MS (ESI) calcd for C<sub>22</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub>S 430.14 [M + H<sup>+</sup>], found 430.27 [M + H<sup>+</sup>].</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> <i>N</i>-(3-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)-3-methylbenzenesulfonamide (<b>17</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.138 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 31%, yellowish solid, mp 136–139 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (br s, 1 H), 7.75 (d, <i>J</i> = 2.1 Hz, 1 H), 7.58 (d, <i>J</i> = 8.5 Hz, 3 H), 7.46–7.35 (m, 3 H), 7.08 (dd, <i>J</i> = 1.9, 8.6 Hz, 1 H), 6.06–5.98 (m, 1 H), 2.99–2.90 (m, 2 H), 2.79 (t, <i>J</i> = 6.5 Hz, 2 H), 2.49 (d, <i>J</i> = 5.6 Hz, 2 H), 2.42–2.38 (m, 2 H), 2.37 (s, 3 H), 2.33–2.27 (m, 2 H), 1.56–1.53 (m, 2 H), NH protons not detected. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 143.8, 140.9, 139.3, 135.8, 133.3, 129.5, 127.2, 126.1, 124.9, 124.4, 124.1, 121.6, 119.6, 118.7, 116.2, 113.7, 55.4, 53.1, 50.8, 41.1, 29.0, 26.9, 21.3. LC-MS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub>S 444.14 [M + H<sup>+</sup>], found 444.39 [M + H<sup>+</sup>].</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> <i>N</i>-(4-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)-3-methylbenzenesulfonamide (<b>18</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 38%, yellowish solid, mp 120–123 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.57 (br s, 1 H), 7.82 (s, 1 H), 7.68 (t, <i>J</i> = 5.9 Hz, 1 H), 7.63–7.55 (m, 3 H), 7.49–7.39 (m, 3 H), 7.12 (d, <i>J</i> = 8.7 Hz, 1 H), 6.07 (br s, 1 H), 3.26 (br s, 2 H), 3.02–2.93 (m, 2 H), 2.76 (d, <i>J</i> = 5.6 Hz, 4 H), 2.39–2.32 (m, 3 H), 2.29–2.21 (m, 2 H), 1.73–1.61 (m, 2 H), 1.43 (d, <i>J</i> = 14.4 Hz, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 140.8, 139.3, 137.3, 135.9, 133.4, 129.7, 129.5, 128.0, 127.1, 126.5, 124.8, 124.1, 123.1, 122.0, 119.5, 114.7, 55.2, 50.4, 48.8, 42.5, 26.9, 25.5, 21.5, 21.3. LC-MS (ESI) calcd for C<sub>24</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>2</sub>S 458.17 [M + H<sup>+</sup>], found 458.32 [M + H<sup>+</sup>].</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> <i>N</i>-{2-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}-3-methylbenzene-1-sulfonamide (<b>19</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.095 g). Yield 54%, yellowish solid, mp 90–93 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 7.65–7.75 (m, 2 H), 7.45 (d, <i>J</i> = 4.36 Hz, 2 H), 7.39 (d, <i>J</i> = 1.80 Hz, 1 H), 7.18 (d, <i>J</i> = 8.46 Hz, 1 H), 6.95 (dd, <i>J</i> = 2.05, 8.46 Hz, 1 H), 5.60 (br s, 1 H), 3.17 (d, <i>J</i> = 2.82 Hz, 2 H), 3.09 (t, <i>J</i> = 6.80 Hz, 2 H), 2.69–2.77 (m, 2 H), 2.63 (t, <i>J</i> = 6.92 Hz, 2 H), 2.51 (d, <i>J</i> = 1.54 Hz, 2 H), 2.43 (s, 3 H), 2.37 (s, 3 H), NH protons not detected. <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): δ 141.7, 140.9, 135.4, 134.7, 134.6, 132.1, 130.3, 130.1, 128.5, 125.6, 125.4, 123.4, 121.6, 119.1, 114.8, 112.7, 58.3, 53.9, 51.6, 41.3, 31.1, 21.5, 12.8. LC-MS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub>S 444.15 [M + H<sup>+</sup>], found 444.36 [M + H<sup>+</sup>].</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> <i>N</i>-{3-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]propyl}-3-methylbenzene-1-sulfonamide (<b>20</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.152 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 58%, yellowish solid, mp 99–101 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.39 (s, 1 H), 7.83 (t, <i>J</i> = 5.90 Hz, 1 H), 7.59–7.69 (m, 2 H), 7.42–7.55 (m, 3 H), 7.29 (d, <i>J</i> = 8.46 Hz, 1 H), 7.01 (dd, <i>J</i> = 2.05, 8.46 Hz, 1 H), 5.63 (br s, 1 H), 3.74 (br s, 2 H), 3.12 (br s, 4 H), 2.57–2.97 (m, 4 H), 2.40 (d, <i>J</i> = 1.80 Hz, 6 H), 1.80–2.03 (m, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 140.1, 139.0, 134.4, 133.5, 133.1, 130.1, 129.1, 127.8, 126.8, 123.7, 123.5, 120.2, 117.5, 112.2, 111.7, 52.7, 49.8, 48.5, 30.7, 26.4, 24.0, 20.9, 12.68. LC-MS (ESI) calcd for C<sub>24</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>2</sub>S 458.17 [M + H<sup>+</sup>], found 458.39 [M + H<sup>+</sup>].</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> <i>N</i>-{4-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]butyl}-2-methylbenzene-1-sulfonamide (<b>21</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.159 g) and 3-methylbenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 72%, yellowish solid, mp 102–105 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 7.60–7.71 (m, 2 H), 7.40–7.48 (m, 3 H), 7.21 (d, <i>J</i> = 8.72 Hz, 1 H), 6.98 (dd, <i>J</i> = 1.80, 8.46 Hz, 1 H), 5.67 (br s, 1 H), 3.62 (d, <i>J</i> = 2.05 Hz, 2 H), 3.21 (t, <i>J</i> = 5.90 Hz, 2 H), 2.86–2.96 (m, 4 H), 2.73 (br s, 2 H), 2.41 (d, <i>J</i> = 2.56 Hz, 6 H), 1.77 (quin, <i>J</i> = 7.63 Hz, 2 H), 1.56 (quin, <i>J</i> = 6.99 Hz, 2 H), NH protons not detected. <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): δ 141.9, 140.9, 135.5, 135.3, 134.5, 132.5, 130.3, 129.8, 128.4, 126.0, 125.3, 121.9, 120.3, 119.0, 113.7, 112.9, 57.9, 52.8, 51.2, 43.6, 29.4, 28.3, 23.5, 21.5, 12.9. LC-MS (ESI) calcd for C<sub>25</sub>H<sub>30</sub>ClN<sub>3</sub>O<sub>2</sub>S 472.18 [M + H<sup>+</sup>], found 472.48 [M + H<sup>+</sup>].</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> <i>N</i>-{2-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}naphthalene-2-sulfonamide (<b>22</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.130 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 62%, yellowish solid, mp 124–128 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.46 (s, 1 H), 8.31 (br s, 1 H), 7.79–8.04 (m, 4 H), 7.63 (dtd, <i>J</i> = 1.32, 7.17, 16.44 Hz, 2 H), 7.46 (dd, <i>J</i> = 2.42, 10.34 Hz, 1 H), 7.29 (dd, <i>J</i> = 4.84, 8.80 Hz, 1 H), 7.16 (d, <i>J</i> = 2.64 Hz, 1 H), 6.96 (dt, <i>J</i> = 2.20, 9.02 Hz, 1 H), 5.92 (t, <i>J</i> = 3.30 Hz, 1 H), 3.05–3.16 (m, 2 H), 2.93 (d, <i>J</i> = 3.08 Hz, 2 H), 2.54 (q, <i>J</i> = 5.72 Hz, 4 H), 2.40–2.48 (m, 2 H), NH (sulfonamide) proton not detected. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 158.1 (d, <i>J</i> = 234.42 Hz), 136.3, 134.7, 133.3, 132.1, 129.4, 129.4, 129.2, 128.8, 128.4, 127.9, 127.6, 125.2 (d, <i>J</i> = 9.95 Hz), 123.0, 122.3, 118.3, 117.7 (d, <i>J</i> = 4.42 Hz), 111.9 (d, <i>J</i> = 9.40 Hz), 110.5 (d, <i>J</i> = 25.43 Hz), 105.62 (d, <i>J</i> = 25.43 Hz), 55.5, 52.2, 49.8, 39.6, 28.7. LC-MS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>2</sub>S 450.16 [M + H<sup>+</sup>], found 450.41 [M + H<sup>+</sup>].</div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> <i>N</i>-{3-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]propyl}naphthalene-2-sulfonamide (<b>23</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.137 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 65%, yellowish solid, mp 179–180 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.59 (br s, 1 H), 8.40 (s, 1 H), 7.75–7.98 (m, 4 H), 7.46–7.67 (m, 3 H), 7.30 (dd, <i>J</i> = 4.49, 8.85 Hz, 1 H), 7.15 (s, 1 H), 6.94 (dt, <i>J</i> = 2.31, 8.98 Hz, 1 H), 6.03 (br s, 1 H), 3.15 (t, <i>J</i> = 5.64 Hz, 2 H), 3.06 (d, <i>J</i> = 2.56 Hz, 2 H), 2.61–2.71 (m, 2 H), 2.43–2.60 (m, 4 H), 1.71 (quin, <i>J</i> = 5.64 Hz, 2 H), NH (sulfonamide) proton not detected. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 158.1 (d, <i>J</i> = 232.76 Hz), 136.8, 134.6, 133.3, 132.1, 129.8, 129.3, 129.1, 128.6, 128.1, 127.8, 127.4, 125.2 (d, <i>J</i> = 9.40 Hz), 123.4, 122.2, 117.7, 117.3 (d, <i>J</i> = 4.98 Hz), 112.1 (d, <i>J</i> = 9.40 Hz), 110.4 (d, <i>J</i> = 26.54 Hz), 105.5 (d, <i>J</i> = 24.88 Hz), 57.5, 53.3, 49.56, 44.2, 28.5, 24.3. LC-MS (ESI) calcd for C<sub>26</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>2</sub>S 464.18 [M + H<sup>+</sup>], found 464.31 [M + H<sup>+</sup>].</div></div><div id="sec4_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <i>N</i>-{4-[4-(5-Fluoro-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]butyl}naphthalene-1-sulfonamide (<b>24</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.144 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 74%, yellowish solid, mp 176–177 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.39 (s, 1 H), 7.98 (d, <i>J</i> = 8.72 Hz, 1 H), 7.92 (d, <i>J</i> = 7.69 Hz, 2 H), 7.83 (dd, <i>J</i> = 1.67, 8.59 Hz, 1 H), 7.52–7.67 (m, 2 H), 7.45 (dd, <i>J</i> = 2.31, 10.52 Hz, 1 H), 7.32 (dd, <i>J</i> = 4.62, 8.98 Hz, 1 H), 7.28 (s, 1 H), 6.89 (dt, <i>J</i> = 2.44, 9.04 Hz, 1 H), 5.95 (br s, 1 H), 2.89–3.04 (m, 4 H), 2.46–2.63 (m, 4 H), 2.32 (t, <i>J</i> = 7.05 Hz, 2 H), 1.46 (br s, 4 H), NH protons not detected. <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): δ 159.4 (d, <i>J</i> = 232.21 Hz), 139.2, 136.2, 135.4, 133.7, 131.4, 130.6, 130.3, 129.89, 129.1, 129.0, 128.7, 126.6 (d, <i>J</i> = 9.95 Hz), 125.3, 123.7, 118.1, 117.9 (d, <i>J</i> = 4.42 Hz), 113.4 (d, <i>J</i> = 9.40 Hz), 110.8 (d, <i>J</i> = 26.54 Hz), 106.1 (d, <i>J</i> = 24.33 Hz), 59.0, 53.7, 51.5, 44.1, 29.4, 29.0, 24.9. LC-MS (ESI) calcd for C<sub>27</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>2</sub>S 478.2 [M + H<sup>+</sup>], found 478.47 [M + H<sup>+</sup>].</div></div><div id="sec4_5_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <i>N</i>-(2-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)naphthalene-2-sulfonamide (<b>25</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.131 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 43%, yellowish solid, mp 145–148 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.47–8.43 (m, 1 H), 8.03–7.98 (m, 2 H), 7.95–7.83 (m, 2 H), 7.71–7.68 (m, 2 H), 7.66–7.57 (m, 2 H), 7.33–7.27 (m, 1 H), 7.08–7.03 (m, 1 H), 5.92 (td, <i>J</i> = 1.9, 3.3 Hz, 1 H), 3.11 (t, <i>J</i> = 6.9 Hz, 2 H), 3.06–3.00 (m, 2 H), 2.64–2.58 (m, 2 H), 2.56–2.50 (m, 2 H), 2.47 (dd, <i>J</i> = 1.8, 5.1 Hz, 2 H), NH protons not detected. <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): δ 137.3, 135.6, 134.8, 132.2, 129.7, 129.1, 128.7, 128.4, 127.7, 127.6, 127.3, 125.9, 124.8, 123.4, 122.0, 121.3, 119.1, 117.0, 116.0, 112.3, 56.7, 52.3, 50.0, 39.9, 27.9. LC-MS calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub>S 466.13 [M + H<sup>+</sup>], found 466.33 [M + H<sup>+</sup>].</div></div><div id="sec4_5_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>N</i>-(3-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)naphthalene-2-sulfonamide (<b>26</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.138 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 32%, yellowish solid, mp 132–135 °C. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.45 (d, <i>J</i> = 1.8 Hz, 1 H), 8.12–8.08 (m, 2 H), 8.04–7.99 (m, 1 H), 7.92–7.80 (m, 3 H), 7.68–7.59 (m, 2 H), 7.43–7.37 (m, 1 H), 7.11 (dd, <i>J</i> = 1.9, 8.6 Hz, 1 H), 6.12–6.05 (m, 1 H), 3.11–2.99 (m, 4 H), 2.63–2.54 (m, 2 H), 2.53–2.49 (m, 2 H), 2.44 (t, <i>J</i> = 6.5 Hz, 2 H), 1.70 (t, <i>J</i> = 6.5 Hz, 2 H), NH protons not detected. <sup>13</sup>C NMR (75 MHz, acetone-<i>d</i><sub>6</sub>): δ 138.0, 134.7, 132.3, 129.5, 129.3, 129.1, 128.5, 127.9, 127.8, 127.5, 127.3, 126.2, 124.7, 123.8, 122.6, 121.5, 119.5, 118.4, 116.6, 112.9, 56.0, 53.0, 49.9, 42.3, 31.7, 25.8. LC-MS calcd for C<sub>26</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub>S 480.14 [M + H<sup>+</sup>], found 480.30 [M + H<sup>+</sup>].</div></div><div id="sec4_5_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>N</i>-(4-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)naphthalene-2-sulfonamide (<b>27</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 36%, yellowish solid, mp 186–189 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.31 (br s, 1 H), 8.40 (s, 1 H), 8.14–8.05 (m, 2 H), 8.00 (d, <i>J</i> = 7.7 Hz, 1 H), 7.85–7.73 (m, 3 H), 7.71–7.57 (m, 2 H), 7.44–7.34 (m, 2 H), 7.09 (dd, <i>J</i> = 2.1, 8.7 Hz, 1 H), 5.98 (br s, 1 H), 2.94 (br s, 2 H), 2.80 (br s, 2 H), 2.40 (br s, 2 H), 2.24 (br s, 2 H), 1.39 (br s, 4 H), 1.29–1.18 (m, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 138.2, 135.8, 134.5, 132.2, 129.7, 129.6, 129.5, 129.0, 128.2, 127.9, 127.6, 126.1, 124.9, 124.4, 122.8, 121.6, 119.6, 118.6, 116.2, 113.7, 57.7, 53.0, 50.4, 43.0, 28.9, 27.6, 24.1. LC-MS (ESI) calcd for C<sub>27</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>2</sub>S 494.17 [M + H<sup>+</sup>], found 494.36 [M + H<sup>+</sup>].</div></div><div id="sec4_5_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <i>N</i>-{2-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl}naphthalene-2-sulfonamide (<b>28</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 56%, yellowish solid, mp 103–107 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.45 (s, 1 H), 7.96–8.07 (m, 2 H), 7.83–7.95 (m, 2 H), 7.53–7.68 (m, 2 H), 7.36 (d, <i>J</i> = 1.80 Hz, 1 H), 7.16 (d, <i>J</i> = 8.46 Hz, 1 H), 6.93 (dd, <i>J</i> = 1.80, 8.46 Hz, 1 H), 5.50 (br s, 1 H), 3.10 (t, <i>J</i> = 6.92 Hz, 2 H), 3.03 (d, <i>J</i> = 2.82 Hz, 2 H), 2.48–2.65 (m, 4 H), 2.40 (br s, 2 H), 2.31 (s, 3 H), NH protons not detected. <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): δ 137.8, 135.4, 134.4, 133.7, 132.8, 131.0, 129.8, 129.4, 129.1, 129.0, 128.4, 128.2, 127.9, 124.7, 122.6, 120.7, 118.1, 113.9, 111.7, 57.4, 52.9, 50.6, 40.5, 30.2, 11.9. LC-MS (ESI) calcd for C<sub>26</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub>S 480.15 [M + H<sup>+</sup>], found 480.39 [M + H<sup>+</sup>].</div></div><div id="sec4_5_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>N</i>-{3-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]propyl}naphthalene-2-sulfonamide (<b>29</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.152 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 64%, yellowish solid, mp 112–114 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.46 (s, 1 H), 8.02–8.13 (m, 2 H), 7.98 (d, <i>J</i> = 7.44 Hz, 1 H), 7.87 (dd, <i>J</i> = 1.67, 8.59 Hz, 1 H), 7.66 (tt, <i>J</i> = 5.39, 7.31 Hz, 2 H), 7.44 (d, <i>J</i> = 1.54 Hz, 1 H), 7.22 (d, <i>J</i> = 8.46 Hz, 1 H), 7.00 (dd, <i>J</i> = 1.80, 8.46 Hz, 1 H), 5.63 (br s, 1 H), 3.69 (br s, 2 H), 3.08–3.17 (m, 2 H), 3.05 (t, <i>J</i> = 6.28 Hz, 2 H), 2.73 (br s, 2 H), 2.41 (s, 3 H), 1.88–2.02 (m, 2 H), NH protons not detected, signals from two aliphatic protons overlap with solvent peak (MeOH: 3.36–3.26 ppm). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (s, 1 H), 8.47 (s, 1 H), 8.10–8.24 (m, 2 H), 8.05 (d, <i>J</i> = 7.44 Hz, 1 H), 7.91–8.00 (m, 1 H), 7.79–7.90 (m, 1 H), 7.69 (t, <i>J</i> = 6.54 Hz, 2 H), 7.43–7.55 (m, 1 H), 7.28 (d, <i>J</i> = 8.46 Hz, 1 H), 7.01 (dd, <i>J</i> = 1.80, 8.72 Hz, 1 H), 5.59 (br s, 1 H), 3.43–3.89 (m, 2 H), 2.94–3.29 (m, 4H signals partially overlap with water peak), 2.90 (q, <i>J</i> = 5.64 Hz, 2 H), 2.54–2.78 (m, 2 H), 2.38 (s, 3 H), 1.89 (d, <i>J</i> = 12.57 Hz, 2 H). <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): δ 138.7, 136.4, 135.5, 133.8, 132.6, 130.9, 130.4, 130.1, 129.7, 129.3, 129.2, 128.9, 126.0, 123.5, 122.0, 119.3, 118.9, 113.3, 112.9, 106.6, 55.6, 52.6, 51.2, 41.7, 28.9, 26.4, 12.9. LC-MS (ESI) calcd for C<sub>27</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>2</sub>S 494.17 [M + H<sup>+</sup>], found 494.42 [M + H<sup>+</sup>].</div></div><div id="sec4_5_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> <i>N</i>-{4-[4-(5-Chloro-2-methyl-1<i>H</i>-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]butyl}naphthalene-1-sulfonamide (<b>30</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.159 g) and naphthalene-2-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 59%, yellowish solid, mp 113–116 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 8.42 (s, 1 H), 7.90–8.08 (m, 3 H), 7.85 (dd, <i>J</i> = 1.80, 8.72 Hz, 1 H), 7.61 (ddd, <i>J</i> = 1.54, 5.39, 7.44 Hz, 2 H), 7.44 (d, <i>J</i> = 1.80 Hz, 1 H), 7.21 (d, <i>J</i> = 8.46 Hz, 1 H), 6.99 (dd, <i>J</i> = 1.92, 8.59 Hz, 1 H), 5.56 (br s, 1 H), 3.53 (d, <i>J</i> = 2.05 Hz, 2 H), 3.12 (t, <i>J</i> = 5.77 Hz, 2 H), 2.96 (t, <i>J</i> = 6.41 Hz, 2 H), 2.81–2.92 (m, 2 H), 2.66 (br s, 2 H), 2.38 (s, 3 H), 1.62–1.78 (m, 2 H), 1.47–1.61 (m, 2 H), NH protons not detected. <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD): δ 139.0, 136.3, 135.4, 135.3, 133.7, 132.5, 130.7, 130.3, 130.0, 129.8, 129.1, 129.1, 128.9, 126.0, 123.6, 121.9, 119.8, 119.0, 113.5, 112.9, 57.6, 52.5, 51.0, 43.6, 29.1, 28.2, 23.3, 12.9. LC-MS (ESI) calcd for C<sub>28</sub>H<sub>30</sub>ClN<sub>3</sub>O<sub>2</sub>S 508.18 [M + H<sup>+</sup>], found 508.45 [M + H<sup>+</sup>].</div></div><div id="sec4_5_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>N</i>-(2-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)naphthalene-1-sulfonamide (<b>31</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.131 g) and naphthalene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 25%, yellowish solid, mp 98–103 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.28 (br s, 1 H), 8.66 (d, <i>J</i> = 7.7 Hz, 1 H), 8.18 (dd, <i>J</i> = 2.6, 7.8 Hz, 2 H), 8.06 (d, <i>J</i> = 8.0 Hz, 1 H), 7.74–7.56 (m, 5 H), 7.41–7.33 (m, 2 H), 7.08 (dd, <i>J</i> = 1.9, 8.5 Hz, 1 H), 5.90 (br s, 1 H), 3.02–2.87 (m, 4 H), 2.46–2.38 (m, 2 H), 2.37–2.27 (m, 4 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 136.3, 135.8, 134.3, 134.0, 129.4, 129.3, 128.8, 128.2, 128.1, 127.2, 126.1, 125.2, 124.9, 124.8, 124.4, 121.6, 119.5, 118.5, 116.2, 113.7, 57.3, 52.8, 50.3, 31.1, 28.7. LC-MS (ESI) calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>2</sub>S 466.14 [M + H<sup>+</sup>], found 466.37 [M + H<sup>+</sup>].</div></div><div id="sec4_5_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> <i>N</i>-(3-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)naphthalene-1-sulfonamide (<b>32</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.138 g) and naphthalene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 40%, yellowish solid, mp 127–130 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.33 (br s, 1 H), 8.64 (d, <i>J</i> = 9.0 Hz, 2 H), 8.14–8.02 (m, 4 H), 7.69–7.60 (m, 3 H), 7.44–7.31 (m, 2 H), 7.16–7.02 (m, 1 H), 6.02–5.88 (m, 1 H), 2.95–2.90 (m, 2 H), 2.89–2.77 (m, 3 H), 2.40 (d, <i>J</i> = 5.4 Hz, 3 H), 2.26 (t, <i>J</i> = 6.8 Hz, 2 H), 1.58–1.41 (m, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 136.0, 135.8, 134.3, 134.1, 129.5, 129.0, 128.2, 128.0, 127.2, 127.3, 126.0, 125.9, 125.8, 125.1, 125.0, 124.4, 121.7, 119.5, 116.0, 113.7, 55.0, 52.7, 50.0, 31.6, 30.3. LC-MS (ESI) calcd for C<sub>26</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub>S 480.14 [M + H<sup>+</sup>], found 480.33 [M + H<sup>+</sup>].</div></div><div id="sec4_5_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <i>N</i>-(4-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)naphthalene-1-sulfonamide (<b>33</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and naphthalene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 43%, yellowish solid, mp 202–205 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.31 (br s, 1 H), 8.66 (d, <i>J</i> = 8.2 Hz, 1 H), 8.19 (d, <i>J</i> = 8.2 Hz, 1 H), 8.13–8.01 (m, 3 H), 7.75 (d, <i>J</i> = 2.1 Hz, 1 H), 7.68–7.59 (m, 3 H), 7.45–7.35 (m, 2 H), 7.09 (dd, <i>J</i> = 2.1, 8.5 Hz, 1 H), 5.98 (s, 1 H), 2.89–2.78 (m, 4 H), 2.40 (s, 4 H), 2.13 (br s, 2 H), 1.32–1.24 (m, 4 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 136.3, 135.8, 134.3, 134.0, 129.4, 129.4, 128.9, 128.2, 128.0, 127.2, 126.1, 125.2, 124.9, 124.9, 124.4, 121.6, 119.6, 118.7, 116.2, 113.7, 57.6, 53.0, 50.3, 42.8, 28.9, 27.5, 23.9. LC-MS (ESI) calcd for C<sub>27</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>2</sub>S 494.17 [M + H<sup>+</sup>], found 494.36 [M + H<sup>+</sup>].</div></div><div id="sec4_5_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> <i>N</i>-(2-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)-3-fluorobenzenesulfonamide (<b>34</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.131 g) and 3-fluorobenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 35%, yellowish solid, mp 149–150 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.59 (d, <i>J</i> = 2.1 Hz, 1 H), 10.81 (br s, 1 H), 8.40 (s, 1 H), 7.82 (d, <i>J</i> = 1.8 Hz, 1 H), 7.75–7.63 (m, 2 H), 7.63–7.49 (m, 2 H), 7.42 (d, <i>J</i> = 8.7 Hz, 1 H), 7.13 (dd, <i>J</i> = 2.1, 8.7 Hz, 1 H), 6.08 (s, 1 H), 4.08–3.92 (m, 1 H), 3.81 (m, 1 H), 3.69–3.53 (m, 1 H), 3.27 (br s, 5 H), 2.85 (br s, 1 H), 2.78–2.57 (m, 1 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 142.2 (d, <i>J</i> = 7.2 Hz), 135.9, 132.3 (d, <i>J</i> = 8.3 Hz), 129.7, 126.2, 125.7, 124.9, 123.4 (d, <i>J</i> = 8.3 Hz), 122.0, 120.5, 120.3, 119.5, 115.6, 114.4, 114.0 (d, <i>J</i> = 8.3 Hz), 112.3, 54.5, 50.3, 48.8, 37.8, 24.8. LC-MS (ESI) calcd for C<sub>21</sub>H<sub>21</sub>ClFN<sub>3</sub>O<sub>2</sub>S 434.10 [M + H<sup>+</sup>], found 434.26 [M + H<sup>+</sup>].</div></div><div id="sec4_5_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>N</i>-(3-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)-3-fluorobenzenesulfonamide (<b>35</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.138 g) and 3-fluorobenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 44%, yellowish solid, mp 175–177 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.54 (br s, 1 H), 10.06 (br s, 1 H), 7.97 (t, <i>J</i> = 5.9 Hz, 1 H), 7.83 (d, <i>J</i> = 1.8 Hz, 1 H), 7.67–7.57 (m, 3 H), 7.42 (d, <i>J</i> = 8.7 Hz, 2 H), 7.16–7.11 (m, 1 H), 6.10 (s, 1 H), 4.04–3.90 (m, 1 H), 3.73 (d, <i>J</i> = 13.8 Hz, 1 H), 3.58 (d, <i>J</i> = 10.5 Hz, 1 H), 3.32–3.09 (m, 3 H), 2.92–2.67 (m, 4 H), 1.89 (dd, <i>J</i> = 5.8, 9.9 Hz, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 142.7 (d, <i>J</i> = 6.6 Hz), 135.9, 132.2 (d, <i>J</i> = 8.3 Hz), 130.3, 129.7, 126.3, 125.7, 124.9, 123.2 (d, <i>J</i> = 3.3 Hz), 122.1, 119.4, 115.9, 115.6, 114.4, 113.9 (d, <i>J</i> = 8.3 Hz), 112.9, 53.1, 50.2, 48.8, 25.0, 24.5. LC-MS (ESI) calcd for C<sub>22</sub>H<sub>23</sub>ClFN<sub>3</sub>O<sub>2</sub>S 448.12 [M + H<sup>+</sup>], found 448.29 [M + H<sup>+</sup>].</div></div><div id="sec4_5_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> <i>N</i>-(4-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)-3-fluorobenzenesulfonamide (<b>36</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and 3-fluorobenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 40%, yellowish solid, mp 97–101 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.31 (br s, 1 H), 7.85 (br s, 1 H), 7.76 (d, <i>J</i> = 2.1 Hz, 1 H), 7.66–7.59 (m, 2 H), 7.55 (td, <i>J</i> = 1.6, 8.8 Hz, 1 H), 7.52–7.45 (m, 1 H), 7.43 (d, <i>J</i> = 2.3 Hz, 1 H), 7.38 (d, <i>J</i> = 8.7 Hz, 1 H), 7.09 (dd, <i>J</i> = 2.1, 8.5 Hz, 1 H), 6.03 (br s, 1 H), 3.01 (d, <i>J</i> = 2.6 Hz, 2 H), 2.79 (br s, 2 H), 2.59–2.50 (m, 2 H), 2.44 (br s, 2 H), 2.28 (br s, 2 H), 1.49–1.34 (m, 4 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.6, 143.3, 135.8, 132.0, 129.5, 126.1, 124.9, 124.4, 123.1, 121.6, 120.0, 119.6, 118.7, 116.2, 114.0, 113.7, 57.7, 53.1, 50.4, 43.0, 29.0, 27.5, 24.1. LC-MS (ESI) calcd for C<sub>23</sub>H<sub>25</sub>ClFN<sub>3</sub>O<sub>2</sub>S 462.14 [M + H<sup>+</sup>], found 462.38 [M + H<sup>+</sup>].</div></div><div id="sec4_5_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 3-Chloro-<i>N</i>-(2-(4-(5-chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)benzenesulfonamide (<b>37</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.760 mmol, 1 equiv, 0.200 g) and 3-chlorobenzene-1-sulfonyl chloride (0.760 mmol, 1 equiv, 0.160 g). Yield 47%, yellowish solid, mp 236–238 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.63 (d, <i>J</i> = 1.5 Hz, 1 H), 10.95 (br s, 1 H), 8.47 (s, 1 H), 7.93–7.71 (m, 3 H), 7.69–7.55 (m, 2 H), 7.42 (d, <i>J</i> = 8.7 Hz, 1 H), 7.12 (dd, <i>J</i> = 1.8, 8.7 Hz, 1 H), 6.07 (s, 1 H), 4.07–3.90 (m, 1 H), 3.85–3.71 (m, 1 H), 3.67–3.53 (m, 1 H), 3.28 (m, 5 H), 2.87–2.86 (m, 1 H), 2.77–2.62 (m, 1 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 142.1, 135.9, 134.4, 133.2, 131.9, 129.7, 126.7, 126.2, 125.9, 125.7, 124.9, 122.0, 119.5, 114.4, 113.9, 112.2, 54.5, 50.2, 48.7, 37.8, 24.8. LC-MS (ESI) calcd for C<sub>21</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S 450.07 [M + H<sup>+</sup>], found 450.21 [M + H<sup>+</sup>].</div></div><div id="sec4_5_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 3-Chloro-<i>N</i>-(3-(4-(5-chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)benzenesulfonamide (<b>38</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.138 g) and 3-chlorobenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.105 g). Yield 63%, yellowish solid, mp 139–140 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.64 (d, <i>J</i> = 2.1 Hz, 1 H), 10.82 (br s, 1 H), 8.11 (t, <i>J</i> = 6.0 Hz, 1 H), 7.86–7.69 (m, 3 H), 7.67–7.56 (m, 2 H), 7.43 (d, <i>J</i> = 8.5 Hz, 1 H), 7.12 (dd, <i>J</i> = 2.1, 8.7 Hz, 1 H), 6.08 (s, 1 H), 4.01–3.85 (m, 1 H), 3.70 (dd, <i>J</i> = 5.5, 16.0 Hz, 1 H), 3.53 (d, <i>J</i> = 11.3 Hz, 1 H), 3.29–3.09 (m, 3 H), 2.85 (q, <i>J</i> = 6.4 Hz, 3 H), 2.77–2.64 (m, 1 H), 1.93 (dd, <i>J</i> = 6.7, 11.3 Hz, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 142.5, 135.9, 134.3, 132.9, 131.8, 129.7, 126.7, 126.7. 126.2, 125.8, 124.9, 122.0, 119.5, 114.4, 114.0, 112.3, 52.9, 49.9, 48.6, 24.8, 24.3. LC-MS (ESI) calcd for C<sub>22</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S 464.09 [M + H<sup>+</sup>], found 464.24 [M + H<sup>+</sup>].</div></div><div id="sec4_5_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 3-Chloro-<i>N</i>-(4-(4-(5-chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)benzenesulfonamide (<b>39</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and 3-chlorobenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.105 g). Yield 38%, yellowish solid, mp 190–193 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (s, 1 H), 7.79 (d, <i>J</i> = 1.5 Hz, 1 H), 7.75 (td, <i>J</i> = 1.4, 7.6 Hz, 1 H), 7.67 (ddd, <i>J</i> = 1.3, 2.1, 8.0 Hz, 1 H), 7.63–7.54 (m, 2 H), 7.49 (s, 1 H), 7.39 (d, <i>J</i> = 8.7 Hz, 1 H), 7.34 (d, <i>J</i> = 4.1 Hz, 1 H), 7.09 (dd, <i>J</i> = 2.1, 8.7 Hz, 1 H), 6.08 (br s, 1 H), 4.00 (br s, 2 H), 2.99 (br s, 1 H), 2.81 (t, <i>J</i> = 6.7 Hz, 2 H), 2.74–2.61 (m, 3 H), 2.26 (s, 1 H), 1.84 (s, 1 H), 1.64–1.52 (m, 2 H), 1.46 (dd, <i>J</i> = 7.2, 13.8 Hz, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 142.9, 135.7, 134.3, 132.6, 131.5, 130.0, 129.7, 128.7, 126.5, 125.9, 125.5, 124.7, 121.7, 119.4, 115.3, 113.6, 56.4, 51.6, 49.6, 42.6, 29.4, 27.1, 22.6. LC-MS (ESI) calcd for C<sub>23</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S 478.11 [M + H<sup>+</sup>], found 478.27 [M + H<sup>+</sup>].</div></div><div id="sec4_5_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>N</i>-(2-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)-3-hydroxybenzenesulfonamide (<b>40</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.131 g) and 3-hydroxybenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 31%, yellowish solid, mp 122–124 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.41 (br s, 1 H), 10.22 (br s, 1 H), 9.34 (br.s., 1H), 7.80 (d, <i>J</i> = 2.1 Hz, 1 H), 7.49–7.39 (m, 3 H), 7.29–7.23 (m, 2 H), 7.13 (dd, <i>J</i> = 2.1, 8.7 Hz, 1 H), 7.06 (ddd, <i>J</i> = 1.0, 2.4, 8.1 Hz, 1 H), 6.07–6.05 (m, 1 H), 3.09–3.01 (m, 2 H), 3.17–3.10 (m, 2 H), 2.97 (t, <i>J</i> = 6.9 Hz, 2 H), 2.64 (d, <i>J</i> = 5.1 Hz, 2 H), 2.53 (td, <i>J</i> = 1.7, 3.7 Hz, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.2, 141.9, 135.8, 130.7, 129.5, 126.0, 124.9, 124.4, 121.6, 119.8, 119.5, 118.2, 117.4, 116.1, 113.7, 113.5, 57.1, 52.8, 50.3, 32.1, 28.6. LC-MS (ESI) calcd for C<sub>21</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>3</sub>S 432,11 [M + H<sup>+</sup>], found 432.25 [M + H<sup>+</sup>].</div></div><div id="sec4_5_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> <i>N</i>-(3-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)-3-hydroxybenzenesulfonamide (<b>41</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.138 g) and 3-hydroxybenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 30%, yellowish solid, mp 141–143 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.63 (d, <i>J</i> = 2.3 Hz, 1 H), 10.28 (br s, 1 H), 9.53 (br s, 1 H), 7.84 (d, <i>J</i> = 2.1 Hz, 1 H), 7.59 (d, <i>J</i> = 2.6 Hz, 1 H), 7.48–7.35 (m, 2 H), 7.26–7.19 (m, 2 H), 7.16–7.01 (m, 2 H), 6.10–6.07 (m, 1 H), 3.79–3.75 (m, 2 H), 3.54–3.41 (m, 2 H), 3.15–3.05 (m, 2 H), 2.81 (d, <i>J</i> = 15.1 Hz, 4 H), 1.97–1.83 (m, 2 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.3, 141.6, 135.9, 130.8, 129.7, 126.1, 125.7, 124.9, 122.0, 120.0, 119.5, 117.4, 116.7, 114.5, 114.0, 113.6, 53.2, 50.2, 49.0, 48.8, 25.2, 24.5. LC-MS (ESI) calcd C<sub>22</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>3</sub>S for 446.12 [M + H<sup>+</sup>] found 446.36 [M + H<sup>+</sup>].</div></div><div id="sec4_5_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>N</i>-(4-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)-3-hydroxybenzenesulfonamide (<b>42</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and 3-hydroxybenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 19%, yellowish solid, mp 99–102 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.33 (br s, 1 H), 10.10 (s, 1 H), 7.77 (d, <i>J</i> = 1.8 Hz, 1 H), 7.64–7.54 (m, 1 H), 7.46 (d, <i>J</i> = 2.6 Hz, 1 H), 7.41–7.31 (m, 2 H), 7.21–7.13 (m, 2 H), 7.09 (dd, <i>J</i> = 2.1, 8.5 Hz, 1 H), 6.98 (ddd, <i>J</i> = 0.9, 2.5, 8.1 Hz, 1 H), 6.04 (br s, 1 H), 3.16 (br s, 2 H), 2.80–2.61 (m, 4 H), 2.50 (br s, 2 H), 2.42 (br s, 2 H), 1.53–1.34 (m, 4 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.6, 158.2, 142.1, 135.8, 130.7, 129.6, 126.0, 125.1, 124.5, 121.7, 119.7, 119.5, 117.4, 115.9, 113.7, 113.5, 57.2, 55.3, 52.6, 50.1, 42.9, 27.3, 23.6. LC-MS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>3</sub>S 460.15 [M + H<sup>+</sup>], found 460.32 [M + H<sup>+</sup>].</div></div><div id="sec4_5_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <i>N</i>-(2-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)-4-fluorobenzenesulfonamide (<b>43</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.131 g) and 4-fluorobenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.09 g). Yield 72%, yellowish solid, mp 117–120 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.30 (br s, 1 H), 7.88 (dd, <i>J</i> = 5.3, 8.6 Hz, 2 H), 7.74 (s, 1 H), 7.64 (br s, 1 H), 7.48–7.30 (m, 4 H), 7.08 (d, <i>J</i> = 6.9 Hz, 1 H), 6.00 (br s, 1 H), 3.02 (br s, 2 H), 2.92 (t, <i>J</i> = 6.5 Hz, 2 H), 2.53 (d, <i>J</i> = 5.1 Hz, 2 H), 2.46–2.37 (m, 4 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 137.5, 135.8, 130.0, 129.5, 126.1, 124.9, 124.4, 121.6, 119.5, 118.5, 116.8, 116.5, 116.2, 113.7, 57.3, 52.9, 50.4, 28.8. LC-MS (ESI) calcd for C<sub>21</sub>H<sub>21</sub>ClFN<sub>3</sub>O<sub>2</sub>S 434.11 [M + H<sup>+</sup>], found 434.33 [M +H<sup>+</sup>].</div></div><div id="sec4_5_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>N</i>-(3-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)-4-fluorobenzenesulfonamide (<b>44</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.138 g) and naphthalene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 48%, yellowish solid, mp 127–128 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.55 (br s, 1 H), 10.25 (br s, 1 H), 7.92–7.79 (m, 3 H), 7.61 (d, <i>J</i> = 2.3 Hz, 1 H), 7.50–7.35 (m, 3 H), 7.20–7.08 (m, 1 H), 6.14–6.05 (m, 1 H), 4.04–3.90 (m, 1 H), 3.78–3.64 (m, 1 H), 3.58 (m, 2 H), 3.21–3.09 (m, 2 H), 2.83 (d, <i>J</i> = 6.2 Hz, 4 H), 1.93–1.81 (m, 1 H), 1.74 (m, 1 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 138.2, 137.0, 135.7, 130.1, 129.9, 129.6, 126.2, 125.7, 124.9, 122.1, 119.4, 117.1, 116.7, 114.4, 114.0, 112.5, 66.9, 53.7, 50.3, 25.5, 23.5. LC-MS (ESI) calcd for C<sub>22</sub>H<sub>23</sub>ClFN<sub>3</sub>O<sub>2</sub>S 448.12 [M + H<sup>+</sup>], found 448.35 [M + H<sup>+</sup>].</div></div><div id="sec4_5_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> <i>N</i>-(4-(4-(5-Chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)-4-fluorobenzenesulfonamide (<b>45</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.145 g) and 4-fluorobenzene-1-sulfonyl chloride (0.541 mmol, 1 equiv, 0.09 g). Yield 38%, yellowish solid, mp 129–132 °C. <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.78–8.57 (m, 1 H), 7.96 (d, <i>J</i> = 7.4 Hz, 1 H), 7.91–7.82 (m, 3 H), 7.49–7.42 (m, 2 H), 7.22 (t, <i>J</i> = 8.8 Hz, 2 H), 7.12 (dd, <i>J</i> = 1.9, 8.6 Hz, 1 H), 6.15 (br s, 1 H), 3.13 (d, <i>J</i> = 3.3 Hz, 2 H), 2.93 (t, <i>J</i> = 6.3 Hz, 2 H), 2.71–2.65 (m, 2 H), 2.63–2.58 (m, 2 H), 2.45–2.40 (m, 2 H), 1.59 (td, <i>J</i> = 3.2, 5.9 Hz, 4 H). <sup>13</sup>C NMR (75 MHz, acetone-<i>d</i><sub>6</sub>): δ 137.6, 137.6, 135.7, 129.8, 129.7, 129.7, 126.2, 124.8, 123.9, 121.5, 119.5, 118.3, 116.5, 116.0, 115.7, 113.0, 57.7, 52.5, 50.4, 42.9, 31.7, 24.3, 22.4. LC-MS (ESI) calcd for C<sub>23</sub>H<sub>25</sub>ClFN<sub>3</sub>O<sub>2</sub>S 462.14 [M + H<sup>+</sup>], found 462.38 [M + H<sup>+</sup>].</div></div><div id="sec4_5_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 4-Chloro-<i>N</i>-(2-(4-(5-chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)ethyl)benzenesulfonamide (<b>46</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.131 g) and 3-chlorobenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.105 g). Yield 47%, yellowish solid, mp 122–125 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.30 (br s, 1 H), 7.82 (d, <i>J</i> = 8.7 Hz, 2 H), 7.74 (d, <i>J</i> = 2.1 Hz, 1 H), 7.64 (d, <i>J</i> = 8.7 Hz, 3 H), 7.44–7.34 (m, 2 H), 7.08 (dd, <i>J</i> = 2.1, 8.5 Hz, 1 H), 6.00 (br s, 1 H), 3.02 (d, <i>J</i> = 2.3 Hz, 2 H), 2.93 (t, <i>J</i> = 6.7 Hz, 2 H), 2.58–2.50 (m, 2 H), 2.42 (t, <i>J</i> = 6.5 Hz, 4 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 140.1, 137.6, 135.8, 129.7, 129.5, 128.9, 126.1, 124.9, 124.4, 121.6, 119.5, 118.5, 116.2, 113.7, 57.3, 52.9, 50.4, 28.8. LC-MS (ESI) calcd for C<sub>21</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S 450.08 [M + H<sup>+</sup>], found 450.28 [M + H<sup>+</sup>].</div></div><div id="sec4_5_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 4-Chloro-<i>N</i>-(3-(4-(5-chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)propyl)benzenesulfonamide (<b>47</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate amine (0.5 mmol, 1 equiv, 0.138 g) and naphthalene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 48%, yellowish solid, mp 142–144 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.55 (br s, 1 H), 10.25 (br s, 1 H), 7.92–7.79 (m, 3 H), 7.61 (d, <i>J</i> = 2.3 Hz, 1 H), 7.50–7.35 (m, 3 H), 7.20–7.08 (m, 1 H), 6.14–6.05 (m, 1 H), 4.04–3.90 (m, 1 H), 3.78–3.64 (m, 1 H), 3.58 (m, 2 H), 3.21–3.09 (m, 2 H), 2.83 (d, <i>J</i> = 6.2 Hz, 4 H), 1.93–1.81 (m, 1 H), 1.74 (m, 1 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 138.2, 137.0, 135.7, 130.1, 129.9, 129.6, 126.2, 125.7, 124.9, 122.1, 119.4, 117.1, 116.7, 114.4, 114.0, 112.5, 66.9, 53.7, 50.3, 25.5, 23.5. LC-MS (ESI) calcd for C<sub>22</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S 464.09 [M + H<sup>+</sup>], found 464.31 [M + H<sup>+</sup>].</div></div><div id="sec4_5_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 4-Chloro-<i>N</i>-(4-(4-(5-chloro-1<i>H</i>-indol-3-yl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)butyl)benzenesulfonamide (<b>48</b>)</h5><div class="NLM_p last">The title compound was prepared starting from intermediate (0.5 mmol, 1 equiv, 0.145 g) and 4-chlorobenzene-1-sulfonyl chloride (0.5 mmol, 1 equiv, 0.113 g). Yield 40%, yellowish solid, mp 195–196 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.33 (br s, 1 H), 7.89–7.71 (m, 4 H), 7.62 (d, <i>J</i> = 8.7 Hz, 2 H), 7.47–7.34 (m, 2 H), 7.09 (dd, <i>J</i> = 1.9, 8.6 Hz, 1 H), 6.04 (br s, 1 H), 3.01 (br s, 2 H), 2.77 (d, <i>J</i> = 3.1 Hz, 2 H), 2.58–2.50 (m, 2 H), 2.45 (br s, 2 H), 2.28 (br s, 2 H), 1.40 (br s, 4 H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 140.0, 137.5, 135.8, 129.7, 129.7, 129.5, 128.8, 128.8, 126.1, 124.9, 124.4, 121.6, 119.6, 118.6, 116.2, 113.7, 57.7, 53.0, 50.4, 43.0, 28.9, 27.5, 24.1. LC-MS (ESI) calcd for C<sub>23</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S 478.11 [M + H<sup>+</sup>], found 478.33 [M + H<sup>+</sup>].</div></div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> In Vitro Studies</h3><div class="NLM_p last">The tested compounds were examined for known classes of assay interference compounds. According to SwissADME tool,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> none of the compounds contain substructural features recognized as pan assay interference compounds (PAINS).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Radioligand Binding Assays for D<sub>2</sub>R, 5-HT<sub>6</sub>R, 5-HT<sub>7</sub>R, 5-HT<sub>1A</sub>R, M<sub>1</sub>R, and SERT</h3><div class="NLM_p">The radioligand binding assays for D<sub>2</sub>R, 5-HT<sub>6</sub>R, 5-HT<sub>7</sub>R, 5-HT<sub>1A</sub>R, and SERT were carried out at the Faculty of Pharmacy, Jagiellonian University Medical College. The remaining in vitro studies (binding to M<sub>1</sub>R and functional activity assays) were performed by Cerep SA (Le Bois l’Evêque, Poitiers, France). Inhibition of hERG was tested by ChanTest (USA).</div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Preparation of Solutions of Test and Reference Compounds</h4><div class="NLM_p last">One mM stock solutions of tested compounds were prepared in DMSO. Serial dilutions of compounds were prepared in 96-well microplate in assay buffers using automated pipetting system epMotion 5070 (Eppendorf). Each compound was tested in 10 concentrations from 1.0 × 10<sup>–6</sup> to 1.0 × 10<sup>–11</sup> M (final concentration).</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 5-HT<sub>1A</sub> Receptor Binding Assay</h4><div class="NLM_p last">Radioligand binding was performed using membranes from CHO-K1 cells stably transfected with the human 5-HT<sub>1A</sub> receptor (PerkinElmer). All assays were carried out in duplicates. First, 50 μL working solutions of the tested compounds, 50 μL of [3H]-8-OH-DPAT (final concentration 1 nM), and 150 μL of diluted membranes (10 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 10 mM MgSO<sub>4</sub>, 0,5 mM EDTA, 0.1% ascorbic acid) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Serotonin (10 μM) was used to define nonspecific binding. Microplate was covered with a sealing tape, mixed, and incubated for 60 min at 27 °C. The reaction was terminated by rapid filtration through a GF/C filter mate presoaked with 0.3% polyethylenimine for 30 min. Ten rapid washes with 200 μL of 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator, and then solid scintillator MeltiLex was melted on filter mates at 90 °C for 4 min. Radioactivity was counted in MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 5-HT<sub>2A</sub> Receptor Binding Assay</h4><div class="NLM_p last">Radioligand binding was performed using membranes from CHO-K1 cells stably transfected with the human 5-HT<sub>2A</sub> receptor (PerkinElmer). All assays were carried out in duplicates. First, 50 μL of working solution of the tested compounds, 50 μL of [3H]-ketanserin (final concentration 1 nM), and 150 μL of diluted membranes (7 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 4 mM CaCl<sub>2</sub>, 0.1% ascorbic acid) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Mianserin (10 μM) was used to define nonspecific binding. Microplate was covered with a sealing tape, mixed, and incubated for 60 min at 27 °C. The reaction was terminated by rapid filtration through a GF/B filter mate presoaked with 0.5% polyethylenimine for 30 min. Ten rapid washes with 200 μL of 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator, and then solid scintillator MeltiLex was melted on filter mates at 90 °C for 5 min. Radioactivity was counted in MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 5-HT<sub>6</sub> Receptor Binding Assay</h4><div class="NLM_p last">Radioligand binding was performed using membranes from CHO-K1 cells stably transfected with the human 5-HT<sub>6</sub> receptor (PerkinElmer). All assays were carried out in duplicates. First, 50 μL of working solution of the tested compounds, 50 μL of [3H]-LSD (final concentration 1 nM), and 150 μL of diluted membranes (8 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 10 mM MgCl<sub>2</sub>, 0.1 mM EDTA) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Methiothepin (10 μM) was used to define nonspecific binding. Microplate was covered with a sealing tape, mixed, and incubated for 60 min at 37 °C. The reaction was terminated by rapid filtration through a GF/A filter mate presoaked with 0.5% polyethylenimine for 30 min. Ten rapid washes with 200 μL of 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator, and then solid scintillator MeltiLex was melted on filter mates at 90 °C for 5 min. Radioactivity was counted in MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 5-HT<sub>7</sub> Receptor Binding Assay</h4><div class="NLM_p last">Radioligand binding was performed using membranes from CHO-K1 cells stably transfected with the human 5-HT<sub>7</sub> receptor (PerkinElmer). All assays were carried out in duplicates. First, 50 μL of working solution of the tested compounds, 50 μL of [3H]-LSD (final concentration 3 nM), and 150 μL of diluted membranes (17 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 10 mM MgSO<sub>4</sub>, 0.5 mM EDTA) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Methiothepin (10 μM) was used to define nonspecific binding. Microplate was covered with a sealing tape, mixed, and incubated for 120 min at 27 °C. The reaction was terminated by rapid filtration through GF/A filter mate presoaked with 0.3% polyethylenimine for 30 min. Ten rapid washes with 200 μL of 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator, and then solid scintillator MeltiLex was melted on filter mates at 90 °C for 5 min. Radioactivity was counted in MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> SERT Binding Assay</h4><div class="NLM_p last">Radioligand binding was performed using membranes from HEK-293 cells stably transfected with the human serotonin transporter (PerkinElmer). All assays were carried out in duplicates. First, 50 μL of working solution of the tested compounds, 50 μL of [3H]-imipramine (final concentration 2 nM), and 150 μL of diluted membranes (9 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 120 mM NaCl, 5 mM KCl) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Imipramine (10 μM) was used to define nonspecific binding. Microplate was covered with a sealing tape, mixed, and incubated for 30 min at 27 °C. The reaction was terminated by rapid filtration through a GF/A filter mate presoaked with 0.5% polyethylenimine for 30 min. Ten rapid washes with 200 μL 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator,, and then solid scintillator MeltiLex was melted on filter mates at 90 °C for 5 min. Radioactivity was counted in MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> D<sub>2</sub> Receptor Binding Assay</h3><div class="NLM_p last">Radioligand binding was performed using membranes from CHO-K1 cells stably transfected with the human D<sub>2</sub> receptor (PerkinElmer). All assays were carried out in duplicates. First, 50 μL of working solution of the tested compounds, 50 μL of [3H]-methylspiperone (final concentration 0.4 nM), and 150 μL of diluted membranes (3 μg protein per well) prepared in assay buffer (50 mM Tris, pH 7.4, 50 mM HEPES, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.5 mM EDTA) were transferred to a polypropylene 96-well microplate using a 96-well pipetting station Rainin Liquidator (MettlerToledo). Haloperidol (10 μM) was used to define nonspecific binding. Microplate was covered with a sealing tape, mixed, and incubated for 60 min at 37 °C. The reaction was terminated by rapid filtration through a GF/B filter mate presoaked with 0.5% polyethylenimine for 30 min. Ten rapid washes with 200 μL of 50 mM Tris buffer (4 °C, pH 7.4) were performed using an automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were dried at 37 °C in a forced air fan incubator, and then solid scintillator MeltiLex was melted on filter mates at 90 °C for 5 min. Radioactivity was counted in MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a one-site curve-fitting equation with Prism 6 (GraphPad Software), and <i>K</i><sub>i</sub> values were estimated from the Cheng–Prusoff equation.</div></div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> M<sub>1</sub> Receptor Binding Assay</h3><div class="NLM_p">Binding affinity for human recombinant M<sub>1</sub> receptor was tested using CHO cells and [3H]pyrilamine radioligand at concentration of 2 nM (<i>K</i><sub>d</sub> 13 nM). Atropine (1 μM) was used to assess nonspecific binding. Incubation time was 60 min at room temperature and the signal level was detected by scintillation counting.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The experiment was performed in duplicate in tested ligand concentration 1.0 × 10<sup>–6</sup> M.</div><div class="NLM_p last">All the radioligand binding assays shown in <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> were performed in three independent experiments in duplicate (<i>n</i> = 2).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Functional Activity Assays for D<sub>2</sub>R, 5-HT<sub>6</sub>R, 5-HT<sub>7</sub>R, 5-HT<sub>1A</sub>R, and 5-HT Uptake</h3><div class="NLM_p">EC<sub>50</sub>, IC<sub>50</sub>, and <i>K</i><sub>B</sub> values were determined from six concentrations (1.0 × 10<sup>–6</sup> to 1.0 × 10<sup>–10</sup> M). Screening assays from <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> were performed in duplicate at concentration 1.0 × 10<sup>–6</sup> M. The results are expressed as a percent of control specific agonist response ((measured specific response/control specific agonist response) × 100) and as a percent inhibition of control specific agonist response (100 – ((measured specific response/control specific agonist response) × 100)) obtained in the presence of the test compounds for agonist and antagonist effect, respectively. An outline of methodologies and references for further methodological details are shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Outline of Methods Used in Functional Activity Assays</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">source</th><th class="colsep0 rowsep0" align="center">substrate/stimulus</th><th class="colsep0 rowsep0" align="center">incubation</th><th class="colsep0 rowsep0" align="center">measured component</th><th class="colsep0 rowsep0" align="center">detection method</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2</sub>S agonist effect<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></td><td class="colsep0 rowsep0" align="left">human recombinant (HEK-293 cells)</td><td class="colsep0 rowsep0" align="left">none (3 μM DA for control)</td><td class="colsep0 rowsep0" align="left">28 °C</td><td class="colsep0 rowsep0" align="left">impedance</td><td class="colsep0 rowsep0" align="left">cellular dielectric spectroscopy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2</sub>S antagonist effect<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></td><td class="colsep0 rowsep0" align="left">human recombinant (HEK-293 cells)</td><td class="colsep0 rowsep0" align="left">DA (30 nM)</td><td class="colsep0 rowsep0" align="left">28 °C</td><td class="colsep0 rowsep0" align="left">impedance</td><td class="colsep0 rowsep0" align="left">cellular dielectric spectroscopy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>6</sub> agonist effect<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></td><td class="colsep0 rowsep0" align="left">human recombinant (CHO cells)</td><td class="colsep0 rowsep0" align="left">none (10 μM 5-HT for control)</td><td class="colsep0 rowsep0" align="left">45 min 37 °C</td><td class="colsep0 rowsep0" align="left">cAMP</td><td class="colsep0 rowsep0" align="left">HTRF</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>6</sub> antagonist effect<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></td><td class="colsep0 rowsep0" align="left">human recombinant (CHO cells)</td><td class="colsep0 rowsep0" align="left">5-HT (300 nM)</td><td class="colsep0 rowsep0" align="left">30 min 37 °C</td><td class="colsep0 rowsep0" align="left">cAMP</td><td class="colsep0 rowsep0" align="left">HTRF</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>7</sub> agonist effect<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></td><td class="colsep0 rowsep0" align="left">human recombinant (CHO cells)</td><td class="colsep0 rowsep0" align="left">none (10 μM 5-HT for control)</td><td class="colsep0 rowsep0" align="left">30 min 37 °C</td><td class="colsep0 rowsep0" align="left">cAMP</td><td class="colsep0 rowsep0" align="left">HTRF</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>7</sub> antagonist effect<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></td><td class="colsep0 rowsep0" align="left">human recombinant (CHO cells)</td><td class="colsep0 rowsep0" align="left">5-HT (300 nM)</td><td class="colsep0 rowsep0" align="left">30 min 37 °C</td><td class="colsep0 rowsep0" align="left">cAMP</td><td class="colsep0 rowsep0" align="left">HTRF</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub> agonist effect<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></td><td class="colsep0 rowsep0" align="left">human recombinant (HEK-293 cells)</td><td class="colsep0 rowsep0" align="left">none (10 μM 8-OH-DPAT for control)</td><td class="colsep0 rowsep0" align="left">37 °C</td><td class="colsep0 rowsep0" align="left">impedance</td><td class="colsep0 rowsep0" align="left">cellular dielectric spectroscopy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub> antagonist effect<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></td><td class="colsep0 rowsep0" align="left">human recombinant (HEK-293 cells)</td><td class="colsep0 rowsep0" align="left">8-OH-DPAT (100 nM)</td><td class="colsep0 rowsep0" align="left">37 °C</td><td class="colsep0 rowsep0" align="left">impedance</td><td class="colsep0 rowsep0" align="left">cellular dielectric spectroscopy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT uptake<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></td><td class="colsep0 rowsep0" align="left">rat brain synaptosomes</td><td class="colsep0 rowsep0" align="left">[3H]5-HT (0.2 μCi/mL)</td><td class="colsep0 rowsep0" align="left">15 min 37 °C</td><td class="colsep0 rowsep0" align="left">[3H]5-HT incorporation into synaptosomes</td><td class="colsep0 rowsep0" align="left">scintillation counting</td></tr></tbody></table></div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Inhibition of hERG Potassium Channel</h3><div class="NLM_p last">Blockade of hERG-mediated potassium currents was carried out by ChanTest (Cleveland, Ohio) and expressed as mean % of inhibition at 1.0 × 10<sup>–6</sup> M (experiment performed in duplicate, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) or IC<sub>50</sub> value determined from six concentrations (1.0 × 10<sup>–6</sup> to 1.0 × 10<sup>–10</sup> M), performed in three experiments in duplicate. Ability to block hERG potassium channels was determined using the electrophysiological method and cloned hERG potassium channels (KCNH2 gene, expressed in CHO cells) as biological material. The effects were evaluated using IonWorks Quattro system (Molecular Devices Corporation, Union City CA). hERG current was elicited using a pulse pattern with fixed amplitudes (conditioning prepulse, −80 mV for 25 ms; test pulse, +40 mV for 80 ms) from a holding potential of 0 mV. hERG current was measured as a difference between the peak current at 1 ms after the test step to +40 mV and the steady-state current at the end of the step to +40 mV. Data acquisition and analyses was performed using the IonWorks QuattroTM system operation software (version 2.0.2; Molecular Devices Corporation, Union City, CA). Data were corrected for leak current. The hERG block was calculated as % Block = (1 – I TA/IControl) × 100%, where IControl and ITA are the currents elicited by the test pulse in control and in the presence of a test compound, respectively. hERG inhibition of reference E-4031 in this assay was determined, EC<sub>50</sub> = 89 nM.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> In Vivo Pharmacological Studies</h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Substances</h4><div class="NLM_p last">Compound <b>16</b>, aripiprazole, and diazepam were prepared as a suspension in 1% aqueous solution of Tween 80, while MK-801, citalopram, imipramine, and scopolamine were dissolved in distilled water. An injection volume 10 mL/kg of all compounds was administered intraperitoneally (ip) for 30 min (for compound <b>4</b>, aripiprazole, citalopram, imipramine, and scopolamine), 60 min (for diazepam), and 15 min (for MK-801) before appropriate experiment. All drugs, except for scopolamine (Sigma-Aldrich, Germany), imipramine (Sigma-Aldrich, UK), and MK-801 (Sigma-Aldrich, UK), were synthesized by Adamed Ltd. (Pieńków, Poland).</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Animals</h4><div class="NLM_p last">Swiss albino mice weighing 21–22 g upon arrival from a licensed breeder (Staniszewska; Ilkowice, Poland) or CD-1 mice from the animal facility localized at Medical College of Jagiellonian University were group-housed for a 3–4 day period in polycarbonate Makrolon type 3 cages (dimensions 26.5 cm × 15 cm × 42 cm) in an environmentally controlled, experimental room (ambient temperature 22 ± 2 °C; relative humidity 50–60%; 12:12 light:dark cycle, lights on at 8:00), in groups of 15. Standard laboratory food (Ssniff M-Z) and filtered water were freely available. On the day before experiments, equipment producing “white noise” was turned on for 30 min and mice were weighted exact to 1 g. Animals were assigned randomly to treatment groups. All the experiments were performed by two observers unaware of the treatment applied between 9:00 and 14:00 on separate groups of animals. All animals were used only once and were killed immediately after the experiment. All the experimental procedures were approved by the IV Local Ethics Commission in Warszawa.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Forced Swim Test in Swiss Albino Mice</h4><div class="NLM_p last">The experiment was carried out according to the method of Porsolt et al.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Briefly, mice were individually placed in a glass cylinder (25 cm high; 10 cm in diameter) containing 6 cm of water maintained at 23–25 °C and were left there for 6 min. A mouse was regarded as immobile when it remained floating on the water, making only small movements to keep its head above it. The total duration of immobility was recorded during the last 4 min of a 6 min test session. Drugs were administered to nine mice per treatment group.</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Four-Plate Test in Swiss Albino Mice</h4><div class="NLM_p last">The four-plate apparatus (BIOSEB, France) consisted of a cage (25 cm × 18 cm × 16 cm) floored by four identical rectangular metal plates (8 cm × 11 cm) separated from one another by a gap of 4 mm. The top of the cage was covered by a transparent Perspex lid that prevents escape behavior. The plates were connected to a device that can generate electric shocks. Following a 15 s habituation period, the animal’s motivation to explore a novel environment was suppressed by an electric foot shock (0.8 mA, 0.5 s) every time it moved from one plate to another during a 1 min test session.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> This action is referred to as a “punished crossing”, and was followed by a 3 s shock interval, during which the animal could move across plates without receiving a shock. Drugs were administered to 10 mice per treatment group.</div></div><div id="sec4_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Spontaneous Locomotor Activity in Swiss Albino Mice</h4><div class="NLM_p last">The locomotor activity was recorded with an Opto M3 multichannel activity monitor (MultiDevice Software v.1.3, Columbus Instruments). Swiss mice were individually placed in plastic cages (22 cm × 12 cm × 13 cm) for a 30 min habituation period, and then the crossings of each channel (ambulation) were counted from 2 to 6 min with data recording every 2 min (i.e., the time equal to the observation period in the forced swim test) or during the first 5 min with data recording every 1 min (i.e., the time equal to the observation period in the four-plate test). The cages were cleaned up with 70% ethanol after each mouse. Drugs were administered to 6 or 10 mice per treatment group. The influence of effective doses only recorded in the forced swim and the four-plate tests was studied in spontaneous locomotor activity in order to exclude the possibility of competing behaviors such as general locomotor activity.</div></div><div id="sec4_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Catalepsy (Bar Test) in CD-1 Mice</h4><div class="NLM_p last">Compounds were administered to 10 mice per treatment group. Animal’s forelimbs were draped over a thin, cylindrical horizontal rod elevated 4 cm above the tabletop at 30, 60, and 120 min after administration of a test compound. The length of time the animal touched the bar with both front paws was measured up to a preset cutoff time of 60 s. A maximum of three trials was used for each animal. A scoring system used by Ögren et al. was employed.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Results of each trial were scored as follows: 0 for holding the position for <15 s, 1 for holding for 15–29.9 s, 2 for holding for 30–59.9 s, and a maximum score of 3 for staying on the bar for >60 s. The minimum cataleptogenic dose was defined as the lowest dose inducing a mean catalepsy score of >1 at 30, 60, or 120 min post-treatment.</div></div><div id="sec4_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Spontaneous Locomotor Activity in CD-1 Mice</h4><div class="NLM_p last">The locomotor activity was recorded with an Opto M3 multichannel activity monitor (MultiDevice Software v.1.3, Columbus Instruments). The mice were individually placed in plastic cages (22 cm × 12 cm × 13 cm), and then the crossings of each channel (ambulation) were counted during 2 h with data recording every 5 min. The cages were cleaned up with 70% ethanol after each mouse. Drugs were administered to 10 mice per treatment group.</div></div><div id="sec4_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> MK-801-Induced Locomotor Hyperactivity in CD-1 Mice</h4><div class="NLM_p last">The locomotor activity was recorded according to method described above. MK-801 was injected at a dose of 0.2 mg/kg 15 min before the test. Drugs were administered to 10 mice per treatment group.</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Passive Avoidance Task in CD-1 Mice</h3><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Animals</h4><div class="NLM_p last">Adult male mice (stock’s name: CD-1, 18–21 g), purchased from Animal House at the Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland, were used in the experiments. The groups of 15 mice were kept to a plastic cage (60 cm × 38 cm × 20 cm) at a room temperature (22 ± 2 °C), on 12 h light/dark cycles (the lights turned on at 7:00 and off at 19:00). Animals had free access to standard laboratory food and tap water. Behavioral experiments were performed between 09:00 am and 14:00, and each experimental group consisted of 8–10 randomly selected animals. Mice were used only once in each test and then killed by cervical dislocation. All experimental procedures were carried out in accordance with EU Directive 2010/63/EU and approved by the I Local Ethics Committee for Experiments on Animals of the Jagiellonian University in Krakow, Poland (approval no. 103/2016).</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Step-Through Passive Avoidance Task in Mice after Acute Administration</h4><div class="NLM_p last">Step-through passive avoidance task was performed according to the method previously described.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The apparatus for step-through passive avoidance task consisted of two compartments, separated by an automated sliding door (LE872, Bioseb, France). For acquisition session, mice were placed individually in an illuminated white compartment (20 cm × 21 cm × 20 cm, 1000 lx) with the closed door to a smaller dark compartment (7.3 cm × 7.5 cm × 14 cm, 10 lx) equipped with an electric grid floor (stainless steel rods through which an electric footshock is delivered). After 30 s, the door to a smaller compartment was opened. Immediately after the mouse entered the smaller dark compartment, the door closed and the rodent was punished by an inescapable electric foot shock (0.2 mA for 2 s). The mice which did not enter the dark compartment within 50 s were excluded from the study. On the following day (24 h later), the pretrained animals were placed again into the illuminated compartment and observed up to 300 s (retention session). The experimental procedure was similar to acquisition session, but this time mice did not receive the electric shock after the entrance to the smaller dark compartment. Mice which avoided the dark compartment for 300 s were considered to remember the task.</div></div><div id="sec4_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Evaluation of Cognitive-Enhancing Properties in Naïve Mice</h4><div class="NLM_p last">Compound <b>16</b> (0.15–5 mg/kg) and aripiprazole (0.25–2 mg/kg) was injected (ip) 30 min before the acquisition trial. Control groups were administered (ip) with saline.</div></div><div id="sec4_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> The Effect on Scopolamine-Induced Cognitive Dysfunction</h4><div class="NLM_p last">Compound <b>16</b> (0.15–0.625 mg/kg), aripiprazole (0.25–2 mg/kg), and scopolamine (1 mg/kg) were administered (ip) 30 min before the acquisition trial. Control groups received (ip) saline.</div></div><div id="sec4_12_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Data Analysis</h4><div class="NLM_p last">Results are presented as means ± SEM. The comparisons between experimental and control groups were performed by one-way ANOVA followed by Tukey’s test post hoc. A value of <i>p</i> < 0.05 was considered to be significant.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00839">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77336" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77336" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This material is available free of charge on the ACS Publications Web site at The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00839" class="ext-link">10.1021/acs.jmedchem.7b00839</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional ligand binding mode descriptions (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Coordinates for homology model of D<sub>2</sub> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates for homology model of 5-HT<sub>1A</sub> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates for homology model of 5-HT<sub>6</sub> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinates for homology model of 5-HT<sub>7</sub> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_006.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf">jm7b00839_si_001.pdf (931.64 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_002.csv">jm7b00839_si_002.csv (4.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_003.pdb">jm7b00839_si_003.pdb (173.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_004.pdb">jm7b00839_si_004.pdb (163.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_005.pdb">jm7b00839_si_005.pdb (170.99 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_006.pdb">jm7b00839_si_006.pdb (165.42 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00839" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam Bucki</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0451-9814" title="Orcid link">http://orcid.org/0000-0003-0451-9814</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d2b3b6b3bffcb0a7b1b9bb92a7b8fcb7b6a7fca2be"><span class="__cf_email__" data-cfemail="bedfdadfd390dccbddd5d7fecbd490dbdacb90ced2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monika Marcinkowska</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4948-6617" title="Orcid link">http://orcid.org/0000-0002-4948-6617</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joanna Śniecikowska</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Krzysztof Więckowski</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maciej Pawłowski</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monika Głuch-Lutwin</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Gryboś</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agata Siwek</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karolina Pytka</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Magdalena Jastrzębska-Więsek</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Partyka</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Wesołowska</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paweł Mierzejewski</span> - <span class="hlFld-Affiliation affiliation">Institute
of Psychiatry and Neurology, 9 Sobieskiego Street, 02-957 Warsaw, Poland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcin Kołaczkowski</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Jagiellonian University Medical
College, 9 Medyczna Street, 30-688 Kraków, Poland</span>; 
    <span class="hlFld-Affiliation affiliation">Adamed
Ltd., Pieńków
149, 05-152 Czosnów, Poland</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors have contributed and have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): AB has received honoraria from Adamed Ltd. and MK is an employee of Adamed Ltd. The other authors report no conflict of interest and have nothing to disclose.<br /></br></div></li></ul></div><div class="ack" id="ACK-d86e6250-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was financially supported by Adamed Ltd. and The National Centre for Research and Development (NCBR) grant No. KB/88/12655/IT1-C/U/08, and The National Science Centre (NCN) grant No. DEC-2014/15/D/NZ7/01789.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i101" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i101"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i102" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i102"> Abbreviations Used</h2><tr><td class="NLM_term">BPSD</td><td class="NLM_def"><p class="first last">behavioral and psychological symptoms of dementia</p></td></tr><tr><td class="NLM_term">DML</td><td class="NLM_def"><p class="first last">designed multiple ligand</p></td></tr><tr><td class="NLM_term">MED</td><td class="NLM_def"><p class="first last">minimum effective dose</p></td></tr><tr><td class="NLM_term">NPS</td><td class="NLM_def"><p class="first last">neuropsychiatric symptoms</p></td></tr><tr><td class="NLM_term">5-HT<sub>1A</sub>R</td><td class="NLM_def"><p class="first last">5-HT<sub>1A</sub> serotonin receptor</p></td></tr><tr><td class="NLM_term">5-HT<sub>6</sub>R</td><td class="NLM_def"><p class="first last">5-HT<sub>6</sub> serotonin receptor</p></td></tr><tr><td class="NLM_term">5-HT<sub>7</sub>R</td><td class="NLM_def"><p class="first last">5-HT<sub>7</sub> serotonin receptor</p></td></tr><tr><td class="NLM_term">D<sub>2</sub>R</td><td class="NLM_def"><p class="first last">D<sub>2</sub> dopamine receptor</p></td></tr><tr><td class="NLM_term">M<sub>1</sub>R</td><td class="NLM_def"><p class="first last">M<sub>1</sub> muscarinic receptor</p></td></tr><tr><td class="NLM_term">β<sub>2</sub>R</td><td class="NLM_def"><p class="first last">β<sub>2</sub> adrenergic receptor</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 77 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Burns, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iliffe, S.</span><span> </span><span class="NLM_article-title">Dementia</span> <span class="citation_source-journal">BMJ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">b75</span><span class="refDoi"> DOI: 10.1136/bmj.b75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1136%2Fbmj.b75" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2009&pages=b75&author=A.+Burnsauthor=S.+Iliffe&title=Dementia&doi=10.1136%2Fbmj.b75"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1136%2Fbmj.b75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.b75%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DA.%26aulast%3DIliffe%26aufirst%3DS.%26atitle%3DDementia%26jtitle%3DBMJ.%26date%3D2009%26volume%3D338%26spage%3Db75%26doi%3D10.1136%2Fbmj.b75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lyketsos, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrillo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khachaturian, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trzepacz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatniek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cedarbaum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brashear, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. S.</span><span> </span><span class="NLM_article-title">Neuropsychiatric Symptoms in Alzheimer’s Disease</span> <span class="citation_source-journal">Alzheimer's Dementia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">532</span><span class="NLM_x">–</span> <span class="NLM_lpage">539</span><span class="refDoi"> DOI: 10.1016/j.jalz.2011.05.2410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.jalz.2011.05.2410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=21889116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC3MfhtVyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=532-539&author=C.+G.+Lyketsosauthor=M.+C.+Carrilloauthor=J.+M.+Ryanauthor=A.+S.+Khachaturianauthor=P.+Trzepaczauthor=J.+Amatniekauthor=J.+Cedarbaumauthor=R.+Brashearauthor=D.+S.+Miller&title=Neuropsychiatric+Symptoms+in+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.jalz.2011.05.2410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropsychiatric symptoms in Alzheimer's disease</span></div><div class="casAuthors">Lyketsos Constantine G; Carrillo Maria C; Ryan J Michael; Khachaturian Ara S; Trzepacz Paula; Amatniek Joan; Cedarbaum Jesse; Brashear Robert; Miller David S</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia : the journal of the Alzheimer's Association</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">532-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuropsychiatric symptoms (NPS) are core features of Alzheimer's disease and related dementias.  Once thought to emerge primarily in people with late-stage disease, these symptoms are currently known to manifest commonly in very early disease and in prodromal phases, such as mild cognitive impairment.  Despite decades of research, reliable treatments for dementia-associated NPS have not been found, and those that are in widespread use present notable risks for people using these medications.  An Alzheimer's Association Research Roundtable was convened in the spring of 2010 to review what is known about NPS in Alzheimer's disease, to discuss classification and underlying neuropathogenesis and vulnerabilities, and to formulate recommendations for new approaches to tailored therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBeAbCFjqvro2y4bB4mnvYfW6udTcc2eYx196Ve_Rlkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfhtVyisA%253D%253D&md5=02b846f7a3ede8fe5c088c9fb2736362</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2011.05.2410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2011.05.2410%26sid%3Dliteratum%253Aachs%26aulast%3DLyketsos%26aufirst%3DC.%2BG.%26aulast%3DCarrillo%26aufirst%3DM.%2BC.%26aulast%3DRyan%26aufirst%3DJ.%2BM.%26aulast%3DKhachaturian%26aufirst%3DA.%2BS.%26aulast%3DTrzepacz%26aufirst%3DP.%26aulast%3DAmatniek%26aufirst%3DJ.%26aulast%3DCedarbaum%26aufirst%3DJ.%26aulast%3DBrashear%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DD.%2BS.%26atitle%3DNeuropsychiatric%2520Symptoms%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2011%26volume%3D7%26spage%3D532%26epage%3D539%26doi%3D10.1016%2Fj.jalz.2011.05.2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Hersch, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falzgraf, S.</span><span> </span><span class="NLM_article-title">Management of the Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">Clin. Interventions Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">621</span><span class="refDoi"> DOI: 10.2147/CIA.S1698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.2147%2FCIA.S1698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=18225462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FntVajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=611-621&author=E.+C.+Herschauthor=S.+Falzgraf&title=Management+of+the+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.2147%2FCIA.S1698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Management of the behavioral and psychological symptoms of dementia</span></div><div class="casAuthors">Hersch Elizabeth C; Falzgraf Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Clinical interventions in aging</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">611-21</span>
        ISSN:<span class="NLM_cas:issn">1176-9092</span>.
    </div><div class="casAbstract">More than 50% of people with dementia experience behavioral and psychological symptoms of dementia (BPSD).  BPSD are distressing for patients and their caregivers, and are often the reason for placement into residential care.  The development of BPSD is associated with a more rapid rate of cognitive decline, greater impairment in activities of daily living, and diminished quality of life (QOL).  Evaluation of BPSD includes a thorough diagnostic investigation, consideration of the etiology of the dementia, and the exclusion of other causes, such as drug-induced delirium, pain, or infection.  Care of patients with BPSD involves psychosocial treatments for both the patient and family.  BPSD may respond to those environmental and psychosocial interventions, however, drug therapy is often required for more severe presentations.  There are multiple classes of drugs used for BPSD, including antipsychotics, anticonvulsants, antidepressants, anxiolytics, cholinesterase inhibitors and NMDA modulators, but the evidence base for pharmacological management is poor, there is no clear standard of care, and treatment is often based on local pharmacotherapy customs.  Clinicians should discuss the potential risks and benefits of treatment with patients and their surrogate decision makers, and must ensure a balance between side effects and tolerability compared with clinical benefit and QOL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOjfmAvz2C3LmQt-ICR3qNfW6udTcc2eYx196Ve_Rlkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FntVajuw%253D%253D&md5=eebc44e212be9e3449f7aafbd7933eb1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2147%2FCIA.S1698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCIA.S1698%26sid%3Dliteratum%253Aachs%26aulast%3DHersch%26aufirst%3DE.%2BC.%26aulast%3DFalzgraf%26aufirst%3DS.%26atitle%3DManagement%2520of%2520the%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DClin.%2520Interventions%2520Aging%26date%3D2007%26volume%3D2%26spage%3D611%26epage%3D621%26doi%3D10.2147%2FCIA.S1698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Liperoti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsonello, A.</span><span> </span><span class="NLM_article-title">Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.2174/157015908784533860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.2174%2F157015908784533860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19305792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVaktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=117-124&author=R.+Liperotiauthor=C.+Pedoneauthor=A.+Corsonello&title=Antipsychotics+for+the+Treatment+of+Behavioral+and+Psychological+Symptoms+of+Dementia+%28BPSD%29&doi=10.2174%2F157015908784533860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD)</span></div><div class="casAuthors">Liperoti, Rosa; Pedone, Claudio; Corsonello, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Behavioral and psychol. symptoms of dementia (BPSD), i.e. verbal and phys. aggression, agitation, psychotic symptoms (hallucinations and delusions), sleep disturbances, oppositional behavior, and wandering, are a common and potentially severe problem complicating dementia.  Their prevalence is very high and it is estd. that up to 90% of patients with Alzheimer's disease (AD) may present at least one BPSD.  Beside the obvious impact on the quality of life of people with dementia, BPSD are responsible for increased risk of patient institutionalization and increased costs.  Furthermore, they are assocd. with caregivers' stress and depression.  Drugs used include antipsychotics, antidepressants, anticonvulsivants, anxiolytics, cholinesterase inhibitors and N-methyl-D-aspartate receptor modulators.  Among these, the most commonly used are anti-psychotics.  These drugs have been used for many decades, but in the last years new compds. have been marketed with the promise of comparable efficacy but less frequent adverse effects (esp. extra-pyramidal side effects).  Their safety, however, has been challenged by data showing a potential increase in adverse cerebrovascular side effects and mortality.  This review will summarize the pathophysiol. and neuropharmacol. of BPSD, it will describe the characteristics of the anti-psychotics most commonly used focusing on their efficacy and safety in BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAjjq7EOofHrVg90H21EOLACvtfcHk0lhDsnj-uLMpQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVaktLc%253D&md5=701fde11f34cc112cff2ba303853e36d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F157015908784533860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015908784533860%26sid%3Dliteratum%253Aachs%26aulast%3DLiperoti%26aufirst%3DR.%26aulast%3DPedone%26aufirst%3DC.%26aulast%3DCorsonello%26aufirst%3DA.%26atitle%3DAntipsychotics%2520for%2520the%2520Treatment%2520of%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%2520%2528BPSD%2529%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2008%26volume%3D6%26spage%3D117%26epage%3D124%26doi%3D10.2174%2F157015908784533860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Gauthier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodaty, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyketsos, C.</span><span> </span><span class="NLM_article-title">Management of Behavioral Problems in Alzheimer’s Disease</span> <span class="citation_source-journal">Int. Psychogeriatr. IPA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1017/S1041610209991505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1017%2FS1041610209991505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=20096151" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=346-372&author=S.+Gauthierauthor=J.+Cummingsauthor=C.+Ballardauthor=H.+Brodatyauthor=G.+Grossbergauthor=P.+Robertauthor=C.+Lyketsos&title=Management+of+Behavioral+Problems+in+Alzheimer%E2%80%99s+Disease&doi=10.1017%2FS1041610209991505"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1017%2FS1041610209991505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1041610209991505%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DCummings%26aufirst%3DJ.%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DBrodaty%26aufirst%3DH.%26aulast%3DGrossberg%26aufirst%3DG.%26aulast%3DRobert%26aufirst%3DP.%26aulast%3DLyketsos%26aufirst%3DC.%26atitle%3DManagement%2520of%2520Behavioral%2520Problems%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DInt.%2520Psychogeriatr.%2520IPA%26date%3D2010%26volume%3D22%26spage%3D346%26epage%3D372%26doi%3D10.1017%2FS1041610209991505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Azermai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elseviers, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourgeois, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Bortel, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Stichele, R. H.</span><span> </span><span class="NLM_article-title">Systematic Appraisal of Dementia Guidelines for the Management of Behavioural and Psychological Symptoms</span> <span class="citation_source-journal">Ageing Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1016/j.arr.2011.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.arr.2011.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=21856452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FnvFOksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=78-86&author=M.+Azermaiauthor=M.+Petrovicauthor=M.+M.+Elseviersauthor=J.+Bourgeoisauthor=L.+M.+Van+Bortelauthor=R.+H.+Vander+Stichele&title=Systematic+Appraisal+of+Dementia+Guidelines+for+the+Management+of+Behavioural+and+Psychological+Symptoms&doi=10.1016%2Fj.arr.2011.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms</span></div><div class="casAuthors">Azermai Majda; Petrovic Mirko; Elseviers Monique M; Bourgeois Jolyce; Van Bortel Luc M; Vander Stichele Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Ageing research reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Within the treatment of dementia, management of behavioural and psychological symptoms (BPSD) is a complex component.  PURPOSE:  We wanted to offer a pragmatic synthesis of existing specific practice recommendations for managing BPSD, based on agreement among systematically appraised dementia guidelines.  DATA SOURCES:  We conducted a systematic search in MEDLINE and guideline organisation databases, supplemented by a hand search of web sites.  STUDY SELECTION:  Fifteen retrieved guidelines were eligible for quality appraisal by the Appraisal of Guidelines Research and Evaluation instrument (AGREE), performed by 2 independent reviewers.  DATA EXTRACTION:  From the 5 included guidelines, 18 specific practice recommendations for BPSD were extracted and compared for their level of evidence and strength.  DATA SYNTHESIS:  No agreement was found among dementia guidelines for the majority of specific practice recommendations with regard to non-pharmacological interventions, although these were recommended as first-line treatment.  Pharmacological specific practice recommendations were proposed as second-line treatment, with agreement for the use of a selection of antipsychotics based on strong supporting evidence, but with guidance for timely discontinuation.  LIMITATIONS:  The appraisal of the level of agreement between guidelines for each specific practice recommendation was complicated by variation in grading systems, and was performed with criteria developed a posteriori.  CONCLUSION:  Despite the limited number of recommendations for which agreement was found, guidelines did agree on careful antipsychotic use for BPSD.  Adverse events might outweigh the supporting evidence of efficacy, weakening the recommendation.  More pivotal trials on the effectiveness of non-pharmacological interventions, as well as guidelines specifically focusing on BPSD, are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMim0DpBc7QOkdrW1FkXG-fW6udTcc2eajAtZxXjuX6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FnvFOksA%253D%253D&md5=acf815e7cdc17f72869dfeb3f897e036</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.arr.2011.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.arr.2011.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DAzermai%26aufirst%3DM.%26aulast%3DPetrovic%26aufirst%3DM.%26aulast%3DElseviers%26aufirst%3DM.%2BM.%26aulast%3DBourgeois%26aufirst%3DJ.%26aulast%3DVan%2BBortel%26aufirst%3DL.%2BM.%26aulast%3DVander%2BStichele%26aufirst%3DR.%2BH.%26atitle%3DSystematic%2520Appraisal%2520of%2520Dementia%2520Guidelines%2520for%2520the%2520Management%2520of%2520Behavioural%2520and%2520Psychological%2520Symptoms%26jtitle%3DAgeing%2520Res.%2520Rev.%26date%3D2012%26volume%3D11%26spage%3D78%26epage%3D86%26doi%3D10.1016%2Fj.arr.2011.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">De Deyn, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirshing, W. C.</span><span> </span><span class="NLM_article-title">Scales to Assess Efficacy and Safety of Pharmacologic Agents in the Treatment of Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 21</span><span class="NLM_x">) </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=11584983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVantrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2001&pages=19-22&issue=Suppl+21&author=P.+P.+De+Deynauthor=W.+C.+Wirshing&title=Scales+to+Assess+Efficacy+and+Safety+of+Pharmacologic+Agents+in+the+Treatment+of+Behavioral+and+Psychological+Symptoms+of+Dementia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia</span></div><div class="casAuthors">De Deyn, Peter Paul; Wirshing, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">Suppl. 21</span>),
    <span class="NLM_cas:pages">19-22</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">A review.  Advances in the assessment of the behavioral and psychol. symptoms of dementia (BPSD) have been employed in large-scale clin. trials of new antipsychotic medications such as risperidone.  These scales can be used to assess drug efficacy and to compare different treatment regimens.  We review 3 valid and reliable scales, the Behavioral Pathol. in Alzheimer's Disease Rating Scale (BEHAVE-AD), the Cohen-Mansfield Agitation Inventory (CMAI), and the Neuropsychiatric Inventory (NPI).  Extrapyramidal side effects (EPS) assocd. with the treatment of BPSD have also been assessed using a no. of rating instruments.  The design of the most comprehensive of these, the Extrapyramidal Symptom Rating Scale (ESRS), is exhaustive, and it successfully quantifies EPS and distinguishes toxic from nontoxic medications.  This publication serves as an aid to researchers and clinicians in their interpretation of qual. and quant. data from trials evaluating antipsychotic agents in the treatment of BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDJ1jbxIe1RLVg90H21EOLACvtfcHk0lhDsnj-uLMpQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVantrw%253D&md5=ecf82edb6928dc3aea6d7b4a392f5048</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BDeyn%26aufirst%3DP.%2BP.%26aulast%3DWirshing%26aufirst%3DW.%2BC.%26atitle%3DScales%2520to%2520Assess%2520Efficacy%2520and%2520Safety%2520of%2520Pharmacologic%2520Agents%2520in%2520the%2520Treatment%2520of%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2001%26volume%3D62%26issue%3DSuppl%252021%26spage%3D19%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ballard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitramohan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aarsland, D.</span><span> </span><span class="NLM_article-title">Management of Agitation and Aggression Associated with Alzheimer’s Disease: Controversies and Possible Solutions</span> <span class="citation_source-journal">Curr. Opin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">532</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span><span class="refDoi"> DOI: 10.1097/YCO.0b013e32833111f9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1097%2FYCO.0b013e32833111f9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19696673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD1Mnot1Ciuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=532-540&author=C.+Ballardauthor=A.+Corbettauthor=R.+Chitramohanauthor=D.+Aarsland&title=Management+of+Agitation+and+Aggression+Associated+with+Alzheimer%E2%80%99s+Disease%3A+Controversies+and+Possible+Solutions&doi=10.1097%2FYCO.0b013e32833111f9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions</span></div><div class="casAuthors">Ballard Clive; Corbett Anne; Chitramohan Ramilgan; Aarsland Das</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">532-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Behavioral and psychological symptoms of dementia (BPSD) are frequent among people with Alzheimer's disease and other dementias, commonly confer risk to the person and others, and present a significant management challenge for clinicians.  The purpose of this review is to describe the current state of knowledge regarding management of BPSD, with a particular focus on agitation.  RECENT FINDINGS:  There is increasing evidence to support the value of simple psychological interventions and staff-training programs as a first-line management strategy for agitation prior to pharmacotherapy.  The most widely prescribed pharmacological treatments - atypical antipsychotics - have a modest but significant beneficial effect in the short-term treatment of aggression (over 6-12 weeks), but limited benefits in longer term therapy.  In addition, there have been increasing concerns regarding the potential for serious adverse outcomes, including stroke and death.  The potential pharmacological alternatives to atypical antipsychotics with the most encouraging preliminary evidence include memantine, carbamazepine and citalopram.  SUMMARY:  Large prospective, randomized, placebo-controlled trials are needed to establish the role of agents other than neuroleptics as clinical therapies for the treatment of BPSD and studies are urgently needed to evaluate BPSD treatments in non-Alzheimer dementias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJsH1WKvRJGcyail4HZd-ifW6udTcc2eYX43KP5TgYkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mnot1Ciuw%253D%253D&md5=fc3187f82f4e46f2575ee88b00fe63fc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2FYCO.0b013e32833111f9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FYCO.0b013e32833111f9%26sid%3Dliteratum%253Aachs%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DCorbett%26aufirst%3DA.%26aulast%3DChitramohan%26aufirst%3DR.%26aulast%3DAarsland%26aufirst%3DD.%26atitle%3DManagement%2520of%2520Agitation%2520and%2520Aggression%2520Associated%2520with%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Controversies%2520and%2520Possible%2520Solutions%26jtitle%3DCurr.%2520Opin.%2520Psychiatry%26date%3D2009%26volume%3D22%26spage%3D532%26epage%3D540%26doi%3D10.1097%2FYCO.0b013e32833111f9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cerejeira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagarto, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukaetova-Ladinska, E. B.</span><span> </span><span class="NLM_article-title">Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">Front. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="refDoi"> DOI: 10.3389/fneur.2012.00073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.3389%2Ffneur.2012.00073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=22586419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC38njt1aitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=73&author=J.+Cerejeiraauthor=L.+Lagartoauthor=E.+B.+Mukaetova-Ladinska&title=Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.3389%2Ffneur.2012.00073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral and psychological symptoms of dementia</span></div><div class="casAuthors">Cerejeira J; Lagarto L; Mukaetova-Ladinska E B</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms, represent a heterogeneous group of non-cognitive symptoms and behaviors occurring in subjects with dementia.  BPSD constitute a major component of the dementia syndrome irrespective of its subtype.  They are as clinically relevant as cognitive symptoms as they strongly correlate with the degree of functional and cognitive impairment.  BPSD include agitation, aberrant motor behavior, anxiety, elation, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite changes.  It is estimated that BPSD affect up to 90% of all dementia subjects over the course of their illness, and is independently associated with poor outcomes, including distress among patients and caregivers, long-term hospitalization, misuse of medication, and increased health care costs.  Although these symptoms can be present individually it is more common that various psychopathological features co-occur simultaneously in the same patient.  Thus, categorization of BPSD in clusters taking into account their natural course, prognosis, and treatment response may be useful in the clinical practice.  The pathogenesis of BPSD has not been clearly delineated but it is probably the result of a complex interplay of psychological, social, and biological factors.  Recent studies have emphasized the role of neurochemical, neuropathological, and genetic factors underlying the clinical manifestations of BPSD.  A high degree of clinical expertise is crucial to appropriately recognize and manage the neuropsychiatric symptoms in a patient with dementia.  Combination of non-pharmacological and careful use of pharmacological interventions is the recommended therapeutic for managing BPSD.  Given the modest efficacy of current strategies, there is an urgent need to identify novel pharmacological targets and develop new non-pharmacological approaches to improve the adverse outcomes associated with BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmgVlZTrvFkTMsgLhIoICsfW6udTcc2eYX43KP5TgYkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38njt1aitg%253D%253D&md5=913c4f4ee720f5d53f065c158780c737</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2012.00073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2012.00073%26sid%3Dliteratum%253Aachs%26aulast%3DCerejeira%26aufirst%3DJ.%26aulast%3DLagarto%26aufirst%3DL.%26aulast%3DMukaetova-Ladinska%26aufirst%3DE.%2BB.%26atitle%3DBehavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DFront.%2520Neurol.%26date%3D2012%26volume%3D3%26spage%3D73%26doi%3D10.3389%2Ffneur.2012.00073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinzi, L.</span><span> </span><span class="NLM_article-title">Computational Polypharmacology Comes of Age</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="refDoi"> DOI: 10.3389/fphar.2015.00157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.3389%2Ffphar.2015.00157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26283966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFals7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=157&author=G.+Rastelliauthor=L.+Pinzi&title=Computational+Polypharmacology+Comes+of+Age&doi=10.3389%2Ffphar.2015.00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Computational polypharmacology comes of age</span></div><div class="casAuthors">Rastelli, Giulio; Pinzi, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157/1-157/4</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  This article describes the predicting drug polypharmacol., the raising no. of computational strategies, frameworks developed at testify that computational polypharmacol. has come of age and increasingly important role in drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiapZ3lz9l4rVg90H21EOLACvtfcHk0lgohrwJ8DatTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFals7zI&md5=4444f48a7d9c80f30a4d9dbf3f6ba2be</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00157%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DPinzi%26aufirst%3DL.%26atitle%3DComputational%2520Polypharmacology%2520Comes%2520of%2520Age%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D157%26doi%3D10.3389%2Ffphar.2015.00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Rodda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, Z.</span><span> </span><span class="NLM_article-title">Are Cholinesterase Inhibitors Effective in the Management of the Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease? A Systematic Review of Randomized, Placebo-Controlled Trials of Donepezil, Rivastigmine and Galantamine</span> <span class="citation_source-journal">Int. Psychogeriatr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1017/S1041610209990354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1017%2FS1041610209990354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19538824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD1MrotFeitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=813-824&author=J.+Roddaauthor=S.+Morganauthor=Z.+Walker&title=Are+Cholinesterase+Inhibitors+Effective+in+the+Management+of+the+Behavioral+and+Psychological+Symptoms+of+Dementia+in+Alzheimer%E2%80%99s+Disease%3F+A+Systematic+Review+of+Randomized%2C+Placebo-Controlled+Trials+of+Donepezil%2C+Rivastigmine+and+Galantamine&doi=10.1017%2FS1041610209990354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine</span></div><div class="casAuthors">Rodda Joanne; Morgan Shirlony; Walker Zuzana</div><div class="citationInfo"><span class="NLM_cas:title">International psychogeriatrics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">813-24</span>
        ISSN:<span class="NLM_cas:issn">1041-6102</span>.
    </div><div class="casAbstract">BACKGROUND:  The study aim was to conduct a systematic review of the evidence from randomized, placebo controlled trials related to the efficacy of donepezil, rivastigmine and galantamine in the treatment of behavioral and psychological symptoms of Alzheimer's disease.  METHODS:  Electronic database searches of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were carried out using multiple search terms.  Articles included were original publications of randomized, placebo-controlled trials of monotherapy of donepezil, rivastigmine or galantamine that reported a behavioral outcome measure.  RESULTS:  14 studies were identified that matched inclusion criteria.  Nine were of donepezil, three of galantamine and two of rivastigmine.  Median study treatment length was 24 weeks (range 12-170).  Most studies used the Neuropsychiatric Inventory as a behavioral outcome measure although three used specific scales for either agitation or apathy.  Four studies were specifically designed to assess behavioral outcomes whilst in the majority of studies behavioral outcomes were only secondary measures.  Three studies found statistically significant, albeit modest, differences in the change of NPI total score between drug and placebo.  The interpretation of the results of many studies is limited by methodological considerations, including generally low NPI scores at baseline and the investigation of behavioral and psychological symptoms of dementia (BPSD) as secondary outcomes.  CONCLUSIONS:  The evidence base regarding the efficacy of cholinesterase inhibitors in BPSD is limited, in part due to methodological considerations.  In the absence of alternative safe and effective management options, the use of cholinesterase inhibitors is an appropriate pharmacological strategy for the management of BPSD in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsQu_Cr4Kxgfx2phytoz6_fW6udTcc2ebpB4-hlz5WqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrotFeitw%253D%253D&md5=5f58607c0f832f1de439f81827d65c87</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1017%2FS1041610209990354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1041610209990354%26sid%3Dliteratum%253Aachs%26aulast%3DRodda%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DZ.%26atitle%3DAre%2520Cholinesterase%2520Inhibitors%2520Effective%2520in%2520the%2520Management%2520of%2520the%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%253F%2520A%2520Systematic%2520Review%2520of%2520Randomized%252C%2520Placebo-Controlled%2520Trials%2520of%2520Donepezil%252C%2520Rivastigmine%2520and%2520Galantamine%26jtitle%3DInt.%2520Psychogeriatr.%26date%3D2009%26volume%3D21%26spage%3D813%26epage%3D824%26doi%3D10.1017%2FS1041610209990354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Holmes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vethanayagam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita-Gunawardena, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damms, J.</span><span> </span><span class="NLM_article-title">The Efficacy of Donepezil in the Treatment of Neuropsychiatric Symptoms in Alzheimer Disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1212/01.WNL.0000129990.32253.7B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1212%2F01.WNL.0000129990.32253.7B" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2004&pages=214-219&author=C.+Holmesauthor=D.+Wilkinsonauthor=C.+Deanauthor=S.+Vethanayagamauthor=S.+Olivieriauthor=A.+Langleyauthor=N.+D.+Pandita-Gunawardenaauthor=F.+Hoggauthor=C.+Clareauthor=J.+Damms&title=The+Efficacy+of+Donepezil+in+the+Treatment+of+Neuropsychiatric+Symptoms+in+Alzheimer+Disease&doi=10.1212%2F01.WNL.0000129990.32253.7B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1212%2F01.WNL.0000129990.32253.7B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252F01.WNL.0000129990.32253.7B%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DC.%26aulast%3DWilkinson%26aufirst%3DD.%26aulast%3DDean%26aufirst%3DC.%26aulast%3DVethanayagam%26aufirst%3DS.%26aulast%3DOlivieri%26aufirst%3DS.%26aulast%3DLangley%26aufirst%3DA.%26aulast%3DPandita-Gunawardena%26aufirst%3DN.%2BD.%26aulast%3DHogg%26aufirst%3DF.%26aulast%3DClare%26aufirst%3DC.%26aulast%3DDamms%26aufirst%3DJ.%26atitle%3DThe%2520Efficacy%2520of%2520Donepezil%2520in%2520the%2520Treatment%2520of%2520Neuropsychiatric%2520Symptoms%2520in%2520Alzheimer%2520Disease%26jtitle%3DNeurology%26date%3D2004%26volume%3D63%26spage%3D214%26epage%3D219%26doi%3D10.1212%2F01.WNL.0000129990.32253.7B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Feldman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vellas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ieni, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwam, E. M.</span><span> </span><span class="NLM_article-title">Donepezil MSAD Study Investigators Group. Efficacy and Safety of Donepezil in Patients with More Severe Alzheimer’s Disease: A Subgroup Analysis from a Randomized, Placebo-Controlled Trial</span> <span class="citation_source-journal">Int. J. Geriatr. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">569</span><span class="refDoi"> DOI: 10.1002/gps.1325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1002%2Fgps.1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=15920715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD2MzivVyqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=559-569&author=H.+Feldmanauthor=S.+Gauthierauthor=J.+Heckerauthor=B.+Vellasauthor=Y.+Xuauthor=J.+R.+Ieniauthor=E.+M.+Schwam&title=Donepezil+MSAD+Study+Investigators+Group.+Efficacy+and+Safety+of+Donepezil+in+Patients+with+More+Severe+Alzheimer%E2%80%99s+Disease%3A+A+Subgroup+Analysis+from+a+Randomized%2C+Placebo-Controlled+Trial&doi=10.1002%2Fgps.1325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial</span></div><div class="casAuthors">Feldman Howard; Gauthier Serge; Hecker Jane; Vellas Bruno; Xu Yikang; Ieni John R; Schwam Elias M</div><div class="citationInfo"><span class="NLM_cas:title">International journal of geriatric psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">559-69</span>
        ISSN:<span class="NLM_cas:issn">0885-6230</span>.
    </div><div class="casAbstract">BACKGROUND:  There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD).  The efficacy and safety of donepezil were evaluated in post hoc analyses of a subgroup of patients with more severe AD (standardized Mini-Mental State Examination [sMMSE] score 5-12) within a randomized, placebo-controlled trial in moderate to severe AD (MSAD study).  Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5-17).  METHODS:  Patients with moderate to severe AD (n = 290) who were living in the community or in assisted living facilities received donepezil or placebo for 24 weeks; n = 145 in the more severe AD subgroup.  The primary outcome measure was the Clinician's Interview-Based Impression of Change (CIBIC-plus) with secondary outcomes including the sMMSE, Severe Impairment Battery, Neuropsychiatric Inventory, and Disability Assessment for Dementia.  Analysis of Variance and Analysis of Covariance models tested for treatment x disease severity interaction in the full MSAD study sample.  RESULTS:  CIBIC-plus scores for donepezil patients were significantly improved compared with placebo for each time-point, with a 0.70 mean treatment difference at Week 24 last observation carried forward (LOCF; p = 0.0002).  Significant differences favoring donepezil were noted at Week 24 LOCF for all secondary measures.  There were no treatment x severity interactions for any of the efficacy measures.  CONCLUSIONS:  In this analysis, donepezil had significant benefits over placebo on global, cognitive, functional, and behavioral measures in a subgroup of patients with more severe AD.  Furthermore, the treatment effects of donepezil were not driven by a particular stratum within the moderate to severe dementia range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFTcbrX9X7Gv_I8Jvzw4xCfW6udTcc2ebpB4-hlz5WqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzivVyqtg%253D%253D&md5=74ab7480521955421b2f80e03b68504d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fgps.1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.1325%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DH.%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DHecker%26aufirst%3DJ.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DIeni%26aufirst%3DJ.%2BR.%26aulast%3DSchwam%26aufirst%3DE.%2BM.%26atitle%3DDonepezil%2520MSAD%2520Study%2520Investigators%2520Group.%2520Efficacy%2520and%2520Safety%2520of%2520Donepezil%2520in%2520Patients%2520with%2520More%2520Severe%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520A%2520Subgroup%2520Analysis%2520from%2520a%2520Randomized%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DInt.%2520J.%2520Geriatr.%2520Psychiatry%26date%3D2005%26volume%3D20%26spage%3D559%26epage%3D569%26doi%3D10.1002%2Fgps.1325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geldenhuys, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span> </span><span class="NLM_article-title">Multifunctional Drugs with Different CNS Targets for Neuropsychiatric Disorders</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1033</span><span class="NLM_x">–</span> <span class="NLM_lpage">1048</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.04141.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1111%2Fj.1471-4159.2006.04141.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=17054441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yks7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=1033-1048&author=C.+J.+Van+der+Schyfauthor=W.+J.+Geldenhuysauthor=M.+B.+H.+Youdim&title=Multifunctional+Drugs+with+Different+CNS+Targets+for+Neuropsychiatric+Disorders&doi=10.1111%2Fj.1471-4159.2006.04141.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional drugs with different CNS targets for neuropsychiatric disorders</span></div><div class="casAuthors">Van der Schyf, Cornelis J.; Geldenhuys, Werner J.; Youdim, Moussa B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1033-1048</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The multiple disease etiologies that lead to neuropsychiatric disorders, such as Parkinson's and Alzheimer's disease, amyotrophic lateral sclerosis, Huntington disease, schizophrenia, depressive illness and stroke, offer significant challenges to drug discovery efforts aimed at preventing or even reversing the progression of these disorders.  Transcriptomic tools and proteomic profiling have clearly indicated that such diseases are multifactorial in origin.  Further, they are thought to be initiated by a cascade of mol. events that involve several neurotransmitter systems.  In response to this complexity, a new paradigm has recently emerged that challenges the widely held assumption that 'silver bullet' agents are superior to 'dirty drugs' in therapeutic approaches aimed at the prevention or treatment of neuropsychiatric diseases.  A similar pattern of drug development has occurred in strategies for the treatment of cancer, AIDS and cardiovascular diseases.  In this review, we offer an overview of therapeutic strategies and novel investigative drugs discovered or developed in our own and other labs., that address multiple CNS etiol. targets assocd. with an array of neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-WgbIJvzwLVg90H21EOLACvtfcHk0lgUOmSX3O1vfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yks7rE&md5=bf77745eb16accd063b0ff8e988dc812</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04141.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04141.x%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26atitle%3DMultifunctional%2520Drugs%2520with%2520Different%2520CNS%2520Targets%2520for%2520Neuropsychiatric%2520Disorders%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D99%26spage%3D1033%26epage%3D1048%26doi%3D10.1111%2Fj.1471-4159.2006.04141.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0ljhq1jWtfKGbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hajjar, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cafiero, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanlon, J. T.</span><span> </span><span class="NLM_article-title">Polypharmacy in Elderly Patients</span> <span class="citation_source-journal">Am. J. Geriatr. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span><span class="refDoi"> DOI: 10.1016/j.amjopharm.2007.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.amjopharm.2007.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=18179993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FhtlChsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=345-351&author=E.+R.+Hajjarauthor=A.+C.+Cafieroauthor=J.+T.+Hanlon&title=Polypharmacy+in+Elderly+Patients&doi=10.1016%2Fj.amjopharm.2007.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacy in elderly patients</span></div><div class="casAuthors">Hajjar Emily R; Cafiero Angela C; Hanlon Joseph T</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of geriatric pharmacotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">345-51</span>
        ISSN:<span class="NLM_cas:issn">1543-5946</span>.
    </div><div class="casAbstract">BACKGROUND:  Polypharmacy (ie, the use of multiple medications and/or the administration of more medications than are clinically indicated, representing unnecessary drug use) is common among the elderly.  OBJECTIVE:  The goal of this research was to provide a description of observational studies examining the epidemiology of polypharmacy and to review randomized controlled studies that have been published in the past 2 decades designed to reduce polypharmacy in older adults.  METHODS:  Materials for this review were gathered from a search of the MEDLINE database (1986-June 2007) and International Pharmaceutical Abstracts (1986-June 2007) to identify articles in people aged >65 years.  We used a combination of the following search terms: polypharmacy, multiple medications, polymedicine, elderly, geriatric, and aged.  A manual search of the reference lists from identified articles and the authors' article files, book chapters, and recent reviews was conducted to identify additional articles.  From these, the authors identified those studies that measured polypharmacy.  RESULTS:  The literature review found that polypharmacy continues to increase and is a known risk factor for important morbidity and mortality.  There are few rigorously designed intervention studies that have been shown to reduce unnecessary polypharmacy in older adults.  The literature review identified 5 articles, which are included here.  All studies showed an improvement in polypharmacy.  CONCLUSIONS:  Many studies have found that various numbers of medications are associated with negative health outcomes, but more research is needed to further delineate the consequences associated with unnecessary drug use in elderly patients.  Health care professionals should be aware of the risks and fully evaluate all medications at each patient visit to prevent polypharmacy from occurring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTi7H1PTbUsBTToTC3aBaesfW6udTcc2eZcnNYUa7aHhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FhtlChsg%253D%253D&md5=252abb3157c8d7d3fbf06ba806eba6b8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.amjopharm.2007.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjopharm.2007.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DHajjar%26aufirst%3DE.%2BR.%26aulast%3DCafiero%26aufirst%3DA.%2BC.%26aulast%3DHanlon%26aufirst%3DJ.%2BT.%26atitle%3DPolypharmacy%2520in%2520Elderly%2520Patients%26jtitle%3DAm.%2520J.%2520Geriatr.%2520Pharmacother.%26date%3D2007%26volume%3D5%26spage%3D345%26epage%3D351%26doi%3D10.1016%2Fj.amjopharm.2007.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Pasqualetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tognini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calsolaro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monzani, F.</span><span> </span><span class="NLM_article-title">Potential Drug–drug Interactions in Alzheimer Patients with Behavioral Symptoms</span> <span class="citation_source-journal">Clin. Interventions Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1457</span><span class="NLM_x">–</span> <span class="NLM_lpage">1466</span><span class="refDoi"> DOI: 10.2147/CIA.S87466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.2147%2FCIA.S87466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26392756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC283lsFOntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1457-1466&author=G.+Pasqualettiauthor=S.+Togniniauthor=V.+Calsolaroauthor=A.+Poliniauthor=F.+Monzani&title=Potential+Drug%E2%80%93drug+Interactions+in+Alzheimer+Patients+with+Behavioral+Symptoms&doi=10.2147%2FCIA.S87466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Potential drug-drug interactions in Alzheimer patients with behavioral symptoms</span></div><div class="casAuthors">Pasqualetti Giuseppe; Tognini Sara; Calsolaro Valeria; Polini Antonio; Monzani Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical interventions in aging</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1457-66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The use of multi drug regimens among the elderly population has increased tremendously over the last decade although the benefits of medications are always accompanied by potential harm, even when prescribed at recommended doses.  The elderly populations are particularly at an increased risk of adverse drug reactions considering comorbidity, poly-therapy, physiological changes affecting the pharmacokinetics and pharmacodynamics of many drugs and, in some cases, poor compliance due to cognitive impairment and/or depression.  In this setting, drug-drug interaction may represent a serious and even life-threatening clinical condition.  Moreover, the inability to distinguish drug-induced symptoms from a definitive medical diagnosis often results in addition of yet another drug to treat the symptoms, which in turn increases drug-drug interactions.  Cognitive enhancers, including acetylcholinesterase inhibitors and memantine, are the most widely prescribed agents for Alzheimer's disease (AD) patients.  Behavioral and psychological symptoms of dementia, including psychotic symptoms and behavioral disorders, represent noncognitive disturbances frequently observed in AD patients.  Antipsychotic drugs are at high risk of adverse events, even at modest doses, and may interfere with the progression of cognitive impairment and interact with several drugs including anti-arrhythmics and acetylcholinesterase inhibitors.  Other medications often used in AD patients are represented by anxiolytic, like benzodiazepine, or antidepressant agents.  These agents also might interfere with other concomitant drugs through both pharmacokinetic and pharmacodynamic mechanisms.  In this review we focus on the most frequent drug-drug interactions, potentially harmful, in AD patients with behavioral symptoms considering both physiological and pathological changes in AD patients, and potential pharmacodynamic/pharmacokinetic drug interaction mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfUvQHd8XXxfx2phytoz6_fW6udTcc2eZdHVx9ECQEp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283lsFOntQ%253D%253D&md5=40b6c46400e66d10e66cdecd93740a7e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2147%2FCIA.S87466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCIA.S87466%26sid%3Dliteratum%253Aachs%26aulast%3DPasqualetti%26aufirst%3DG.%26aulast%3DTognini%26aufirst%3DS.%26aulast%3DCalsolaro%26aufirst%3DV.%26aulast%3DPolini%26aufirst%3DA.%26aulast%3DMonzani%26aufirst%3DF.%26atitle%3DPotential%2520Drug%25E2%2580%2593drug%2520Interactions%2520in%2520Alzheimer%2520Patients%2520with%2520Behavioral%2520Symptoms%26jtitle%3DClin.%2520Interventions%2520Aging%26date%3D2015%26volume%3D10%26spage%3D1457%26epage%3D1466%26doi%3D10.2147%2FCIA.S87466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Oesterhus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aarsland, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soennesyn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rongve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selbaek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjosavik, S. R.</span><span> </span><span class="NLM_article-title">Potentially Inappropriate Medications and Drug–drug Interactions in Home-Dwelling People with Mild Dementia</span> <span class="citation_source-journal">Int. J. Geriatr. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1002/gps.4456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1002%2Fgps.4456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26924491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC28jlt1yktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=183-192&author=R.+Oesterhusauthor=D.+Aarslandauthor=H.+Soennesynauthor=A.+Rongveauthor=G.+Selbaekauthor=S.+R.+Kjosavik&title=Potentially+Inappropriate+Medications+and+Drug%E2%80%93drug+Interactions+in+Home-Dwelling+People+with+Mild+Dementia&doi=10.1002%2Fgps.4456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia</span></div><div class="casAuthors">Oesterhus Ragnhild; Aarsland Dag; Soennesyn Hogne; Kjosavik Svein R; Oesterhus Ragnhild; Rongve Arvid; Aarsland Dag; Rongve Arvid; Selbaek Geir; Selbaek Geir; Kjosavik Svein R</div><div class="citationInfo"><span class="NLM_cas:title">International journal of geriatric psychiatry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-192</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The objectives of this study were to describe the use of psychotropic drugs among home-dwelling people with mild dementia, to identify potentially inappropriate medications (PIM) and drug-drug interactions (DDI), and to analyze potential variables associated with having PIM and DDI.  METHODS:  Patients (n = 251) with a first-time diagnosis of mild dementia (defined as a mini-mental state examination score >20) were included from outpatient clinics.  Prevalence of psychotropic drug use, polypharmacy, and psychotropic polypharmacy were investigated.  The prevalence of PIM and DDI were defined using the Norwegian general practice criteria and an interactions database, respectively.  Variables associated with having PIM and DDI were assessed using a multivariable logistic regression analysis adjusting for relevant demographic and clinical variables.  RESULTS:  Almost 96% of the patients used one or more medications.  Polypharmacy was found in 45% of the patients, and nearly 70% of the patients were using one or more psychotropic drugs.  Psychotropic polypharmacy was found in seven patients.  PIM were identified in 35 patients (14%), while only four severe DDI were found.  Female sex and number of medications were significantly associated with having PIM, whereas only number of medications was significantly associated with having DDI.  CONCLUSION:  Few patients had PIM or severe DDI, indicating that the quality of prescribing was acceptable.  However, psychotropic drug use was common in home-dwelling people with mild dementia despite limited evidence of benefit in dementia.  More knowledge is needed about the potential risks associated with psychotropic drug use and having PIM and DDI in people with mild dementia.  Copyright © 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThdaxKPKRS4P6BottYdIAWfW6udTcc2eZdHVx9ECQEp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jlt1yktw%253D%253D&md5=e44625f8010f2f050093c262fb5b50d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fgps.4456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.4456%26sid%3Dliteratum%253Aachs%26aulast%3DOesterhus%26aufirst%3DR.%26aulast%3DAarsland%26aufirst%3DD.%26aulast%3DSoennesyn%26aufirst%3DH.%26aulast%3DRongve%26aufirst%3DA.%26aulast%3DSelbaek%26aufirst%3DG.%26aulast%3DKjosavik%26aufirst%3DS.%2BR.%26atitle%3DPotentially%2520Inappropriate%2520Medications%2520and%2520Drug%25E2%2580%2593drug%2520Interactions%2520in%2520Home-Dwelling%2520People%2520with%2520Mild%2520Dementia%26jtitle%3DInt.%2520J.%2520Geriatr.%2520Psychiatry%26date%3D2017%26volume%3D32%26spage%3D183%26epage%3D192%26doi%3D10.1002%2Fgps.4456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lu, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-T.</span><span> </span><span class="NLM_article-title">Multi-Target Drugs: The Trend of Drug Research and Development</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e40262</span><span class="refDoi"> DOI: 10.1371/journal.pone.0040262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1371%2Fjournal.pone.0040262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=22768266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e40262&author=J.-J.+Luauthor=W.+Panauthor=Y.-J.+Huauthor=Y.-T.+Wang&title=Multi-Target+Drugs%3A+The+Trend+of+Drug+Research+and+Development&doi=10.1371%2Fjournal.pone.0040262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target drugs: the trend of drug research and development</span></div><div class="casAuthors">Lu, Jin-Jian; Pan, Wei; Hu, Yuan-Jia; Wang, Yi-Tao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e40262</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Summarizing the status of drugs in the market and examg. the trend of drug research and development is important in drug discovery.  In this study, we compared the drug targets and the market sales of the new mol. entities approved by the U.S. Food and Drug Administration from Jan. 2000 to Dec. 2009.  Two networks, namely, the target-target and drug-drug networks, have been set up using the network anal. tools.  The multi-target drugs have much more potential, as shown by the network visualization and the market trends.  We discussed the possible reasons and proposed the rational strategies for drug research and development in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrapZATY1GnWbVg90H21EOLACvtfcHk0lhoTm-J0Qhm6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D&md5=79489aaf7a36ee9c30287621a7244a6a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0040262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0040262%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.-J.%26aulast%3DWang%26aufirst%3DY.-T.%26atitle%3DMulti-Target%2520Drugs%253A%2520The%2520Trend%2520of%2520Drug%2520Research%2520and%2520Development%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De40262%26doi%3D10.1371%2Fjournal.pone.0040262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Unzeta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteban, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogel, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsay, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipton, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span> </span><span class="NLM_article-title">Multi-Target Directed Donepezil-Like Ligands for Alzheimer’s Disease</span> <span class="citation_source-journal">Front. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="refDoi"> DOI: 10.3389/fnins.2016.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.3389%2Ffnins.2016.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27252617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FmtV2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=205&author=M.+Unzetaauthor=G.+Estebanauthor=I.+Boleaauthor=W.+A.+Fogelauthor=R.+R.+Ramsayauthor=M.+B.+H.+Youdimauthor=K.+F.+Tiptonauthor=J.+Marco-Contelles&title=Multi-Target+Directed+Donepezil-Like+Ligands+for+Alzheimer%E2%80%99s+Disease&doi=10.3389%2Ffnins.2016.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease</span></div><div class="casAuthors">Unzeta Mercedes; Bolea Irene; Esteban Gerard; Tipton Keith F; Fogel Wieslawa A; Ramsay Rona R; Youdim Moussa B H; Marco-Contelles Jose</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS ASS234 is a MTDL compound containing a moiety from Donepezil and the propargyl group from the PF 9601N, a potent and selective MAO B inhibitor.  This compound is the most advanced anti-Alzheimer agent for preclinical studies identified in our laboratory.Derived from ASS234 both multipotent donepezil-indolyl (MTDL-1) and donepezil-pyridyl hybrids (MTDL-2) were designed and evaluated as inhibitors of AChE/BuChE and both MAO isoforms.  MTDL-2 showed more high affinity toward the four enzymes than MTDL-1.MTDL-3 and MTDL-4, were designed containing the N-benzylpiperidinium moiety from Donepezil, a metal- chelating 8-hydroxyquinoline group and linked to a N-propargyl core and they were pharmacologically evaluated.The presence of the cyano group in MTDL-3, enhanced binding to AChE, BuChE and MAO A.  It showed antioxidant behavior and it was able to strongly complex Cu(II), Zn(II) and Fe(III).MTDL-4 showed higher affinity toward AChE, BuChE.MTDL-3 exhibited good brain penetration capacity (ADMET) and less toxicity than Donepezil.  Memory deficits in scopolamine-lesioned animals were restored by MTDL-3.MTDL-3 particularly emerged as a ligand showing remarkable potential benefits for its use in AD therapy.  Alzheimer's disease (AD), the most common form of adult onset dementia, is an age-related neurodegenerative disorder characterized by progressive memory loss, decline in language skills, and other cognitive impairments.  Although its etiology is not completely known, several factors including deficits of acetylcholine, β-amyloid deposits, τ-protein phosphorylation, oxidative stress, and neuroinflammation are considered to play significant roles in the pathophysiology of this disease.  For a long time, AD patients have been treated with acetylcholinesterase inhibitors such as donepezil (Aricept®) but with limited therapeutic success.  This might be due to the complex multifactorial nature of AD, a fact that has prompted the design of new Multi-Target-Directed Ligands (MTDL) based on the "one molecule, multiple targets" paradigm.  Thus, in this context, different series of novel multifunctional molecules with antioxidant, anti-amyloid, anti-inflammatory, and metal-chelating properties able to interact with multiple enzymes of therapeutic interest in AD pathology including acetylcholinesterase, butyrylcholinesterase, and monoamine oxidases A and B have been designed and assessed biologically.  This review describes the multiple targets, the design rationale and an in-house MTDL library, bearing the N-benzylpiperidine motif present in donepezil, linked to different heterocyclic ring systems (indole, pyridine, or 8-hydroxyquinoline) with special emphasis on compound ASS234, an N-propargylindole derivative.  The description of the in vitro biological properties of the compounds and discussion of the corresponding structure-activity-relationships allows us to highlight new issues for the identification of more efficient MTDL for use in AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAKdUtVDXRPgpJitSxOdIlfW6udTcc2eZjMRnSAHl3Ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FmtV2hsw%253D%253D&md5=0904cb1e4e1c700e575e192e9d3bebb3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00205%26sid%3Dliteratum%253Aachs%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DFogel%26aufirst%3DW.%2BA.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DMulti-Target%2520Directed%2520Donepezil-Like%2520Ligands%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D205%26doi%3D10.3389%2Ffnins.2016.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccafusco, J. J.</span><span> </span><span class="NLM_article-title">CNS Targets for Multi-Functional Drugs in the Treatment of Alzheimer’s and Parkinson’s Diseases</span> <span class="citation_source-journal">J. Neural Transm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span><span class="refDoi"> DOI: 10.1007/s00702-004-0214-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs00702-004-0214-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2005&pages=519-537&author=M.+B.+H.+Youdimauthor=J.+J.+Buccafusco&title=CNS+Targets+for+Multi-Functional+Drugs+in+the+Treatment+of+Alzheimer%E2%80%99s+and+Parkinson%E2%80%99s+Diseases&doi=10.1007%2Fs00702-004-0214-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs00702-004-0214-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-004-0214-z%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DBuccafusco%26aufirst%3DJ.%2BJ.%26atitle%3DCNS%2520Targets%2520for%2520Multi-Functional%2520Drugs%2520in%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520and%2520Parkinson%25E2%2580%2599s%2520Diseases%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2005%26volume%3D112%26spage%3D519%26epage%3D537%26doi%3D10.1007%2Fs00702-004-0214-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Reus, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fochtmann, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyler, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilty, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvitz-Lennon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jibson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahoney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wills, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhoads, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yager, J.</span><span> </span><span class="NLM_article-title">The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1176/appi.ajp.2015.173501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1176%2Fappi.ajp.2015.173501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27133416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC28bltleruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=543-546&author=V.+I.+Reusauthor=L.+J.+Fochtmannauthor=A.+E.+Eylerauthor=D.+M.+Hiltyauthor=M.+Horvitz-Lennonauthor=M.+D.+Jibsonauthor=O.+L.+Lopezauthor=J.+Mahoneyauthor=J.+Pasicauthor=Z.+S.+Tanauthor=C.+D.+Willsauthor=R.+Rhoadsauthor=J.+Yager&title=The+American+Psychiatric+Association+Practice+Guideline+on+the+Use+of+Antipsychotics+to+Treat+Agitation+or+Psychosis+in+Patients+With+Dementia&doi=10.1176%2Fappi.ajp.2015.173501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia</span></div><div class="casAuthors">Reus Victor I; Fochtmann Laura J; Eyler A Evan; Hilty Donald M; Horvitz-Lennon Marcela; Jibson Michael D; Lopez Oscar L; Mahoney Jane; Pasic Jagoda; Tan Zaldy S; Wills Cheryl D; Rhoads Richard; Yager Joel</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdiYJwQsXFcvxQvRxYU81tfW6udTcc2eZjMRnSAHl3Ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bltleruw%253D%253D&md5=eed0b88a9353b0ea6add176fa2082c5c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2015.173501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2015.173501%26sid%3Dliteratum%253Aachs%26aulast%3DReus%26aufirst%3DV.%2BI.%26aulast%3DFochtmann%26aufirst%3DL.%2BJ.%26aulast%3DEyler%26aufirst%3DA.%2BE.%26aulast%3DHilty%26aufirst%3DD.%2BM.%26aulast%3DHorvitz-Lennon%26aufirst%3DM.%26aulast%3DJibson%26aufirst%3DM.%2BD.%26aulast%3DLopez%26aufirst%3DO.%2BL.%26aulast%3DMahoney%26aufirst%3DJ.%26aulast%3DPasic%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DZ.%2BS.%26aulast%3DWills%26aufirst%3DC.%2BD.%26aulast%3DRhoads%26aufirst%3DR.%26aulast%3DYager%26aufirst%3DJ.%26atitle%3DThe%2520American%2520Psychiatric%2520Association%2520Practice%2520Guideline%2520on%2520the%2520Use%2520of%2520Antipsychotics%2520to%2520Treat%2520Agitation%2520or%2520Psychosis%2520in%2520Patients%2520With%2520Dementia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2016%26volume%3D173%26spage%3D543%26epage%3D546%26doi%3D10.1176%2Fappi.ajp.2015.173501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">De Deyn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeste, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breder, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, T.</span><span> </span><span class="NLM_article-title">Aripiprazole for the Treatment of Psychosis in Patients with Alzheimer’s Disease: A Randomized, Placebo-Controlled Study</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1097/01.jcp.0000178415.22309.8f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1097%2F01.jcp.0000178415.22309.8f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=16160622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVShsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=463-467&author=P.+De+Deynauthor=D.+V.+Jesteauthor=R.+Swaninkauthor=D.+Kosticauthor=C.+Brederauthor=W.+H.+Carsonauthor=T.+Iwamoto&title=Aripiprazole+for+the+Treatment+of+Psychosis+in+Patients+with+Alzheimer%E2%80%99s+Disease%3A+A+Randomized%2C+Placebo-Controlled+Study&doi=10.1097%2F01.jcp.0000178415.22309.8f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study</span></div><div class="casAuthors">De Deyn, Peter; Jeste, Dilip V.; Swanink, Rene; Kostic, Dusan; Breder, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-467</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This study compared the efficacy, safety, and tolerability of aripiprazole, a novel antipsychotic, with placebo in patients with psychosis assocd. with Alzheimer's Disease (AD).  This 10-wk, double-blind, multicenter study randomized 208 outpatients (mean age, 81.5 years) with AD-assocd. psychosis to aripiprazole (n = 106) or placebo (n = 102).  The initial aripiprazole dose of 2 mg/d was titrated upwards (5, 10, or 15 mg/d) according to efficacy and tolerability.  Evaluations included Neuropsychiatric Inventory (NPI) Psychosis subscale and Brief Psychiatric Rating Scale (BPRS), adverse event (AE) reports, extrapyramidal symptoms (EPS) rating scales, and body wt.  Overall, 172 patients (83%) completed the study.  Mean aripiprazole dose at end point was 10.0 mg/d.  The NPI Psychosis subscale score showed improvements in both groups (aripiprazole, -6.55; placebo, -5.52; P = 0.17 at end point).  Aripiprazole-treated patients showed significantly greater improvements from baseline in BPRS Psychosis and BPRS Core subscale scores at end point compared with placebo.  AEs were generally mild to moderate in severity and included (aripiprazole vs. placebo): urinary tract infection (8% vs. 12%), accidental injury (8% vs. 5%), somnolence (8% vs. 1%), and bronchitis (6% vs. 3%).  Somnolence was mild and not assocd. with falls or accidental injury.  There were no significant differences from placebo in EPS scores, or clin. significant ECG abnormalities, vital signs, or wt.  In conclusion, aripiprazole showed similar improvements to placebo in psychotic symptoms as assessed by NPI Psychosis subscale scores, but significantly greater effects on BPRS Core and Psychosis assessments in community-living AD patients with psychosis.  Aripiprazole was safe and well tolerated in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcxfeaX0-hlrVg90H21EOLACvtfcHk0ljc3uh4lq4T9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVShsLjP&md5=1f6f19fd6321c2060958ccf31ea1a71b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2F01.jcp.0000178415.22309.8f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.jcp.0000178415.22309.8f%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BDeyn%26aufirst%3DP.%26aulast%3DJeste%26aufirst%3DD.%2BV.%26aulast%3DSwanink%26aufirst%3DR.%26aulast%3DKostic%26aufirst%3DD.%26aulast%3DBreder%26aufirst%3DC.%26aulast%3DCarson%26aufirst%3DW.%2BH.%26aulast%3DIwamoto%26aufirst%3DT.%26atitle%3DAripiprazole%2520for%2520the%2520Treatment%2520of%2520Psychosis%2520in%2520Patients%2520with%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520A%2520Randomized%252C%2520Placebo-Controlled%2520Study%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2005%26volume%3D25%26spage%3D463%26epage%3D467%26doi%3D10.1097%2F01.jcp.0000178415.22309.8f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Farlow, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shamliyan, T. A.</span><span> </span><span class="NLM_article-title">Benefits and Harms of Atypical Antipsychotics for Agitation in Adults with Dementia</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1016/j.euroneuro.2017.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.euroneuro.2017.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=28111239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=217-231&author=M.+R.+Farlowauthor=T.+A.+Shamliyan&title=Benefits+and+Harms+of+Atypical+Antipsychotics+for+Agitation+in+Adults+with+Dementia&doi=10.1016%2Fj.euroneuro.2017.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Benefits and harms of atypical antipsychotics for agitation in adults with dementia</span></div><div class="casAuthors">Farlow, Martin R.; Shamliyan, Tatyana A.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-231</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the most current evidence regarding the benefits and harms of atypical antipsychotics in adults with dementia.In June 2016, following a protocol developed a priori, we systematically searched several databases for published and unpublished data from randomized controlled trials (RCT), observational studies, and meta-analyses; conducted direct meta-analyses using a random effects model; and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.One high-quality meta-anal. and published and unpublished data from 8 RCTs and 12 large observational studies met inclusion criteria.  When compared with placebo, aripiprazole, risperidone, and olanzapine but not quetiapine result in modest (standardized mean difference <0.5 std. deviations) improvement in neuropsychiatric symptoms.  Aripiprazole, risperidone, quetiapine, and olanzapine are assocd. with increased odds of acute myocardial infraction, and risperidone and olanzapine are assocd. with increased odds of hip fracture.  Observational studies suggest no differences in all-cause mortality between atypical antipsychotics.Observational studies suggest that atypical antipsychotics are assocd. with lower risk of all-cause mortality and extrapyramidal symptoms but higher risk of stroke when compared with conventional antipsychotics.To manage agitation in adults with progressive dementia, clinicians may recommend atypical antipsychotics with continuous monitoring of behavioral symptoms, informing patients and their families or caregivers of the significant risk of adverse effects and baseline risk of acute myocardial infraction and bone fractures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcVDxK-KxFdLVg90H21EOLACvtfcHk0ljc3uh4lq4T9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOisr4%253D&md5=a76d8a8f7d8185544cff0ebe559a89b1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2017.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2017.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DFarlow%26aufirst%3DM.%2BR.%26aulast%3DShamliyan%26aufirst%3DT.%2BA.%26atitle%3DBenefits%2520and%2520Harms%2520of%2520Atypical%2520Antipsychotics%2520for%2520Agitation%2520in%2520Adults%2520with%2520Dementia%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2017%26volume%3D27%26spage%3D217%26epage%3D231%26doi%3D10.1016%2Fj.euroneuro.2017.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Reese, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiel, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocker, K. E.</span><span> </span><span class="NLM_article-title">Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use</span> <span class="citation_source-journal">Am. Fam. Physician</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">276</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27548592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC2szjtlemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=276-282&author=T.+R.+Reeseauthor=D.+J.+Thielauthor=K.+E.+Cocker&title=Behavioral+Disorders+in+Dementia%3A+Appropriate+Nondrug+Interventions+and+Antipsychotic+Use"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use</span></div><div class="casAuthors">Reese Tyler R; Thiel Derrick J; Cocker Katherine E</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">276-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Behavioral and psychological symptoms of dementia pose management challenges for caregivers and clinicians.  Firstline nonpharmacologic treatments include eliminating physical and emotional stressors, modifying the patient's environment, and establishing daily routines.  Family members and caregivers benefit from education about dementia symptoms and reminders that the behaviors are normal and unintentional.  Cognitive and emotion-oriented interventions, sensory stimulation interventions, behavior management techniques, and other psychosocial interventions are modestly effective.  In refractory cases, physicians may choose to prescribe off-label antipsychotics.  Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small.  Olanzapine, quetiapine, and risperidone have inconsistent evidence of benefit.  Physicians should use the smallest effective dose for the shortest possible duration to minimize adverse effects, most notably an increased mortality risk.  Other adverse effects include anticholinergic and antidopaminergic effects, extrapyramidal symptoms, neuroleptic malignant syndrome, postural hypotension, metabolic syndrome, cardiac arrhythmia, and sedation.  Patients should be monitored for these effects while receiving treatment; however, laboratory monitoring may be limited to patients receiving long-term therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuBB4uZP1pszToTC3aBaesfW6udTcc2eb_a6C-Jhe_-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szjtlemtA%253D%253D&md5=2fef69bca4d0cc89f0485be9a0fd7de6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReese%26aufirst%3DT.%2BR.%26aulast%3DThiel%26aufirst%3DD.%2BJ.%26aulast%3DCocker%26aufirst%3DK.%2BE.%26atitle%3DBehavioral%2520Disorders%2520in%2520Dementia%253A%2520Appropriate%2520Nondrug%2520Interventions%2520and%2520Antipsychotic%2520Use%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2016%26volume%3D94%26spage%3D276%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Davies, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology</span> <span class="citation_source-journal">CNS Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1111/j.1527-3458.2004.tb00030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1111%2Fj.1527-3458.2004.tb00030.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=15592581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFejsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=317-336&author=M.+A.+Daviesauthor=D.+J.+Shefflerauthor=B.+L.+Roth&title=Aripiprazole%3A+A+Novel+Atypical+Antipsychotic+Drug+With+a+Uniquely+Robust+Pharmacology&doi=10.1111%2Fj.1527-3458.2004.tb00030.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology</span></div><div class="casAuthors">Davies, Marilyn A.; Sheffler, Douglas J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-336</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Aripiprazole (Abilify) is an atypical antipsychotic drug that has been recently introduced for clin. use in the treatment of schizophrenia.  Aripiprazole has a unique pharmacol. profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [esp. dopamine (D2) and 5-HT1A] and antagonistic action at others (esp. 5-HT2A).  Clin. trials indicate that aripiprazole is effective in treating the pos. and neg. symptoms of schizophrenia.  In short-term studies rapid onset of action (within one week) has been demonstrated.  Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder.  At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder.  There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on wt., is indicated in this population.  In the long-term studies, the use of aripiprazole was assocd. with continued efficacy, good compliance and increased time-to-relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUPyxiyqhQzrVg90H21EOLACvtfcHk0ljc3uh4lq4T9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFejsLo%253D&md5=dc4d48c70799660137c731cee3c67f42</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2004.tb00030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2004.tb00030.x%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DAripiprazole%253A%2520A%2520Novel%2520Atypical%2520Antipsychotic%2520Drug%2520With%2520a%2520Uniquely%2520Robust%2520Pharmacology%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2004%26volume%3D10%26spage%3D317%26epage%3D336%26doi%3D10.1111%2Fj.1527-3458.2004.tb00030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Worthington, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinrys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wygant, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, M. H.</span><span> </span><span class="NLM_article-title">Aripiprazole as an Augmentor of Selective Serotonin Reuptake Inhibitors in Depression and Anxiety Disorder Patients</span> <span class="citation_source-journal">Int. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1097/00004850-200501000-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1097%2F00004850-200501000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=15602109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252Fps1ajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=9-11&author=J.+J.+Worthingtonauthor=G.+Kinrysauthor=L.+E.+Wygantauthor=M.+H.+Pollack&title=Aripiprazole+as+an+Augmentor+of+Selective+Serotonin+Reuptake+Inhibitors+in+Depression+and+Anxiety+Disorder+Patients&doi=10.1097%2F00004850-200501000-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients</span></div><div class="casAuthors">Worthington John J 3rd; Kinrys Gustavo; Wygant Lisa E; Pollack Mark H</div><div class="citationInfo"><span class="NLM_cas:title">International clinical psychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-11</span>
        ISSN:<span class="NLM_cas:issn">0268-1315</span>.
    </div><div class="casAbstract">More than half of anxiety and depression patients treated with an adequate course of antidepressants fail to fully improve.  We retrospectively examined whether treatment-resistant depression and anxiety disorder patients responded to and tolerated augmentation with the atypical antipsychotic, aripiprazole.  We report on patients with depression and anxiety disorders, including panic disorder, generalized anxiety disorder, social anxiety and post-traumatic stress disorder, who had an incomplete response to a variety of selective serotonin reuptake inhibitors (SSRIs) and who received augmentation with aripiprazole.  The primary outcome measure was the Clinical Global Impression of Improvement (CGI-I).  In the intent-to-treat analysis, the mean+/-SD CGI-S was 3.8+/-1.3 at endpoint.  Fifty-nine percent of subjects received CGI-I ratings of 1 or 2, 'much improved' or 'very much improved,' in terms of their depression and anxiety symptoms at the end of 12 weeks.  Several patients showed an early (weeks 1-5), as well as sustained, response to augmentation with doses of aripiprazole between 15 and 30 mg/day.  The results suggest that aripiprazole may be effective as an augmentation for patients with persistent depressive and anxiety disorders despite initial SSRI treatment.  Because this is a retrospective case review, further prospective studies are required to confirm these findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxhskuaFxFO56KlWarZTAzfW6udTcc2eZmqRgmyUHI5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252Fps1ajuw%253D%253D&md5=da4bfe4897e13e4cb86b91a1fd1a404a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2F00004850-200501000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004850-200501000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DWorthington%26aufirst%3DJ.%2BJ.%26aulast%3DKinrys%26aufirst%3DG.%26aulast%3DWygant%26aufirst%3DL.%2BE.%26aulast%3DPollack%26aufirst%3DM.%2BH.%26atitle%3DAripiprazole%2520as%2520an%2520Augmentor%2520of%2520Selective%2520Serotonin%2520Reuptake%2520Inhibitors%2520in%2520Depression%2520and%2520Anxiety%2520Disorder%2520Patients%26jtitle%3DInt.%2520Clin.%2520Psychopharmacol.%26date%3D2005%26volume%3D20%26spage%3D9%26epage%3D11%26doi%3D10.1097%2F00004850-200501000-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Sheffrin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenze, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulsant, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butters, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dew, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. F.</span><span> </span><span class="NLM_article-title">Pilot Study of Augmentation with Aripiprazole for Incomplete Response in Late-Life Depression: Getting to Remission</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">208</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span><span class="refDoi"> DOI: 10.4088/JCP.07m03805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.4088%2FJCP.07m03805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19210951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvFOls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2009&pages=208-213&author=M.+Sheffrinauthor=H.+C.+Driscollauthor=E.+J.+Lenzeauthor=B.+H.+Mulsantauthor=B.+G.+Pollockauthor=M.+D.+Millerauthor=M.+A.+Buttersauthor=M.+A.+Dewauthor=C.+F.+Reynolds&title=Pilot+Study+of+Augmentation+with+Aripiprazole+for+Incomplete+Response+in+Late-Life+Depression%3A+Getting+to+Remission&doi=10.4088%2FJCP.07m03805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission</span></div><div class="casAuthors">Sheffrin, Meera; Driscoll, Henry C.; Lenze, Eric J.; Mulsant, Benoit H.; Pollock, Bruce G.; Miller, Mark D.; Butters, Meryl A.; Dew, Mary Amanda; Reynolds, Charles F., III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry (Memphis, TN, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">208-213</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">To det. the feasibility and safety of aripiprazole augmentation for incomplete response to sequential selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) pharmacotherapy in late-life depression.  This study was a 12-wk, open-label pilot study of 24 patients (recruited from June 1, 2006, to June 1, 2007) aged 65 years and above (mean, 73.9 years) diagnosed with major depressive disorder (MDD) (according to DSM-IV) who responded partially (17-item Hamilton Rating Scale for Depression [HAM-D-17] score of 11 to 15) or not at all (HAM-D score > 15) to a 16-wk trial of escitalopram (up to 20 mg/day), followed by either duloxetine (up to 120 mg/day) or venlafaxine (up to 225 mg/day) for 12 wk.  Subjects received 2.5 to 15 mg per day of adjunctive aripiprazole (mean dose, 9.0 mg/day) for 12 wk.  The criterion for remission during treatment with aripiprazole was a HAM-D score ≤ 10 for 2 consecutive weeks.  Of 24 subjects in the intent-to-treat study group, 19 completed 12 wk of augmentation with aripiprazole, 12 of 24 (50%) met criteria for remission, and 2 of 24 discontinued due to side effects (sedation, akathisia).  The mean (SD) HAM-D score decreased significantly by 6.4 (5.8) points (paired t test for means, p < .01, df = 16).  There were no relapses among the 12 subjects who participated in continuation treatment over a median period of 27.6 wk.  In older adults with MDD with incomplete response to SSRI and SNRI pharmacotherapy, aripiprazole was well tolerated, and symptoms of depression improved significantly during treatment with aripiprazole.  A randomized, double-blind, placebo-controlled trial of adjunctive aripiprazole for incomplete response in late-life depression is warranted to further evaluate benefit and risk.  Trial Registration: clinicaltrials.gov Identifier: NCT00177671.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEaoK6ZZrs0LVg90H21EOLACvtfcHk0lj8vX5hEfgDGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvFOls7Y%253D&md5=61ddaf256238432a0c7d8e7f0c1c2b27</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4088%2FJCP.07m03805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.07m03805%26sid%3Dliteratum%253Aachs%26aulast%3DSheffrin%26aufirst%3DM.%26aulast%3DDriscoll%26aufirst%3DH.%2BC.%26aulast%3DLenze%26aufirst%3DE.%2BJ.%26aulast%3DMulsant%26aufirst%3DB.%2BH.%26aulast%3DPollock%26aufirst%3DB.%2BG.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DButters%26aufirst%3DM.%2BA.%26aulast%3DDew%26aufirst%3DM.%2BA.%26aulast%3DReynolds%26aufirst%3DC.%2BF.%26atitle%3DPilot%2520Study%2520of%2520Augmentation%2520with%2520Aripiprazole%2520for%2520Incomplete%2520Response%2520in%2520Late-Life%2520Depression%253A%2520Getting%2520to%2520Remission%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2009%26volume%3D70%26spage%3D208%26epage%3D213%26doi%3D10.4088%2FJCP.07m03805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Pollock, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulsant, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweet, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazumdar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharucha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacob, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastango, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chew, M. L.</span><span> </span><span class="NLM_article-title">Comparison of Citalopram, Perphenazine, and Placebo for the Acute Treatment of Psychosis and Behavioral Disturbances in Hospitalized, Demented Patients</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">460</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1176/appi.ajp.159.3.460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1176%2Fappi.ajp.159.3.460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=11870012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD387jsVagsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=460-465&author=B.+G.+Pollockauthor=B.+H.+Mulsantauthor=J.+Rosenauthor=R.+A.+Sweetauthor=S.+Mazumdarauthor=A.+Bharuchaauthor=R.+Marinauthor=N.+J.+Jacobauthor=K.+A.+Huberauthor=K.+B.+Kastangoauthor=M.+L.+Chew&title=Comparison+of+Citalopram%2C+Perphenazine%2C+and+Placebo+for+the+Acute+Treatment+of+Psychosis+and+Behavioral+Disturbances+in+Hospitalized%2C+Demented+Patients&doi=10.1176%2Fappi.ajp.159.3.460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients</span></div><div class="casAuthors">Pollock Bruce G; Mulsant Benoit H; Rosen Jules; Sweet Robert A; Mazumdar Sati; Bharucha Ashok; Marin Robert; Jacob N J; Huber Kimberly A; Kastango Kari B; Chew Marci L</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">460-5</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Until recently, conventional antipsychotics were the standard pharmacotherapy for psychosis and behavioral disturbances associated with dementia.  This double-blind, placebo-controlled study compared the acute efficacy of the selective serotonin reuptake inhibitor citalopram and the neuroleptic perphenazine with placebo for the treatment of psychosis and behavioral disturbances in nondepressed patients with dementia.  METHOD:  Eighty-five hospitalized patients with at least one moderate to severe target symptom (aggression, agitation, hostility, suspiciousness, hallucinations, or delusions) were randomly assigned to receive either citalopram, perphenazine, or placebo under double-blind conditions for up to 17 days.  RESULTS:  Patients treated with citalopram or perphenazine showed statistically significant improvement on several Neurobehavioral Rating Scale factor scores.  Compared to those receiving placebo, only patients treated with citalopram showed significantly greater improvement in their total Neurobehavioral Rating Scale score as well as in the scores for the agitation/aggression and lability/tension factors.  Side effect scores were similar among the three treatment groups.  CONCLUSIONS:  Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiYhb6luDvsAyMywPm6HgQfW6udTcc2eZmqRgmyUHI5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387jsVagsw%253D%253D&md5=c711511cc219d301fb5420560fb808d8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.3.460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.3.460%26sid%3Dliteratum%253Aachs%26aulast%3DPollock%26aufirst%3DB.%2BG.%26aulast%3DMulsant%26aufirst%3DB.%2BH.%26aulast%3DRosen%26aufirst%3DJ.%26aulast%3DSweet%26aufirst%3DR.%2BA.%26aulast%3DMazumdar%26aufirst%3DS.%26aulast%3DBharucha%26aufirst%3DA.%26aulast%3DMarin%26aufirst%3DR.%26aulast%3DJacob%26aufirst%3DN.%2BJ.%26aulast%3DHuber%26aufirst%3DK.%2BA.%26aulast%3DKastango%26aufirst%3DK.%2BB.%26aulast%3DChew%26aufirst%3DM.%2BL.%26atitle%3DComparison%2520of%2520Citalopram%252C%2520Perphenazine%252C%2520and%2520Placebo%2520for%2520the%2520Acute%2520Treatment%2520of%2520Psychosis%2520and%2520Behavioral%2520Disturbances%2520in%2520Hospitalized%252C%2520Demented%2520Patients%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D460%26epage%3D465%26doi%3D10.1176%2Fappi.ajp.159.3.460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Bains, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dening, T.</span><span> </span><span class="NLM_article-title">Antidepressants for Treating Depression in Dementia</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD003944</span><span class="refDoi"> DOI: 10.1002/14651858.CD003944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1002%2F14651858.CD003944" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=CD003944&author=J.+Bainsauthor=J.+Birksauthor=T.+Dening&title=Antidepressants+for+Treating+Depression+in+Dementia&doi=10.1002%2F14651858.CD003944"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD003944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD003944%26sid%3Dliteratum%253Aachs%26aulast%3DBains%26aufirst%3DJ.%26aulast%3DBirks%26aufirst%3DJ.%26aulast%3DDening%26aufirst%3DT.%26atitle%3DAntidepressants%2520for%2520Treating%2520Depression%2520in%2520Dementia%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2002%26spage%3DCD003944%26doi%3D10.1002%2F14651858.CD003944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Connolly, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thase, M. E.</span><span> </span><span class="NLM_article-title">Vortioxetine: A New Treatment for Major Depressive Disorder</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1517/14656566.2016.1133588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1517%2F14656566.2016.1133588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26679430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XislSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=421-431&author=K.+R.+Connollyauthor=M.+E.+Thase&title=Vortioxetine%3A+A+New+Treatment+for+Major+Depressive+Disorder&doi=10.1517%2F14656566.2016.1133588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Vortioxetine: a New Treatment for Major Depressive Disorder</span></div><div class="casAuthors">Connolly, K. Ryan; Thase, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">421-431</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD).  This medication is a serotonin reuptake inhibitor that also has a no. of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's effects from those of current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs).  This article will review the basic clin. pharmacol. of vortioxetine, summarize the major clin. trials that were performed prior to approval by the US Food and Drug Administration (FDA), discuss relevant post-marketing studies of this drug, and offer expert commentary on the significance of this new agent in clin. practice.  Pre-approval studies were identified as all randomized, placebo-controlled studies of vortioxetine listed on clinicaltrials.gov.  Other referenced studies were identified via a MEDLINE database literature search in August 2015 using the key search terms, vortioxetine and Lu AA21004, combined with addnl. terms that included pharmacol. profile, pharmacokinetics, drug interactions, adverse effects, side effects, safety, major depression, and major depressive disorder.  We identified relevant systematic reviews, meta-analyses, randomized trials and preclin. studies of importance.  Results of placebo-controlled trials suggest efficacy and an overall safety profile comparable to existing first-line antidepressants.  The most common side effects are nausea, vomiting and constipation.  Results of several studies indicate that vortioxetine may have therapeutic effects on cognition (e.g., memory and executive functioning) that exceed that of std. antidepressants.  Disadvantages include cost and the current paucity of long-term efficacy data from large clin. trials.  The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending addnl. long-term data, to become a first-line antidepressant option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfx6OO5BUAzrVg90H21EOLACvtfcHk0lhv4cXb8GJ-UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XislSltbc%253D&md5=986c06cd18eb8e9b2c14b24ef684d8d7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1133588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1133588%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DK.%2BR.%26aulast%3DThase%26aufirst%3DM.%2BE.%26atitle%3DVortioxetine%253A%2520A%2520New%2520Treatment%2520for%2520Major%2520Depressive%2520Disorder%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D421%26epage%3D431%26doi%3D10.1517%2F14656566.2016.1133588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Köhler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cierpinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kronenberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adli, M.</span><span> </span><span class="NLM_article-title">The Serotonergic System in the Neurobiology of Depression: Relevance for Novel Antidepressants</span> <span class="citation_source-journal">J. Psychopharmacol. (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1177/0269881115609072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1177%2F0269881115609072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26464458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC28zhslChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=13-22&author=S.+K%C3%B6hlerauthor=K.+Cierpinskyauthor=G.+Kronenbergauthor=M.+Adli&title=The+Serotonergic+System+in+the+Neurobiology+of+Depression%3A+Relevance+for+Novel+Antidepressants&doi=10.1177%2F0269881115609072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants</span></div><div class="casAuthors">Kohler Stephan; Cierpinsky Katharina; Kronenberg Golo; Adli Mazda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychopharmacology (Oxford, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The monoamine hypothesis of depression posits that an imbalance in monoaminergic neurotransmission is causally related to the clinical features of depression.  Antidepressants influencing serotonin mainly aim at raising serotonin concentrations, thereby increasing serotonergic transmission at the level of the synapse, for example by inhibiting the serotonin transporter.  However, the serotonin system is multifaceted.  Different serotonin receptor subtypes turn the serotonergic system into a complex neurochemical arrangement that influences diverse neurotransmitters in various brain regions.  Classical antidepressants as well as other psychopharmacological agents have various crucial effects on serotonin receptors.  We aim at providing a clinically useful characterization of serotonin receptor subtypes in the treatment of depression.  Clarifying the mode of action and the interplay of serotonin receptors with pharmacological agents should help antidepressant mechanisms and typical side effects to be better understood.  Against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-HT1A, 5-HT3 and 5-HT7 which may account for their specific effects on certain symptoms of depression (e.g. cognition and anxiety) as well as a characteristic side-effect profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Urdg3usjp7HHuJhbyicZfW6udTcc2eboAOBoutVRxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zhslChug%253D%253D&md5=8040ec875099176ce62ae7572e02a178</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1177%2F0269881115609072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881115609072%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%26aulast%3DCierpinsky%26aufirst%3DK.%26aulast%3DKronenberg%26aufirst%3DG.%26aulast%3DAdli%26aufirst%3DM.%26atitle%3DThe%2520Serotonergic%2520System%2520in%2520the%2520Neurobiology%2520of%2520Depression%253A%2520Relevance%2520for%2520Novel%2520Antidepressants%26jtitle%3DJ.%2520Psychopharmacol.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2016%26volume%3D30%26spage%3D13%26epage%3D22%26doi%3D10.1177%2F0269881115609072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kelliny, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croarkin, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobo, W. V.</span><span> </span><span class="NLM_article-title">Profile of Vortioxetine in the Treatment of Major Depressive Disorder: An Overview of the Primary and Secondary Literature</span> <span class="citation_source-journal">Ther. Clin. Risk Manage.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">2015</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1193</span><span class="NLM_x">–</span> <span class="NLM_lpage">1212</span><span class="refDoi"> DOI: 10.2147/TCRM.S55313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.2147%2FTCRM.S55313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1193-1212&issue=11&author=M.+Kellinyauthor=P.+E.+Croarkinauthor=K.+M.+Mooreauthor=W.+V.+Bobo&title=Profile+of+Vortioxetine+in+the+Treatment+of+Major+Depressive+Disorder%3A+An+Overview+of+the+Primary+and+Secondary+Literature&doi=10.2147%2FTCRM.S55313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S55313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S55313%26sid%3Dliteratum%253Aachs%26aulast%3DKelliny%26aufirst%3DM.%26aulast%3DCroarkin%26aufirst%3DP.%2BE.%26aulast%3DMoore%26aufirst%3DK.%2BM.%26aulast%3DBobo%26aufirst%3DW.%2BV.%26atitle%3DProfile%2520of%2520Vortioxetine%2520in%2520the%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%253A%2520An%2520Overview%2520of%2520the%2520Primary%2520and%2520Secondary%2520Literature%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2015%26volume%3D2015%26issue%3D11%26spage%3D1193%26epage%3D1212%26doi%3D10.2147%2FTCRM.S55313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Bang-Andersen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruhland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jørgensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederiksen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mørk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensbøl, T. B.</span><span> </span><span class="NLM_article-title">Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3206</span><span class="NLM_x">–</span> <span class="NLM_lpage">3221</span><span class="refDoi"> DOI: 10.1021/jm101459g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101459g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFGgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3206-3221&author=B.+Bang-Andersenauthor=T.+Ruhlandauthor=M.+J%C3%B8rgensenauthor=G.+Smithauthor=K.+Frederiksenauthor=K.+G.+Jensenauthor=H.+Zhongauthor=S.+M.+Nielsenauthor=S.+Hoggauthor=A.+M%C3%B8rkauthor=T.+B.+Stensb%C3%B8l&title=Discovery+of+1-%5B2-%282%2C4-Dimethylphenylsulfanyl%29Phenyl%5DPiperazine+%28Lu+AA21004%29%3A+A+Novel+Multimodal+Compound+for+the+Treatment+of+Major+Depressive+Disorder&doi=10.1021%2Fjm101459g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder</span></div><div class="casAuthors">Bang-Andersen, Benny; Ruhland, Thomas; Jorgensen, Morten; Smith, Garrick; Frederiksen, Kristen; Jensen, Klaus Gjervig; Zhong, Huailing; Nielsen, Soren Moller; Hogg, Sandra; Mork, Arne; Stensbol, Tine Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3206-3221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and structure-activity relationship of a novel series of compds. with combined effects on 5-HT3A and 5-HT1A receptors and on the serotonin (5-HT) transporter (SERT) are described.  Compd. 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004) was the lead compd., displaying high affinity for recombinant human 5-HT1A (Ki = 15 nM), 5-HT1B (Ki = 33 nM), 5-HT3A (Ki = 3.7 nM), 5-HT7 (Ki = 19 nM), and noradrenergic β1 (Ki = 46 nM) receptors, and SERT (Ki = 1.6 nM).  Lu AA21004 displayed antagonistic properties at 5-HT3A and 5-HT7 receptors, partial agonist properties at 5-HT1B receptors, agonistic properties at 5-HT1A receptors, and potent inhibition of SERT.  In conscious rats, Lu AA21004 significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment.  Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, resp.  These characteristics indicate that Lu AA21004 is a novel multimodal serotonergic compd., and is currently in clin. development for major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAspA4Bk8ro7Vg90H21EOLACvtfcHk0lhYZCh_VQc1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFGgtLs%253D&md5=b9823f8a86f6d4d44d4a17cb510ea903</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm101459g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101459g%26sid%3Dliteratum%253Aachs%26aulast%3DBang-Andersen%26aufirst%3DB.%26aulast%3DRuhland%26aufirst%3DT.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DJensen%26aufirst%3DK.%2BG.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DNielsen%26aufirst%3DS.%2BM.%26aulast%3DHogg%26aufirst%3DS.%26aulast%3DM%25C3%25B8rk%26aufirst%3DA.%26aulast%3DStensb%25C3%25B8l%26aufirst%3DT.%2BB.%26atitle%3DDiscovery%2520of%25201-%255B2-%25282%252C4-Dimethylphenylsulfanyl%2529Phenyl%255DPiperazine%2520%2528Lu%2520AA21004%2529%253A%2520A%2520Novel%2520Multimodal%2520Compound%2520for%2520the%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3206%26epage%3D3221%26doi%3D10.1021%2Fjm101459g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Montgomery, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Häggström, L.</span><span> </span><span class="NLM_article-title">A Randomised, Double-Blind Study in Adults with Major Depressive Disorder with an Inadequate Response to a Single Course of Selective Serotonin Reuptake Inhibitor or Serotonin-Noradrenaline Reuptake Inhibitor Treatment Switched to Vortioxetine or Agomelatine</span> <span class="citation_source-journal">Hum. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1002/hup.2424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1002%2Fhup.2424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=25087600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFahtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=470-482&author=S.+A.+Montgomeryauthor=R.+Z.+Nielsenauthor=L.+H.+Poulsenauthor=L.+H%C3%A4ggstr%C3%B6m&title=A+Randomised%2C+Double-Blind+Study+in+Adults+with+Major+Depressive+Disorder+with+an+Inadequate+Response+to+a+Single+Course+of+Selective+Serotonin+Reuptake+Inhibitor+or+Serotonin-Noradrenaline+Reuptake+Inhibitor+Treatment+Switched+to+Vortioxetine+or+Agomelatine&doi=10.1002%2Fhup.2424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine</span></div><div class="casAuthors">Montgomery, Stuart A.; Nielsen, Rebecca Z.; Poulsen, Lis H.; Haeggstroem, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Human Psychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">470-482</span>CODEN:
                <span class="NLM_cas:coden">HUPSEC</span>;
        ISSN:<span class="NLM_cas:issn">0885-6222</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objective : This randomised, double-blind, 12-wk study compared efficacy and tolerability of flexible-dose treatment with vortioxetine (10-20 mg/day) vs. agomelatine (25-50 mg/day) in major depressive disorder patients with inadequate response to selective serotonin reuptake inhibitor (SSRI)/serotonin-noradrenaline reuptake inhibitor (SNRI) monotherapy.  Methods : Patients were switched directly from SSRI/SNRI to vortioxetine or agomelatine.  Primary endpoint was change from baseline to week 8 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score analyzed by mixed model for repeated measurements, using a noninferiority test followed by a superiority test.  Secondary endpoints included response and remission rates, anxiety symptoms (Hamilton Anxiety Rating Scale), Clin. Global Impression, overall functioning (Sheehan Disability Scale), health-related quality of life (EuroQol 5 Dimensions), productivity (work limitation questionnaire) and family functioning (Depression and Family Functioning Scale).  Results : Primary endpoint noninferiority was established and vortioxetine (n = 252) was superior to agomelatine (n = 241) by 2.2 MADRS points (p < 0.01).  Vortioxetine was also significantly superior in response and remission rates at weeks 8 and 12; MADRS, Hamilton Anxiety Rating Scale, Clin. Global Impression, Sheehan Disability Scale and EuroQol 5 Dimensions scores at week 4 onwards; work limitation questionnaire at week 8 and Depression and Family Functioning Scale at weeks 8 and 12.  Fewer patients withdrew because of adverse events with vortioxetine (5.9% vs 9.5%).  Adverse events (incidence ≥5%) were nausea, headache, dizziness and somnolence.  Conclusions : Vortioxetine was noninferior and significantly superior to agomelatine in major depressive disorder patients with previous inadequate response to a single course of SSRI/SNRI monotherapy.  Vortioxetine was safe and well tolerated. cpr 2014 The Authors.  Human Psychopharmacol.: Clin. and Exptl. published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouSJ12k3scHbVg90H21EOLACvtfcHk0lhYZCh_VQc1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFahtLfO&md5=56f57ef33d73912b462281e2e29209b1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fhup.2424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhup.2424%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DS.%2BA.%26aulast%3DNielsen%26aufirst%3DR.%2BZ.%26aulast%3DPoulsen%26aufirst%3DL.%2BH.%26aulast%3DH%25C3%25A4ggstr%25C3%25B6m%26aufirst%3DL.%26atitle%3DA%2520Randomised%252C%2520Double-Blind%2520Study%2520in%2520Adults%2520with%2520Major%2520Depressive%2520Disorder%2520with%2520an%2520Inadequate%2520Response%2520to%2520a%2520Single%2520Course%2520of%2520Selective%2520Serotonin%2520Reuptake%2520Inhibitor%2520or%2520Serotonin-Noradrenaline%2520Reuptake%2520Inhibitor%2520Treatment%2520Switched%2520to%2520Vortioxetine%2520or%2520Agomelatine%26jtitle%3DHum.%2520Psychopharmacol.%26date%3D2014%26volume%3D29%26spage%3D470%26epage%3D482%26doi%3D10.1002%2Fhup.2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Snyder, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrick, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestler, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wennogle, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mates, S.</span><span> </span><span class="NLM_article-title">Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission</span> <span class="citation_source-journal">Psychopharmacology (Berl.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">621</span><span class="refDoi"> DOI: 10.1007/s00213-014-3704-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs00213-014-3704-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=25120104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhsVGlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2015&pages=605-621&author=G.+L.+Snyderauthor=K.+E.+Vanoverauthor=H.+Zhuauthor=D.+B.+Millerauthor=J.+P.+O%E2%80%99Callaghanauthor=J.+Tomeschauthor=P.+Liauthor=Q.+Zhangauthor=V.+Krishnanauthor=J.+P.+Hendrickauthor=E.+J.+Nestlerauthor=R.+E.+Davisauthor=L.+P.+Wennogleauthor=S.+Mates&title=Functional+Profile+of+a+Novel+Modulator+of+Serotonin%2C+Dopamine%2C+and+Glutamate+Neurotransmission&doi=10.1007%2Fs00213-014-3704-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission</span></div><div class="casAuthors">Snyder Gretchen L; Vanover Kimberly E; Zhu Hongwen; Miller Diane B; O'Callaghan James P; Tomesch John; Li Peng; Zhang Qiang; Krishnan Vaishnav; Hendrick Joseph P; Nestler Eric J; Davis Robert E; Wennogle Lawrence P; Mates Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">605-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Schizophrenia remains among the most prevalent neuropsychiatric disorders, and current treatment options are accompanied by unwanted side effects.  New treatments that better address core features of the disease with minimal side effects are needed.  OBJECTIVES:  As a new therapeutic approach, 1-(4-fluoro-phenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007) is currently in human clinical trials for the treatment of schizophrenia.  Here, we characterize the preclinical functional activity of ITI-007.  RESULTS:  ITI-007 is a potent 5-HT2A receptor ligand (K i  = 0.5 nM) with strong affinity for dopamine (DA) D2 receptors (K i  = 32 nM) and the serotonin transporter (SERT) (K i  = 62 nM) but negligible binding to receptors (e.g., H1 histaminergic, 5-HT2C, and muscarinic) associated with cognitive and metabolic side effects of antipsychotic drugs.  In vivo it is a 5-HT2A antagonist, blocking (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI)-induced headtwitch in mice with an inhibitory dose 50 (ID50) = 0.09 mg/kg, per oral (p.o.), and has dual properties at D2 receptors, acting as a postsynaptic D2 receptor antagonist to block D-amphetamine hydrochloride (D-AMPH) hyperlocomotion (ID50 = 0.95 mg/kg, p.o.), yet acting as a partial agonist at presynaptic striatal D2 receptors in assays measuring striatal DA neurotransmission.  Further, in microdialysis studies, this compound significantly and preferentially enhances mesocortical DA release.  At doses relevant for antipsychotic activity in rodents, ITI-007 has no demonstrable cataleptogenic activity.  ITI-007 indirectly modulates glutamatergic neurotransmission by increasing phosphorylation of GluN2B-type N-methyl-D-aspartate (NMDA) receptors and preferentially increases phosphorylation of glycogen synthase kinase 3β (GSK-3β) in mesolimbic/mesocortical dopamine systems.  CONCLUSION:  The combination of in vitro and in vivo activities of this compound support its development for the treatment of schizophrenia and other psychiatric and neurologic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7sJSko_pZPXqj_yg7twvpfW6udTcc2eZo6v3FPJPjPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhsVGlsA%253D%253D&md5=95a6b91827ab2af5e48af458f4330419</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3704-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3704-1%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DD.%2BB.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DJ.%2BP.%26aulast%3DTomesch%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3DHendrick%26aufirst%3DJ.%2BP.%26aulast%3DNestler%26aufirst%3DE.%2BJ.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26aulast%3DMates%26aufirst%3DS.%26atitle%3DFunctional%2520Profile%2520of%2520a%2520Novel%2520Modulator%2520of%2520Serotonin%252C%2520Dopamine%252C%2520and%2520Glutamate%2520Neurotransmission%26jtitle%3DPsychopharmacology%2520%2528Berl.%2529%26date%3D2015%26volume%3D232%26spage%3D605%26epage%3D621%26doi%3D10.1007%2Fs00213-014-3704-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Terry, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccafusco, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span> </span><span class="NLM_article-title">Cognitive Dysfunction in Neuropsychiatric Disorders: Selected Serotonin Receptor Subtypes as Therapeutic Targets</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1016/j.bbr.2007.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.bbr.2007.12.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2008&pages=30-38&author=A.+V.+Terryauthor=J.+J.+Buccafuscoauthor=C.+Wilson&title=Cognitive+Dysfunction+in+Neuropsychiatric+Disorders%3A+Selected+Serotonin+Receptor+Subtypes+as+Therapeutic+Targets&doi=10.1016%2Fj.bbr.2007.12.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2007.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2007.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DTerry%26aufirst%3DA.%2BV.%26aulast%3DBuccafusco%26aufirst%3DJ.%2BJ.%26aulast%3DWilson%26aufirst%3DC.%26atitle%3DCognitive%2520Dysfunction%2520in%2520Neuropsychiatric%2520Disorders%253A%2520Selected%2520Serotonin%2520Receptor%2520Subtypes%2520as%2520Therapeutic%2520Targets%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2008%26volume%3D195%26spage%3D30%26epage%3D38%26doi%3D10.1016%2Fj.bbr.2007.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkowska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaśkowska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, P.</span><span> </span><span class="NLM_article-title">Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4543</span><span class="NLM_x">–</span> <span class="NLM_lpage">4557</span><span class="refDoi"> DOI: 10.1021/jm401895u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401895u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Chs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4543-4557&author=M.+Ko%C5%82aczkowskiauthor=M.+Marcinkowskaauthor=A.+Buckiauthor=M.+Paw%C5%82owskiauthor=K.+Mitkaauthor=J.+Ja%C5%9Bkowskaauthor=P.+Kowalskiauthor=G.+Kazekauthor=A.+Siwekauthor=A.+Wasikauthor=A.+Weso%C5%82owskaauthor=P.+Mierzejewskiauthor=P.+Bienkowski&title=Novel+Arylsulfonamide+Derivatives+with+5-HT6%2F5-HT7+Receptor+Antagonism+Targeting+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.1021%2Fjm401895u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia</span></div><div class="casAuthors">Kolaczkowski, Marcin; Marcinkowska, Monika; Bucki, Adam; Pawlowski, Maciej; Mitka, Katarzyna; Jaskowska, Jolanta; Kowalski, Piotr; Kazek, Grzegorz; Siwek, Agata; Wasik, Anna; Wesolowska, Anna; Mierzejewski, Pawel; Bienkowski, Przemyslaw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4543-4557</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to target behavioral and psychol. symptoms of dementia (BPSD), we used mol. modeling-assisted design to obtain novel multifunctional arylsulfonamide derivs. that potently antagonize 5-HT6/7/2A and D2 receptors, without interacting with M1 receptors and hERG channels.  In vitro studies confirmed their antagonism of 5-HT7/2A and D2 receptors and weak interactions with key antitargets (M1R and hERG) assocd. with side effects.  Marked 5-HT6 receptor affinities were also obsd., notably for 6-fluoro-3-(piperidin-4-yl)-1,2-benzoxazole derivs. connected by a 3-4 unit alkyl linker with mono- or bicyclic, lipophilic arylsulfonamide moieties.  N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulfonamide (I) was characterized in vitro on 14 targets and antitargets.  It displayed dual blockade of 5-HT6 and D2 receptors and negligible interactions at hERG and M1 receptors.  Unlike ref. antipsychotics, I displayed marked antipsychotic and antidepressant activity in rats after oral administration, in the absence of cognitive or motor impairment.  This profile is particularly attractive when targeting a fragile, elderly BPSD patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXCVqnVgswvLVg90H21EOLACvtfcHk0lhjdNnYHWhC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Chs7k%253D&md5=83ff946d12d3de66d40f91c1f90fabee</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm401895u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401895u%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26aulast%3DMitka%26aufirst%3DK.%26aulast%3DJa%25C5%259Bkowska%26aufirst%3DJ.%26aulast%3DKowalski%26aufirst%3DP.%26aulast%3DKazek%26aufirst%3DG.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DWasik%26aufirst%3DA.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26atitle%3DNovel%2520Arylsulfonamide%2520Derivatives%2520with%25205-HT6%252F5-HT7%2520Receptor%2520Antagonism%2520Targeting%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4543%26epage%3D4557%26doi%3D10.1021%2Fjm401895u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Wicke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haupt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bespalov, A.</span><span> </span><span class="NLM_article-title">Investigational Drugs Targeting 5-HT6 Receptors for the Treatment of Alzheimer’s Disease</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1515</span><span class="NLM_x">–</span> <span class="NLM_lpage">1528</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1102884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1517%2F13543784.2015.1102884" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1515-1528&author=K.+Wickeauthor=A.+Hauptauthor=A.+Bespalov&title=Investigational+Drugs+Targeting+5-HT6+Receptors+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1517%2F13543784.2015.1102884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1102884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1102884%26sid%3Dliteratum%253Aachs%26aulast%3DWicke%26aufirst%3DK.%26aulast%3DHaupt%26aufirst%3DA.%26aulast%3DBespalov%26aufirst%3DA.%26atitle%3DInvestigational%2520Drugs%2520Targeting%25205-HT6%2520Receptors%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1515%26epage%3D1528%26doi%3D10.1517%2F13543784.2015.1102884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Codony, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vela, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramírez, M. J.</span><span> </span><span class="NLM_article-title">5-HT6 Receptor and Cognition</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1016/j.coph.2011.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.coph.2011.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=21330210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=94-100&author=X.+Codonyauthor=J.+M.+Velaauthor=M.+J.+Ram%C3%ADrez&title=5-HT6+Receptor+and+Cognition&doi=10.1016%2Fj.coph.2011.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT6 receptor and cognition</span></div><div class="casAuthors">Codony, Xabier; Vela, Jose Miguel; Ramirez, Maria Javier</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-100</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since its discovery in 1993 and subsequent development of selective antagonists, a growing no. of studies support the use of serotonin 5-HT6 receptor antagonism as a promising mechanism for treating cognitive dysfunction.  Lately, several studies with structurally different compds. have shown that not only antagonists, but also 5-HT6 receptor agonists improve learning and memory in animal models.  There is even an antagonist, SB-742457, that has completed phase II trials for the treatment of Alzheimer's disease.  In addn. to describe preclin. and clin. evidence of the effect of 5-HT6 receptor compds. on cognition, this article will also focus on the purported biochem. and neurochem. mechanisms of action by which 5-HT6 receptor compds. could influence cognition in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2u6LBrBGWo7Vg90H21EOLACvtfcHk0lhjdNnYHWhC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7c%253D&md5=af905f7a2b2934b32fcd879e25fd7dc4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2011.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2011.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DRam%25C3%25ADrez%26aufirst%3DM.%2BJ.%26atitle%3D5-HT6%2520Receptor%2520and%2520Cognition%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D94%26epage%3D100%26doi%3D10.1016%2Fj.coph.2011.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Ramírez, M. J.</span><span> </span><span class="NLM_article-title">5-HT6 Receptors and Alzheimer’s Disease</span> <span class="citation_source-journal">Alzheimer’s Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="refDoi"> DOI: 10.1186/alzrt169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1186%2Falzrt169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=23607787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC3srntlKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=15&author=M.+J.+Ram%C3%ADrez&title=5-HT6+Receptors+and+Alzheimer%E2%80%99s+Disease&doi=10.1186%2Falzrt169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT6 receptors and Alzheimer's disease</span></div><div class="casAuthors">Ramirez Maria Javier</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's research & therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">During the past 20 years, the 5-HT6 receptor has received increasing attention and become a promising target for improving cognition.  Several studies with structurally different compounds have shown that not only antagonists but also 5-HT6 receptor agonists improve learning and memory in animal models.  A large number of publications describing the development of ligands for this receptor have come to light, and it is now quite evident that 5-HT6 receptors have great pharmaceutical potential in terms of related patents.  However, 5-HT6 receptor functionality is much more complex than initially defined.  According to the existing data, different cellular pathways may be activated, depending on the drug being used.  This article reviews preclinical and clinical evidence of the effects that 5-HT6 receptor compounds have on cognition.  In addition, the biochemical and neurochemical mechanisms of action through which 5-HT6 receptor compounds can influence cognition will be described.  Overall, several 5-HT6-targeted compounds can reasonably be regarded as powerful drug candidates for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7pHigIdj7Tv6BottYdIAWfW6udTcc2eaUnPY9qwvU9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srntlKisw%253D%253D&md5=01d0f60c195c30be179e3dde935b6c46</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1186%2Falzrt169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Falzrt169%26sid%3Dliteratum%253Aachs%26aulast%3DRam%25C3%25ADrez%26aufirst%3DM.%2BJ.%26atitle%3D5-HT6%2520Receptors%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2013%26volume%3D5%26spage%3D15%26doi%3D10.1186%2Falzrt169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Calhoun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossberg, G. T.</span><span> </span><span class="NLM_article-title">Emerging Chemical Therapies Targeting 5-Hydroxytryptamine in the Treatment of Alzheimer’s Disease</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1080/14728214.2017.1293651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1080%2F14728214.2017.1293651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=28253832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVOqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=101-105&author=A.+Calhounauthor=J.+Koauthor=G.+T.+Grossberg&title=Emerging+Chemical+Therapies+Targeting+5-Hydroxytryptamine+in+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1080%2F14728214.2017.1293651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease</span></div><div class="casAuthors">Calhoun, Amanda; Ko, Je; Grossberg, George T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-105</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a major neuropsychiatric disorder affecting more than 5 million Americans over age 65.  By the year 2050, AD is expected to affect over 30 million.  Characterized by neuronal cell death accompanied by the accumulation of neurofibrillary tangles and neuritic plaques, AD results in devastating clin. symptomatol. with a lasting psychosocial and financial impact.  Studies have shown that the current treatments for AD, cholinesterase inhibitors (ChEI's) and NMDA receptor antagonists, have limited efficacy.  The 5-HT-6 receptor antagonists Idalopirdine and Intepirdine have shown the most progress in current clin. trials and warrant consideration as emerging treatments for AD.  This review discusses 5-HT6 antagonists currently in clin. trials as potential treatments for AD symptomatol. and how 5-HT6 physiol. may play a pos. role in alleviating AD symptom pathophysiol.  A literature search using PubMed was conducted using the terms Idalopirdine, Intepirdine, 5-HT-6 antagonist, and AD as keywords.  Clinicaltrials.gov and Alzforum were also used to obtain information on clin. trials.  If current Phase-3 trials are pos., 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyTJA1x4adLLVg90H21EOLACvtfcHk0lhOmfSndgW2Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVOqurs%253D&md5=3765256d30cd7bf2d6e10070db6eba7b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1080%2F14728214.2017.1293651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728214.2017.1293651%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DA.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DGrossberg%26aufirst%3DG.%2BT.%26atitle%3DEmerging%2520Chemical%2520Therapies%2520Targeting%25205-Hydroxytryptamine%2520in%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2017%26volume%3D22%26spage%3D101%26epage%3D105%26doi%3D10.1080%2F14728214.2017.1293651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Ferrero, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, M. J.</span><span> </span><span class="NLM_article-title">Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span><span class="refDoi"> DOI: 10.1007/s40263-016-0399-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs40263-016-0399-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27914038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVaqtLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=19-32&author=H.+Ferreroauthor=M.+Solasauthor=P.+T.+Francisauthor=M.+J.+Ramirez&title=Serotonin+5-HT6+Receptor+Antagonists+in+Alzheimer%E2%80%99s+Disease%3A+Therapeutic+Rationale+and+Current+Development+Status&doi=10.1007%2Fs40263-016-0399-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status</span></div><div class="casAuthors">Ferrero, Hilda; Solas, Maite; Francis, Paul T.; Ramirez, Maria J.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-32</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common cause of dementia in elderly people.  Because of the lack of effective treatments for this illness, research focused on identifying compds. that restore cognition and functional impairments in patients with AD is a very active field.  Since its discovery in 1993, the serotonin 5-HT6 receptor has received increasing attention, and a growing no. of studies supported 5-HT6 receptor antagonism as a target for improving cognitive dysfunction in AD.  This article reviews the rationale behind investigations into the targeting of 5-HT6 receptors as a symptomatic treatment for cognitive and/or behavioral symptoms of AD.  In addn. to describing the available clin. evidence, this article also describes the purported biochem. and neurochem. mechanisms of action by which 5-HT6 receptor antagonists could influence cognition, and the preclin. data supporting this therapeutic approach to AD.  A large no. of publications describing the development of ligands for this receptor have come to light and preclin. data indicate the procognitive efficacy of 5-HT6 receptor antagonists.  Subsequently, the no. of patents protecting 5-HT6 chem. entities has continuously grown.  Some of these compds. have successfully undergone phase I clin. studies and have been further evaluated in clin. phase II trials with variable success.  Phase II studies have also revealed the potential of combining 5-HT6 receptor antagonism and cholinesterase inhibition.  Two of these antagonists, idalopirdine and RVT-101, have been further developed into ongoing phase III clin. trials.  Overall, 5-HT6 receptor antagonists can reasonably be regarded as potential drug candidates for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbBi5osKkbbbVg90H21EOLACvtfcHk0lhOmfSndgW2Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVaqtLfK&md5=f8a9d3bb9b1d986b81aae755ac2e72bb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs40263-016-0399-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-016-0399-3%26sid%3Dliteratum%253Aachs%26aulast%3DFerrero%26aufirst%3DH.%26aulast%3DSolas%26aufirst%3DM.%26aulast%3DFrancis%26aufirst%3DP.%2BT.%26aulast%3DRamirez%26aufirst%3DM.%2BJ.%26atitle%3DSerotonin%25205-HT6%2520Receptor%2520Antagonists%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Therapeutic%2520Rationale%2520and%2520Current%2520Development%2520Status%26jtitle%3DCNS%2520Drugs%26date%3D2017%26volume%3D31%26spage%3D19%26epage%3D32%26doi%3D10.1007%2Fs40263-016-0399-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Wilkinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windfeld, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colding-Jørgensen, E.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of Idalopirdine, a 5-HT6 Receptor Antagonist, in Patients with Moderate Alzheimer’s Disease (LADDER): A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1092</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span><span class="refDoi"> DOI: 10.1016/S1474-4422(14)70198-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2FS1474-4422%2814%2970198-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=25297016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslagsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1092-1099&author=D.+Wilkinsonauthor=K.+Windfeldauthor=E.+Colding-J%C3%B8rgensen&title=Safety+and+Efficacy+of+Idalopirdine%2C+a+5-HT6+Receptor+Antagonist%2C+in+Patients+with+Moderate+Alzheimer%E2%80%99s+Disease+%28LADDER%29%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Phase+2+Trial&doi=10.1016%2FS1474-4422%2814%2970198-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial</span></div><div class="casAuthors">Wilkinson, David; Windfeld, Kristian; Colding-Joergensen, Eskild</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1092-1099</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In human beings, 5-HT6 receptors are almost exclusively expressed in the brain, particularly in areas relevant for cognition, such as the hippocampus and frontal cortex.  We assessed the effect on cognitive performance of Lu AE58054 (idalopirdine), a selective 5-HT6 receptor antagonist, in donepezil-treated patients with moderate Alzheimer's disease.  For this randomised, double-blind, placebo-controlled phase 2 trial (LADDER), we recruited patients from 48 outpatient clin. sites in seven countries.  Patients were 50 years or older, had moderate Alzheimer's disease (a mini-mental state examn. score of 12-19), and had been stably treated with donepezil 10 mg per day for 3 or more months.  Using a computer-generated sequence, we randomly assigned patients (1:1, stratified by site) to receive either idalopirdine 90 mg per day (30 mg thrice daily) or placebo.  The primary endpoint was change from baseline in the 11-item Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at week 24.  We analyzed all efficacy endpoints in the full-anal. set (modified intention-to-treat anal.).  This trial is registered with ClinicalTrials.gov, no. NCT01019421.  Between Dec 8, 2009, and Dec 23, 2011, we randomly allocated 278 patients to treatment: 133 to placebo and 145 to idalopirdine. 132 patients in the placebo group and 140 in the exptl. group were included in the final anal.  At week 24, the change from baseline in ADAS-cog total score was +1·38 (SD 0·53) in the placebo group and -0·77 (0·55) in the idalopirdine group (treatment difference of -2·16 points, 95% CI -3·62 to -0·69; p=0·0040). 25 patients (seven taking placebo and 18 taking idalopirdine) discontinued treatment because of adverse events, the difference between groups being mainly due to asymptomatic transient increases in transaminase concns. in some idalopirdine-treated patients.  The most common adverse events (occurring in >3% of patients) were increased γ-glutamyltransferase (14 [10%] patients in the idalopirdine group vs two [2%] in the placebo group), diarrhoea (six [4%] vs nine [7%]), urinary tract infection (three [2%] vs nine [7%]), fall (three [2%] vs eight [6%]), increased alanine aminotransferase (nine [6%] vs none), and benign prostatic hyperplasia (two [5%] vs none).  Serious adverse events were reported by 14 (10%) patients in the idalopirdine group and 13 (10%) patients in the placebo group.  One death occurred in each treatment group, neither were regarded as being related to treatment.  Idalopirdine improved cognitive function in donepezil-treated patients with moderate Alzheimer's disease.  Larger studies in a broader population of patients are ongoing to substantiate the effects reported here.H Lundbeck A/S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL5ZnwmPwC7bVg90H21EOLACvtfcHk0lhOmfSndgW2Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslagsb3E&md5=6bb5b0b63785839b26b618ae121e805c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2814%2970198-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252814%252970198-X%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DD.%26aulast%3DWindfeld%26aufirst%3DK.%26aulast%3DColding-J%25C3%25B8rgensen%26aufirst%3DE.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Idalopirdine%252C%2520a%25205-HT6%2520Receptor%2520Antagonist%252C%2520in%2520Patients%2520with%2520Moderate%2520Alzheimer%25E2%2580%2599s%2520Disease%2520%2528LADDER%2529%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%25202%2520Trial%26jtitle%3DLancet%2520Neurol.%26date%3D2014%26volume%3D13%26spage%3D1092%26epage%3D1099%26doi%3D10.1016%2FS1474-4422%2814%2970198-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Galimberti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpini, E.</span><span> </span><span class="NLM_article-title">Idalopirdine as a Treatment for Alzheimer’s Disease</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">981</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1052402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1517%2F13543784.2015.1052402" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=981-987&author=D.+Galimbertiauthor=E.+Scarpini&title=Idalopirdine+as+a+Treatment+for+Alzheimer%E2%80%99s+Disease&doi=10.1517%2F13543784.2015.1052402"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1052402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1052402%26sid%3Dliteratum%253Aachs%26aulast%3DGalimberti%26aufirst%3DD.%26aulast%3DScarpini%26aufirst%3DE.%26atitle%3DIdalopirdine%2520as%2520a%2520Treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D981%26epage%3D987%26doi%3D10.1517%2F13543784.2015.1052402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieńkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">ADN-1184 a Monoaminergic Ligand with 5-HT6/7 Receptor Antagonist Activity: Pharmacological Profile and Potential Therapeutic Utility</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span><span class="refDoi"> DOI: 10.1111/bph.12509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1111%2Fbph.12509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=24199650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ehtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=973-984&author=M.+Ko%C5%82aczkowskiauthor=P.+Mierzejewskiauthor=P.+Bie%C5%84kowskiauthor=A.+Weso%C5%82owskaauthor=A.+Newman-Tancredi&title=ADN-1184+a+Monoaminergic+Ligand+with+5-HT6%2F7+Receptor+Antagonist+Activity%3A+Pharmacological+Profile+and+Potential+Therapeutic+Utility&doi=10.1111%2Fbph.12509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">ADN-1184 a monoaminergic ligand with 5-HT6/7 receptor antagonist activity: pharmacological profile and potential therapeutic utility</span></div><div class="casAuthors">Kolaczkowski, M.; Mierzejewski, P.; Bienkowski, P.; Wesolowska, A.; Newman-Tancredi, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">973-984</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Many dementia patients exhibit behavioral and psychol. symptoms (BPSD) that include psychosis, aggressivity, depression and anxiety.  Antipsychotic drugs are frequently prescribed but fail to significantly attenuate mood deficits, may interfere with cognitive function and are assocd. with motor and cardiac side effects, which are problematic in elderly patients.  A need therefore exists for drugs that are better suited for the treatment of BPSD.  Exptl. Approach: We used in vitro cellular and in vivo behavioral tests to characterize ADN-1184, a novel arylsulfonamide ligand with potential utility for treatment of BPSD.  Key Results: ADN-1184 exhibits substantial 5-HT6/5-HT7/5-HT2A/D2 receptor affinity and antagonist properties in vitro.  In tests of antipsychotic-like activity, it reversed MK-801-induced hyperactivity and stereotypies and inhibited conditioned avoidance response (MED = 3 mg·kg-1 i.p.).  Remarkably, ADN-1184 also reduced immobility time in the forced swim test at low doses (0.3 and 1 mg·kg-1 i.p.; higher doses were not significantly active).  Notably, up to 30 mg·kg-1 ADN-1184 did not impair memory performance in the passive avoidance test or elicit significant catalepsy and only modestly inhibited spontaneous locomotor activity (MED = 30 mg·kg-1 i.p.).  Conclusions and Implications: ADN-1184 combines antipsychotic-like with antidepressant-like properties without interfering with memory function or locomotion.  This profile is better than that of commonly used atypical antipsychotics tested under the same conditions and suggests that it is feasible to identify drugs that improve BPSD, without exacerbating cognitive deficit or movement impairment, which are of particular concern in patients with dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRj9iM1zSMXrVg90H21EOLACvtfcHk0lhbQr9gJ6g6mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ehtbw%253D&md5=d72b8585ba495cc647ba280bbcf0d896</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fbph.12509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12509%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBie%25C5%2584kowski%26aufirst%3DP.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DADN-1184%2520a%2520Monoaminergic%2520Ligand%2520with%25205-HT6%252F7%2520Receptor%2520Antagonist%2520Activity%253A%2520Pharmacological%2520Profile%2520and%2520Potential%2520Therapeutic%2520Utility%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D973%26epage%3D984%26doi%3D10.1111%2Fbph.12509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojarski, A. J.</span><span> </span><span class="NLM_article-title">Receptor-Based Pharmacophores for Serotonin 5-HT7R Antagonists-Implications to Selectivity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6732</span><span class="NLM_x">–</span> <span class="NLM_lpage">6741</span><span class="refDoi"> DOI: 10.1021/jm060300c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060300c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6732-6741&author=M.+Ko%C5%82aczkowskiauthor=M.+Nowakauthor=M.+Paw%C5%82owskiauthor=A.+J.+Bojarski&title=Receptor-Based+Pharmacophores+for+Serotonin+5-HT7R+Antagonists-Implications+to+Selectivity&doi=10.1021%2Fjm060300c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm060300c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060300c%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DNowak%26aufirst%3DM.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26atitle%3DReceptor-Based%2520Pharmacophores%2520for%2520Serotonin%25205-HT7R%2520Antagonists-Implications%2520to%2520Selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6732%26epage%3D6741%26doi%3D10.1021%2Fjm060300c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Kolaczkowski, M.; Kowalski, P.; Jaskowska, J.; Marcinkowski, M.; Mitka, K.; Bucki, A.; Wesolowska, A.; Pawlowski, M.</span><span> </span><span class="NLM_article-title">Arylsulfonamides for the Treatment of CNS Diseases</span>. WO2012035123(A1), March 22,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Kolaczkowski&author=P.+Kowalski&author=J.+Jaskowska&author=M.+Marcinkowski&author=K.+Mitka&author=A.+Bucki&author=A.+Wesolowska&author=M.+Pawlowski&title=Arylsulfonamides+for+the+Treatment+of+CNS+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKolaczkowski%26aufirst%3DM.%26atitle%3DArylsulfonamides%2520for%2520the%2520Treatment%2520of%2520CNS%2520Diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">van Hes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smid, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroomer, C. N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulp, M. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heyden, J. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreary, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselink, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">SLV310, a Novel, Potential Antipsychotic, Combining Potent Dopamine D2 Receptor Antagonism with Serotonin Reuptake Inhibition</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">408</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00996-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2FS0960-894X%2802%2900996-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=405-408&author=R.+van+Hesauthor=P.+Smidauthor=C.+N.+J.+Stroomerauthor=K.+Tipkerauthor=M.+T.+M.+Tulpauthor=J.+A.+M.+van+der+Heydenauthor=A.+C.+McCrearyauthor=M.+B.+Hesselinkauthor=C.+G.+Kruse&title=SLV310%2C+a+Novel%2C+Potential+Antipsychotic%2C+Combining+Potent+Dopamine+D2+Receptor+Antagonism+with+Serotonin+Reuptake+Inhibition&doi=10.1016%2FS0960-894X%2802%2900996-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900996-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900996-4%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BHes%26aufirst%3DR.%26aulast%3DSmid%26aufirst%3DP.%26aulast%3DStroomer%26aufirst%3DC.%2BN.%2BJ.%26aulast%3DTipker%26aufirst%3DK.%26aulast%3DTulp%26aufirst%3DM.%2BT.%2BM.%26aulast%3Dvan%2Bder%2BHeyden%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DHesselink%26aufirst%3DM.%2BB.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DSLV310%252C%2520a%2520Novel%252C%2520Potential%2520Antipsychotic%252C%2520Combining%2520Potent%2520Dopamine%2520D2%2520Receptor%2520Antagonism%2520with%2520Serotonin%2520Reuptake%2520Inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D405%26epage%3D408%26doi%3D10.1016%2FS0960-894X%2802%2900996-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Wesolowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partyka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jastrzebska-Wiesek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolarz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieńkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaczkowski, M.</span><span> </span><span class="NLM_article-title">Tail Suspension Test Does Not Detect Antidepressant-like Properties of Atypical Antipsychotics</span> <span class="citation_source-journal">Behav. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1097/FBP.0b013e3283423d6b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1097%2FFBP.0b013e3283423d6b" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=7-13&author=A.+Wesolowskaauthor=A.+Partykaauthor=M.+Jastrzebska-Wiesekauthor=A.+Kolarzauthor=P.+Mierzejewskiauthor=P.+Bie%C5%84kowskiauthor=M.+Kolaczkowski&title=Tail+Suspension+Test+Does+Not+Detect+Antidepressant-like+Properties+of+Atypical+Antipsychotics&doi=10.1097%2FFBP.0b013e3283423d6b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1097%2FFBP.0b013e3283423d6b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0b013e3283423d6b%26sid%3Dliteratum%253Aachs%26aulast%3DWesolowska%26aufirst%3DA.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DJastrzebska-Wiesek%26aufirst%3DM.%26aulast%3DKolarz%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBie%25C5%2584kowski%26aufirst%3DP.%26aulast%3DKolaczkowski%26aufirst%3DM.%26atitle%3DTail%2520Suspension%2520Test%2520Does%2520Not%2520Detect%2520Antidepressant-like%2520Properties%2520of%2520Atypical%2520Antipsychotics%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2011%26volume%3D22%26spage%3D7%26epage%3D13%26doi%3D10.1097%2FFBP.0b013e3283423d6b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Partyka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jastrzębska-Więsek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieńkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span> </span><span class="NLM_article-title">ADN-1184, a Monoaminergic Ligand with 5-HT6/7 Receptor Antagonist Action, Exhibits Activity in Animal Models of Anxiety</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">389</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1007/s00210-016-1229-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs00210-016-1229-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26979176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1WlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2016&pages=593-602&author=A.+Partykaauthor=A.+Wasikauthor=M.+Jastrz%C4%99bska-Wi%C4%99sekauthor=P.+Mierzejewskiauthor=P.+Bie%C5%84kowskiauthor=M.+Ko%C5%82aczkowskiauthor=A.+Weso%C5%82owska&title=ADN-1184%2C+a+Monoaminergic+Ligand+with+5-HT6%2F7+Receptor+Antagonist+Action%2C+Exhibits+Activity+in+Animal+Models+of+Anxiety&doi=10.1007%2Fs00210-016-1229-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety</span></div><div class="casAuthors">Partyka, Anna; Wasik, Anna; Jastrzebska-Wiesek, Magdalena; Mierzejewski, Pawel; Bienkowski, Przemyslaw; Kolaczkowski, Marcin; Wesolowska, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">593-602</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Behavioral and psychol. symptoms of dementia (BPSD) include apathy, sleep problems, irritability, wandering, elation, agitation/aggression, and mood disorders such as depression and/or anxiety.  Elderly patients are usually treated with second-generation antipsychotics; however, they present not enough efficacy against all symptoms obsd.  Hence, there still is an unmet need for novel pharmacotherapeutic agents targeted BPSD.  A novel arylsulfonamide deriv. ADN-1184 has been developed that possesses a preclin. profile of activity corresponding to criteria required for treatment of both psychosis and depressive symptoms of BPSD without exacerbating cognitive impairment or inducing motor disturbances.  To broaden its pharmacol. efficacy toward anxiety symptoms, its anxiolytic properties have been examd. in common animal preclin. models in rats and mice.  ADN-1184 significantly increased the no. of entries into open arms measured in the elevated plus-maze test; however, it simultaneously increased parameters of exploratory activity.  In the Vogel conflict drinking test, ADN-1184 dose-dependently and significantly increased the no. of shocks accepted and the no. of licks.  Moreover, in mice, it also had specific anxiolytic-like activity in the four-plate test, and only negligible one at a specific mid-range dose measured in the spontaneous marble burying test.  The obtained findings reveal that ADN-1184 displays anxiolytic-like activity in animal models of anxiety which employed punished stimuli.  In its unusual combination of some anxiolytic action with already proven antipsychotic and antidepressant properties, and lack of any disruptive impact on learning and memory processes and motor coordination, ADN-1184 displays a profile that would be desired for a novel therapeutic for BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHrAzMiwXrn7Vg90H21EOLACvtfcHk0ljOZ_oTYzhLRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1WlsL0%253D&md5=e898720612e6573efa6fa8389f7af195</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00210-016-1229-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-016-1229-3%26sid%3Dliteratum%253Aachs%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DWasik%26aufirst%3DA.%26aulast%3DJastrz%25C4%2599bska-Wi%25C4%2599sek%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBie%25C5%2584kowski%26aufirst%3DP.%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26atitle%3DADN-1184%252C%2520a%2520Monoaminergic%2520Ligand%2520with%25205-HT6%252F7%2520Receptor%2520Antagonist%2520Action%252C%2520Exhibits%2520Activity%2520in%2520Animal%2520Models%2520of%2520Anxiety%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2016%26volume%3D389%26spage%3D593%26epage%3D602%26doi%3D10.1007%2Fs00210-016-1229-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Pytka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlik, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlica-Gosiewska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witalis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkielewicz, A.</span><span> </span><span class="NLM_article-title">HBK-14 and HBK-15 with Antidepressant-like and/or Memory-Enhancing Properties Increase Serotonin Levels in the Hippocampus after Chronic Treatment in Mice</span> <span class="citation_source-journal">Metab. Brain Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span><span class="refDoi"> DOI: 10.1007/s11011-016-9932-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs11011-016-9932-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27888375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyms73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=547-556&author=K.+Pytkaauthor=K.+Gawlikauthor=D.+Pawlica-Gosiewskaauthor=J.+Witalisauthor=A.+Waszkielewicz&title=HBK-14+and+HBK-15+with+Antidepressant-like+and%2For+Memory-Enhancing+Properties+Increase+Serotonin+Levels+in+the+Hippocampus+after+Chronic+Treatment+in+Mice&doi=10.1007%2Fs11011-016-9932-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">HBK-14 and HBK-15 with antidepressant-like and/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice</span></div><div class="casAuthors">Pytka, Karolina; Gawlik, Katarzyna; Pawlica-Gosiewska, Dorota; Witalis, Jadwiga; Waszkielewicz, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Metabolic Brain Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">547-556</span>CODEN:
                <span class="NLM_cas:coden">MBDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0885-7490</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">5-HT1A and 5-HT7 receptor ligands might have antidepressant-like properties and improve cognitive function.  We previously reported significant antidepressant- and anxiolytic-like effects of two dual 5-HT1A and 5-HT7 receptor antagonists in various behavioral tests in rodents.  As a continuation of our previous expts., in this study we aimed to investigate whether chronic administration of 1-[(2,6-dimethylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-14) and 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-15) caused antidepressant-like effects and elevated serotonin levels in the murine hippocampus.  We also evaluated cholinolytic properties and the influence of acute administration of both compds. on cognitive function in mice.  To assess antidepressant-like properties and the influence on learning and memory we used forced swim test and step-through passive avoidance task in mice, resp.  Both compds. showed antidepressant-like properties and significantly elevated serotonin levels in the hippocampus after chronic treatment (HBK-14 - 2.5 mg/kg; HBK-15 - 0.625 and 1.25 mg/kg).  HBK-15 administered chronically antidepressant-like activity at lower dose (0.625 mg/kg) than the dose active after acute treatment (1.25 mg/kg).  None of the compds. affected locomotor activity of mice.  HBK-15 possessed very weak cholinolytic properties, whereas HBK-14 did not show any effect on muscarinic receptors.  Only HBK-15 (0.625 mg/kg) presented memory-enhancing properties and ameliorated cognitive impairments caused by scopolamine (1 mg/kg).  Our results indicate that 5-HT1A and 5-HT7 antagonists might have potential in the treatment of depression and possess pos. influence on cognitive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKcqgQuWut47Vg90H21EOLACvtfcHk0ljOZ_oTYzhLRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyms73K&md5=594131745bf434fa2d335b728e66aa6d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs11011-016-9932-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11011-016-9932-9%26sid%3Dliteratum%253Aachs%26aulast%3DPytka%26aufirst%3DK.%26aulast%3DGawlik%26aufirst%3DK.%26aulast%3DPawlica-Gosiewska%26aufirst%3DD.%26aulast%3DWitalis%26aufirst%3DJ.%26aulast%3DWaszkielewicz%26aufirst%3DA.%26atitle%3DHBK-14%2520and%2520HBK-15%2520with%2520Antidepressant-like%2520and%252For%2520Memory-Enhancing%2520Properties%2520Increase%2520Serotonin%2520Levels%2520in%2520the%2520Hippocampus%2520after%2520Chronic%2520Treatment%2520in%2520Mice%26jtitle%3DMetab.%2520Brain%2520Dis.%26date%3D2017%26volume%3D32%26spage%3D547%26epage%3D556%26doi%3D10.1007%2Fs11011-016-9932-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">Antipsychotic, Antidepressant, and Cognitive-Impairment Properties of Antipsychotics: Rat Profile and Implications for Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span><span class="refDoi"> DOI: 10.1007/s00210-014-0966-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs00210-014-0966-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=24599316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsF2isbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2014&pages=545-557&author=M.+Ko%C5%82aczkowskiauthor=P.+Mierzejewskiauthor=P.+Bienkowskiauthor=A.+Weso%C5%82owskaauthor=A.+Newman-Tancredi&title=Antipsychotic%2C+Antidepressant%2C+and+Cognitive-Impairment+Properties+of+Antipsychotics%3A+Rat+Profile+and+Implications+for+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.1007%2Fs00210-014-0966-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia</span></div><div class="casAuthors">Kolaczkowski, Marcin; Mierzejewski, Pawel; Bienkowski, Przemyslaw; Wesolowska, Anna; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-557</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Many dementia patients exhibit behavioral and psychol. symptoms (BPSD), including psychosis and depression.  Although antipsychotics are frequently prescribed off-label, they can have marked side effects.  In addn., comparative preclin. studies of their effects are surprisingly scarce, and strategies for discovery of novel pharmacotherapeutics are lacking.  We therefore compared eight antipsychotics in rat behavioral tests of psychosis, antidepressant-like activity, and cognitive impairment as a basis for preclin. evaluation of new drug candidates.  The methods used in this study include inhibition of MK-801-induced hyperactivity, forced swim test (FST), passive avoidance (PA), spontaneous locomotor activity, and catalepsy.  The drugs exhibited antipsychotic-like activity in the MK-801 test but with diverse profiles in the other models.  Risperidone impaired PA performance, but with some dose sepn. vs. its actions in the MK-801 test.  In contrast, clozapine, olanzapine, lurasidone, and asenapine showed little or no dose sepn. in these tests.  Aripiprazole did not impair PA performance but was poorly active in the MK-801 test.  Diverse effects were also obsd. in the FST: chlorpromazine was inactive and most other drugs reduced immobility over narrow dose ranges, whereas clozapine reduced immobility over a wider dose range, overlapping with antipsychotic activity.  Although the propensity of second-generation antipsychotics to produce catalepsy was lower, they all elicited pronounced sedation.  Consistent with clin. data, most currently available second-generation antipsychotics induced cognitive and motor side effects with little sepn. from therapeutic-like doses.  This study provides a uniform in vivo comparative basis on which to evaluate future early-stage drug candidates intended for potential pharmacotherapy of BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjkNKMBogumrVg90H21EOLACvtfcHk0ljOZ_oTYzhLRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsF2isbc%253D&md5=1202744b1594b23d9fa454061ef45ee6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00210-014-0966-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-014-0966-4%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DAntipsychotic%252C%2520Antidepressant%252C%2520and%2520Cognitive-Impairment%2520Properties%2520of%2520Antipsychotics%253A%2520Rat%2520Profile%2520and%2520Implications%2520for%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2014%26volume%3D387%26spage%3D545%26epage%3D557%26doi%3D10.1007%2Fs00210-014-0966-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span> </span><span class="NLM_article-title">Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span><span class="refDoi"> DOI: 10.1021/ci300413h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300413h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1yhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=638-648&author=M.+Ko%C5%82aczkowskiauthor=A.+Buckiauthor=M.+Federauthor=M.+Paw%C5%82owski&title=Ligand-Optimized+Homology+Models+of+D1+and+D2+Dopamine+Receptors%3A+Application+for+Virtual+Screening&doi=10.1021%2Fci300413h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening</span></div><div class="casAuthors">Kolaczkowski, Marcin; Bucki, Adam; Feder, Marcin; Pawlowski, Maciej</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">638-648</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent breakthroughs in crystallog. studies of G protein-coupled receptors (GPCRs), together with continuous progress in mol. modeling methods, have opened new perspectives for structure-based drug discovery.  A crucial enhancement in this area was development of induced fit docking procedures that allow optimization of binding pocket conformation guided by the features of its active ligands.  In the course of our research program aimed at discovery of novel antipsychotic agents, our attention focused on dopaminergic D2 and D1 receptors (D2R and D1R).  Thus, we decided to investigate whether the availability of a novel structure of the closely related D3 receptor and application of induced fit docking procedures for binding pocket refinement would permit the building of models of D2R and D1R that facilitate a successful virtual screening (VS).  Here, we provide an in-depth description of the modeling procedure and the discussion of the results of a VS benchmark we performed to compare efficiency of the ligand-optimized receptors in comparison with the regular homol. models.  We obsd. that application of the ligand-optimized models significantly improved the VS performance both in terms of BEDROC (0.325 vs 0.182 for D1R and 0.383 vs 0.301 for D2R) as well as EF1% (20 vs 11 for D1R and 18 vs 10 for D2R).  In contrast, no improvement was obsd. for the performance of a D2R model built on the D3R template, when compared with that derived from the structure of the previously published and more evolutionary distant β2 adrenergic receptor.  The comparison of results for receptors built according to various protocols and templates revealed that the most significant factor for the receptor performance was a proper selection of tool ligand used in induced fit docking procedure.  Taken together, our results suggest that the described homol. modeling procedure could be a viable tool for structure-based GPCR ligand design, even for the targets for which only a relatively distant structural template is available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHGgw5lOnO9bVg90H21EOLACvtfcHk0liW-rlo7Qp9fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1yhsb0%253D&md5=58f111e8132b7229898f1a44feb6199b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fci300413h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300413h%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DFeder%26aufirst%3DM.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26atitle%3DLigand-Optimized%2520Homology%2520Models%2520of%2520D1%2520and%2520D2%2520Dopamine%2520Receptors%253A%2520Application%2520for%2520Virtual%2520Screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D638%26epage%3D648%26doi%3D10.1021%2Fci300413h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Coleman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouaux, E.</span><span> </span><span class="NLM_article-title">X-Ray Structures and Mechanism of the Human Serotonin Transporter</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">532</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1038/nature17629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1038%2Fnature17629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27049939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=334-339&author=J.+A.+Colemanauthor=E.+M.+Greenauthor=E.+Gouaux&title=X-Ray+Structures+and+Mechanism+of+the+Human+Serotonin+Transporter&doi=10.1038%2Fnature17629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structures and mechanism of the human serotonin transporter</span></div><div class="casAuthors">Coleman, Jonathan A.; Green, Evan M.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7599</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The serotonin transporter (SERT) terminates serotonergic signaling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons.  SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signaling.  Here the authors report x-ray crystallog. structures of human SERT at 3.15 Å resoln. bound to the antidepressants (S)-citalopram or paroxetine.  Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helixes 1, 3, 6, 8 and 10, directly blocking serotonin binding.  The authors further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helixes 1, 6, 10 and 11.  Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand.  These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAxl5tROCorVg90H21EOLACvtfcHk0liW-rlo7Qp9fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D&md5=e4fa11a1e5abdd7b39f44375506aa249</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnature17629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17629%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DGreen%26aufirst%3DE.%2BM.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DX-Ray%2520Structures%2520and%2520Mechanism%2520of%2520the%2520Human%2520Serotonin%2520Transporter%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D334%26epage%3D339%26doi%3D10.1038%2Fnature17629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Thal, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawaratne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bures, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachhawat, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Crystal Structures of the M1 and M4Muscarinic Acetylcholine Receptors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">531</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1038/nature17188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1038%2Fnature17188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26958838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlGjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=531&publication_year=2016&pages=335-340&author=D.+M.+Thalauthor=B.+Sunauthor=D.+Fengauthor=V.+Nawaratneauthor=K.+Leachauthor=C.+C.+Felderauthor=M.+G.+Buresauthor=D.+A.+Evansauthor=W.+I.+Weisauthor=P.+Bachhawatauthor=T.+S.+Kobilkaauthor=P.+M.+Sextonauthor=B.+K.+Kobilkaauthor=A.+Christopoulos&title=Crystal+Structures+of+the+M1+and+M4Muscarinic+Acetylcholine+Receptors&doi=10.1038%2Fnature17188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the M1 and M4 muscarinic acetylcholine receptors</span></div><div class="casAuthors">Thal, David M.; Sun, Bingfa; Feng, Dan; Nawaratne, Vindhya; Leach, Katie; Felder, Christian C.; Bures, Mark G.; Evans, David A.; Weis, William I.; Bachhawat, Priti; Kobilka, Tong Sun; Sexton, Patrick M.; Kobilka, Brian K.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">531</span>
        (<span class="NLM_cas:issue">7594</span>),
    <span class="NLM_cas:pages">335-340</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Muscarinic M1-M5 acetylcholine receptors are G protein-coupled receptors (GPCRs) that regulate many vital functions of the central and peripheral nervous systems.  In particular, the M1 and M4 receptor subtypes have emerged as attractive drug targets for treatments of neurol. disorders, such as Alzheimer's disease and schizophrenia, but the high conservation of the acetylcholine-binding pocket has spurred current research into targeting allosteric sites on these receptors.  Here we report the crystal structures of the M1 and M4 muscarinic receptors bound to the inverse agonist, tiotropium.  Comparison of these structures with each other, as well as with the previously reported M2 and M3 receptor structures, reveals differences in the orthosteric and allosteric binding sites that contribute to a role in drug selectivity at this important receptor family.  We also report identification of a cluster of residues that form a network linking the orthosteric and allosteric sites of the M4 receptor, which provides new insight into how allosteric modulation may be transmitted between the two spatially distinct domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3oy2Ml852CrVg90H21EOLACvtfcHk0liW-rlo7Qp9fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlGjurg%253D&md5=8ed3f453737ad0291cf5b2c088f528da</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnature17188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17188%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DNawaratne%26aufirst%3DV.%26aulast%3DLeach%26aufirst%3DK.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DBures%26aufirst%3DM.%2BG.%26aulast%3DEvans%26aufirst%3DD.%2BA.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DBachhawat%26aufirst%3DP.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520M1%2520and%2520M4Muscarinic%2520Acetylcholine%2520Receptors%26jtitle%3DNature%26date%3D2016%26volume%3D531%26spage%3D335%26epage%3D340%26doi%3D10.1038%2Fnature17188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Farid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlstein, R. A.</span><span> </span><span class="NLM_article-title">New Insights about HERG Blockade Obtained from Protein Modeling, Potential Energy Mapping, and Docking Studies</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3160</span><span class="NLM_x">–</span> <span class="NLM_lpage">3173</span><span class="refDoi"> DOI: 10.1016/j.bmc.2005.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.bmc.2005.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=16413785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1ehs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=3160-3173&author=R.+Faridauthor=T.+Dayauthor=R.+A.+Friesnerauthor=R.+A.+Pearlstein&title=New+Insights+about+HERG+Blockade+Obtained+from+Protein+Modeling%2C+Potential+Energy+Mapping%2C+and+Docking+Studies&doi=10.1016%2Fj.bmc.2005.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies</span></div><div class="casAuthors">Farid, Ramy; Day, Tyler; Friesner, Richard A.; Pearlstein, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3160-3173</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We created a homol. model of the homo-tetrameric pore domain of HERG using the crystal structure of the bacterial potassium channel, KvAP, as a template.  We docked a set of known blockers with well-characterized effects on channel function into the lumen of the pore between the selectivity filter and extracellular entrance using a novel docking and refinement procedure incorporating Glide and Prime.  Key arom. groups of the blockers are predicted to form multiple simultaneous ring stacking and hydrophobic interactions among the eight arom. residues lining the pore.  Furthermore, each blocker can achieve these interactions via multiple docking configurations.  To further interpret the docking results, we mapped hydrophobic and hydrophilic potentials within the lumen of each refined docked complex.  Hydrophilic iso-potential contours define a 'propeller-shaped' vol. at the selectivity filter entrance.  Hydrophobic contours define a hollow 'crown-shaped' vol. located above the 'propeller', whose hydrophobic 'rim' extends along the pore axis between Tyr652 and Phe656.  Blockers adopt conformations/binding orientations that closely mimic the shapes and properties of these contours.  Blocker basic groups are localized in the hydrophilic 'propeller', forming electrostatic interactions with Ser624 rather than a generally accepted π-cation interaction with Tyr652.  Terfenadine, cisapride, sertindole, ibutilide, and clofilium adopt similar docked poses, in which their N-substituents bridge radially across the hollow interior of the 'crown' (analogous to the hub and spokes of a wheel), and project arom./hydrophobic portions into the hydrophobic 'rim'.  MK-499 docks with its longitudinal axis parallel to the axis of the pore and crown', and its hydrophobic groups buried within the hydrophobic 'rim'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-1RsiljwGxrVg90H21EOLACvtfcHk0liwW_fWMKcxIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1ehs7o%253D&md5=8df638aa78d2d35337bb82d8a94357c4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DPearlstein%26aufirst%3DR.%2BA.%26atitle%3DNew%2520Insights%2520about%2520HERG%2520Blockade%2520Obtained%2520from%2520Protein%2520Modeling%252C%2520Potential%2520Energy%2520Mapping%252C%2520and%2520Docking%2520Studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D3160%26epage%3D3173%26doi%3D10.1016%2Fj.bmc.2005.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Kurowski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bujnicki, J. M.</span><span> </span><span class="NLM_article-title">GeneSilico Protein Structure Prediction Meta-Server</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3305</span><span class="NLM_x">–</span> <span class="NLM_lpage">3307</span><span class="refDoi"> DOI: 10.1093/nar/gkg557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1093%2Fnar%2Fgkg557" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=3305-3307&author=M.+A.+Kurowskiauthor=J.+M.+Bujnicki&title=GeneSilico+Protein+Structure+Prediction+Meta-Server&doi=10.1093%2Fnar%2Fgkg557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkg557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkg557%26sid%3Dliteratum%253Aachs%26aulast%3DKurowski%26aufirst%3DM.%2BA.%26aulast%3DBujnicki%26aufirst%3DJ.%2BM.%26atitle%3DGeneSilico%2520Protein%2520Structure%2520Prediction%2520Meta-Server%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2003%26volume%3D31%26spage%3D3305%26epage%3D3307%26doi%3D10.1093%2Fnar%2Fgkg557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">High-Resolution Crystal Structure of an Engineered Human Beta2-Adrenergic G Protein-Coupled Receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1258</span><span class="NLM_x">–</span> <span class="NLM_lpage">1265</span><span class="refDoi"> DOI: 10.1126/science.1150577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1126%2Fscience.1150577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=17962520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1258-1265&author=V.+Cherezovauthor=D.+M.+Rosenbaumauthor=M.+A.+Hansonauthor=S.+G.+F.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.-J.+Choiauthor=P.+Kuhnauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=R.+C.+Stevens&title=High-Resolution+Crystal+Structure+of+an+Engineered+Human+Beta2-Adrenergic+G+Protein-Coupled+Receptor&doi=10.1126%2Fscience.1150577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor</span></div><div class="casAuthors">Cherezov, Vadim; Rosenbaum, Daniel M.; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Kuhn, Peter; Weis, William I.; Kobilka, Brian K.; Stevens, Raymond C.; Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S.; Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Lefkowitz, R. J.; Shenoy, S. K.; Rosenbaum, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Second extracellular loop, which in the β2-adrenergic receptor contains an unusual pair of disulfide bonds and an extra helix.  This loop and the absence Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane.  We report the crystal structure of a human β2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resoln.  The structure provides a high-resoln. view of a human G protein-coupled receptor bound to a diffusible ligand.  Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop.  Cholesterol, a necessary component for crystn., mediates an intriguing parallel assocn. of receptor mols. in the crystal lattice.  Although the location of carazolol in the β2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-8wZ2k2GHLVg90H21EOLACvtfcHk0liwW_fWMKcxIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I&md5=12c5bacb8464a4b243fe9341192b5b3b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150577%26sid%3Dliteratum%253Aachs%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.-J.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHigh-Resolution%2520Crystal%2520Structure%2520of%2520an%2520Engineered%2520Human%2520Beta2-Adrenergic%2520G%2520Protein-Coupled%2520Receptor%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1258%26epage%3D1265%26doi%3D10.1126%2Fscience.1150577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Chien, E. Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">1091</span><span class="NLM_x">–</span> <span class="NLM_lpage">1095</span><span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+Human+Dopamine+D3+Receptor+in+Complex+with+a+D2%2FD3+Selective+Antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0ljSwbJsgqEFVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520Human%2520Dopamine%2520D3%2520Receptor%2520in%2520Complex%2520with%2520a%2520D2%252FD3%2520Selective%2520Antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkowska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Śniecikowska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jastrzębska-Więsek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partyka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, P.</span><span> </span><span class="NLM_article-title">Novel 5-HT6 Receptor Antagonists/D2 Receptor Partial Agonists Targeting Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.ejmech.2014.12.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=221-235&author=M.+Ko%C5%82aczkowskiauthor=M.+Marcinkowskaauthor=A.+Buckiauthor=J.+%C5%9Aniecikowskaauthor=M.+Paw%C5%82owskiauthor=G.+Kazekauthor=A.+Siwekauthor=M.+Jastrz%C4%99bska-Wi%C4%99sekauthor=A.+Partykaauthor=A.+Wasikauthor=A.+Weso%C5%82owskaauthor=P.+Mierzejewskiauthor=P.+Bienkowski&title=Novel+5-HT6+Receptor+Antagonists%2FD2+Receptor+Partial+Agonists+Targeting+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.1016%2Fj.ejmech.2014.12.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3D%25C5%259Aniecikowska%26aufirst%3DJ.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26aulast%3DKazek%26aufirst%3DG.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DJastrz%25C4%2599bska-Wi%25C4%2599sek%26aufirst%3DM.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DWasik%26aufirst%3DA.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26atitle%3DNovel%25205-HT6%2520Receptor%2520Antagonists%252FD2%2520Receptor%2520Partial%2520Agonists%2520Targeting%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D221%26epage%3D235%26doi%3D10.1016%2Fj.ejmech.2014.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Więckowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godyń, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkowska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Więckowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaręba, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Głuch-Lutwin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sienkiewicz-Jarosz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wichur, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobec, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malawska, B.</span><span> </span><span class="NLM_article-title">Novel Multi-Target-Directed Ligands for Alzheimer’s Disease: Combining Cholinesterase Inhibitors and 5-HT6 Receptor Antagonists. Design, Synthesis and Biological Evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2016.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.ejmech.2016.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27560283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=63-81&author=A.+Wi%C4%99ckowskaauthor=M.+Ko%C5%82aczkowskiauthor=A.+Buckiauthor=J.+Gody%C5%84author=M.+Marcinkowskaauthor=K.+Wi%C4%99ckowskiauthor=P.+Zar%C4%99baauthor=A.+Siwekauthor=G.+Kazekauthor=M.+G%C5%82uch-Lutwinauthor=P.+Mierzejewskiauthor=P.+Bienkowskiauthor=H.+Sienkiewicz-Jaroszauthor=D.+Knezauthor=T.+Wichurauthor=S.+Gobecauthor=B.+Malawska&title=Novel+Multi-Target-Directed+Ligands+for+Alzheimer%E2%80%99s+Disease%3A+Combining+Cholinesterase+Inhibitors+and+5-HT6+Receptor+Antagonists.+Design%2C+Synthesis+and+Biological+Evaluation&doi=10.1016%2Fj.ejmech.2016.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation</span></div><div class="casAuthors">Wieckowska, Anna; Kolaczkowski, Marcin; Bucki, Adam; Godyn, Justyna; Marcinkowska, Monika; Wieckowski, Krzysztof; Zareba, Paula; Siwek, Agata; Kazek, Grzegorz; Gluch-Lutwin, Monika; Mierzejewski, Pawel; Bienkowski, Przemyslaw; Sienkiewicz-Jarosz, Halina; Knez, Damijan; Wichur, Tomasz; Gobec, Stanislav; Malawska, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-81</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluation of a novel class of multifunctional ligands that combined a 5-HT6 receptor antagonist with a cholinesterase inhibitor was reported.  Novel multi-target-directed ligands (MTDLs) were designed by combining pharmacophores directed against the 5-HT6 receptor (1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole) and cholinesterases (tacrine or N-benzylpiperidine analogs).  In-vitro evaluation led to the identification of tacrine deriv. I with well-balanced potencies against the 5-HT6 receptor (Kb = 27 nM), acetylcholinesterase and butyrylcholinesterase (IC50hAChE = 12 nM, IC50hBuChE = 29 nM).  The compd. also showed good in vitro blood-brain-barrier permeability (PAMPA-BBB assay), which was confirmed in-vivo (open field study).  Central cholinomimetic activity was confirmed in-vivo in rats using a scopolamine-induced hyperlocomotion model.  A novel class of multifunctional ligands with compd. I as the best deriv. in a series represented an excellent starting point for the further development of an effective treatment for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosefvo-I6wD7Vg90H21EOLACvtfcHk0ljSwbJsgqEFVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqsrzF&md5=861844a56249e97199907c4d8a8dff7e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWi%25C4%2599ckowska%26aufirst%3DA.%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DGody%25C5%2584%26aufirst%3DJ.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3DWi%25C4%2599ckowski%26aufirst%3DK.%26aulast%3DZar%25C4%2599ba%26aufirst%3DP.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DKazek%26aufirst%3DG.%26aulast%3DG%25C5%2582uch-Lutwin%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26aulast%3DSienkiewicz-Jarosz%26aufirst%3DH.%26aulast%3DKnez%26aufirst%3DD.%26aulast%3DWichur%26aufirst%3DT.%26aulast%3DGobec%26aufirst%3DS.%26aulast%3DMalawska%26aufirst%3DB.%26atitle%3DNovel%2520Multi-Target-Directed%2520Ligands%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Combining%2520Cholinesterase%2520Inhibitors%2520and%25205-HT6%2520Receptor%2520Antagonists.%2520Design%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D63%26epage%3D81%26doi%3D10.1016%2Fj.ejmech.2016.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vardy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, E. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melcher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H. E.</span><span> </span><span class="NLM_article-title">Structural Basis for Molecular Recognition at Serotonin Receptors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">–</span> <span class="NLM_lpage">614</span><span class="refDoi"> DOI: 10.1126/science.1232807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1126%2Fscience.1232807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=23519210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=610-614&author=C.+Wangauthor=Y.+Jiangauthor=J.+Maauthor=H.+Wuauthor=D.+Wackerauthor=V.+Katritchauthor=G.+W.+Hanauthor=W.+Liuauthor=X.-P.+Huangauthor=E.+Vardyauthor=J.+D.+McCorvyauthor=X.+Gaoauthor=E.+X.+Zhouauthor=K.+Melcherauthor=C.+Zhangauthor=F.+Baiauthor=H.+Yangauthor=L.+Yangauthor=H.+Jiangauthor=B.+L.+Rothauthor=V.+Cherezovauthor=R.+C.+Stevensauthor=H.+E.+Xu&title=Structural+Basis+for+Molecular+Recognition+at+Serotonin+Receptors&doi=10.1126%2Fscience.1232807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Molecular Recognition at Serotonin Receptors</span></div><div class="casAuthors">Wang, Chong; Jiang, Yi; Ma, Jinming; Wu, Huixian; Wacker, Daniel; Katritch, Vsevolod; Han, Gye Won; Liu, Wei; Huang, Xi-Ping; Vardy, Eyal; McCorvy, John D.; Gao, Xiang; Zhou, X. Edward; Melcher, Karsten; Zhang, Chenghai; Bai, Fang; Yang, Huaiyu; Yang, Linlin; Jiang, Hualiang; Roth, Bryan L.; Cherezov, Vadim; Stevens, Raymond C.; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6132</span>),
    <span class="NLM_cas:pages">610-614</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Serotonin or 5-hydroxytryptamine (5-HT) regulates a wide spectrum of human physiol. through the 5-HT receptor family.  The authors report the crystal structures of the human 5-HT1B G protein-coupled receptor bound to the agonist antimigraine medications ergotamine and dihydroergotamine.  The structures reveal similar binding modes for these ligands, which occupy the orthosteric pocket and an extended binding pocket close to the extracellular loops.  The orthosteric pocket is formed by residues conserved in the 5-HT receptor family, clarifying the family-wide agonist activity of 5-HT.  Compared with the structure of the 5-HT2B receptor, the 5-HT1B receptor displays a 3 angstrom outward shift at the extracellular end of helix V, resulting in a more open extended pocket that explains subtype selectivity.  Together with docking and mutagenesis studies, these structures provide a comprehensive structural basis for understanding receptor-ligand interactions and designing subtype-selective serotonergic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLc0rOIqg_2bVg90H21EOLACvtfcHk0lg6IlJ3PH4ECw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D&md5=ce0773088a86f6a2c83b6cb77a63e708</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1126%2Fscience.1232807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1232807%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DE.%2BX.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DStructural%2520Basis%2520for%2520Molecular%2520Recognition%2520at%2520Serotonin%2520Receptors%26jtitle%3DScience%26date%3D2013%26volume%3D340%26spage%3D610%26epage%3D614%26doi%3D10.1126%2Fscience.1232807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Bordoli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwede, T.</span><span> </span><span class="NLM_article-title">Automated Protein Structure Modeling with SWISS-MODEL Workspace and the Protein Model Portal</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">857</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1007/978-1-61779-588-6_5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2F978-1-61779-588-6_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=857&publication_year=2011&pages=107-136&author=L.+Bordoliauthor=T.+Schwede&title=Automated+Protein+Structure+Modeling+with+SWISS-MODEL+Workspace+and+the+Protein+Model+Portal&doi=10.1007%2F978-1-61779-588-6_5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-588-6_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-588-6_5%26sid%3Dliteratum%253Aachs%26aulast%3DBordoli%26aufirst%3DL.%26aulast%3DSchwede%26aufirst%3DT.%26atitle%3DAutomated%2520Protein%2520Structure%2520Modeling%2520with%2520SWISS-MODEL%2520Workspace%2520and%2520the%2520Protein%2520Model%2520Portal%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D857%26spage%3D107%26epage%3D136%26doi%3D10.1007%2F978-1-61779-588-6_5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Bollinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinemann, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Novel Pyridylmethylamines as Highly Selective 5-HT1A Superagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7167</span><span class="NLM_x">–</span> <span class="NLM_lpage">7179</span><span class="refDoi"> DOI: 10.1021/jm100835q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100835q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7167-7179&author=S.+Bollingerauthor=H.+H%C3%BCbnerauthor=F.+W.+Heinemannauthor=K.+Meyerauthor=P.+Gmeiner&title=Novel+Pyridylmethylamines+as+Highly+Selective+5-HT1A+Superagonists&doi=10.1021%2Fjm100835q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm100835q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100835q%26sid%3Dliteratum%253Aachs%26aulast%3DBollinger%26aufirst%3DS.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DNovel%2520Pyridylmethylamines%2520as%2520Highly%2520Selective%25205-HT1A%2520Superagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7167%26epage%3D7179%26doi%3D10.1021%2Fjm100835q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Daina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michielin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoete, V.</span><span> </span><span class="NLM_article-title">SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">42717</span><span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=SwissADME%3A+A+Free+Web+Tool+to+Evaluate+Pharmacokinetics%2C+Drug-Likeness+and+Medicinal+Chemistry+Friendliness+of+Small+Molecules&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2ebvNXKPpIRNwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwissADME%253A%2520A%2520Free%2520Web%2520Tool%2520to%2520Evaluate%2520Pharmacokinetics%252C%2520Drug-Likeness%2520and%2520Medicinal%2520Chemistry%2520Friendliness%2520of%2520Small%2520Molecules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lg6IlJ3PH4ECw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Dörje, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wess, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambrecht, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutschler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span> </span><span class="NLM_article-title">Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1994002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADyaK3M7jt1CrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1991&pages=727-733&author=F.+D%C3%B6rjeauthor=J.+Wessauthor=G.+Lambrechtauthor=R.+Tackeauthor=E.+Mutschlerauthor=M.+R.+Brann&title=Antagonist+Binding+Profiles+of+Five+Cloned+Human+Muscarinic+Receptor+Subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonist binding profiles of five cloned human muscarinic receptor subtypes</span></div><div class="casAuthors">Dorje F; Wess J; Lambrecht G; Tacke R; Mutschler E; Brann M R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">727-33</span>
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">A variety of muscarinic antagonists are currently used as tools to pharmacologically subclassify muscarinic receptors into M1, M2 and M3 subtypes.  In the present study, we have determined the affinity profiles of several of these antagonists at five cloned human muscarinic receptors (m1-m5) stably expressed in Chinese hamster ovary cells (CHO-K1).  At all five receptors, the (R)-enantiomers of trihexyphenidyl and hexbutinol displayed considerably higher affinities (up to 525-fold) than their corresponding (S)-isomers.  The stereoselectivity ratios [inhibition constant(S)/inhibition constant(R)] for both pairs of enantiomers were lowest at m2 receptors, suggesting that less stringent configurational demands are made by this receptor subtype.  The "M1-selective" antagonist (R)-trihexyphenidyl displayed high affinities for m1 and m4 receptors.  The "M2-selective" antagonists himbacine, (+-)-5,11-dihydro-11- ([(2-[(dipropylamino)methyl]-1- piperidinyl)ethyl)amino]carbonyl)-6H-pyrido(2,3-b)(1,4)benzodiazepine-6- one (AF-DX 384), 11-[4-[4-(diethylamino)butyl]-1-piperidinyl)acetyl)-5,11- dihydro-6H-pyrido(2,3-b) (1,4)benzodiazepine-6-one (AQ-RA 741) and (+)-(11-[2-[(diethylamino) methyl]-1-piperidinyl)acetyl)-5,11-di-hydro-6H-pyrido(2,3-b)(1,4) benzodiazepine-6-one [AF-DX 250; the (+)-enantiomer of AF-DX 116] exhibited high affinities for m2 and m4, intermediate affinities for m1 and m3 and low affinities for m5 receptors.  This selectivity profile was most prominent for AQ-RA 741, which displayed 195- and 129-fold higher affinities for m2 and m4 receptors than for m5 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4swN6h2ItNhKDYG3bNImrfW6udTcc2eaumVuSdT_4Fbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7jt1CrtQ%253D%253D&md5=24fb5162f94b5e0163c9ae9ca2a5a582</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6rje%26aufirst%3DF.%26aulast%3DWess%26aufirst%3DJ.%26aulast%3DLambrecht%26aufirst%3DG.%26aulast%3DTacke%26aufirst%3DR.%26aulast%3DMutschler%26aufirst%3DE.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26atitle%3DAntagonist%2520Binding%2520Profiles%2520of%2520Five%2520Cloned%2520Human%2520Muscarinic%2520Receptor%2520Subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1991%26volume%3D256%26spage%3D727%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Payne, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, P. G.</span><span> </span><span class="NLM_article-title">Mechanisms of Ligand Binding and Efficacy at the Human D2(Short) Dopamine Receptor</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">1106</span><span class="NLM_x">–</span> <span class="NLM_lpage">1117</span><span class="refDoi"> DOI: 10.1046/j.1471-4159.2002.01046.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1046%2Fj.1471-4159.2002.01046.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=12358758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvVertLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2002&pages=1106-1117&author=S.+L.+Payneauthor=A.+M.+Johanssonauthor=P.+G.+Strange&title=Mechanisms+of+Ligand+Binding+and+Efficacy+at+the+Human+D2%28Short%29+Dopamine+Receptor&doi=10.1046%2Fj.1471-4159.2002.01046.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor</span></div><div class="casAuthors">Payne, Sarah L.; Johansson, Anette M.; Strange, Philip G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1106-1117</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Mechanisms of ligand binding and receptor activation for the human D2(short) dopamine receptor have been probed using two homologous series of monohydroxylated and dihydroxylated agonists (phenylethylamines and 2-dipropylaminotetralins).  In ligand binding studies, the majority of compds. exhibited competition curves vs. [3H]spiperone that were best fitted using a two site binding model.  The compds. had different abilities (potencies and maximal effects) to stimulate [35S]GTPγS binding and to inhibit forskolin-stimulated cAMP accumulation.  From the data it can be concluded that: (i) the ability of an agonist to stabilize receptor/G protein coupling can be used to predict agonist efficacy for some groups of compds. (2-dipropylaminotetralins) but not for others (phenylethylamines); (ii) the receptor may be activated by unhydroxylated compds.; (iii) single hydroxyl groups or pairs of hydroxyl groups on the agonist may contribute to binding affinity, potency and efficacy; and (iv) for the 2-dipropylaminotetralin series two modes of agonist/receptor interaction have been identified assocd. with different relative efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsUeXSzj0F5rVg90H21EOLACvtfcHk0ljvTqX2E1QBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvVertLo%253D&md5=d2772f4bee642c50bcb6f7721ad84d84</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2002.01046.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2002.01046.x%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DS.%2BL.%26aulast%3DJohansson%26aufirst%3DA.%2BM.%26aulast%3DStrange%26aufirst%3DP.%2BG.%26atitle%3DMechanisms%2520of%2520Ligand%2520Binding%2520and%2520Efficacy%2520at%2520the%2520Human%2520D2%2528Short%2529%2520Dopamine%2520Receptor%26jtitle%3DJ.%2520Neurochem.%26date%3D2002%26volume%3D82%26spage%3D1106%26epage%3D1117%26doi%3D10.1046%2Fj.1471-4159.2002.01046.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Kohen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druck, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamblin, M. W.</span><span> </span><span class="NLM_article-title">Cloning, Characterization, and Chromosomal Localization of a Human 5-HT6 Serotonin Receptor</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span><span class="refDoi"> DOI: 10.1046/j.1471-4159.1996.66010047.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1046%2Fj.1471-4159.1996.66010047.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=8522988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSns7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1996&pages=47-56&author=R.+Kohenauthor=M.+A.+Metcalfauthor=N.+Khanauthor=T.+Druckauthor=K.+Huebnerauthor=J.+E.+Lachowiczauthor=H.+Y.+Meltzerauthor=D.+R.+Sibleyauthor=B.+L.+Rothauthor=M.+W.+Hamblin&title=Cloning%2C+Characterization%2C+and+Chromosomal+Localization+of+a+Human+5-HT6+Serotonin+Receptor&doi=10.1046%2Fj.1471-4159.1996.66010047.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor</span></div><div class="casAuthors">Kohen, Ruth; Metcalf, Mark A.; Khan, Naseem; Druck, Teresa; Huebner, Kay; Lachowicz, Jean E.; Meltzer, Herbert Y.; Sibley, David R.; Roth, Bryan L.; Hamblin, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">The authors describe the cloning and characterization of a human 5-HT6 serotonin receptor.  The open reading frame is interrupted by two introns in positions corresponding to the third cytoplasmic loop and the third extracellular loop.  The human 5-HT6 cDNA encodes a 440-amino-acid polypeptide whose sequence diverges significantly from that published for the rat 5-HT6 receptor.  Resequencing of the rat cDNA revealed a sequencing error producing a frame shift within the open reading frame.  The human 5-HT6 amino acid sequence is 89% similar to the cor. rat sequence.  The recombinant human 5-HT6 receptor is pos. coupled to adenylyl cyclase and has pharmacol. properties similar to the rat receptor with high affinity for several typical and atypical antipsychotics, including clozapine.  The receptor is expressed in several human brain regions, most prominently in the caudate nucleus.  The gene for the receptor maps to the human chromosome region 1p35-p36.  This localization overlaps that established for the serotonin 5-HT1Dα receptor, suggesting that these may be closely linked.  Comparison of genomic and cDNA clones for the human 5-HT6 receptor also reveals an Rsal restriction fragment length polymorphism within the coding region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWMnEw6_ukEbVg90H21EOLACvtfcHk0ljvTqX2E1QBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSns7rI&md5=751bb21c3a65f2fe052a9f9d79990699</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1996.66010047.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1996.66010047.x%26sid%3Dliteratum%253Aachs%26aulast%3DKohen%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DM.%2BA.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DDruck%26aufirst%3DT.%26aulast%3DHuebner%26aufirst%3DK.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHamblin%26aufirst%3DM.%2BW.%26atitle%3DCloning%252C%2520Characterization%252C%2520and%2520Chromosomal%2520Localization%2520of%2520a%2520Human%25205-HT6%2520Serotonin%2520Receptor%26jtitle%3DJ.%2520Neurochem.%26date%3D1996%26volume%3D66%26spage%3D47%26epage%3D56%26doi%3D10.1046%2Fj.1471-4159.1996.66010047.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Adham, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zgombick, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branchek, T. A.</span><span> </span><span class="NLM_article-title">Functional Characterization of the Recombinant Human 5-Hydroxytryptamine7(a) Receptor Isoform Coupled to Adenylate Cyclase Stimulation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">508</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=9808674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVertrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1998&pages=508-514&author=N.+Adhamauthor=J.+M.+Zgombickauthor=J.+Bardauthor=T.+A.+Branchek&title=Functional+Characterization+of+the+Recombinant+Human+5-Hydroxytryptamine7%28a%29+Receptor+Isoform+Coupled+to+Adenylate+Cyclase+Stimulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation</span></div><div class="casAuthors">Adham, Nika; Zgombick, John M.; Bard, Jonathan; Branchek, Theresa A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">508-514</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Lippencott Williams & Wilkins</span>)
        </div><div class="casAbstract">Functional characterization of the recombinant human 5-hydroxytryptamine7(a) (h5-HT7(a)) receptor isoform was performed using stably transfected LM(tk-) cells.  Expression levels of the h5-HT7(a) receptor detd. from satn. studies using either a labeled agonist ([3H]5-HT) or antagonist ([3H]LSD) were very similar (Bmax = 160-190 fmol/mg protein), suggesting that all receptors may exist in the high affinity (G protein-coupled) state.  In intact cells, 5-HT produced a concn.-dependent elevation of intracellular cAMP levels ([cAMP]i) with an EC50 value of 80 nM and a maximal response of 5-fold increase above basal levels.  The rank order of agonist potencies in the second messenger assay paralleled their rank order of binding affinities: 5-carboxamidotryptamine > 5-hydroxytryptamine ≥ 5-methoxytryptamine > 8-hydroxy N,N-di-Pr aminotetralin > sumatriptan.  Agonist potencies (EC50 values) to stimulate [cAMP]i were more than 25-fold lower relative to their resp. binding affinities (Ki values) obtained in [3H]5-HT competition assays.  In contrast, antagonist potencies (Kb values) to block 5-HT-stimulated [cAMP]i were in close agreement with their corresponding Ki values.  These data may indicate low efficiency of receptor-effector coupling to adenylate cyclase stimulation.  Pretreatment of stably transfected cells with cholera toxin abolished the 5-HT-mediated elevation of [cAMP]i, indicating that the 5-HT7(a) subtype directly interacts with Gαs protein(s) to activate adenylate cyclase(s).  Clonal cell lines stably expressing h5-HT7 receptor isoforms will serve as valuable cellular models to study their function and regulation, as well as assist in the development of selective 5-HT7 receptor agents to uncover the biol. roles and potential therapeutic applications of this novel receptor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBBA4yPrxxArVg90H21EOLACvtfcHk0ljvTqX2E1QBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVertrc%253D&md5=d5f48b703c9e8c82ea0692f623052b94</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdham%26aufirst%3DN.%26aulast%3DZgombick%26aufirst%3DJ.%2BM.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DBranchek%26aufirst%3DT.%2BA.%26atitle%3DFunctional%2520Characterization%2520of%2520the%2520Recombinant%2520Human%25205-Hydroxytryptamine7%2528a%2529%2520Receptor%2520Isoform%2520Coupled%2520to%2520Adenylate%2520Cyclase%2520Stimulation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D287%26spage%3D508%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Martel, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assié, M.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depoortère, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cussac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">5-HT1A Receptors Are Involved in the Effects of Xaliproden on G-Protein Activation, Neurotransmitter Release and Nociception</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00249.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1111%2Fj.1476-5381.2009.00249.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19508400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=232-242&author=J.-C.+Martelauthor=M.-B.+Assi%C3%A9author=L.+Bardinauthor=R.+Depoort%C3%A8reauthor=D.+Cussacauthor=A.+Newman-Tancredi&title=5-HT1A+Receptors+Are+Involved+in+the+Effects+of+Xaliproden+on+G-Protein+Activation%2C+Neurotransmitter+Release+and+Nociception&doi=10.1111%2Fj.1476-5381.2009.00249.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception</span></div><div class="casAuthors">Martel, J-C.; Assie, M.-B.; Bardin, L.; Depoortere, R.; Cussac, D.; Newman-Tancredi, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">232-242</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Xaliproden (SR57746A) is a 5-HT1A receptor agonist and neurotrophic agent that reduces oxaliplatin-mediated neuropathy in clin. trials.  The present study investigated its profile on in vitro transduction, neurochem. responses and acute nociceptive pain tests in rats.  Xaliproden was tested on models assocd. with 5-HT1A receptor activation including G-protein activation, extracellular dopamine and 5-HT levels measured by microdialysis and formalin-induced pain.  Activation of 5-HT1A receptors was confirmed by antagonism with WAY100635.  Xaliproden exhibited high affinity for rat (r) and human (h) 5-HT1A receptors (pKi = 8.84 and 9.00).  In [35S]GTPγS (guanosine 5'-O-(3-[35S]thio)triphosphate) assays it activated both hippocampal r5-HT1A [pEC50/EMAX of 7.58/61% (%5-HT)] and recombinant h5-HT1A receptors (glioma C6-h5-HT1A: 7.39/62%; HeLa-h5-HT1A: 7.24/93%).  In functional [35S]GTPγS autoradiog., xaliproden induced labeling in structures enriched with 5-HT1A receptors (hippocampus, lateral septum, prefrontal and entorhinal cortices).  Xaliproden inhibited in vivo binding of [3H]WAY100635 to 5-HT1A receptors in mouse frontal cortex and hippocampus (ID50: 3.5 and 3.3 mg/kg-1, p.o. resp.).  In rat, it increased extracellular dopamine levels in frontal cortex and reduced hippocampal 5-HT levels (ED50: 1.2 and 0.7 mg/kg-1, i.p. resp.).  In a rat pain model, xaliproden inhibited paw licking and elevation (ED50: 1 and 3 mg/kg-1, i.p. resp.) following formalin injection in the paw.  All effects were reversed by pretreatment with WAY100635.  These results indicate that activation of 5-HT1A receptors is the principal mechanism of action of xaliproden and provide further support for the utility of 5-HT1A receptor activation as an anti-nociceptive strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYZSCqUkhYYrVg90H21EOLACvtfcHk0liRfjAF-z5Lfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsr%252FO&md5=26321f915552dbbda3285c0b3603a8c4</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00249.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00249.x%26sid%3Dliteratum%253Aachs%26aulast%3DMartel%26aufirst%3DJ.-C.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DR.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3D5-HT1A%2520Receptors%2520Are%2520Involved%2520in%2520the%2520Effects%2520of%2520Xaliproden%2520on%2520G-Protein%2520Activation%252C%2520Neurotransmitter%2520Release%2520and%2520Nociception%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D232%26epage%3D242%26doi%3D10.1111%2Fj.1476-5381.2009.00249.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Perovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, W. E.</span><span> </span><span class="NLM_article-title">Pharmacological Profile of Hypericum Extract. Effect on Serotonin Uptake by Postsynaptic Receptors</span> <span class="citation_source-journal">Arzneim.-Forsch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1145</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=8929227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSmt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1995&pages=1145-1148&author=S.+Perovicauthor=W.+E.+M%C3%BCller&title=Pharmacological+Profile+of+Hypericum+Extract.+Effect+on+Serotonin+Uptake+by+Postsynaptic+Receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of Hypericum extract: effect on serotonin uptake by postsynaptic receptors</span></div><div class="casAuthors">Perovic, S.; Mueller, W. E. G.</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1145-8</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    
            (<span class="NLM_cas:orgname">Cantor</span>)
        </div><div class="casAbstract">In the present study it is reported that the methanolic Hypericum ext. LI 160 (Jarsin 300) exerts no protective effect against NMDA- or gpl120- (from the HIV virus)-induced cytotoxicity.  Moreover, it is established that Hypericum ext. causes no activation of arachidonic acid release from neurons activated by gp120; hence it displays no sensitization effect on the NMDA receptor channel.  The main outcome of this study is the finding that Hypericum ext. causes a 50% inhibition (IC50 value) of serotonin uptake by rat synaptosomes at a concn. of 6.2 μg/mL.  Therefore it is concluded, that the antidepressant activity of Hypericum ext. is due to an inhibition of serotonin uptake by postsynaptic receptors.  Future studies might focus on the effect of Hypericum ext. on serotonin binding to neurons, serotonin storage in granules, the rate of synthesis of serotonin, and on the activity of monoamine oxidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPyzkv5O0PhLVg90H21EOLACvtfcHk0liRfjAF-z5Lfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSmt77N&md5=b28ebd2a2e70560f4f90a25670cb82e2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerovic%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DW.%2BE.%26atitle%3DPharmacological%2520Profile%2520of%2520Hypericum%2520Extract.%2520Effect%2520on%2520Serotonin%2520Uptake%2520by%2520Postsynaptic%2520Receptors%26jtitle%3DArzneim.-Forsch.%26date%3D1995%26volume%3D45%26spage%3D1145%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalfre, M.</span><span> </span><span class="NLM_article-title">Behavioral Despair in Mice: A Primary Screening Test for Antidepressants</span> <span class="citation_source-journal">Arch. Int. Pharmacodyn. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">229</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=596982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADyaE1cXktlKgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=1977&pages=327-336&author=R.+D.+Porsoltauthor=A.+Bertinauthor=M.+Jalfre&title=Behavioral+Despair+in+Mice%3A+A+Primary+Screening+Test+for+Antidepressants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral despair in mice:  a primary screening test for antidepressants</span></div><div class="casAuthors">Porsolt, R. D.; Bertin, A.; Jalfre, M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives Internationales de Pharmacodynamie et de Therapie</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-36</span>CODEN:
                <span class="NLM_cas:coden">AIPTAK</span>;
        ISSN:<span class="NLM_cas:issn">0003-9780</span>.
    </div><div class="casAbstract">A depressed state can be induced in mice by forcing them to swim in a narrow cylinder from which they cannot escape.  After a brief period of vigorous activity the mice adopt a characteristic immobile posture which is readily identifiable.  Immobility was reduced by tricyclic antidepressants, monoamine oxidase inhibitors and atypical antidepressants, as well as by electroconvulsive shock.  Psychostimulants also reduced immobility but in contrast to antidepressants caused marked motor stimulation.  Immobility was not affected by minor or major tranquilizers.  These findings, closely parallel to those previously reported in rats, suggest that the procedure is selectively senstitive to antidepressant treatments.  The mouse procedure is, however, more rapid and less costly than that with rats and is thus more suitable for the primary screening of antidepressant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3THea0LRwE7Vg90H21EOLACvtfcHk0liRfjAF-z5Lfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXktlKgsbs%253D&md5=70dd5706992ee8151a9801a2aeb42961</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DBertin%26aufirst%3DA.%26aulast%3DJalfre%26aufirst%3DM.%26atitle%3DBehavioral%2520Despair%2520in%2520Mice%253A%2520A%2520Primary%2520Screening%2520Test%2520for%2520Antidepressants%26jtitle%3DArch.%2520Int.%2520Pharmacodyn.%2520Ther.%26date%3D1977%26volume%3D229%26spage%3D327%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Aron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larousse, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boissier, J. R.</span><span> </span><span class="NLM_article-title">Evaluation of a Rapid Technique for Detecting Minor Tranquilizers</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span><span class="refDoi"> DOI: 10.1016/0028-3908(71)90074-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2F0028-3908%2871%2990074-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1971&pages=459-469&author=C.+Aronauthor=P.+Simonauthor=C.+Larousseauthor=J.+R.+Boissier&title=Evaluation+of+a+Rapid+Technique+for+Detecting+Minor+Tranquilizers&doi=10.1016%2F0028-3908%2871%2990074-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0028-3908%2871%2990074-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0028-3908%252871%252990074-8%26sid%3Dliteratum%253Aachs%26aulast%3DAron%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DP.%26aulast%3DLarousse%26aufirst%3DC.%26aulast%3DBoissier%26aufirst%3DJ.%2BR.%26atitle%3DEvaluation%2520of%2520a%2520Rapid%2520Technique%2520for%2520Detecting%2520Minor%2520Tranquilizers%26jtitle%3DNeuropharmacology%26date%3D1971%26volume%3D10%26spage%3D459%26epage%3D469%26doi%3D10.1016%2F0028-3908%2871%2990074-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Ogren, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köhler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjöstrand, S. E.</span><span> </span><span class="NLM_article-title">The Selective Dopamine D2 Receptor Antagonist Raclopride Discriminates between Dopamine-Mediated Motor Functions</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1007/BF00179179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2FBF00179179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=2947255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADyaL2s%252FmvVWmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1986&pages=287-294&author=S.+O.+Ogrenauthor=H.+Hallauthor=C.+K%C3%B6hlerauthor=O.+Magnussonauthor=S.+E.+Sj%C3%B6strand&title=The+Selective+Dopamine+D2+Receptor+Antagonist+Raclopride+Discriminates+between+Dopamine-Mediated+Motor+Functions&doi=10.1007%2FBF00179179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions</span></div><div class="casAuthors">Ogren S O; Hall H; Kohler C; Magnusson O; Sjostrand S E</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-94</span>
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">The actions on central dopamine (DA) mechanisms of raclopride, a new substituted benzamide, were studied by means of behavioural and biochemical methods in the rat.  Raclopride blocked the in vitro binding of the dopamine D2 antagonist 3H-spiperone (IC50 = 32 nM), but not of the unselective D1 antagonist 3H-flupenthixol (IC50 greater than 100,000 nM) in rat striatum, and failed to inhibit striatal DA-sensitive adenylate cyclase in vitro (IC50 greater than 100,000 nM).  Raclopride caused a dose-dependent increase in the DA metabolites HVA and DOPAC in the striatum and olfactory tubercle.  Behavioural studies showed that raclopride discriminates between the motor behaviours induced by the DA agonist apomorphine.  Thus, unlike haloperidol, raclopride blocked apomorphine-induced hyperactivity at considerably lower doses than those inhibiting oral stereotypies.  Moreover, raclopride showed a high separation between the doses for blockade of apomorphine-induced hyperactivity and those inducing catalepsy in rats.  Raclopride caused a dose-dependent blockade of the specific binding of 3H-spiperone and 3H-N-n-propylnorapomorphine (3H-NPA) in vivo at doses similar to those blocking the behavioural effects of apomorphine.  The maximal blockade of 3H-spiperone binding in vivo was lower for raclopride than for haloperidol.  Raclopride caused a greater inhibition of 3H-NPA than of 3H-spiperone in vivo binding in the striatum.  It is suggested that the ability of raclopride to discriminate between different DA-mediated functions may be attributed to a preferential blockade of a subclass of functionally coupled dopamine D2 receptors in striatal as well as in extrastriatal brain regions in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp_jirgeZI142y4bB4mnvYfW6udTcc2eYKm9fTwN_M_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FmvVWmtA%253D%253D&md5=2f4f6d142c66252853dac308966f18d9</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2FBF00179179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00179179%26sid%3Dliteratum%253Aachs%26aulast%3DOgren%26aufirst%3DS.%2BO.%26aulast%3DHall%26aufirst%3DH.%26aulast%3DK%25C3%25B6hler%26aufirst%3DC.%26aulast%3DMagnusson%26aufirst%3DO.%26aulast%3DSj%25C3%25B6strand%26aufirst%3DS.%2BE.%26atitle%3DThe%2520Selective%2520Dopamine%2520D2%2520Receptor%2520Antagonist%2520Raclopride%2520Discriminates%2520between%2520Dopamine-Mediated%2520Motor%2520Functions%26jtitle%3DPsychopharmacology%26date%3D1986%26volume%3D90%26spage%3D287%26epage%3D294%26doi%3D10.1007%2FBF00179179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Pytka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mordyl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Głuch-Lutwin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapacz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gałuszka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkielewicz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marona, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zygmunt, M.</span><span> </span><span class="NLM_article-title">HBK-7 - A New Xanthone Derivative and a 5-HT1A Receptor Antagonist with Antidepressant-like Properties</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">146–147</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1016/j.pbb.2016.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.pbb.2016.04.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146%E2%80%93147&publication_year=2016&pages=35-43&author=K.+Pytkaauthor=G.+Kazekauthor=A.+Siwekauthor=B.+Mordylauthor=M.+G%C5%82uch-Lutwinauthor=A.+Rapaczauthor=A.+Olczykauthor=A.+Ga%C5%82uszkaauthor=A.+Waszkielewiczauthor=H.+Maronaauthor=J.+Sapaauthor=B.+Filipekauthor=M.+Zygmunt&title=HBK-7+-+A+New+Xanthone+Derivative+and+a+5-HT1A+Receptor+Antagonist+with+Antidepressant-like+Properties&doi=10.1016%2Fj.pbb.2016.04.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2016.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2016.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DPytka%26aufirst%3DK.%26aulast%3DKazek%26aufirst%3DG.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DMordyl%26aufirst%3DB.%26aulast%3DG%25C5%2582uch-Lutwin%26aufirst%3DM.%26aulast%3DRapacz%26aufirst%3DA.%26aulast%3DOlczyk%26aufirst%3DA.%26aulast%3DGa%25C5%2582uszka%26aufirst%3DA.%26aulast%3DWaszkielewicz%26aufirst%3DA.%26aulast%3DMarona%26aufirst%3DH.%26aulast%3DSapa%26aufirst%3DJ.%26aulast%3DFilipek%26aufirst%3DB.%26aulast%3DZygmunt%26aufirst%3DM.%26atitle%3DHBK-7%2520-%2520A%2520New%2520Xanthone%2520Derivative%2520and%2520a%25205-HT1A%2520Receptor%2520Antagonist%2520with%2520Antidepressant-like%2520Properties%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2016%26volume%3D146%25E2%2580%2593147%26spage%3D35%26epage%3D43%26doi%3D10.1016%2Fj.pbb.2016.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Joanna Sniecikowska, Monika Gluch-Lutwin, Adam Bucki, Anna Więckowska, Agata Siwek, Magdalena Jastrzebska-Wiesek, Anna Partyka, Daria Wilczyńska, Karolina Pytka, Gniewomir Latacz, Katarzyna Przejczowska-Pomierny, Elżbieta Wyska, Anna Wesołowska, Maciej Pawłowski, Adrian Newman-Tancredi, <span class="NLM_string-name hlFld-ContribAuthor">Marcin Kolaczkowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1A Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10946-10971. <a href="https://doi.org/10.1021/acs.jmedchem.0c00814" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00814</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00814%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BpERK1%25252F2-%252Bor%252B%2525CE%2525B2-Arrestin-Preferring%252B5-HT1A%252BReceptor-Biased%252BAgonists%25253A%252BDiversified%252BTherapeutic-like%252Bversus%252BSide%252BEffect%252BProfile%26aulast%3DSniecikowska%26aufirst%3DJoanna%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13052020%26date%3D23092020%26date%3D04092020%26volume%3D63%26issue%3D19%26spage%3D10946%26epage%3D10971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joanna Sniecikowska, Monika Gluch-Lutwin, Adam Bucki, Anna Więckowska, Agata Siwek, Magdalena Jastrzebska-Wiesek, Anna Partyka, Daria Wilczyńska, Karolina Pytka, Krzysztof Pociecha, Agnieszka Cios, Elżbieta Wyska, Anna Wesołowska, Maciej Pawłowski, Mark A. Varney, Adrian Newman-Tancredi, <span class="NLM_string-name hlFld-ContribAuthor">Marcin Kolaczkowski</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2750-2771. <a href="https://doi.org/10.1021/acs.jmedchem.9b00062" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00062%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BAryloxyethyl%252BDerivatives%252Bof%252B1-%2525281-Benzoylpiperidin-4-yl%252529methanamine%252Bas%252Bthe%252BExtracellular%252BRegulated%252BKinases%252B1%25252F2%252B%252528ERK1%25252F2%252529%252BPhosphorylation-Preferring%252BSerotonin%252B5-HT1A%252BReceptor-Biased%252BAgonists%252Bwith%252BRobust%252BAntidepressant-like%252BActivity%26aulast%3DSniecikowska%26aufirst%3DJoanna%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D10012019%26date%3D02032019%26date%3D05022019%26volume%3D62%26issue%3D5%26spage%3D2750%26epage%3D2771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xudong Cao, Yifang Zhang, Yin Chen, Yinli Qiu, Minquan Yu, Xiangqing Xu, Xin Liu, Bi-Feng Liu, Liangren Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Guisen Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 10017-10039. <a href="https://doi.org/10.1021/acs.jmedchem.8b01096" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01096%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BFused%252BTricyclic%252BHeterocycle%252BPiperazine%252B%252528Piperidine%252529%252BDerivatives%252BAs%252BPotential%252BMultireceptor%252BAtypical%252BAntipsychotics%26aulast%3DCao%26aufirst%3DXudong%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12072018%26date%3D09112018%26date%3D01112018%26volume%3D61%26issue%3D22%26spage%3D10017%26epage%3D10039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisa  Magli</span>, <span class="hlFld-ContribAuthor ">Ewa  Kędzierska</span>, <span class="hlFld-ContribAuthor ">Agnieszka A.  Kaczor</span>, <span class="hlFld-ContribAuthor ">Anna  Bielenica</span>, <span class="hlFld-ContribAuthor ">Beatrice  Severino</span>, <span class="hlFld-ContribAuthor ">Ewa  Gibuła‐Tarłowska</span>, <span class="hlFld-ContribAuthor ">Jolanta H.  Kotlińska</span>, <span class="hlFld-ContribAuthor ">Angela  Corvino</span>, <span class="hlFld-ContribAuthor ">Rosa  Sparaco</span>, <span class="hlFld-ContribAuthor ">Giovanna  Esposito</span>, <span class="hlFld-ContribAuthor ">Stefania  Albrizio</span>, <span class="hlFld-ContribAuthor ">Elisa  Perissutti</span>, <span class="hlFld-ContribAuthor ">Francesco  Frecentese</span>, <span class="hlFld-ContribAuthor ">Anna  Leśniak</span>, <span class="hlFld-ContribAuthor ">Magdalena  Bujalska‐Zadrożny</span>, <span class="hlFld-ContribAuthor ">Marta  Struga</span>, <span class="hlFld-ContribAuthor ">Raffaele  Capasso</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Santagada</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Caliendo</span>, <span class="hlFld-ContribAuthor ">Ferdinando  Fiorino</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, docking studies, and pharmacological evaluation of 2‐hydroxypropyl‐4‐arylpiperazine derivatives as serotoninergic ligands. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>25 </em><a href="https://doi.org/10.1002/ardp.202000414" title="DOI URL">https://doi.org/10.1002/ardp.202000414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000414%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%25252C%252Bdocking%252Bstudies%25252C%252Band%252Bpharmacological%252Bevaluation%252Bof%252B2%2525E2%252580%252590hydroxypropyl%2525E2%252580%2525904%2525E2%252580%252590arylpiperazine%252Bderivatives%252Bas%252Bserotoninergic%252Bligands%26aulast%3DMagli%26aufirst%3DElisa%26date%3D2021%26date%3D2021%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Agnieszka  Jankowska</span>, <span class="hlFld-ContribAuthor ">Grzegorz  Satała</span>, <span class="hlFld-ContribAuthor ">Marcin  Kołaczkowski</span>, <span class="hlFld-ContribAuthor ">Adam  Bucki</span>, <span class="hlFld-ContribAuthor ">Monika  Głuch-Lutwin</span>, <span class="hlFld-ContribAuthor ">Artur  Świerczek</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Pociecha</span>, <span class="hlFld-ContribAuthor ">Anna  Partyka</span>, <span class="hlFld-ContribAuthor ">Magdalena  Jastrzębska-Więsek</span>, <span class="hlFld-ContribAuthor ">Annamaria  Lubelska</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Alicja  Gawalska</span>, <span class="hlFld-ContribAuthor ">Andrzej J.  Bojarski</span>, <span class="hlFld-ContribAuthor ">Elżbieta  Wyska</span>, <span class="hlFld-ContribAuthor ">Grażyna  Chłoń-Rzepa</span>. </span><span class="cited-content_cbyCitation_article-title">Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>201 </em>, 112437. <a href="https://doi.org/10.1016/j.ejmech.2020.112437" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112437%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Banilide%252Band%252Bbenzylamide%252Bderivatives%252Bof%252Barylpiperazinylalkanoic%252Bacids%252Bas%252B5-HT1A%25252F5-HT7%252Breceptor%252Bantagonists%252Band%252Bphosphodiesterase%252B4%25252F7%252Binhibitors%252Bwith%252Bprocognitive%252Band%252Bantidepressant%252Bactivity%26aulast%3DJankowska%26aufirst%3DAgnieszka%26date%3D2020%26volume%3D201%26spage%3D112437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam  Bucki</span>, <span class="hlFld-ContribAuthor ">Monika  Marcinkowska</span>, <span class="hlFld-ContribAuthor ">Joanna  Śniecikowska</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Zagórska</span>, <span class="hlFld-ContribAuthor ">Marek  Jamrozik</span>, <span class="hlFld-ContribAuthor ">Maciej  Pawłowski</span>, <span class="hlFld-ContribAuthor ">Monika  Głuch-Lutwin</span>, <span class="hlFld-ContribAuthor ">Agata  Siwek</span>, <span class="hlFld-ContribAuthor ">Magdalena  Jakubczyk</span>, <span class="hlFld-ContribAuthor ">Karolina  Pytka</span>, <span class="hlFld-ContribAuthor ">Magdalena  Jastrzębska-Więsek</span>, <span class="hlFld-ContribAuthor ">Anna  Partyka</span>, <span class="hlFld-ContribAuthor ">Anna  Wesołowska</span>, <span class="hlFld-ContribAuthor ">Paweł  Mierzejewski</span>, <span class="hlFld-ContribAuthor ">Marcin  Kołaczkowski</span>. </span><span class="cited-content_cbyCitation_article-title">Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>191 </em>, 112149. <a href="https://doi.org/10.1016/j.ejmech.2020.112149" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112149%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMultifunctional%252B6-fluoro-3-%25255B3-%252528pyrrolidin-1-yl%252529propyl%25255D-1%25252C2-benzoxazoles%252Btargeting%252Bbehavioral%252Band%252Bpsychological%252Bsymptoms%252Bof%252Bdementia%252B%252528BPSD%252529%26aulast%3DBucki%26aufirst%3DAdam%26date%3D2020%26volume%3D191%26spage%3D112149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monika  Marcinkowska</span>, <span class="hlFld-ContribAuthor ">Joanna  Śniecikowska</span>, <span class="hlFld-ContribAuthor ">Nikola  Fajkis</span>, <span class="hlFld-ContribAuthor ">Paweł  Paśko</span>, <span class="hlFld-ContribAuthor ">Weronika  Franczyk</span>, <span class="hlFld-ContribAuthor ">Marcin  Kołaczkowski</span>. </span><span class="cited-content_cbyCitation_article-title">Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates. </span><span class="cited-content_cbyCitation_journal-name">CNS Drugs</span><span> <strong>2020,</strong> <em>34 </em>
                                    (3)
                                     , 243-268. <a href="https://doi.org/10.1007/s40263-020-00707-7" title="DOI URL">https://doi.org/10.1007/s40263-020-00707-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40263-020-00707-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40263-020-00707-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCNS%2520Drugs%26atitle%3DManagement%252Bof%252BDementia-Related%252BPsychosis%25252C%252BAgitation%252Band%252BAggression%25253A%252BA%252BReview%252Bof%252Bthe%252BPharmacology%252Band%252BClinical%252BEffects%252Bof%252BPotential%252BDrug%252BCandidates%26aulast%3DMarcinkowska%26aufirst%3DMonika%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D3%26spage%3D243%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna  Sniecikowska</span>, <span class="hlFld-ContribAuthor ">Adrian  Newman-Tancredi</span>, <span class="hlFld-ContribAuthor ">Marcin  Kolaczkowski</span>. </span><span class="cited-content_cbyCitation_article-title">From Receptor Selectivity to Functional Selectivity: The Rise of Biased Agonism in 5-HT1A Receptor Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (26)
                                     , 2393-2420. <a href="https://doi.org/10.2174/1568026619666190911122040" title="DOI URL">https://doi.org/10.2174/1568026619666190911122040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190911122040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190911122040%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DFrom%252BReceptor%252BSelectivity%252Bto%252BFunctional%252BSelectivity%25253A%252BThe%252BRise%252Bof%252BBiased%252BAgonism%252Bin%252B5-HT1A%252BReceptor%252BDrug%252BDiscovery%26aulast%3DSniecikowska%26aufirst%3DJoanna%26date%3D2019%26volume%3D19%26issue%3D26%26spage%3D2393%26epage%3D2420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Romeo</span>, <span class="hlFld-ContribAuthor ">Loredana  Salerno</span>, <span class="hlFld-ContribAuthor ">Valeria  Pittalà</span>, <span class="hlFld-ContribAuthor ">Marialuisa  Candido</span>, <span class="hlFld-ContribAuthor ">Sebastiano  Intagliata</span>, <span class="hlFld-ContribAuthor ">Emanuele  Amata</span>, <span class="hlFld-ContribAuthor ">Mario  Salmona</span>, <span class="hlFld-ContribAuthor ">Alfredo  Cagnotto</span>, <span class="hlFld-ContribAuthor ">Antonio  Rescifina</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Floresta</span>, <span class="hlFld-ContribAuthor ">Maria Nunziata  Modica</span>. </span><span class="cited-content_cbyCitation_article-title">[1]Benzothieno[3,2-d]pyrimidine derivatives as ligands for the serotonergic 5-HT7 receptor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111690. <a href="https://doi.org/10.1016/j.ejmech.2019.111690" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111690</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111690%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%25255B1%25255DBenzothieno%25255B3%25252C2-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bligands%252Bfor%252Bthe%252Bserotonergic%252B5-HT7%252Breceptor%26aulast%3DRomeo%26aufirst%3DGiuseppe%26date%3D2019%26volume%3D183%26spage%3D111690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marlene  Jacobson</span>, <span class="hlFld-ContribAuthor ">Wayne  Childers</span>, <span class="hlFld-ContribAuthor ">Magid  Abou‐Gharbia</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine D
              2
              Partial Agonists – Discovery, Evolution, and Therapeutic Potential. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 83-130. <a href="https://doi.org/10.1002/9783527814695.ch4" title="DOI URL">https://doi.org/10.1002/9783527814695.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527814695.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527814695.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DDopamine%252BD%252B2%252BPartial%252BAgonists%252B%2525E2%252580%252593%252BDiscovery%25252C%252BEvolution%25252C%252Band%252BTherapeutic%252BPotential%26aulast%3DJacobson%26aufirst%3DMarlene%26date%3D2019%26date%3D2019%26spage%3D83%26epage%3D130%26pub%3DWiley%26atitle%3DSuccessful%252BDrug%252BDiscovery%26aulast%3DFischer%26aufirst%3DJ%25C3%25A1nos%26date%3D2019%26date%3D2019%26volume%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Megan D.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Felagot A.  Abebe</span>, <span class="hlFld-ContribAuthor ">Kristina A.  Scott</span>, <span class="hlFld-ContribAuthor ">Garett L.  Ozmer</span>, <span class="hlFld-ContribAuthor ">Alec A.  Sheir</span>, <span class="hlFld-ContribAuthor ">Lucas J.  Schroeder</span>, <span class="hlFld-ContribAuthor ">Robert J.  Sheaff</span>, <span class="hlFld-ContribAuthor ">Angus A.  Lamar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and identification of heteroaromatic
              N
              -benzyl sulfonamides as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (36)
                                     , 8391-8402. <a href="https://doi.org/10.1039/C9OB01694E" title="DOI URL">https://doi.org/10.1039/C9OB01694E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01694E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01694E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Band%252Bidentification%252Bof%252Bheteroaromatic%252BN%252B-benzyl%252Bsulfonamides%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DHopkins%26aufirst%3DMegan%2BD.%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D36%26spage%3D8391%26epage%3D8402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Agnieszka  Zagórska</span>, <span class="hlFld-ContribAuthor ">Anna  Partyka</span>, <span class="hlFld-ContribAuthor ">Adam  Bucki</span>, <span class="hlFld-ContribAuthor ">Marcin  Kołaczkowski</span>, <span class="hlFld-ContribAuthor ">Magdalena  Jastrzębska‐Więsek</span>, <span class="hlFld-ContribAuthor ">Anna  Czopek</span>, <span class="hlFld-ContribAuthor ">Agata  Siwek</span>, <span class="hlFld-ContribAuthor ">Monika  Głuch‐Lutwin</span>, <span class="hlFld-ContribAuthor ">Marek  Bednarski</span>, <span class="hlFld-ContribAuthor ">Marek  Bajda</span>, <span class="hlFld-ContribAuthor ">Jakub  Jończyk</span>, <span class="hlFld-ContribAuthor ">Kamil  Piska</span>, <span class="hlFld-ContribAuthor ">Paulina  Koczurkiewicz</span>, <span class="hlFld-ContribAuthor ">Anna  Wesołowska</span>, <span class="hlFld-ContribAuthor ">Maciej  Pawłowski</span>. </span><span class="cited-content_cbyCitation_article-title">Characteristics of metabolic stability and the cell permeability of 2‐pyrimidinyl‐piperazinyl‐alkyl derivatives of 1H‐imidazo[2,1
              ‐f
              ]purine‐2,4(3
              H
              ,8
              H
              )‐dione with antidepressant‐ and anxiolytic‐like activities. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2019,</strong> <em>93 </em>
                                    (4)
                                     , 511-521. <a href="https://doi.org/10.1111/cbdd.13442" title="DOI URL">https://doi.org/10.1111/cbdd.13442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13442%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DCharacteristics%252Bof%252Bmetabolic%252Bstability%252Band%252Bthe%252Bcell%252Bpermeability%252Bof%252B2%2525E2%252580%252590pyrimidinyl%2525E2%252580%252590piperazinyl%2525E2%252580%252590alkyl%252Bderivatives%252Bof%252B1H%2525E2%252580%252590imidazo%25255B2%25252C1%252B%2525E2%252580%252590f%252B%25255Dpurine%2525E2%252580%2525902%25252C4%2525283%252BH%252B%25252C8%252BH%252B%252529%2525E2%252580%252590dione%252Bwith%252Bantidepressant%2525E2%252580%252590%252Band%252Banxiolytic%2525E2%252580%252590like%252Bactivities%26aulast%3DZag%25C3%25B3rska%26aufirst%3DAgnieszka%26date%3D2019%26date%3D2018%26volume%3D93%26issue%3D4%26spage%3D511%26epage%3D521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katarzyna  Pańczyk</span>, <span class="hlFld-ContribAuthor ">Karolina  Pytka</span>, <span class="hlFld-ContribAuthor ">Magdalena  Jakubczyk</span>, <span class="hlFld-ContribAuthor ">Anna  Rapacz</span>, <span class="hlFld-ContribAuthor ">Kinga  Sałat</span>, <span class="hlFld-ContribAuthor ">Anna  Furgała</span>, <span class="hlFld-ContribAuthor ">Agata  Siwek</span>, <span class="hlFld-ContribAuthor ">Monika  Głuch-Lutwin</span>, <span class="hlFld-ContribAuthor ">Anna  Gryboś</span>, <span class="hlFld-ContribAuthor ">Karolina  Słoczyńska</span>, <span class="hlFld-ContribAuthor ">Elżbieta  Pękala</span>, <span class="hlFld-ContribAuthor ">Paweł  Żmudzki</span>, <span class="hlFld-ContribAuthor ">Adam  Bucki</span>, <span class="hlFld-ContribAuthor ">Marcin  Kołaczkowski</span>, <span class="hlFld-ContribAuthor ">Dorota  Żelaszczyk</span>, <span class="hlFld-ContribAuthor ">Henryk  Marona</span>, <span class="hlFld-ContribAuthor ">Anna M.  Waszkielewicz</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and activity of di- or trisubstituted N -(phenoxyalkyl)- or N -{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives on the central nervous system. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (11)
                                     , 2039-2049. <a href="https://doi.org/10.1016/j.bmcl.2018.04.059" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.04.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.04.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.04.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bactivity%252Bof%252Bdi-%252Bor%252Btrisubstituted%252BN%252B-%252528phenoxyalkyl%252529-%252Bor%252BN%252B-%25257B2-%25255B2-%252528phenoxy%252529ethoxy%25255Dethyl%25257Dpiperazine%252Bderivatives%252Bon%252Bthe%252Bcentral%252Bnervous%252Bsystem%26aulast%3DPa%25C5%2584czyk%26aufirst%3DKatarzyna%26date%3D2018%26volume%3D28%26issue%3D11%26spage%3D2039%26epage%3D2049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00839&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of multifunctional ligands. Proposed binding mode of the prototype compound <b>14</b>, the arylsulfonamide fragment of which mimics interactions of (1<i>R</i>)-3,<i>N</i>-dimethyl-<i>N</i>-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide (SB-258719)<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> in the 5-HT<sub>7</sub> receptor site (A) and the 3-(1,2,3,6-tetrahydropyridin-4-yl)-1<i>H</i>-indole moiety is responsible for SERT blocking properties (B). Structure of compound <b>14</b> (C) proved to satisfy steric and electrostatic requirements in docking studies to the homology models of the 5-HT<sub>6</sub>, 5-HT<sub>1A</sub>, and D<sub>2</sub> receptors (D). Furthermore, the molecule was incompatible with structural representations of hERG channel and M<sub>1</sub> receptor (E). The design stage resulted in a series of 36 multiple ligands characterized by potentially high affinity for the desirable biological targets and low risk of binding to the off-targets (F). Amino acid residues engaged in ligand binding (within 4 Å from the ligand atoms) are displayed as sticks, whereas those forming H-bonds (dotted yellow lines), π–π stacking (dotted blue lines), or cation−π (dotted green lines) are represented as thick sticks. M<sub>1</sub> receptor structure displayed with antagonist tiotropium because docking of <b>14</b> resulted in no valid poses (E). For the sake of clarity, extracellular loop 2 (ECL2) of the given GPCRs was hidden (A,D). The detailed complexes are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf" class="ext-link">Figures S1–S6</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00839&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/medium/jm-2017-00839u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Final Compounds <b>13</b>–<b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-17/acs.jmedchem.7b00839/20170908/images/large/jm-2017-00839u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00839&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, Kl, CH<sub>3</sub>CN, 70 °C, 12 h; (b) 40% aq MeNH<sub>2</sub>, 50 °C, 4 h; (c) THF drv, 1 M KOH solution, rt, 12 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 77 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Burns, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iliffe, S.</span><span> </span><span class="NLM_article-title">Dementia</span> <span class="citation_source-journal">BMJ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">b75</span><span class="refDoi"> DOI: 10.1136/bmj.b75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1136%2Fbmj.b75" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2009&pages=b75&author=A.+Burnsauthor=S.+Iliffe&title=Dementia&doi=10.1136%2Fbmj.b75"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1136%2Fbmj.b75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.b75%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DA.%26aulast%3DIliffe%26aufirst%3DS.%26atitle%3DDementia%26jtitle%3DBMJ.%26date%3D2009%26volume%3D338%26spage%3Db75%26doi%3D10.1136%2Fbmj.b75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lyketsos, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrillo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khachaturian, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trzepacz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatniek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cedarbaum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brashear, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. S.</span><span> </span><span class="NLM_article-title">Neuropsychiatric Symptoms in Alzheimer’s Disease</span> <span class="citation_source-journal">Alzheimer's Dementia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">532</span><span class="NLM_x">–</span> <span class="NLM_lpage">539</span><span class="refDoi"> DOI: 10.1016/j.jalz.2011.05.2410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.jalz.2011.05.2410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=21889116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC3MfhtVyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=532-539&author=C.+G.+Lyketsosauthor=M.+C.+Carrilloauthor=J.+M.+Ryanauthor=A.+S.+Khachaturianauthor=P.+Trzepaczauthor=J.+Amatniekauthor=J.+Cedarbaumauthor=R.+Brashearauthor=D.+S.+Miller&title=Neuropsychiatric+Symptoms+in+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.jalz.2011.05.2410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropsychiatric symptoms in Alzheimer's disease</span></div><div class="casAuthors">Lyketsos Constantine G; Carrillo Maria C; Ryan J Michael; Khachaturian Ara S; Trzepacz Paula; Amatniek Joan; Cedarbaum Jesse; Brashear Robert; Miller David S</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia : the journal of the Alzheimer's Association</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">532-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuropsychiatric symptoms (NPS) are core features of Alzheimer's disease and related dementias.  Once thought to emerge primarily in people with late-stage disease, these symptoms are currently known to manifest commonly in very early disease and in prodromal phases, such as mild cognitive impairment.  Despite decades of research, reliable treatments for dementia-associated NPS have not been found, and those that are in widespread use present notable risks for people using these medications.  An Alzheimer's Association Research Roundtable was convened in the spring of 2010 to review what is known about NPS in Alzheimer's disease, to discuss classification and underlying neuropathogenesis and vulnerabilities, and to formulate recommendations for new approaches to tailored therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBeAbCFjqvro2y4bB4mnvYfW6udTcc2ebNKOpMwmvRyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfhtVyisA%253D%253D&md5=02b846f7a3ede8fe5c088c9fb2736362</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2011.05.2410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2011.05.2410%26sid%3Dliteratum%253Aachs%26aulast%3DLyketsos%26aufirst%3DC.%2BG.%26aulast%3DCarrillo%26aufirst%3DM.%2BC.%26aulast%3DRyan%26aufirst%3DJ.%2BM.%26aulast%3DKhachaturian%26aufirst%3DA.%2BS.%26aulast%3DTrzepacz%26aufirst%3DP.%26aulast%3DAmatniek%26aufirst%3DJ.%26aulast%3DCedarbaum%26aufirst%3DJ.%26aulast%3DBrashear%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DD.%2BS.%26atitle%3DNeuropsychiatric%2520Symptoms%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2011%26volume%3D7%26spage%3D532%26epage%3D539%26doi%3D10.1016%2Fj.jalz.2011.05.2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Hersch, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falzgraf, S.</span><span> </span><span class="NLM_article-title">Management of the Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">Clin. Interventions Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">611</span><span class="NLM_x">–</span> <span class="NLM_lpage">621</span><span class="refDoi"> DOI: 10.2147/CIA.S1698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.2147%2FCIA.S1698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=18225462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FntVajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=611-621&author=E.+C.+Herschauthor=S.+Falzgraf&title=Management+of+the+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.2147%2FCIA.S1698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Management of the behavioral and psychological symptoms of dementia</span></div><div class="casAuthors">Hersch Elizabeth C; Falzgraf Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Clinical interventions in aging</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">611-21</span>
        ISSN:<span class="NLM_cas:issn">1176-9092</span>.
    </div><div class="casAbstract">More than 50% of people with dementia experience behavioral and psychological symptoms of dementia (BPSD).  BPSD are distressing for patients and their caregivers, and are often the reason for placement into residential care.  The development of BPSD is associated with a more rapid rate of cognitive decline, greater impairment in activities of daily living, and diminished quality of life (QOL).  Evaluation of BPSD includes a thorough diagnostic investigation, consideration of the etiology of the dementia, and the exclusion of other causes, such as drug-induced delirium, pain, or infection.  Care of patients with BPSD involves psychosocial treatments for both the patient and family.  BPSD may respond to those environmental and psychosocial interventions, however, drug therapy is often required for more severe presentations.  There are multiple classes of drugs used for BPSD, including antipsychotics, anticonvulsants, antidepressants, anxiolytics, cholinesterase inhibitors and NMDA modulators, but the evidence base for pharmacological management is poor, there is no clear standard of care, and treatment is often based on local pharmacotherapy customs.  Clinicians should discuss the potential risks and benefits of treatment with patients and their surrogate decision makers, and must ensure a balance between side effects and tolerability compared with clinical benefit and QOL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOjfmAvz2C3LmQt-ICR3qNfW6udTcc2eZKuT2f6bPbq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FntVajuw%253D%253D&md5=eebc44e212be9e3449f7aafbd7933eb1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2147%2FCIA.S1698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCIA.S1698%26sid%3Dliteratum%253Aachs%26aulast%3DHersch%26aufirst%3DE.%2BC.%26aulast%3DFalzgraf%26aufirst%3DS.%26atitle%3DManagement%2520of%2520the%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DClin.%2520Interventions%2520Aging%26date%3D2007%26volume%3D2%26spage%3D611%26epage%3D621%26doi%3D10.2147%2FCIA.S1698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Liperoti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsonello, A.</span><span> </span><span class="NLM_article-title">Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.2174/157015908784533860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.2174%2F157015908784533860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19305792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVaktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=117-124&author=R.+Liperotiauthor=C.+Pedoneauthor=A.+Corsonello&title=Antipsychotics+for+the+Treatment+of+Behavioral+and+Psychological+Symptoms+of+Dementia+%28BPSD%29&doi=10.2174%2F157015908784533860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD)</span></div><div class="casAuthors">Liperoti, Rosa; Pedone, Claudio; Corsonello, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Behavioral and psychol. symptoms of dementia (BPSD), i.e. verbal and phys. aggression, agitation, psychotic symptoms (hallucinations and delusions), sleep disturbances, oppositional behavior, and wandering, are a common and potentially severe problem complicating dementia.  Their prevalence is very high and it is estd. that up to 90% of patients with Alzheimer's disease (AD) may present at least one BPSD.  Beside the obvious impact on the quality of life of people with dementia, BPSD are responsible for increased risk of patient institutionalization and increased costs.  Furthermore, they are assocd. with caregivers' stress and depression.  Drugs used include antipsychotics, antidepressants, anticonvulsivants, anxiolytics, cholinesterase inhibitors and N-methyl-D-aspartate receptor modulators.  Among these, the most commonly used are anti-psychotics.  These drugs have been used for many decades, but in the last years new compds. have been marketed with the promise of comparable efficacy but less frequent adverse effects (esp. extra-pyramidal side effects).  Their safety, however, has been challenged by data showing a potential increase in adverse cerebrovascular side effects and mortality.  This review will summarize the pathophysiol. and neuropharmacol. of BPSD, it will describe the characteristics of the anti-psychotics most commonly used focusing on their efficacy and safety in BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAjjq7EOofHrVg90H21EOLACvtfcHk0lgHJPddsNBrBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVaktLc%253D&md5=701fde11f34cc112cff2ba303853e36d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F157015908784533860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015908784533860%26sid%3Dliteratum%253Aachs%26aulast%3DLiperoti%26aufirst%3DR.%26aulast%3DPedone%26aufirst%3DC.%26aulast%3DCorsonello%26aufirst%3DA.%26atitle%3DAntipsychotics%2520for%2520the%2520Treatment%2520of%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%2520%2528BPSD%2529%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2008%26volume%3D6%26spage%3D117%26epage%3D124%26doi%3D10.2174%2F157015908784533860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Gauthier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodaty, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyketsos, C.</span><span> </span><span class="NLM_article-title">Management of Behavioral Problems in Alzheimer’s Disease</span> <span class="citation_source-journal">Int. Psychogeriatr. IPA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1017/S1041610209991505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1017%2FS1041610209991505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=20096151" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=346-372&author=S.+Gauthierauthor=J.+Cummingsauthor=C.+Ballardauthor=H.+Brodatyauthor=G.+Grossbergauthor=P.+Robertauthor=C.+Lyketsos&title=Management+of+Behavioral+Problems+in+Alzheimer%E2%80%99s+Disease&doi=10.1017%2FS1041610209991505"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1017%2FS1041610209991505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1041610209991505%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DCummings%26aufirst%3DJ.%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DBrodaty%26aufirst%3DH.%26aulast%3DGrossberg%26aufirst%3DG.%26aulast%3DRobert%26aufirst%3DP.%26aulast%3DLyketsos%26aufirst%3DC.%26atitle%3DManagement%2520of%2520Behavioral%2520Problems%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DInt.%2520Psychogeriatr.%2520IPA%26date%3D2010%26volume%3D22%26spage%3D346%26epage%3D372%26doi%3D10.1017%2FS1041610209991505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Azermai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elseviers, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourgeois, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Bortel, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Stichele, R. H.</span><span> </span><span class="NLM_article-title">Systematic Appraisal of Dementia Guidelines for the Management of Behavioural and Psychological Symptoms</span> <span class="citation_source-journal">Ageing Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1016/j.arr.2011.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.arr.2011.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=21856452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FnvFOksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=78-86&author=M.+Azermaiauthor=M.+Petrovicauthor=M.+M.+Elseviersauthor=J.+Bourgeoisauthor=L.+M.+Van+Bortelauthor=R.+H.+Vander+Stichele&title=Systematic+Appraisal+of+Dementia+Guidelines+for+the+Management+of+Behavioural+and+Psychological+Symptoms&doi=10.1016%2Fj.arr.2011.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms</span></div><div class="casAuthors">Azermai Majda; Petrovic Mirko; Elseviers Monique M; Bourgeois Jolyce; Van Bortel Luc M; Vander Stichele Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Ageing research reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Within the treatment of dementia, management of behavioural and psychological symptoms (BPSD) is a complex component.  PURPOSE:  We wanted to offer a pragmatic synthesis of existing specific practice recommendations for managing BPSD, based on agreement among systematically appraised dementia guidelines.  DATA SOURCES:  We conducted a systematic search in MEDLINE and guideline organisation databases, supplemented by a hand search of web sites.  STUDY SELECTION:  Fifteen retrieved guidelines were eligible for quality appraisal by the Appraisal of Guidelines Research and Evaluation instrument (AGREE), performed by 2 independent reviewers.  DATA EXTRACTION:  From the 5 included guidelines, 18 specific practice recommendations for BPSD were extracted and compared for their level of evidence and strength.  DATA SYNTHESIS:  No agreement was found among dementia guidelines for the majority of specific practice recommendations with regard to non-pharmacological interventions, although these were recommended as first-line treatment.  Pharmacological specific practice recommendations were proposed as second-line treatment, with agreement for the use of a selection of antipsychotics based on strong supporting evidence, but with guidance for timely discontinuation.  LIMITATIONS:  The appraisal of the level of agreement between guidelines for each specific practice recommendation was complicated by variation in grading systems, and was performed with criteria developed a posteriori.  CONCLUSION:  Despite the limited number of recommendations for which agreement was found, guidelines did agree on careful antipsychotic use for BPSD.  Adverse events might outweigh the supporting evidence of efficacy, weakening the recommendation.  More pivotal trials on the effectiveness of non-pharmacological interventions, as well as guidelines specifically focusing on BPSD, are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMim0DpBc7QOkdrW1FkXG-fW6udTcc2eYZMdrU372Lsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FnvFOksA%253D%253D&md5=acf815e7cdc17f72869dfeb3f897e036</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.arr.2011.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.arr.2011.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DAzermai%26aufirst%3DM.%26aulast%3DPetrovic%26aufirst%3DM.%26aulast%3DElseviers%26aufirst%3DM.%2BM.%26aulast%3DBourgeois%26aufirst%3DJ.%26aulast%3DVan%2BBortel%26aufirst%3DL.%2BM.%26aulast%3DVander%2BStichele%26aufirst%3DR.%2BH.%26atitle%3DSystematic%2520Appraisal%2520of%2520Dementia%2520Guidelines%2520for%2520the%2520Management%2520of%2520Behavioural%2520and%2520Psychological%2520Symptoms%26jtitle%3DAgeing%2520Res.%2520Rev.%26date%3D2012%26volume%3D11%26spage%3D78%26epage%3D86%26doi%3D10.1016%2Fj.arr.2011.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">De Deyn, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirshing, W. C.</span><span> </span><span class="NLM_article-title">Scales to Assess Efficacy and Safety of Pharmacologic Agents in the Treatment of Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 21</span><span class="NLM_x">) </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=11584983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVantrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2001&pages=19-22&issue=Suppl+21&author=P.+P.+De+Deynauthor=W.+C.+Wirshing&title=Scales+to+Assess+Efficacy+and+Safety+of+Pharmacologic+Agents+in+the+Treatment+of+Behavioral+and+Psychological+Symptoms+of+Dementia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia</span></div><div class="casAuthors">De Deyn, Peter Paul; Wirshing, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">Suppl. 21</span>),
    <span class="NLM_cas:pages">19-22</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">A review.  Advances in the assessment of the behavioral and psychol. symptoms of dementia (BPSD) have been employed in large-scale clin. trials of new antipsychotic medications such as risperidone.  These scales can be used to assess drug efficacy and to compare different treatment regimens.  We review 3 valid and reliable scales, the Behavioral Pathol. in Alzheimer's Disease Rating Scale (BEHAVE-AD), the Cohen-Mansfield Agitation Inventory (CMAI), and the Neuropsychiatric Inventory (NPI).  Extrapyramidal side effects (EPS) assocd. with the treatment of BPSD have also been assessed using a no. of rating instruments.  The design of the most comprehensive of these, the Extrapyramidal Symptom Rating Scale (ESRS), is exhaustive, and it successfully quantifies EPS and distinguishes toxic from nontoxic medications.  This publication serves as an aid to researchers and clinicians in their interpretation of qual. and quant. data from trials evaluating antipsychotic agents in the treatment of BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDJ1jbxIe1RLVg90H21EOLACvtfcHk0lgP-T7WKfpsRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVantrw%253D&md5=ecf82edb6928dc3aea6d7b4a392f5048</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BDeyn%26aufirst%3DP.%2BP.%26aulast%3DWirshing%26aufirst%3DW.%2BC.%26atitle%3DScales%2520to%2520Assess%2520Efficacy%2520and%2520Safety%2520of%2520Pharmacologic%2520Agents%2520in%2520the%2520Treatment%2520of%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2001%26volume%3D62%26issue%3DSuppl%252021%26spage%3D19%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ballard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitramohan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aarsland, D.</span><span> </span><span class="NLM_article-title">Management of Agitation and Aggression Associated with Alzheimer’s Disease: Controversies and Possible Solutions</span> <span class="citation_source-journal">Curr. Opin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">532</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span><span class="refDoi"> DOI: 10.1097/YCO.0b013e32833111f9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1097%2FYCO.0b013e32833111f9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19696673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD1Mnot1Ciuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=532-540&author=C.+Ballardauthor=A.+Corbettauthor=R.+Chitramohanauthor=D.+Aarsland&title=Management+of+Agitation+and+Aggression+Associated+with+Alzheimer%E2%80%99s+Disease%3A+Controversies+and+Possible+Solutions&doi=10.1097%2FYCO.0b013e32833111f9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions</span></div><div class="casAuthors">Ballard Clive; Corbett Anne; Chitramohan Ramilgan; Aarsland Das</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">532-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Behavioral and psychological symptoms of dementia (BPSD) are frequent among people with Alzheimer's disease and other dementias, commonly confer risk to the person and others, and present a significant management challenge for clinicians.  The purpose of this review is to describe the current state of knowledge regarding management of BPSD, with a particular focus on agitation.  RECENT FINDINGS:  There is increasing evidence to support the value of simple psychological interventions and staff-training programs as a first-line management strategy for agitation prior to pharmacotherapy.  The most widely prescribed pharmacological treatments - atypical antipsychotics - have a modest but significant beneficial effect in the short-term treatment of aggression (over 6-12 weeks), but limited benefits in longer term therapy.  In addition, there have been increasing concerns regarding the potential for serious adverse outcomes, including stroke and death.  The potential pharmacological alternatives to atypical antipsychotics with the most encouraging preliminary evidence include memantine, carbamazepine and citalopram.  SUMMARY:  Large prospective, randomized, placebo-controlled trials are needed to establish the role of agents other than neuroleptics as clinical therapies for the treatment of BPSD and studies are urgently needed to evaluate BPSD treatments in non-Alzheimer dementias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJsH1WKvRJGcyail4HZd-ifW6udTcc2eYZMdrU372Lsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mnot1Ciuw%253D%253D&md5=fc3187f82f4e46f2575ee88b00fe63fc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2FYCO.0b013e32833111f9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FYCO.0b013e32833111f9%26sid%3Dliteratum%253Aachs%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DCorbett%26aufirst%3DA.%26aulast%3DChitramohan%26aufirst%3DR.%26aulast%3DAarsland%26aufirst%3DD.%26atitle%3DManagement%2520of%2520Agitation%2520and%2520Aggression%2520Associated%2520with%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Controversies%2520and%2520Possible%2520Solutions%26jtitle%3DCurr.%2520Opin.%2520Psychiatry%26date%3D2009%26volume%3D22%26spage%3D532%26epage%3D540%26doi%3D10.1097%2FYCO.0b013e32833111f9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cerejeira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagarto, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukaetova-Ladinska, E. B.</span><span> </span><span class="NLM_article-title">Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">Front. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="refDoi"> DOI: 10.3389/fneur.2012.00073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.3389%2Ffneur.2012.00073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=22586419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC38njt1aitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=73&author=J.+Cerejeiraauthor=L.+Lagartoauthor=E.+B.+Mukaetova-Ladinska&title=Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.3389%2Ffneur.2012.00073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral and psychological symptoms of dementia</span></div><div class="casAuthors">Cerejeira J; Lagarto L; Mukaetova-Ladinska E B</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms, represent a heterogeneous group of non-cognitive symptoms and behaviors occurring in subjects with dementia.  BPSD constitute a major component of the dementia syndrome irrespective of its subtype.  They are as clinically relevant as cognitive symptoms as they strongly correlate with the degree of functional and cognitive impairment.  BPSD include agitation, aberrant motor behavior, anxiety, elation, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite changes.  It is estimated that BPSD affect up to 90% of all dementia subjects over the course of their illness, and is independently associated with poor outcomes, including distress among patients and caregivers, long-term hospitalization, misuse of medication, and increased health care costs.  Although these symptoms can be present individually it is more common that various psychopathological features co-occur simultaneously in the same patient.  Thus, categorization of BPSD in clusters taking into account their natural course, prognosis, and treatment response may be useful in the clinical practice.  The pathogenesis of BPSD has not been clearly delineated but it is probably the result of a complex interplay of psychological, social, and biological factors.  Recent studies have emphasized the role of neurochemical, neuropathological, and genetic factors underlying the clinical manifestations of BPSD.  A high degree of clinical expertise is crucial to appropriately recognize and manage the neuropsychiatric symptoms in a patient with dementia.  Combination of non-pharmacological and careful use of pharmacological interventions is the recommended therapeutic for managing BPSD.  Given the modest efficacy of current strategies, there is an urgent need to identify novel pharmacological targets and develop new non-pharmacological approaches to improve the adverse outcomes associated with BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmgVlZTrvFkTMsgLhIoICsfW6udTcc2ebMu6HSFLhTXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38njt1aitg%253D%253D&md5=913c4f4ee720f5d53f065c158780c737</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2012.00073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2012.00073%26sid%3Dliteratum%253Aachs%26aulast%3DCerejeira%26aufirst%3DJ.%26aulast%3DLagarto%26aufirst%3DL.%26aulast%3DMukaetova-Ladinska%26aufirst%3DE.%2BB.%26atitle%3DBehavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DFront.%2520Neurol.%26date%3D2012%26volume%3D3%26spage%3D73%26doi%3D10.3389%2Ffneur.2012.00073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinzi, L.</span><span> </span><span class="NLM_article-title">Computational Polypharmacology Comes of Age</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="refDoi"> DOI: 10.3389/fphar.2015.00157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.3389%2Ffphar.2015.00157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26283966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFals7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=157&author=G.+Rastelliauthor=L.+Pinzi&title=Computational+Polypharmacology+Comes+of+Age&doi=10.3389%2Ffphar.2015.00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Computational polypharmacology comes of age</span></div><div class="casAuthors">Rastelli, Giulio; Pinzi, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157/1-157/4</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  This article describes the predicting drug polypharmacol., the raising no. of computational strategies, frameworks developed at testify that computational polypharmacol. has come of age and increasingly important role in drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiapZ3lz9l4rVg90H21EOLACvtfcHk0lhiud9dXfW0JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFals7zI&md5=4444f48a7d9c80f30a4d9dbf3f6ba2be</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00157%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DPinzi%26aufirst%3DL.%26atitle%3DComputational%2520Polypharmacology%2520Comes%2520of%2520Age%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D157%26doi%3D10.3389%2Ffphar.2015.00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Rodda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, Z.</span><span> </span><span class="NLM_article-title">Are Cholinesterase Inhibitors Effective in the Management of the Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease? A Systematic Review of Randomized, Placebo-Controlled Trials of Donepezil, Rivastigmine and Galantamine</span> <span class="citation_source-journal">Int. Psychogeriatr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1017/S1041610209990354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1017%2FS1041610209990354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19538824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD1MrotFeitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=813-824&author=J.+Roddaauthor=S.+Morganauthor=Z.+Walker&title=Are+Cholinesterase+Inhibitors+Effective+in+the+Management+of+the+Behavioral+and+Psychological+Symptoms+of+Dementia+in+Alzheimer%E2%80%99s+Disease%3F+A+Systematic+Review+of+Randomized%2C+Placebo-Controlled+Trials+of+Donepezil%2C+Rivastigmine+and+Galantamine&doi=10.1017%2FS1041610209990354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine</span></div><div class="casAuthors">Rodda Joanne; Morgan Shirlony; Walker Zuzana</div><div class="citationInfo"><span class="NLM_cas:title">International psychogeriatrics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">813-24</span>
        ISSN:<span class="NLM_cas:issn">1041-6102</span>.
    </div><div class="casAbstract">BACKGROUND:  The study aim was to conduct a systematic review of the evidence from randomized, placebo controlled trials related to the efficacy of donepezil, rivastigmine and galantamine in the treatment of behavioral and psychological symptoms of Alzheimer's disease.  METHODS:  Electronic database searches of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were carried out using multiple search terms.  Articles included were original publications of randomized, placebo-controlled trials of monotherapy of donepezil, rivastigmine or galantamine that reported a behavioral outcome measure.  RESULTS:  14 studies were identified that matched inclusion criteria.  Nine were of donepezil, three of galantamine and two of rivastigmine.  Median study treatment length was 24 weeks (range 12-170).  Most studies used the Neuropsychiatric Inventory as a behavioral outcome measure although three used specific scales for either agitation or apathy.  Four studies were specifically designed to assess behavioral outcomes whilst in the majority of studies behavioral outcomes were only secondary measures.  Three studies found statistically significant, albeit modest, differences in the change of NPI total score between drug and placebo.  The interpretation of the results of many studies is limited by methodological considerations, including generally low NPI scores at baseline and the investigation of behavioral and psychological symptoms of dementia (BPSD) as secondary outcomes.  CONCLUSIONS:  The evidence base regarding the efficacy of cholinesterase inhibitors in BPSD is limited, in part due to methodological considerations.  In the absence of alternative safe and effective management options, the use of cholinesterase inhibitors is an appropriate pharmacological strategy for the management of BPSD in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsQu_Cr4Kxgfx2phytoz6_fW6udTcc2ebMu6HSFLhTXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrotFeitw%253D%253D&md5=5f58607c0f832f1de439f81827d65c87</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1017%2FS1041610209990354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1041610209990354%26sid%3Dliteratum%253Aachs%26aulast%3DRodda%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DZ.%26atitle%3DAre%2520Cholinesterase%2520Inhibitors%2520Effective%2520in%2520the%2520Management%2520of%2520the%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%253F%2520A%2520Systematic%2520Review%2520of%2520Randomized%252C%2520Placebo-Controlled%2520Trials%2520of%2520Donepezil%252C%2520Rivastigmine%2520and%2520Galantamine%26jtitle%3DInt.%2520Psychogeriatr.%26date%3D2009%26volume%3D21%26spage%3D813%26epage%3D824%26doi%3D10.1017%2FS1041610209990354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Holmes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vethanayagam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita-Gunawardena, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damms, J.</span><span> </span><span class="NLM_article-title">The Efficacy of Donepezil in the Treatment of Neuropsychiatric Symptoms in Alzheimer Disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1212/01.WNL.0000129990.32253.7B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1212%2F01.WNL.0000129990.32253.7B" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2004&pages=214-219&author=C.+Holmesauthor=D.+Wilkinsonauthor=C.+Deanauthor=S.+Vethanayagamauthor=S.+Olivieriauthor=A.+Langleyauthor=N.+D.+Pandita-Gunawardenaauthor=F.+Hoggauthor=C.+Clareauthor=J.+Damms&title=The+Efficacy+of+Donepezil+in+the+Treatment+of+Neuropsychiatric+Symptoms+in+Alzheimer+Disease&doi=10.1212%2F01.WNL.0000129990.32253.7B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1212%2F01.WNL.0000129990.32253.7B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252F01.WNL.0000129990.32253.7B%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DC.%26aulast%3DWilkinson%26aufirst%3DD.%26aulast%3DDean%26aufirst%3DC.%26aulast%3DVethanayagam%26aufirst%3DS.%26aulast%3DOlivieri%26aufirst%3DS.%26aulast%3DLangley%26aufirst%3DA.%26aulast%3DPandita-Gunawardena%26aufirst%3DN.%2BD.%26aulast%3DHogg%26aufirst%3DF.%26aulast%3DClare%26aufirst%3DC.%26aulast%3DDamms%26aufirst%3DJ.%26atitle%3DThe%2520Efficacy%2520of%2520Donepezil%2520in%2520the%2520Treatment%2520of%2520Neuropsychiatric%2520Symptoms%2520in%2520Alzheimer%2520Disease%26jtitle%3DNeurology%26date%3D2004%26volume%3D63%26spage%3D214%26epage%3D219%26doi%3D10.1212%2F01.WNL.0000129990.32253.7B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Feldman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vellas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ieni, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwam, E. M.</span><span> </span><span class="NLM_article-title">Donepezil MSAD Study Investigators Group. Efficacy and Safety of Donepezil in Patients with More Severe Alzheimer’s Disease: A Subgroup Analysis from a Randomized, Placebo-Controlled Trial</span> <span class="citation_source-journal">Int. J. Geriatr. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">569</span><span class="refDoi"> DOI: 10.1002/gps.1325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1002%2Fgps.1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=15920715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD2MzivVyqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=559-569&author=H.+Feldmanauthor=S.+Gauthierauthor=J.+Heckerauthor=B.+Vellasauthor=Y.+Xuauthor=J.+R.+Ieniauthor=E.+M.+Schwam&title=Donepezil+MSAD+Study+Investigators+Group.+Efficacy+and+Safety+of+Donepezil+in+Patients+with+More+Severe+Alzheimer%E2%80%99s+Disease%3A+A+Subgroup+Analysis+from+a+Randomized%2C+Placebo-Controlled+Trial&doi=10.1002%2Fgps.1325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial</span></div><div class="casAuthors">Feldman Howard; Gauthier Serge; Hecker Jane; Vellas Bruno; Xu Yikang; Ieni John R; Schwam Elias M</div><div class="citationInfo"><span class="NLM_cas:title">International journal of geriatric psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">559-69</span>
        ISSN:<span class="NLM_cas:issn">0885-6230</span>.
    </div><div class="casAbstract">BACKGROUND:  There have been very limited investigations of cholinesterase inhibitor therapy in more advanced stages of Alzheimer's disease (AD).  The efficacy and safety of donepezil were evaluated in post hoc analyses of a subgroup of patients with more severe AD (standardized Mini-Mental State Examination [sMMSE] score 5-12) within a randomized, placebo-controlled trial in moderate to severe AD (MSAD study).  Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5-17).  METHODS:  Patients with moderate to severe AD (n = 290) who were living in the community or in assisted living facilities received donepezil or placebo for 24 weeks; n = 145 in the more severe AD subgroup.  The primary outcome measure was the Clinician's Interview-Based Impression of Change (CIBIC-plus) with secondary outcomes including the sMMSE, Severe Impairment Battery, Neuropsychiatric Inventory, and Disability Assessment for Dementia.  Analysis of Variance and Analysis of Covariance models tested for treatment x disease severity interaction in the full MSAD study sample.  RESULTS:  CIBIC-plus scores for donepezil patients were significantly improved compared with placebo for each time-point, with a 0.70 mean treatment difference at Week 24 last observation carried forward (LOCF; p = 0.0002).  Significant differences favoring donepezil were noted at Week 24 LOCF for all secondary measures.  There were no treatment x severity interactions for any of the efficacy measures.  CONCLUSIONS:  In this analysis, donepezil had significant benefits over placebo on global, cognitive, functional, and behavioral measures in a subgroup of patients with more severe AD.  Furthermore, the treatment effects of donepezil were not driven by a particular stratum within the moderate to severe dementia range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFTcbrX9X7Gv_I8Jvzw4xCfW6udTcc2ebqN0SJm0KTjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzivVyqtg%253D%253D&md5=74ab7480521955421b2f80e03b68504d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fgps.1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.1325%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DH.%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DHecker%26aufirst%3DJ.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DIeni%26aufirst%3DJ.%2BR.%26aulast%3DSchwam%26aufirst%3DE.%2BM.%26atitle%3DDonepezil%2520MSAD%2520Study%2520Investigators%2520Group.%2520Efficacy%2520and%2520Safety%2520of%2520Donepezil%2520in%2520Patients%2520with%2520More%2520Severe%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520A%2520Subgroup%2520Analysis%2520from%2520a%2520Randomized%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DInt.%2520J.%2520Geriatr.%2520Psychiatry%26date%3D2005%26volume%3D20%26spage%3D559%26epage%3D569%26doi%3D10.1002%2Fgps.1325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geldenhuys, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span> </span><span class="NLM_article-title">Multifunctional Drugs with Different CNS Targets for Neuropsychiatric Disorders</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1033</span><span class="NLM_x">–</span> <span class="NLM_lpage">1048</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.04141.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1111%2Fj.1471-4159.2006.04141.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=17054441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yks7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=1033-1048&author=C.+J.+Van+der+Schyfauthor=W.+J.+Geldenhuysauthor=M.+B.+H.+Youdim&title=Multifunctional+Drugs+with+Different+CNS+Targets+for+Neuropsychiatric+Disorders&doi=10.1111%2Fj.1471-4159.2006.04141.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional drugs with different CNS targets for neuropsychiatric disorders</span></div><div class="casAuthors">Van der Schyf, Cornelis J.; Geldenhuys, Werner J.; Youdim, Moussa B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1033-1048</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The multiple disease etiologies that lead to neuropsychiatric disorders, such as Parkinson's and Alzheimer's disease, amyotrophic lateral sclerosis, Huntington disease, schizophrenia, depressive illness and stroke, offer significant challenges to drug discovery efforts aimed at preventing or even reversing the progression of these disorders.  Transcriptomic tools and proteomic profiling have clearly indicated that such diseases are multifactorial in origin.  Further, they are thought to be initiated by a cascade of mol. events that involve several neurotransmitter systems.  In response to this complexity, a new paradigm has recently emerged that challenges the widely held assumption that 'silver bullet' agents are superior to 'dirty drugs' in therapeutic approaches aimed at the prevention or treatment of neuropsychiatric diseases.  A similar pattern of drug development has occurred in strategies for the treatment of cancer, AIDS and cardiovascular diseases.  In this review, we offer an overview of therapeutic strategies and novel investigative drugs discovered or developed in our own and other labs., that address multiple CNS etiol. targets assocd. with an array of neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-WgbIJvzwLVg90H21EOLACvtfcHk0lhlsg2hYT0A9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yks7rE&md5=bf77745eb16accd063b0ff8e988dc812</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04141.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04141.x%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26atitle%3DMultifunctional%2520Drugs%2520with%2520Different%2520CNS%2520Targets%2520for%2520Neuropsychiatric%2520Disorders%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D99%26spage%3D1033%26epage%3D1048%26doi%3D10.1111%2Fj.1471-4159.2006.04141.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhlsg2hYT0A9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hajjar, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cafiero, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanlon, J. T.</span><span> </span><span class="NLM_article-title">Polypharmacy in Elderly Patients</span> <span class="citation_source-journal">Am. J. Geriatr. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span><span class="refDoi"> DOI: 10.1016/j.amjopharm.2007.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.amjopharm.2007.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=18179993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FhtlChsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=345-351&author=E.+R.+Hajjarauthor=A.+C.+Cafieroauthor=J.+T.+Hanlon&title=Polypharmacy+in+Elderly+Patients&doi=10.1016%2Fj.amjopharm.2007.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacy in elderly patients</span></div><div class="casAuthors">Hajjar Emily R; Cafiero Angela C; Hanlon Joseph T</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of geriatric pharmacotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">345-51</span>
        ISSN:<span class="NLM_cas:issn">1543-5946</span>.
    </div><div class="casAbstract">BACKGROUND:  Polypharmacy (ie, the use of multiple medications and/or the administration of more medications than are clinically indicated, representing unnecessary drug use) is common among the elderly.  OBJECTIVE:  The goal of this research was to provide a description of observational studies examining the epidemiology of polypharmacy and to review randomized controlled studies that have been published in the past 2 decades designed to reduce polypharmacy in older adults.  METHODS:  Materials for this review were gathered from a search of the MEDLINE database (1986-June 2007) and International Pharmaceutical Abstracts (1986-June 2007) to identify articles in people aged >65 years.  We used a combination of the following search terms: polypharmacy, multiple medications, polymedicine, elderly, geriatric, and aged.  A manual search of the reference lists from identified articles and the authors' article files, book chapters, and recent reviews was conducted to identify additional articles.  From these, the authors identified those studies that measured polypharmacy.  RESULTS:  The literature review found that polypharmacy continues to increase and is a known risk factor for important morbidity and mortality.  There are few rigorously designed intervention studies that have been shown to reduce unnecessary polypharmacy in older adults.  The literature review identified 5 articles, which are included here.  All studies showed an improvement in polypharmacy.  CONCLUSIONS:  Many studies have found that various numbers of medications are associated with negative health outcomes, but more research is needed to further delineate the consequences associated with unnecessary drug use in elderly patients.  Health care professionals should be aware of the risks and fully evaluate all medications at each patient visit to prevent polypharmacy from occurring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTi7H1PTbUsBTToTC3aBaesfW6udTcc2eajxWby3Q7iX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FhtlChsg%253D%253D&md5=252abb3157c8d7d3fbf06ba806eba6b8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.amjopharm.2007.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjopharm.2007.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DHajjar%26aufirst%3DE.%2BR.%26aulast%3DCafiero%26aufirst%3DA.%2BC.%26aulast%3DHanlon%26aufirst%3DJ.%2BT.%26atitle%3DPolypharmacy%2520in%2520Elderly%2520Patients%26jtitle%3DAm.%2520J.%2520Geriatr.%2520Pharmacother.%26date%3D2007%26volume%3D5%26spage%3D345%26epage%3D351%26doi%3D10.1016%2Fj.amjopharm.2007.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Pasqualetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tognini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calsolaro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monzani, F.</span><span> </span><span class="NLM_article-title">Potential Drug–drug Interactions in Alzheimer Patients with Behavioral Symptoms</span> <span class="citation_source-journal">Clin. Interventions Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1457</span><span class="NLM_x">–</span> <span class="NLM_lpage">1466</span><span class="refDoi"> DOI: 10.2147/CIA.S87466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.2147%2FCIA.S87466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26392756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC283lsFOntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1457-1466&author=G.+Pasqualettiauthor=S.+Togniniauthor=V.+Calsolaroauthor=A.+Poliniauthor=F.+Monzani&title=Potential+Drug%E2%80%93drug+Interactions+in+Alzheimer+Patients+with+Behavioral+Symptoms&doi=10.2147%2FCIA.S87466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Potential drug-drug interactions in Alzheimer patients with behavioral symptoms</span></div><div class="casAuthors">Pasqualetti Giuseppe; Tognini Sara; Calsolaro Valeria; Polini Antonio; Monzani Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical interventions in aging</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1457-66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The use of multi drug regimens among the elderly population has increased tremendously over the last decade although the benefits of medications are always accompanied by potential harm, even when prescribed at recommended doses.  The elderly populations are particularly at an increased risk of adverse drug reactions considering comorbidity, poly-therapy, physiological changes affecting the pharmacokinetics and pharmacodynamics of many drugs and, in some cases, poor compliance due to cognitive impairment and/or depression.  In this setting, drug-drug interaction may represent a serious and even life-threatening clinical condition.  Moreover, the inability to distinguish drug-induced symptoms from a definitive medical diagnosis often results in addition of yet another drug to treat the symptoms, which in turn increases drug-drug interactions.  Cognitive enhancers, including acetylcholinesterase inhibitors and memantine, are the most widely prescribed agents for Alzheimer's disease (AD) patients.  Behavioral and psychological symptoms of dementia, including psychotic symptoms and behavioral disorders, represent noncognitive disturbances frequently observed in AD patients.  Antipsychotic drugs are at high risk of adverse events, even at modest doses, and may interfere with the progression of cognitive impairment and interact with several drugs including anti-arrhythmics and acetylcholinesterase inhibitors.  Other medications often used in AD patients are represented by anxiolytic, like benzodiazepine, or antidepressant agents.  These agents also might interfere with other concomitant drugs through both pharmacokinetic and pharmacodynamic mechanisms.  In this review we focus on the most frequent drug-drug interactions, potentially harmful, in AD patients with behavioral symptoms considering both physiological and pathological changes in AD patients, and potential pharmacodynamic/pharmacokinetic drug interaction mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfUvQHd8XXxfx2phytoz6_fW6udTcc2eajxWby3Q7iX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283lsFOntQ%253D%253D&md5=40b6c46400e66d10e66cdecd93740a7e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2147%2FCIA.S87466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCIA.S87466%26sid%3Dliteratum%253Aachs%26aulast%3DPasqualetti%26aufirst%3DG.%26aulast%3DTognini%26aufirst%3DS.%26aulast%3DCalsolaro%26aufirst%3DV.%26aulast%3DPolini%26aufirst%3DA.%26aulast%3DMonzani%26aufirst%3DF.%26atitle%3DPotential%2520Drug%25E2%2580%2593drug%2520Interactions%2520in%2520Alzheimer%2520Patients%2520with%2520Behavioral%2520Symptoms%26jtitle%3DClin.%2520Interventions%2520Aging%26date%3D2015%26volume%3D10%26spage%3D1457%26epage%3D1466%26doi%3D10.2147%2FCIA.S87466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Oesterhus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aarsland, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soennesyn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rongve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selbaek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjosavik, S. R.</span><span> </span><span class="NLM_article-title">Potentially Inappropriate Medications and Drug–drug Interactions in Home-Dwelling People with Mild Dementia</span> <span class="citation_source-journal">Int. J. Geriatr. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1002/gps.4456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1002%2Fgps.4456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26924491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC28jlt1yktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=183-192&author=R.+Oesterhusauthor=D.+Aarslandauthor=H.+Soennesynauthor=A.+Rongveauthor=G.+Selbaekauthor=S.+R.+Kjosavik&title=Potentially+Inappropriate+Medications+and+Drug%E2%80%93drug+Interactions+in+Home-Dwelling+People+with+Mild+Dementia&doi=10.1002%2Fgps.4456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia</span></div><div class="casAuthors">Oesterhus Ragnhild; Aarsland Dag; Soennesyn Hogne; Kjosavik Svein R; Oesterhus Ragnhild; Rongve Arvid; Aarsland Dag; Rongve Arvid; Selbaek Geir; Selbaek Geir; Kjosavik Svein R</div><div class="citationInfo"><span class="NLM_cas:title">International journal of geriatric psychiatry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-192</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The objectives of this study were to describe the use of psychotropic drugs among home-dwelling people with mild dementia, to identify potentially inappropriate medications (PIM) and drug-drug interactions (DDI), and to analyze potential variables associated with having PIM and DDI.  METHODS:  Patients (n = 251) with a first-time diagnosis of mild dementia (defined as a mini-mental state examination score >20) were included from outpatient clinics.  Prevalence of psychotropic drug use, polypharmacy, and psychotropic polypharmacy were investigated.  The prevalence of PIM and DDI were defined using the Norwegian general practice criteria and an interactions database, respectively.  Variables associated with having PIM and DDI were assessed using a multivariable logistic regression analysis adjusting for relevant demographic and clinical variables.  RESULTS:  Almost 96% of the patients used one or more medications.  Polypharmacy was found in 45% of the patients, and nearly 70% of the patients were using one or more psychotropic drugs.  Psychotropic polypharmacy was found in seven patients.  PIM were identified in 35 patients (14%), while only four severe DDI were found.  Female sex and number of medications were significantly associated with having PIM, whereas only number of medications was significantly associated with having DDI.  CONCLUSION:  Few patients had PIM or severe DDI, indicating that the quality of prescribing was acceptable.  However, psychotropic drug use was common in home-dwelling people with mild dementia despite limited evidence of benefit in dementia.  More knowledge is needed about the potential risks associated with psychotropic drug use and having PIM and DDI in people with mild dementia.  Copyright © 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThdaxKPKRS4P6BottYdIAWfW6udTcc2eajxWby3Q7iX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jlt1yktw%253D%253D&md5=e44625f8010f2f050093c262fb5b50d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fgps.4456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.4456%26sid%3Dliteratum%253Aachs%26aulast%3DOesterhus%26aufirst%3DR.%26aulast%3DAarsland%26aufirst%3DD.%26aulast%3DSoennesyn%26aufirst%3DH.%26aulast%3DRongve%26aufirst%3DA.%26aulast%3DSelbaek%26aufirst%3DG.%26aulast%3DKjosavik%26aufirst%3DS.%2BR.%26atitle%3DPotentially%2520Inappropriate%2520Medications%2520and%2520Drug%25E2%2580%2593drug%2520Interactions%2520in%2520Home-Dwelling%2520People%2520with%2520Mild%2520Dementia%26jtitle%3DInt.%2520J.%2520Geriatr.%2520Psychiatry%26date%3D2017%26volume%3D32%26spage%3D183%26epage%3D192%26doi%3D10.1002%2Fgps.4456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lu, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-T.</span><span> </span><span class="NLM_article-title">Multi-Target Drugs: The Trend of Drug Research and Development</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e40262</span><span class="refDoi"> DOI: 10.1371/journal.pone.0040262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1371%2Fjournal.pone.0040262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=22768266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e40262&author=J.-J.+Luauthor=W.+Panauthor=Y.-J.+Huauthor=Y.-T.+Wang&title=Multi-Target+Drugs%3A+The+Trend+of+Drug+Research+and+Development&doi=10.1371%2Fjournal.pone.0040262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target drugs: the trend of drug research and development</span></div><div class="casAuthors">Lu, Jin-Jian; Pan, Wei; Hu, Yuan-Jia; Wang, Yi-Tao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e40262</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Summarizing the status of drugs in the market and examg. the trend of drug research and development is important in drug discovery.  In this study, we compared the drug targets and the market sales of the new mol. entities approved by the U.S. Food and Drug Administration from Jan. 2000 to Dec. 2009.  Two networks, namely, the target-target and drug-drug networks, have been set up using the network anal. tools.  The multi-target drugs have much more potential, as shown by the network visualization and the market trends.  We discussed the possible reasons and proposed the rational strategies for drug research and development in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrapZATY1GnWbVg90H21EOLACvtfcHk0lhThhUxe952xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D&md5=79489aaf7a36ee9c30287621a7244a6a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0040262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0040262%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.-J.%26aulast%3DWang%26aufirst%3DY.-T.%26atitle%3DMulti-Target%2520Drugs%253A%2520The%2520Trend%2520of%2520Drug%2520Research%2520and%2520Development%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De40262%26doi%3D10.1371%2Fjournal.pone.0040262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Unzeta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteban, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogel, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsay, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipton, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span> </span><span class="NLM_article-title">Multi-Target Directed Donepezil-Like Ligands for Alzheimer’s Disease</span> <span class="citation_source-journal">Front. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="refDoi"> DOI: 10.3389/fnins.2016.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.3389%2Ffnins.2016.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27252617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FmtV2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=205&author=M.+Unzetaauthor=G.+Estebanauthor=I.+Boleaauthor=W.+A.+Fogelauthor=R.+R.+Ramsayauthor=M.+B.+H.+Youdimauthor=K.+F.+Tiptonauthor=J.+Marco-Contelles&title=Multi-Target+Directed+Donepezil-Like+Ligands+for+Alzheimer%E2%80%99s+Disease&doi=10.3389%2Ffnins.2016.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease</span></div><div class="casAuthors">Unzeta Mercedes; Bolea Irene; Esteban Gerard; Tipton Keith F; Fogel Wieslawa A; Ramsay Rona R; Youdim Moussa B H; Marco-Contelles Jose</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS ASS234 is a MTDL compound containing a moiety from Donepezil and the propargyl group from the PF 9601N, a potent and selective MAO B inhibitor.  This compound is the most advanced anti-Alzheimer agent for preclinical studies identified in our laboratory.Derived from ASS234 both multipotent donepezil-indolyl (MTDL-1) and donepezil-pyridyl hybrids (MTDL-2) were designed and evaluated as inhibitors of AChE/BuChE and both MAO isoforms.  MTDL-2 showed more high affinity toward the four enzymes than MTDL-1.MTDL-3 and MTDL-4, were designed containing the N-benzylpiperidinium moiety from Donepezil, a metal- chelating 8-hydroxyquinoline group and linked to a N-propargyl core and they were pharmacologically evaluated.The presence of the cyano group in MTDL-3, enhanced binding to AChE, BuChE and MAO A.  It showed antioxidant behavior and it was able to strongly complex Cu(II), Zn(II) and Fe(III).MTDL-4 showed higher affinity toward AChE, BuChE.MTDL-3 exhibited good brain penetration capacity (ADMET) and less toxicity than Donepezil.  Memory deficits in scopolamine-lesioned animals were restored by MTDL-3.MTDL-3 particularly emerged as a ligand showing remarkable potential benefits for its use in AD therapy.  Alzheimer's disease (AD), the most common form of adult onset dementia, is an age-related neurodegenerative disorder characterized by progressive memory loss, decline in language skills, and other cognitive impairments.  Although its etiology is not completely known, several factors including deficits of acetylcholine, β-amyloid deposits, τ-protein phosphorylation, oxidative stress, and neuroinflammation are considered to play significant roles in the pathophysiology of this disease.  For a long time, AD patients have been treated with acetylcholinesterase inhibitors such as donepezil (Aricept®) but with limited therapeutic success.  This might be due to the complex multifactorial nature of AD, a fact that has prompted the design of new Multi-Target-Directed Ligands (MTDL) based on the "one molecule, multiple targets" paradigm.  Thus, in this context, different series of novel multifunctional molecules with antioxidant, anti-amyloid, anti-inflammatory, and metal-chelating properties able to interact with multiple enzymes of therapeutic interest in AD pathology including acetylcholinesterase, butyrylcholinesterase, and monoamine oxidases A and B have been designed and assessed biologically.  This review describes the multiple targets, the design rationale and an in-house MTDL library, bearing the N-benzylpiperidine motif present in donepezil, linked to different heterocyclic ring systems (indole, pyridine, or 8-hydroxyquinoline) with special emphasis on compound ASS234, an N-propargylindole derivative.  The description of the in vitro biological properties of the compounds and discussion of the corresponding structure-activity-relationships allows us to highlight new issues for the identification of more efficient MTDL for use in AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAKdUtVDXRPgpJitSxOdIlfW6udTcc2eaHpBi0qAui6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FmtV2hsw%253D%253D&md5=0904cb1e4e1c700e575e192e9d3bebb3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00205%26sid%3Dliteratum%253Aachs%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DFogel%26aufirst%3DW.%2BA.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DMulti-Target%2520Directed%2520Donepezil-Like%2520Ligands%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D205%26doi%3D10.3389%2Ffnins.2016.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Youdim, M. B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccafusco, J. J.</span><span> </span><span class="NLM_article-title">CNS Targets for Multi-Functional Drugs in the Treatment of Alzheimer’s and Parkinson’s Diseases</span> <span class="citation_source-journal">J. Neural Transm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span><span class="refDoi"> DOI: 10.1007/s00702-004-0214-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs00702-004-0214-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2005&pages=519-537&author=M.+B.+H.+Youdimauthor=J.+J.+Buccafusco&title=CNS+Targets+for+Multi-Functional+Drugs+in+the+Treatment+of+Alzheimer%E2%80%99s+and+Parkinson%E2%80%99s+Diseases&doi=10.1007%2Fs00702-004-0214-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs00702-004-0214-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-004-0214-z%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DBuccafusco%26aufirst%3DJ.%2BJ.%26atitle%3DCNS%2520Targets%2520for%2520Multi-Functional%2520Drugs%2520in%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520and%2520Parkinson%25E2%2580%2599s%2520Diseases%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2005%26volume%3D112%26spage%3D519%26epage%3D537%26doi%3D10.1007%2Fs00702-004-0214-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Reus, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fochtmann, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyler, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilty, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvitz-Lennon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jibson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahoney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wills, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhoads, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yager, J.</span><span> </span><span class="NLM_article-title">The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1176/appi.ajp.2015.173501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1176%2Fappi.ajp.2015.173501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27133416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC28bltleruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=543-546&author=V.+I.+Reusauthor=L.+J.+Fochtmannauthor=A.+E.+Eylerauthor=D.+M.+Hiltyauthor=M.+Horvitz-Lennonauthor=M.+D.+Jibsonauthor=O.+L.+Lopezauthor=J.+Mahoneyauthor=J.+Pasicauthor=Z.+S.+Tanauthor=C.+D.+Willsauthor=R.+Rhoadsauthor=J.+Yager&title=The+American+Psychiatric+Association+Practice+Guideline+on+the+Use+of+Antipsychotics+to+Treat+Agitation+or+Psychosis+in+Patients+With+Dementia&doi=10.1176%2Fappi.ajp.2015.173501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia</span></div><div class="casAuthors">Reus Victor I; Fochtmann Laura J; Eyler A Evan; Hilty Donald M; Horvitz-Lennon Marcela; Jibson Michael D; Lopez Oscar L; Mahoney Jane; Pasic Jagoda; Tan Zaldy S; Wills Cheryl D; Rhoads Richard; Yager Joel</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdiYJwQsXFcvxQvRxYU81tfW6udTcc2eaHpBi0qAui6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bltleruw%253D%253D&md5=eed0b88a9353b0ea6add176fa2082c5c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2015.173501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2015.173501%26sid%3Dliteratum%253Aachs%26aulast%3DReus%26aufirst%3DV.%2BI.%26aulast%3DFochtmann%26aufirst%3DL.%2BJ.%26aulast%3DEyler%26aufirst%3DA.%2BE.%26aulast%3DHilty%26aufirst%3DD.%2BM.%26aulast%3DHorvitz-Lennon%26aufirst%3DM.%26aulast%3DJibson%26aufirst%3DM.%2BD.%26aulast%3DLopez%26aufirst%3DO.%2BL.%26aulast%3DMahoney%26aufirst%3DJ.%26aulast%3DPasic%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DZ.%2BS.%26aulast%3DWills%26aufirst%3DC.%2BD.%26aulast%3DRhoads%26aufirst%3DR.%26aulast%3DYager%26aufirst%3DJ.%26atitle%3DThe%2520American%2520Psychiatric%2520Association%2520Practice%2520Guideline%2520on%2520the%2520Use%2520of%2520Antipsychotics%2520to%2520Treat%2520Agitation%2520or%2520Psychosis%2520in%2520Patients%2520With%2520Dementia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2016%26volume%3D173%26spage%3D543%26epage%3D546%26doi%3D10.1176%2Fappi.ajp.2015.173501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">De Deyn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeste, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breder, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, T.</span><span> </span><span class="NLM_article-title">Aripiprazole for the Treatment of Psychosis in Patients with Alzheimer’s Disease: A Randomized, Placebo-Controlled Study</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1097/01.jcp.0000178415.22309.8f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1097%2F01.jcp.0000178415.22309.8f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=16160622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVShsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=463-467&author=P.+De+Deynauthor=D.+V.+Jesteauthor=R.+Swaninkauthor=D.+Kosticauthor=C.+Brederauthor=W.+H.+Carsonauthor=T.+Iwamoto&title=Aripiprazole+for+the+Treatment+of+Psychosis+in+Patients+with+Alzheimer%E2%80%99s+Disease%3A+A+Randomized%2C+Placebo-Controlled+Study&doi=10.1097%2F01.jcp.0000178415.22309.8f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study</span></div><div class="casAuthors">De Deyn, Peter; Jeste, Dilip V.; Swanink, Rene; Kostic, Dusan; Breder, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-467</span>CODEN:
                <span class="NLM_cas:coden">JCPYDR</span>;
        ISSN:<span class="NLM_cas:issn">0271-0749</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This study compared the efficacy, safety, and tolerability of aripiprazole, a novel antipsychotic, with placebo in patients with psychosis assocd. with Alzheimer's Disease (AD).  This 10-wk, double-blind, multicenter study randomized 208 outpatients (mean age, 81.5 years) with AD-assocd. psychosis to aripiprazole (n = 106) or placebo (n = 102).  The initial aripiprazole dose of 2 mg/d was titrated upwards (5, 10, or 15 mg/d) according to efficacy and tolerability.  Evaluations included Neuropsychiatric Inventory (NPI) Psychosis subscale and Brief Psychiatric Rating Scale (BPRS), adverse event (AE) reports, extrapyramidal symptoms (EPS) rating scales, and body wt.  Overall, 172 patients (83%) completed the study.  Mean aripiprazole dose at end point was 10.0 mg/d.  The NPI Psychosis subscale score showed improvements in both groups (aripiprazole, -6.55; placebo, -5.52; P = 0.17 at end point).  Aripiprazole-treated patients showed significantly greater improvements from baseline in BPRS Psychosis and BPRS Core subscale scores at end point compared with placebo.  AEs were generally mild to moderate in severity and included (aripiprazole vs. placebo): urinary tract infection (8% vs. 12%), accidental injury (8% vs. 5%), somnolence (8% vs. 1%), and bronchitis (6% vs. 3%).  Somnolence was mild and not assocd. with falls or accidental injury.  There were no significant differences from placebo in EPS scores, or clin. significant ECG abnormalities, vital signs, or wt.  In conclusion, aripiprazole showed similar improvements to placebo in psychotic symptoms as assessed by NPI Psychosis subscale scores, but significantly greater effects on BPRS Core and Psychosis assessments in community-living AD patients with psychosis.  Aripiprazole was safe and well tolerated in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcxfeaX0-hlrVg90H21EOLACvtfcHk0likbCaHAr5mqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVShsLjP&md5=1f6f19fd6321c2060958ccf31ea1a71b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1097%2F01.jcp.0000178415.22309.8f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.jcp.0000178415.22309.8f%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BDeyn%26aufirst%3DP.%26aulast%3DJeste%26aufirst%3DD.%2BV.%26aulast%3DSwanink%26aufirst%3DR.%26aulast%3DKostic%26aufirst%3DD.%26aulast%3DBreder%26aufirst%3DC.%26aulast%3DCarson%26aufirst%3DW.%2BH.%26aulast%3DIwamoto%26aufirst%3DT.%26atitle%3DAripiprazole%2520for%2520the%2520Treatment%2520of%2520Psychosis%2520in%2520Patients%2520with%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520A%2520Randomized%252C%2520Placebo-Controlled%2520Study%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2005%26volume%3D25%26spage%3D463%26epage%3D467%26doi%3D10.1097%2F01.jcp.0000178415.22309.8f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Farlow, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shamliyan, T. A.</span><span> </span><span class="NLM_article-title">Benefits and Harms of Atypical Antipsychotics for Agitation in Adults with Dementia</span> <span class="citation_source-journal">Eur. Neuropsychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1016/j.euroneuro.2017.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.euroneuro.2017.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=28111239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=217-231&author=M.+R.+Farlowauthor=T.+A.+Shamliyan&title=Benefits+and+Harms+of+Atypical+Antipsychotics+for+Agitation+in+Adults+with+Dementia&doi=10.1016%2Fj.euroneuro.2017.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Benefits and harms of atypical antipsychotics for agitation in adults with dementia</span></div><div class="casAuthors">Farlow, Martin R.; Shamliyan, Tatyana A.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-231</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the most current evidence regarding the benefits and harms of atypical antipsychotics in adults with dementia.In June 2016, following a protocol developed a priori, we systematically searched several databases for published and unpublished data from randomized controlled trials (RCT), observational studies, and meta-analyses; conducted direct meta-analyses using a random effects model; and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.One high-quality meta-anal. and published and unpublished data from 8 RCTs and 12 large observational studies met inclusion criteria.  When compared with placebo, aripiprazole, risperidone, and olanzapine but not quetiapine result in modest (standardized mean difference <0.5 std. deviations) improvement in neuropsychiatric symptoms.  Aripiprazole, risperidone, quetiapine, and olanzapine are assocd. with increased odds of acute myocardial infraction, and risperidone and olanzapine are assocd. with increased odds of hip fracture.  Observational studies suggest no differences in all-cause mortality between atypical antipsychotics.Observational studies suggest that atypical antipsychotics are assocd. with lower risk of all-cause mortality and extrapyramidal symptoms but higher risk of stroke when compared with conventional antipsychotics.To manage agitation in adults with progressive dementia, clinicians may recommend atypical antipsychotics with continuous monitoring of behavioral symptoms, informing patients and their families or caregivers of the significant risk of adverse effects and baseline risk of acute myocardial infraction and bone fractures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcVDxK-KxFdLVg90H21EOLACvtfcHk0likbCaHAr5mqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOisr4%253D&md5=a76d8a8f7d8185544cff0ebe559a89b1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2017.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2017.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DFarlow%26aufirst%3DM.%2BR.%26aulast%3DShamliyan%26aufirst%3DT.%2BA.%26atitle%3DBenefits%2520and%2520Harms%2520of%2520Atypical%2520Antipsychotics%2520for%2520Agitation%2520in%2520Adults%2520with%2520Dementia%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2017%26volume%3D27%26spage%3D217%26epage%3D231%26doi%3D10.1016%2Fj.euroneuro.2017.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Reese, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiel, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocker, K. E.</span><span> </span><span class="NLM_article-title">Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use</span> <span class="citation_source-journal">Am. Fam. Physician</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">276</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27548592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC2szjtlemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=276-282&author=T.+R.+Reeseauthor=D.+J.+Thielauthor=K.+E.+Cocker&title=Behavioral+Disorders+in+Dementia%3A+Appropriate+Nondrug+Interventions+and+Antipsychotic+Use"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use</span></div><div class="casAuthors">Reese Tyler R; Thiel Derrick J; Cocker Katherine E</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">276-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Behavioral and psychological symptoms of dementia pose management challenges for caregivers and clinicians.  Firstline nonpharmacologic treatments include eliminating physical and emotional stressors, modifying the patient's environment, and establishing daily routines.  Family members and caregivers benefit from education about dementia symptoms and reminders that the behaviors are normal and unintentional.  Cognitive and emotion-oriented interventions, sensory stimulation interventions, behavior management techniques, and other psychosocial interventions are modestly effective.  In refractory cases, physicians may choose to prescribe off-label antipsychotics.  Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small.  Olanzapine, quetiapine, and risperidone have inconsistent evidence of benefit.  Physicians should use the smallest effective dose for the shortest possible duration to minimize adverse effects, most notably an increased mortality risk.  Other adverse effects include anticholinergic and antidopaminergic effects, extrapyramidal symptoms, neuroleptic malignant syndrome, postural hypotension, metabolic syndrome, cardiac arrhythmia, and sedation.  Patients should be monitored for these effects while receiving treatment; however, laboratory monitoring may be limited to patients receiving long-term therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuBB4uZP1pszToTC3aBaesfW6udTcc2eZP3JmwNxcP_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szjtlemtA%253D%253D&md5=2fef69bca4d0cc89f0485be9a0fd7de6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReese%26aufirst%3DT.%2BR.%26aulast%3DThiel%26aufirst%3DD.%2BJ.%26aulast%3DCocker%26aufirst%3DK.%2BE.%26atitle%3DBehavioral%2520Disorders%2520in%2520Dementia%253A%2520Appropriate%2520Nondrug%2520Interventions%2520and%2520Antipsychotic%2520Use%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2016%26volume%3D94%26spage%3D276%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Davies, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology</span> <span class="citation_source-journal">CNS Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1111/j.1527-3458.2004.tb00030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1111%2Fj.1527-3458.2004.tb00030.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=15592581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFejsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=317-336&author=M.+A.+Daviesauthor=D.+J.+Shefflerauthor=B.+L.+Roth&title=Aripiprazole%3A+A+Novel+Atypical+Antipsychotic+Drug+With+a+Uniquely+Robust+Pharmacology&doi=10.1111%2Fj.1527-3458.2004.tb00030.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology</span></div><div class="casAuthors">Davies, Marilyn A.; Sheffler, Douglas J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-336</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Aripiprazole (Abilify) is an atypical antipsychotic drug that has been recently introduced for clin. use in the treatment of schizophrenia.  Aripiprazole has a unique pharmacol. profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [esp. dopamine (D2) and 5-HT1A] and antagonistic action at others (esp. 5-HT2A).  Clin. trials indicate that aripiprazole is effective in treating the pos. and neg. symptoms of schizophrenia.  In short-term studies rapid onset of action (within one week) has been demonstrated.  Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder.  At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder.  There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on wt., is indicated in this population.  In the long-term studies, the use of aripiprazole was assocd. with continued efficacy, good compliance and increased time-to-relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUPyxiyqhQzrVg90H21EOLACvtfcHk0lhanzhAH-mqnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFejsLo%253D&md5=dc4d48c70799660137c731cee3c67f42</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2004.tb00030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2004.tb00030.x%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DAripiprazole%253A%2520A%2520Novel%2520Atypical%2520Antipsychotic%2520Drug%2520With%2520a%2520Uniquely%2520Robust%2520Pharmacology%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2004%26volume%3D10%26spage%3D317%26epage%3D336%26doi%3D10.1111%2Fj.1527-3458.2004.tb00030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Worthington, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinrys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wygant, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, M. H.</span><span> </span><span class="NLM_article-title">Aripiprazole as an Augmentor of Selective Serotonin Reuptake Inhibitors in Depression and Anxiety Disorder Patients</span> <span class="citation_source-journal">Int. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1097/00004850-200501000-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1097%2F00004850-200501000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=15602109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252Fps1ajuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=9-11&author=J.+J.+Worthingtonauthor=G.+Kinrysauthor=L.+E.+Wygantauthor=M.+H.+Pollack&title=Aripiprazole+as+an+Augmentor+of+Selective+Serotonin+Reuptake+Inhibitors+in+Depression+and+Anxiety+Disorder+Patients&doi=10.1097%2F00004850-200501000-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients</span></div><div class="casAuthors">Worthington John J 3rd; Kinrys Gustavo; Wygant Lisa E; Pollack Mark H</div><div class="citationInfo"><span class="NLM_cas:title">International clinical psychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-11</span>
        ISSN:<span class="NLM_cas:issn">0268-1315</span>.
    </div><div class="casAbstract">More than half of anxiety and depression patients treated with an adequate course of antidepressants fail to fully improve.  We retrospectively examined whether treatment-resistant depression and anxiety disorder patients responded to and tolerated augmentation with the atypical antipsychotic, aripiprazole.  We report on patients with depression and anxiety disorders, including panic disorder, generalized anxiety disorder, social anxiety and post-traumatic stress disorder, who had an incomplete response to a variety of selective serotonin reuptake inhibitors (SSRIs) and who received augmentation with aripiprazole.  The primary outcome measure was the Clinical Global Impression of Improvement (CGI-I).  In the intent-to-treat analysis, the mean+/-SD CGI-S was 3.8+/-1.3 at endpoint.  Fifty-nine percent of subjects received CGI-I ratings of 1 or 2, 'much improved' or 'very much improved,' in terms of their depression and anxiety symptoms at the end of 12 weeks.  Several patients showed an early (weeks 1-5), as well as sustained, response to augmentation with doses of aripiprazole between 15 and 30 mg/day.  The results suggest that aripiprazole may be effective as an augmentation for patients with persistent depressive and anxiety disorders despite initial SSRI treatment.  Because this is a retrospective case review, further prospective studies are required to confirm these findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxhskuaFxFO56KlWarZTAzfW6udTcc2eaA52qxvm-9N7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252Fps1ajuw%253D%253D&md5=da4bfe4897e13e4cb86b91a1fd1a404a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2F00004850-200501000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00004850-200501000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DWorthington%26aufirst%3DJ.%2BJ.%26aulast%3DKinrys%26aufirst%3DG.%26aulast%3DWygant%26aufirst%3DL.%2BE.%26aulast%3DPollack%26aufirst%3DM.%2BH.%26atitle%3DAripiprazole%2520as%2520an%2520Augmentor%2520of%2520Selective%2520Serotonin%2520Reuptake%2520Inhibitors%2520in%2520Depression%2520and%2520Anxiety%2520Disorder%2520Patients%26jtitle%3DInt.%2520Clin.%2520Psychopharmacol.%26date%3D2005%26volume%3D20%26spage%3D9%26epage%3D11%26doi%3D10.1097%2F00004850-200501000-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Sheffrin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenze, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulsant, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butters, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dew, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. F.</span><span> </span><span class="NLM_article-title">Pilot Study of Augmentation with Aripiprazole for Incomplete Response in Late-Life Depression: Getting to Remission</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">208</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span><span class="refDoi"> DOI: 10.4088/JCP.07m03805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.4088%2FJCP.07m03805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19210951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvFOls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2009&pages=208-213&author=M.+Sheffrinauthor=H.+C.+Driscollauthor=E.+J.+Lenzeauthor=B.+H.+Mulsantauthor=B.+G.+Pollockauthor=M.+D.+Millerauthor=M.+A.+Buttersauthor=M.+A.+Dewauthor=C.+F.+Reynolds&title=Pilot+Study+of+Augmentation+with+Aripiprazole+for+Incomplete+Response+in+Late-Life+Depression%3A+Getting+to+Remission&doi=10.4088%2FJCP.07m03805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission</span></div><div class="casAuthors">Sheffrin, Meera; Driscoll, Henry C.; Lenze, Eric J.; Mulsant, Benoit H.; Pollock, Bruce G.; Miller, Mark D.; Butters, Meryl A.; Dew, Mary Amanda; Reynolds, Charles F., III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry (Memphis, TN, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">208-213</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">To det. the feasibility and safety of aripiprazole augmentation for incomplete response to sequential selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) pharmacotherapy in late-life depression.  This study was a 12-wk, open-label pilot study of 24 patients (recruited from June 1, 2006, to June 1, 2007) aged 65 years and above (mean, 73.9 years) diagnosed with major depressive disorder (MDD) (according to DSM-IV) who responded partially (17-item Hamilton Rating Scale for Depression [HAM-D-17] score of 11 to 15) or not at all (HAM-D score > 15) to a 16-wk trial of escitalopram (up to 20 mg/day), followed by either duloxetine (up to 120 mg/day) or venlafaxine (up to 225 mg/day) for 12 wk.  Subjects received 2.5 to 15 mg per day of adjunctive aripiprazole (mean dose, 9.0 mg/day) for 12 wk.  The criterion for remission during treatment with aripiprazole was a HAM-D score ≤ 10 for 2 consecutive weeks.  Of 24 subjects in the intent-to-treat study group, 19 completed 12 wk of augmentation with aripiprazole, 12 of 24 (50%) met criteria for remission, and 2 of 24 discontinued due to side effects (sedation, akathisia).  The mean (SD) HAM-D score decreased significantly by 6.4 (5.8) points (paired t test for means, p < .01, df = 16).  There were no relapses among the 12 subjects who participated in continuation treatment over a median period of 27.6 wk.  In older adults with MDD with incomplete response to SSRI and SNRI pharmacotherapy, aripiprazole was well tolerated, and symptoms of depression improved significantly during treatment with aripiprazole.  A randomized, double-blind, placebo-controlled trial of adjunctive aripiprazole for incomplete response in late-life depression is warranted to further evaluate benefit and risk.  Trial Registration: clinicaltrials.gov Identifier: NCT00177671.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEaoK6ZZrs0LVg90H21EOLACvtfcHk0lhanzhAH-mqnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvFOls7Y%253D&md5=61ddaf256238432a0c7d8e7f0c1c2b27</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4088%2FJCP.07m03805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.07m03805%26sid%3Dliteratum%253Aachs%26aulast%3DSheffrin%26aufirst%3DM.%26aulast%3DDriscoll%26aufirst%3DH.%2BC.%26aulast%3DLenze%26aufirst%3DE.%2BJ.%26aulast%3DMulsant%26aufirst%3DB.%2BH.%26aulast%3DPollock%26aufirst%3DB.%2BG.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DButters%26aufirst%3DM.%2BA.%26aulast%3DDew%26aufirst%3DM.%2BA.%26aulast%3DReynolds%26aufirst%3DC.%2BF.%26atitle%3DPilot%2520Study%2520of%2520Augmentation%2520with%2520Aripiprazole%2520for%2520Incomplete%2520Response%2520in%2520Late-Life%2520Depression%253A%2520Getting%2520to%2520Remission%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2009%26volume%3D70%26spage%3D208%26epage%3D213%26doi%3D10.4088%2FJCP.07m03805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Pollock, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulsant, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweet, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazumdar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharucha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacob, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastango, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chew, M. L.</span><span> </span><span class="NLM_article-title">Comparison of Citalopram, Perphenazine, and Placebo for the Acute Treatment of Psychosis and Behavioral Disturbances in Hospitalized, Demented Patients</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">460</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1176/appi.ajp.159.3.460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1176%2Fappi.ajp.159.3.460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=11870012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BD387jsVagsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2002&pages=460-465&author=B.+G.+Pollockauthor=B.+H.+Mulsantauthor=J.+Rosenauthor=R.+A.+Sweetauthor=S.+Mazumdarauthor=A.+Bharuchaauthor=R.+Marinauthor=N.+J.+Jacobauthor=K.+A.+Huberauthor=K.+B.+Kastangoauthor=M.+L.+Chew&title=Comparison+of+Citalopram%2C+Perphenazine%2C+and+Placebo+for+the+Acute+Treatment+of+Psychosis+and+Behavioral+Disturbances+in+Hospitalized%2C+Demented+Patients&doi=10.1176%2Fappi.ajp.159.3.460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients</span></div><div class="casAuthors">Pollock Bruce G; Mulsant Benoit H; Rosen Jules; Sweet Robert A; Mazumdar Sati; Bharucha Ashok; Marin Robert; Jacob N J; Huber Kimberly A; Kastango Kari B; Chew Marci L</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">460-5</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Until recently, conventional antipsychotics were the standard pharmacotherapy for psychosis and behavioral disturbances associated with dementia.  This double-blind, placebo-controlled study compared the acute efficacy of the selective serotonin reuptake inhibitor citalopram and the neuroleptic perphenazine with placebo for the treatment of psychosis and behavioral disturbances in nondepressed patients with dementia.  METHOD:  Eighty-five hospitalized patients with at least one moderate to severe target symptom (aggression, agitation, hostility, suspiciousness, hallucinations, or delusions) were randomly assigned to receive either citalopram, perphenazine, or placebo under double-blind conditions for up to 17 days.  RESULTS:  Patients treated with citalopram or perphenazine showed statistically significant improvement on several Neurobehavioral Rating Scale factor scores.  Compared to those receiving placebo, only patients treated with citalopram showed significantly greater improvement in their total Neurobehavioral Rating Scale score as well as in the scores for the agitation/aggression and lability/tension factors.  Side effect scores were similar among the three treatment groups.  CONCLUSIONS:  Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiYhb6luDvsAyMywPm6HgQfW6udTcc2ebxDkg_Zdiu-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387jsVagsw%253D%253D&md5=c711511cc219d301fb5420560fb808d8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.159.3.460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.159.3.460%26sid%3Dliteratum%253Aachs%26aulast%3DPollock%26aufirst%3DB.%2BG.%26aulast%3DMulsant%26aufirst%3DB.%2BH.%26aulast%3DRosen%26aufirst%3DJ.%26aulast%3DSweet%26aufirst%3DR.%2BA.%26aulast%3DMazumdar%26aufirst%3DS.%26aulast%3DBharucha%26aufirst%3DA.%26aulast%3DMarin%26aufirst%3DR.%26aulast%3DJacob%26aufirst%3DN.%2BJ.%26aulast%3DHuber%26aufirst%3DK.%2BA.%26aulast%3DKastango%26aufirst%3DK.%2BB.%26aulast%3DChew%26aufirst%3DM.%2BL.%26atitle%3DComparison%2520of%2520Citalopram%252C%2520Perphenazine%252C%2520and%2520Placebo%2520for%2520the%2520Acute%2520Treatment%2520of%2520Psychosis%2520and%2520Behavioral%2520Disturbances%2520in%2520Hospitalized%252C%2520Demented%2520Patients%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2002%26volume%3D159%26spage%3D460%26epage%3D465%26doi%3D10.1176%2Fappi.ajp.159.3.460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Bains, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dening, T.</span><span> </span><span class="NLM_article-title">Antidepressants for Treating Depression in Dementia</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD003944</span><span class="refDoi"> DOI: 10.1002/14651858.CD003944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1002%2F14651858.CD003944" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=CD003944&author=J.+Bainsauthor=J.+Birksauthor=T.+Dening&title=Antidepressants+for+Treating+Depression+in+Dementia&doi=10.1002%2F14651858.CD003944"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD003944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD003944%26sid%3Dliteratum%253Aachs%26aulast%3DBains%26aufirst%3DJ.%26aulast%3DBirks%26aufirst%3DJ.%26aulast%3DDening%26aufirst%3DT.%26atitle%3DAntidepressants%2520for%2520Treating%2520Depression%2520in%2520Dementia%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2002%26spage%3DCD003944%26doi%3D10.1002%2F14651858.CD003944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Connolly, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thase, M. E.</span><span> </span><span class="NLM_article-title">Vortioxetine: A New Treatment for Major Depressive Disorder</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1517/14656566.2016.1133588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1517%2F14656566.2016.1133588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26679430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XislSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=421-431&author=K.+R.+Connollyauthor=M.+E.+Thase&title=Vortioxetine%3A+A+New+Treatment+for+Major+Depressive+Disorder&doi=10.1517%2F14656566.2016.1133588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Vortioxetine: a New Treatment for Major Depressive Disorder</span></div><div class="casAuthors">Connolly, K. Ryan; Thase, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">421-431</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD).  This medication is a serotonin reuptake inhibitor that also has a no. of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's effects from those of current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs).  This article will review the basic clin. pharmacol. of vortioxetine, summarize the major clin. trials that were performed prior to approval by the US Food and Drug Administration (FDA), discuss relevant post-marketing studies of this drug, and offer expert commentary on the significance of this new agent in clin. practice.  Pre-approval studies were identified as all randomized, placebo-controlled studies of vortioxetine listed on clinicaltrials.gov.  Other referenced studies were identified via a MEDLINE database literature search in August 2015 using the key search terms, vortioxetine and Lu AA21004, combined with addnl. terms that included pharmacol. profile, pharmacokinetics, drug interactions, adverse effects, side effects, safety, major depression, and major depressive disorder.  We identified relevant systematic reviews, meta-analyses, randomized trials and preclin. studies of importance.  Results of placebo-controlled trials suggest efficacy and an overall safety profile comparable to existing first-line antidepressants.  The most common side effects are nausea, vomiting and constipation.  Results of several studies indicate that vortioxetine may have therapeutic effects on cognition (e.g., memory and executive functioning) that exceed that of std. antidepressants.  Disadvantages include cost and the current paucity of long-term efficacy data from large clin. trials.  The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending addnl. long-term data, to become a first-line antidepressant option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfx6OO5BUAzrVg90H21EOLACvtfcHk0lgMLnnq_LdwBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XislSltbc%253D&md5=986c06cd18eb8e9b2c14b24ef684d8d7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1133588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1133588%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DK.%2BR.%26aulast%3DThase%26aufirst%3DM.%2BE.%26atitle%3DVortioxetine%253A%2520A%2520New%2520Treatment%2520for%2520Major%2520Depressive%2520Disorder%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D421%26epage%3D431%26doi%3D10.1517%2F14656566.2016.1133588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Köhler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cierpinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kronenberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adli, M.</span><span> </span><span class="NLM_article-title">The Serotonergic System in the Neurobiology of Depression: Relevance for Novel Antidepressants</span> <span class="citation_source-journal">J. Psychopharmacol. (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1177/0269881115609072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1177%2F0269881115609072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26464458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC28zhslChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=13-22&author=S.+K%C3%B6hlerauthor=K.+Cierpinskyauthor=G.+Kronenbergauthor=M.+Adli&title=The+Serotonergic+System+in+the+Neurobiology+of+Depression%3A+Relevance+for+Novel+Antidepressants&doi=10.1177%2F0269881115609072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants</span></div><div class="casAuthors">Kohler Stephan; Cierpinsky Katharina; Kronenberg Golo; Adli Mazda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychopharmacology (Oxford, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The monoamine hypothesis of depression posits that an imbalance in monoaminergic neurotransmission is causally related to the clinical features of depression.  Antidepressants influencing serotonin mainly aim at raising serotonin concentrations, thereby increasing serotonergic transmission at the level of the synapse, for example by inhibiting the serotonin transporter.  However, the serotonin system is multifaceted.  Different serotonin receptor subtypes turn the serotonergic system into a complex neurochemical arrangement that influences diverse neurotransmitters in various brain regions.  Classical antidepressants as well as other psychopharmacological agents have various crucial effects on serotonin receptors.  We aim at providing a clinically useful characterization of serotonin receptor subtypes in the treatment of depression.  Clarifying the mode of action and the interplay of serotonin receptors with pharmacological agents should help antidepressant mechanisms and typical side effects to be better understood.  Against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-HT1A, 5-HT3 and 5-HT7 which may account for their specific effects on certain symptoms of depression (e.g. cognition and anxiety) as well as a characteristic side-effect profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6Urdg3usjp7HHuJhbyicZfW6udTcc2ebxDkg_Zdiu-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zhslChug%253D%253D&md5=8040ec875099176ce62ae7572e02a178</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1177%2F0269881115609072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881115609072%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%26aulast%3DCierpinsky%26aufirst%3DK.%26aulast%3DKronenberg%26aufirst%3DG.%26aulast%3DAdli%26aufirst%3DM.%26atitle%3DThe%2520Serotonergic%2520System%2520in%2520the%2520Neurobiology%2520of%2520Depression%253A%2520Relevance%2520for%2520Novel%2520Antidepressants%26jtitle%3DJ.%2520Psychopharmacol.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2016%26volume%3D30%26spage%3D13%26epage%3D22%26doi%3D10.1177%2F0269881115609072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kelliny, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croarkin, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobo, W. V.</span><span> </span><span class="NLM_article-title">Profile of Vortioxetine in the Treatment of Major Depressive Disorder: An Overview of the Primary and Secondary Literature</span> <span class="citation_source-journal">Ther. Clin. Risk Manage.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">2015</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1193</span><span class="NLM_x">–</span> <span class="NLM_lpage">1212</span><span class="refDoi"> DOI: 10.2147/TCRM.S55313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.2147%2FTCRM.S55313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1193-1212&issue=11&author=M.+Kellinyauthor=P.+E.+Croarkinauthor=K.+M.+Mooreauthor=W.+V.+Bobo&title=Profile+of+Vortioxetine+in+the+Treatment+of+Major+Depressive+Disorder%3A+An+Overview+of+the+Primary+and+Secondary+Literature&doi=10.2147%2FTCRM.S55313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S55313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S55313%26sid%3Dliteratum%253Aachs%26aulast%3DKelliny%26aufirst%3DM.%26aulast%3DCroarkin%26aufirst%3DP.%2BE.%26aulast%3DMoore%26aufirst%3DK.%2BM.%26aulast%3DBobo%26aufirst%3DW.%2BV.%26atitle%3DProfile%2520of%2520Vortioxetine%2520in%2520the%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%253A%2520An%2520Overview%2520of%2520the%2520Primary%2520and%2520Secondary%2520Literature%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2015%26volume%3D2015%26issue%3D11%26spage%3D1193%26epage%3D1212%26doi%3D10.2147%2FTCRM.S55313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Bang-Andersen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruhland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jørgensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederiksen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mørk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensbøl, T. B.</span><span> </span><span class="NLM_article-title">Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3206</span><span class="NLM_x">–</span> <span class="NLM_lpage">3221</span><span class="refDoi"> DOI: 10.1021/jm101459g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101459g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFGgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3206-3221&author=B.+Bang-Andersenauthor=T.+Ruhlandauthor=M.+J%C3%B8rgensenauthor=G.+Smithauthor=K.+Frederiksenauthor=K.+G.+Jensenauthor=H.+Zhongauthor=S.+M.+Nielsenauthor=S.+Hoggauthor=A.+M%C3%B8rkauthor=T.+B.+Stensb%C3%B8l&title=Discovery+of+1-%5B2-%282%2C4-Dimethylphenylsulfanyl%29Phenyl%5DPiperazine+%28Lu+AA21004%29%3A+A+Novel+Multimodal+Compound+for+the+Treatment+of+Major+Depressive+Disorder&doi=10.1021%2Fjm101459g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder</span></div><div class="casAuthors">Bang-Andersen, Benny; Ruhland, Thomas; Jorgensen, Morten; Smith, Garrick; Frederiksen, Kristen; Jensen, Klaus Gjervig; Zhong, Huailing; Nielsen, Soren Moller; Hogg, Sandra; Mork, Arne; Stensbol, Tine Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3206-3221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and structure-activity relationship of a novel series of compds. with combined effects on 5-HT3A and 5-HT1A receptors and on the serotonin (5-HT) transporter (SERT) are described.  Compd. 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004) was the lead compd., displaying high affinity for recombinant human 5-HT1A (Ki = 15 nM), 5-HT1B (Ki = 33 nM), 5-HT3A (Ki = 3.7 nM), 5-HT7 (Ki = 19 nM), and noradrenergic β1 (Ki = 46 nM) receptors, and SERT (Ki = 1.6 nM).  Lu AA21004 displayed antagonistic properties at 5-HT3A and 5-HT7 receptors, partial agonist properties at 5-HT1B receptors, agonistic properties at 5-HT1A receptors, and potent inhibition of SERT.  In conscious rats, Lu AA21004 significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment.  Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, resp.  These characteristics indicate that Lu AA21004 is a novel multimodal serotonergic compd., and is currently in clin. development for major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAspA4Bk8ro7Vg90H21EOLACvtfcHk0ljkDoDtcJgZZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFGgtLs%253D&md5=b9823f8a86f6d4d44d4a17cb510ea903</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm101459g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101459g%26sid%3Dliteratum%253Aachs%26aulast%3DBang-Andersen%26aufirst%3DB.%26aulast%3DRuhland%26aufirst%3DT.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DJensen%26aufirst%3DK.%2BG.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DNielsen%26aufirst%3DS.%2BM.%26aulast%3DHogg%26aufirst%3DS.%26aulast%3DM%25C3%25B8rk%26aufirst%3DA.%26aulast%3DStensb%25C3%25B8l%26aufirst%3DT.%2BB.%26atitle%3DDiscovery%2520of%25201-%255B2-%25282%252C4-Dimethylphenylsulfanyl%2529Phenyl%255DPiperazine%2520%2528Lu%2520AA21004%2529%253A%2520A%2520Novel%2520Multimodal%2520Compound%2520for%2520the%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3206%26epage%3D3221%26doi%3D10.1021%2Fjm101459g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Montgomery, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Häggström, L.</span><span> </span><span class="NLM_article-title">A Randomised, Double-Blind Study in Adults with Major Depressive Disorder with an Inadequate Response to a Single Course of Selective Serotonin Reuptake Inhibitor or Serotonin-Noradrenaline Reuptake Inhibitor Treatment Switched to Vortioxetine or Agomelatine</span> <span class="citation_source-journal">Hum. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1002/hup.2424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1002%2Fhup.2424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=25087600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFahtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=470-482&author=S.+A.+Montgomeryauthor=R.+Z.+Nielsenauthor=L.+H.+Poulsenauthor=L.+H%C3%A4ggstr%C3%B6m&title=A+Randomised%2C+Double-Blind+Study+in+Adults+with+Major+Depressive+Disorder+with+an+Inadequate+Response+to+a+Single+Course+of+Selective+Serotonin+Reuptake+Inhibitor+or+Serotonin-Noradrenaline+Reuptake+Inhibitor+Treatment+Switched+to+Vortioxetine+or+Agomelatine&doi=10.1002%2Fhup.2424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine</span></div><div class="casAuthors">Montgomery, Stuart A.; Nielsen, Rebecca Z.; Poulsen, Lis H.; Haeggstroem, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Human Psychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">470-482</span>CODEN:
                <span class="NLM_cas:coden">HUPSEC</span>;
        ISSN:<span class="NLM_cas:issn">0885-6222</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objective : This randomised, double-blind, 12-wk study compared efficacy and tolerability of flexible-dose treatment with vortioxetine (10-20 mg/day) vs. agomelatine (25-50 mg/day) in major depressive disorder patients with inadequate response to selective serotonin reuptake inhibitor (SSRI)/serotonin-noradrenaline reuptake inhibitor (SNRI) monotherapy.  Methods : Patients were switched directly from SSRI/SNRI to vortioxetine or agomelatine.  Primary endpoint was change from baseline to week 8 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score analyzed by mixed model for repeated measurements, using a noninferiority test followed by a superiority test.  Secondary endpoints included response and remission rates, anxiety symptoms (Hamilton Anxiety Rating Scale), Clin. Global Impression, overall functioning (Sheehan Disability Scale), health-related quality of life (EuroQol 5 Dimensions), productivity (work limitation questionnaire) and family functioning (Depression and Family Functioning Scale).  Results : Primary endpoint noninferiority was established and vortioxetine (n = 252) was superior to agomelatine (n = 241) by 2.2 MADRS points (p < 0.01).  Vortioxetine was also significantly superior in response and remission rates at weeks 8 and 12; MADRS, Hamilton Anxiety Rating Scale, Clin. Global Impression, Sheehan Disability Scale and EuroQol 5 Dimensions scores at week 4 onwards; work limitation questionnaire at week 8 and Depression and Family Functioning Scale at weeks 8 and 12.  Fewer patients withdrew because of adverse events with vortioxetine (5.9% vs 9.5%).  Adverse events (incidence ≥5%) were nausea, headache, dizziness and somnolence.  Conclusions : Vortioxetine was noninferior and significantly superior to agomelatine in major depressive disorder patients with previous inadequate response to a single course of SSRI/SNRI monotherapy.  Vortioxetine was safe and well tolerated. cpr 2014 The Authors.  Human Psychopharmacol.: Clin. and Exptl. published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouSJ12k3scHbVg90H21EOLACvtfcHk0ljkDoDtcJgZZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFahtLfO&md5=56f57ef33d73912b462281e2e29209b1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fhup.2424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhup.2424%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DS.%2BA.%26aulast%3DNielsen%26aufirst%3DR.%2BZ.%26aulast%3DPoulsen%26aufirst%3DL.%2BH.%26aulast%3DH%25C3%25A4ggstr%25C3%25B6m%26aufirst%3DL.%26atitle%3DA%2520Randomised%252C%2520Double-Blind%2520Study%2520in%2520Adults%2520with%2520Major%2520Depressive%2520Disorder%2520with%2520an%2520Inadequate%2520Response%2520to%2520a%2520Single%2520Course%2520of%2520Selective%2520Serotonin%2520Reuptake%2520Inhibitor%2520or%2520Serotonin-Noradrenaline%2520Reuptake%2520Inhibitor%2520Treatment%2520Switched%2520to%2520Vortioxetine%2520or%2520Agomelatine%26jtitle%3DHum.%2520Psychopharmacol.%26date%3D2014%26volume%3D29%26spage%3D470%26epage%3D482%26doi%3D10.1002%2Fhup.2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Snyder, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanover, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrick, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestler, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wennogle, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mates, S.</span><span> </span><span class="NLM_article-title">Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission</span> <span class="citation_source-journal">Psychopharmacology (Berl.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">621</span><span class="refDoi"> DOI: 10.1007/s00213-014-3704-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs00213-014-3704-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=25120104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhsVGlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2015&pages=605-621&author=G.+L.+Snyderauthor=K.+E.+Vanoverauthor=H.+Zhuauthor=D.+B.+Millerauthor=J.+P.+O%E2%80%99Callaghanauthor=J.+Tomeschauthor=P.+Liauthor=Q.+Zhangauthor=V.+Krishnanauthor=J.+P.+Hendrickauthor=E.+J.+Nestlerauthor=R.+E.+Davisauthor=L.+P.+Wennogleauthor=S.+Mates&title=Functional+Profile+of+a+Novel+Modulator+of+Serotonin%2C+Dopamine%2C+and+Glutamate+Neurotransmission&doi=10.1007%2Fs00213-014-3704-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission</span></div><div class="casAuthors">Snyder Gretchen L; Vanover Kimberly E; Zhu Hongwen; Miller Diane B; O'Callaghan James P; Tomesch John; Li Peng; Zhang Qiang; Krishnan Vaishnav; Hendrick Joseph P; Nestler Eric J; Davis Robert E; Wennogle Lawrence P; Mates Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">605-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Schizophrenia remains among the most prevalent neuropsychiatric disorders, and current treatment options are accompanied by unwanted side effects.  New treatments that better address core features of the disease with minimal side effects are needed.  OBJECTIVES:  As a new therapeutic approach, 1-(4-fluoro-phenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007) is currently in human clinical trials for the treatment of schizophrenia.  Here, we characterize the preclinical functional activity of ITI-007.  RESULTS:  ITI-007 is a potent 5-HT2A receptor ligand (K i  = 0.5 nM) with strong affinity for dopamine (DA) D2 receptors (K i  = 32 nM) and the serotonin transporter (SERT) (K i  = 62 nM) but negligible binding to receptors (e.g., H1 histaminergic, 5-HT2C, and muscarinic) associated with cognitive and metabolic side effects of antipsychotic drugs.  In vivo it is a 5-HT2A antagonist, blocking (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI)-induced headtwitch in mice with an inhibitory dose 50 (ID50) = 0.09 mg/kg, per oral (p.o.), and has dual properties at D2 receptors, acting as a postsynaptic D2 receptor antagonist to block D-amphetamine hydrochloride (D-AMPH) hyperlocomotion (ID50 = 0.95 mg/kg, p.o.), yet acting as a partial agonist at presynaptic striatal D2 receptors in assays measuring striatal DA neurotransmission.  Further, in microdialysis studies, this compound significantly and preferentially enhances mesocortical DA release.  At doses relevant for antipsychotic activity in rodents, ITI-007 has no demonstrable cataleptogenic activity.  ITI-007 indirectly modulates glutamatergic neurotransmission by increasing phosphorylation of GluN2B-type N-methyl-D-aspartate (NMDA) receptors and preferentially increases phosphorylation of glycogen synthase kinase 3β (GSK-3β) in mesolimbic/mesocortical dopamine systems.  CONCLUSION:  The combination of in vitro and in vivo activities of this compound support its development for the treatment of schizophrenia and other psychiatric and neurologic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7sJSko_pZPXqj_yg7twvpfW6udTcc2eZKsUuQu2B0c7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhsVGlsA%253D%253D&md5=95a6b91827ab2af5e48af458f4330419</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00213-014-3704-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-014-3704-1%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DD.%2BB.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DJ.%2BP.%26aulast%3DTomesch%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3DHendrick%26aufirst%3DJ.%2BP.%26aulast%3DNestler%26aufirst%3DE.%2BJ.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26aulast%3DMates%26aufirst%3DS.%26atitle%3DFunctional%2520Profile%2520of%2520a%2520Novel%2520Modulator%2520of%2520Serotonin%252C%2520Dopamine%252C%2520and%2520Glutamate%2520Neurotransmission%26jtitle%3DPsychopharmacology%2520%2528Berl.%2529%26date%3D2015%26volume%3D232%26spage%3D605%26epage%3D621%26doi%3D10.1007%2Fs00213-014-3704-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Terry, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccafusco, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C.</span><span> </span><span class="NLM_article-title">Cognitive Dysfunction in Neuropsychiatric Disorders: Selected Serotonin Receptor Subtypes as Therapeutic Targets</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1016/j.bbr.2007.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.bbr.2007.12.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2008&pages=30-38&author=A.+V.+Terryauthor=J.+J.+Buccafuscoauthor=C.+Wilson&title=Cognitive+Dysfunction+in+Neuropsychiatric+Disorders%3A+Selected+Serotonin+Receptor+Subtypes+as+Therapeutic+Targets&doi=10.1016%2Fj.bbr.2007.12.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2007.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2007.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DTerry%26aufirst%3DA.%2BV.%26aulast%3DBuccafusco%26aufirst%3DJ.%2BJ.%26aulast%3DWilson%26aufirst%3DC.%26atitle%3DCognitive%2520Dysfunction%2520in%2520Neuropsychiatric%2520Disorders%253A%2520Selected%2520Serotonin%2520Receptor%2520Subtypes%2520as%2520Therapeutic%2520Targets%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2008%26volume%3D195%26spage%3D30%26epage%3D38%26doi%3D10.1016%2Fj.bbr.2007.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkowska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaśkowska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, P.</span><span> </span><span class="NLM_article-title">Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4543</span><span class="NLM_x">–</span> <span class="NLM_lpage">4557</span><span class="refDoi"> DOI: 10.1021/jm401895u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401895u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Chs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4543-4557&author=M.+Ko%C5%82aczkowskiauthor=M.+Marcinkowskaauthor=A.+Buckiauthor=M.+Paw%C5%82owskiauthor=K.+Mitkaauthor=J.+Ja%C5%9Bkowskaauthor=P.+Kowalskiauthor=G.+Kazekauthor=A.+Siwekauthor=A.+Wasikauthor=A.+Weso%C5%82owskaauthor=P.+Mierzejewskiauthor=P.+Bienkowski&title=Novel+Arylsulfonamide+Derivatives+with+5-HT6%2F5-HT7+Receptor+Antagonism+Targeting+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.1021%2Fjm401895u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia</span></div><div class="casAuthors">Kolaczkowski, Marcin; Marcinkowska, Monika; Bucki, Adam; Pawlowski, Maciej; Mitka, Katarzyna; Jaskowska, Jolanta; Kowalski, Piotr; Kazek, Grzegorz; Siwek, Agata; Wasik, Anna; Wesolowska, Anna; Mierzejewski, Pawel; Bienkowski, Przemyslaw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4543-4557</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to target behavioral and psychol. symptoms of dementia (BPSD), we used mol. modeling-assisted design to obtain novel multifunctional arylsulfonamide derivs. that potently antagonize 5-HT6/7/2A and D2 receptors, without interacting with M1 receptors and hERG channels.  In vitro studies confirmed their antagonism of 5-HT7/2A and D2 receptors and weak interactions with key antitargets (M1R and hERG) assocd. with side effects.  Marked 5-HT6 receptor affinities were also obsd., notably for 6-fluoro-3-(piperidin-4-yl)-1,2-benzoxazole derivs. connected by a 3-4 unit alkyl linker with mono- or bicyclic, lipophilic arylsulfonamide moieties.  N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulfonamide (I) was characterized in vitro on 14 targets and antitargets.  It displayed dual blockade of 5-HT6 and D2 receptors and negligible interactions at hERG and M1 receptors.  Unlike ref. antipsychotics, I displayed marked antipsychotic and antidepressant activity in rats after oral administration, in the absence of cognitive or motor impairment.  This profile is particularly attractive when targeting a fragile, elderly BPSD patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXCVqnVgswvLVg90H21EOLACvtfcHk0lhlIdKwmU150w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Chs7k%253D&md5=83ff946d12d3de66d40f91c1f90fabee</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm401895u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401895u%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26aulast%3DMitka%26aufirst%3DK.%26aulast%3DJa%25C5%259Bkowska%26aufirst%3DJ.%26aulast%3DKowalski%26aufirst%3DP.%26aulast%3DKazek%26aufirst%3DG.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DWasik%26aufirst%3DA.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26atitle%3DNovel%2520Arylsulfonamide%2520Derivatives%2520with%25205-HT6%252F5-HT7%2520Receptor%2520Antagonism%2520Targeting%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4543%26epage%3D4557%26doi%3D10.1021%2Fjm401895u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Wicke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haupt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bespalov, A.</span><span> </span><span class="NLM_article-title">Investigational Drugs Targeting 5-HT6 Receptors for the Treatment of Alzheimer’s Disease</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1515</span><span class="NLM_x">–</span> <span class="NLM_lpage">1528</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1102884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1517%2F13543784.2015.1102884" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1515-1528&author=K.+Wickeauthor=A.+Hauptauthor=A.+Bespalov&title=Investigational+Drugs+Targeting+5-HT6+Receptors+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1517%2F13543784.2015.1102884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1102884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1102884%26sid%3Dliteratum%253Aachs%26aulast%3DWicke%26aufirst%3DK.%26aulast%3DHaupt%26aufirst%3DA.%26aulast%3DBespalov%26aufirst%3DA.%26atitle%3DInvestigational%2520Drugs%2520Targeting%25205-HT6%2520Receptors%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1515%26epage%3D1528%26doi%3D10.1517%2F13543784.2015.1102884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Codony, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vela, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramírez, M. J.</span><span> </span><span class="NLM_article-title">5-HT6 Receptor and Cognition</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1016/j.coph.2011.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.coph.2011.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=21330210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=94-100&author=X.+Codonyauthor=J.+M.+Velaauthor=M.+J.+Ram%C3%ADrez&title=5-HT6+Receptor+and+Cognition&doi=10.1016%2Fj.coph.2011.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT6 receptor and cognition</span></div><div class="casAuthors">Codony, Xabier; Vela, Jose Miguel; Ramirez, Maria Javier</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-100</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since its discovery in 1993 and subsequent development of selective antagonists, a growing no. of studies support the use of serotonin 5-HT6 receptor antagonism as a promising mechanism for treating cognitive dysfunction.  Lately, several studies with structurally different compds. have shown that not only antagonists, but also 5-HT6 receptor agonists improve learning and memory in animal models.  There is even an antagonist, SB-742457, that has completed phase II trials for the treatment of Alzheimer's disease.  In addn. to describe preclin. and clin. evidence of the effect of 5-HT6 receptor compds. on cognition, this article will also focus on the purported biochem. and neurochem. mechanisms of action by which 5-HT6 receptor compds. could influence cognition in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2u6LBrBGWo7Vg90H21EOLACvtfcHk0lhlIdKwmU150w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7c%253D&md5=af905f7a2b2934b32fcd879e25fd7dc4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2011.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2011.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DCodony%26aufirst%3DX.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DRam%25C3%25ADrez%26aufirst%3DM.%2BJ.%26atitle%3D5-HT6%2520Receptor%2520and%2520Cognition%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D94%26epage%3D100%26doi%3D10.1016%2Fj.coph.2011.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Ramírez, M. J.</span><span> </span><span class="NLM_article-title">5-HT6 Receptors and Alzheimer’s Disease</span> <span class="citation_source-journal">Alzheimer’s Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="refDoi"> DOI: 10.1186/alzrt169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1186%2Falzrt169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=23607787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC3srntlKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=15&author=M.+J.+Ram%C3%ADrez&title=5-HT6+Receptors+and+Alzheimer%E2%80%99s+Disease&doi=10.1186%2Falzrt169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT6 receptors and Alzheimer's disease</span></div><div class="casAuthors">Ramirez Maria Javier</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's research & therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">During the past 20 years, the 5-HT6 receptor has received increasing attention and become a promising target for improving cognition.  Several studies with structurally different compounds have shown that not only antagonists but also 5-HT6 receptor agonists improve learning and memory in animal models.  A large number of publications describing the development of ligands for this receptor have come to light, and it is now quite evident that 5-HT6 receptors have great pharmaceutical potential in terms of related patents.  However, 5-HT6 receptor functionality is much more complex than initially defined.  According to the existing data, different cellular pathways may be activated, depending on the drug being used.  This article reviews preclinical and clinical evidence of the effects that 5-HT6 receptor compounds have on cognition.  In addition, the biochemical and neurochemical mechanisms of action through which 5-HT6 receptor compounds can influence cognition will be described.  Overall, several 5-HT6-targeted compounds can reasonably be regarded as powerful drug candidates for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7pHigIdj7Tv6BottYdIAWfW6udTcc2eZbmCL--Xgfv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srntlKisw%253D%253D&md5=01d0f60c195c30be179e3dde935b6c46</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1186%2Falzrt169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Falzrt169%26sid%3Dliteratum%253Aachs%26aulast%3DRam%25C3%25ADrez%26aufirst%3DM.%2BJ.%26atitle%3D5-HT6%2520Receptors%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2013%26volume%3D5%26spage%3D15%26doi%3D10.1186%2Falzrt169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Calhoun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossberg, G. T.</span><span> </span><span class="NLM_article-title">Emerging Chemical Therapies Targeting 5-Hydroxytryptamine in the Treatment of Alzheimer’s Disease</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1080/14728214.2017.1293651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1080%2F14728214.2017.1293651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=28253832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVOqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=101-105&author=A.+Calhounauthor=J.+Koauthor=G.+T.+Grossberg&title=Emerging+Chemical+Therapies+Targeting+5-Hydroxytryptamine+in+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1080%2F14728214.2017.1293651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease</span></div><div class="casAuthors">Calhoun, Amanda; Ko, Je; Grossberg, George T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-105</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a major neuropsychiatric disorder affecting more than 5 million Americans over age 65.  By the year 2050, AD is expected to affect over 30 million.  Characterized by neuronal cell death accompanied by the accumulation of neurofibrillary tangles and neuritic plaques, AD results in devastating clin. symptomatol. with a lasting psychosocial and financial impact.  Studies have shown that the current treatments for AD, cholinesterase inhibitors (ChEI's) and NMDA receptor antagonists, have limited efficacy.  The 5-HT-6 receptor antagonists Idalopirdine and Intepirdine have shown the most progress in current clin. trials and warrant consideration as emerging treatments for AD.  This review discusses 5-HT6 antagonists currently in clin. trials as potential treatments for AD symptomatol. and how 5-HT6 physiol. may play a pos. role in alleviating AD symptom pathophysiol.  A literature search using PubMed was conducted using the terms Idalopirdine, Intepirdine, 5-HT-6 antagonist, and AD as keywords.  Clinicaltrials.gov and Alzforum were also used to obtain information on clin. trials.  If current Phase-3 trials are pos., 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyTJA1x4adLLVg90H21EOLACvtfcHk0lh5znhwebLHYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVOqurs%253D&md5=3765256d30cd7bf2d6e10070db6eba7b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1080%2F14728214.2017.1293651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728214.2017.1293651%26sid%3Dliteratum%253Aachs%26aulast%3DCalhoun%26aufirst%3DA.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DGrossberg%26aufirst%3DG.%2BT.%26atitle%3DEmerging%2520Chemical%2520Therapies%2520Targeting%25205-Hydroxytryptamine%2520in%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2017%26volume%3D22%26spage%3D101%26epage%3D105%26doi%3D10.1080%2F14728214.2017.1293651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Ferrero, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, M. J.</span><span> </span><span class="NLM_article-title">Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span><span class="refDoi"> DOI: 10.1007/s40263-016-0399-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs40263-016-0399-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27914038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVaqtLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=19-32&author=H.+Ferreroauthor=M.+Solasauthor=P.+T.+Francisauthor=M.+J.+Ramirez&title=Serotonin+5-HT6+Receptor+Antagonists+in+Alzheimer%E2%80%99s+Disease%3A+Therapeutic+Rationale+and+Current+Development+Status&doi=10.1007%2Fs40263-016-0399-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status</span></div><div class="casAuthors">Ferrero, Hilda; Solas, Maite; Francis, Paul T.; Ramirez, Maria J.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-32</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common cause of dementia in elderly people.  Because of the lack of effective treatments for this illness, research focused on identifying compds. that restore cognition and functional impairments in patients with AD is a very active field.  Since its discovery in 1993, the serotonin 5-HT6 receptor has received increasing attention, and a growing no. of studies supported 5-HT6 receptor antagonism as a target for improving cognitive dysfunction in AD.  This article reviews the rationale behind investigations into the targeting of 5-HT6 receptors as a symptomatic treatment for cognitive and/or behavioral symptoms of AD.  In addn. to describing the available clin. evidence, this article also describes the purported biochem. and neurochem. mechanisms of action by which 5-HT6 receptor antagonists could influence cognition, and the preclin. data supporting this therapeutic approach to AD.  A large no. of publications describing the development of ligands for this receptor have come to light and preclin. data indicate the procognitive efficacy of 5-HT6 receptor antagonists.  Subsequently, the no. of patents protecting 5-HT6 chem. entities has continuously grown.  Some of these compds. have successfully undergone phase I clin. studies and have been further evaluated in clin. phase II trials with variable success.  Phase II studies have also revealed the potential of combining 5-HT6 receptor antagonism and cholinesterase inhibition.  Two of these antagonists, idalopirdine and RVT-101, have been further developed into ongoing phase III clin. trials.  Overall, 5-HT6 receptor antagonists can reasonably be regarded as potential drug candidates for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbBi5osKkbbbVg90H21EOLACvtfcHk0lh5znhwebLHYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVaqtLfK&md5=f8a9d3bb9b1d986b81aae755ac2e72bb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs40263-016-0399-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-016-0399-3%26sid%3Dliteratum%253Aachs%26aulast%3DFerrero%26aufirst%3DH.%26aulast%3DSolas%26aufirst%3DM.%26aulast%3DFrancis%26aufirst%3DP.%2BT.%26aulast%3DRamirez%26aufirst%3DM.%2BJ.%26atitle%3DSerotonin%25205-HT6%2520Receptor%2520Antagonists%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Therapeutic%2520Rationale%2520and%2520Current%2520Development%2520Status%26jtitle%3DCNS%2520Drugs%26date%3D2017%26volume%3D31%26spage%3D19%26epage%3D32%26doi%3D10.1007%2Fs40263-016-0399-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Wilkinson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windfeld, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colding-Jørgensen, E.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of Idalopirdine, a 5-HT6 Receptor Antagonist, in Patients with Moderate Alzheimer’s Disease (LADDER): A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1092</span><span class="NLM_x">–</span> <span class="NLM_lpage">1099</span><span class="refDoi"> DOI: 10.1016/S1474-4422(14)70198-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2FS1474-4422%2814%2970198-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=25297016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslagsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1092-1099&author=D.+Wilkinsonauthor=K.+Windfeldauthor=E.+Colding-J%C3%B8rgensen&title=Safety+and+Efficacy+of+Idalopirdine%2C+a+5-HT6+Receptor+Antagonist%2C+in+Patients+with+Moderate+Alzheimer%E2%80%99s+Disease+%28LADDER%29%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Phase+2+Trial&doi=10.1016%2FS1474-4422%2814%2970198-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial</span></div><div class="casAuthors">Wilkinson, David; Windfeld, Kristian; Colding-Joergensen, Eskild</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1092-1099</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In human beings, 5-HT6 receptors are almost exclusively expressed in the brain, particularly in areas relevant for cognition, such as the hippocampus and frontal cortex.  We assessed the effect on cognitive performance of Lu AE58054 (idalopirdine), a selective 5-HT6 receptor antagonist, in donepezil-treated patients with moderate Alzheimer's disease.  For this randomised, double-blind, placebo-controlled phase 2 trial (LADDER), we recruited patients from 48 outpatient clin. sites in seven countries.  Patients were 50 years or older, had moderate Alzheimer's disease (a mini-mental state examn. score of 12-19), and had been stably treated with donepezil 10 mg per day for 3 or more months.  Using a computer-generated sequence, we randomly assigned patients (1:1, stratified by site) to receive either idalopirdine 90 mg per day (30 mg thrice daily) or placebo.  The primary endpoint was change from baseline in the 11-item Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at week 24.  We analyzed all efficacy endpoints in the full-anal. set (modified intention-to-treat anal.).  This trial is registered with ClinicalTrials.gov, no. NCT01019421.  Between Dec 8, 2009, and Dec 23, 2011, we randomly allocated 278 patients to treatment: 133 to placebo and 145 to idalopirdine. 132 patients in the placebo group and 140 in the exptl. group were included in the final anal.  At week 24, the change from baseline in ADAS-cog total score was +1·38 (SD 0·53) in the placebo group and -0·77 (0·55) in the idalopirdine group (treatment difference of -2·16 points, 95% CI -3·62 to -0·69; p=0·0040). 25 patients (seven taking placebo and 18 taking idalopirdine) discontinued treatment because of adverse events, the difference between groups being mainly due to asymptomatic transient increases in transaminase concns. in some idalopirdine-treated patients.  The most common adverse events (occurring in >3% of patients) were increased γ-glutamyltransferase (14 [10%] patients in the idalopirdine group vs two [2%] in the placebo group), diarrhoea (six [4%] vs nine [7%]), urinary tract infection (three [2%] vs nine [7%]), fall (three [2%] vs eight [6%]), increased alanine aminotransferase (nine [6%] vs none), and benign prostatic hyperplasia (two [5%] vs none).  Serious adverse events were reported by 14 (10%) patients in the idalopirdine group and 13 (10%) patients in the placebo group.  One death occurred in each treatment group, neither were regarded as being related to treatment.  Idalopirdine improved cognitive function in donepezil-treated patients with moderate Alzheimer's disease.  Larger studies in a broader population of patients are ongoing to substantiate the effects reported here.H Lundbeck A/S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL5ZnwmPwC7bVg90H21EOLACvtfcHk0lgNJQRdThRv3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslagsb3E&md5=6bb5b0b63785839b26b618ae121e805c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2814%2970198-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252814%252970198-X%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DD.%26aulast%3DWindfeld%26aufirst%3DK.%26aulast%3DColding-J%25C3%25B8rgensen%26aufirst%3DE.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Idalopirdine%252C%2520a%25205-HT6%2520Receptor%2520Antagonist%252C%2520in%2520Patients%2520with%2520Moderate%2520Alzheimer%25E2%2580%2599s%2520Disease%2520%2528LADDER%2529%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%25202%2520Trial%26jtitle%3DLancet%2520Neurol.%26date%3D2014%26volume%3D13%26spage%3D1092%26epage%3D1099%26doi%3D10.1016%2FS1474-4422%2814%2970198-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Galimberti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpini, E.</span><span> </span><span class="NLM_article-title">Idalopirdine as a Treatment for Alzheimer’s Disease</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">981</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1052402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1517%2F13543784.2015.1052402" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=981-987&author=D.+Galimbertiauthor=E.+Scarpini&title=Idalopirdine+as+a+Treatment+for+Alzheimer%E2%80%99s+Disease&doi=10.1517%2F13543784.2015.1052402"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1052402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1052402%26sid%3Dliteratum%253Aachs%26aulast%3DGalimberti%26aufirst%3DD.%26aulast%3DScarpini%26aufirst%3DE.%26atitle%3DIdalopirdine%2520as%2520a%2520Treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D981%26epage%3D987%26doi%3D10.1517%2F13543784.2015.1052402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieńkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">ADN-1184 a Monoaminergic Ligand with 5-HT6/7 Receptor Antagonist Activity: Pharmacological Profile and Potential Therapeutic Utility</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span><span class="refDoi"> DOI: 10.1111/bph.12509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1111%2Fbph.12509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=24199650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ehtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=973-984&author=M.+Ko%C5%82aczkowskiauthor=P.+Mierzejewskiauthor=P.+Bie%C5%84kowskiauthor=A.+Weso%C5%82owskaauthor=A.+Newman-Tancredi&title=ADN-1184+a+Monoaminergic+Ligand+with+5-HT6%2F7+Receptor+Antagonist+Activity%3A+Pharmacological+Profile+and+Potential+Therapeutic+Utility&doi=10.1111%2Fbph.12509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">ADN-1184 a monoaminergic ligand with 5-HT6/7 receptor antagonist activity: pharmacological profile and potential therapeutic utility</span></div><div class="casAuthors">Kolaczkowski, M.; Mierzejewski, P.; Bienkowski, P.; Wesolowska, A.; Newman-Tancredi, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">973-984</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Many dementia patients exhibit behavioral and psychol. symptoms (BPSD) that include psychosis, aggressivity, depression and anxiety.  Antipsychotic drugs are frequently prescribed but fail to significantly attenuate mood deficits, may interfere with cognitive function and are assocd. with motor and cardiac side effects, which are problematic in elderly patients.  A need therefore exists for drugs that are better suited for the treatment of BPSD.  Exptl. Approach: We used in vitro cellular and in vivo behavioral tests to characterize ADN-1184, a novel arylsulfonamide ligand with potential utility for treatment of BPSD.  Key Results: ADN-1184 exhibits substantial 5-HT6/5-HT7/5-HT2A/D2 receptor affinity and antagonist properties in vitro.  In tests of antipsychotic-like activity, it reversed MK-801-induced hyperactivity and stereotypies and inhibited conditioned avoidance response (MED = 3 mg·kg-1 i.p.).  Remarkably, ADN-1184 also reduced immobility time in the forced swim test at low doses (0.3 and 1 mg·kg-1 i.p.; higher doses were not significantly active).  Notably, up to 30 mg·kg-1 ADN-1184 did not impair memory performance in the passive avoidance test or elicit significant catalepsy and only modestly inhibited spontaneous locomotor activity (MED = 30 mg·kg-1 i.p.).  Conclusions and Implications: ADN-1184 combines antipsychotic-like with antidepressant-like properties without interfering with memory function or locomotion.  This profile is better than that of commonly used atypical antipsychotics tested under the same conditions and suggests that it is feasible to identify drugs that improve BPSD, without exacerbating cognitive deficit or movement impairment, which are of particular concern in patients with dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRj9iM1zSMXrVg90H21EOLACvtfcHk0lgNJQRdThRv3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ehtbw%253D&md5=d72b8585ba495cc647ba280bbcf0d896</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fbph.12509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12509%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBie%25C5%2584kowski%26aufirst%3DP.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DADN-1184%2520a%2520Monoaminergic%2520Ligand%2520with%25205-HT6%252F7%2520Receptor%2520Antagonist%2520Activity%253A%2520Pharmacological%2520Profile%2520and%2520Potential%2520Therapeutic%2520Utility%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D973%26epage%3D984%26doi%3D10.1111%2Fbph.12509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojarski, A. J.</span><span> </span><span class="NLM_article-title">Receptor-Based Pharmacophores for Serotonin 5-HT7R Antagonists-Implications to Selectivity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6732</span><span class="NLM_x">–</span> <span class="NLM_lpage">6741</span><span class="refDoi"> DOI: 10.1021/jm060300c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060300c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6732-6741&author=M.+Ko%C5%82aczkowskiauthor=M.+Nowakauthor=M.+Paw%C5%82owskiauthor=A.+J.+Bojarski&title=Receptor-Based+Pharmacophores+for+Serotonin+5-HT7R+Antagonists-Implications+to+Selectivity&doi=10.1021%2Fjm060300c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm060300c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060300c%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DNowak%26aufirst%3DM.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26atitle%3DReceptor-Based%2520Pharmacophores%2520for%2520Serotonin%25205-HT7R%2520Antagonists-Implications%2520to%2520Selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6732%26epage%3D6741%26doi%3D10.1021%2Fjm060300c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Kolaczkowski, M.; Kowalski, P.; Jaskowska, J.; Marcinkowski, M.; Mitka, K.; Bucki, A.; Wesolowska, A.; Pawlowski, M.</span><span> </span><span class="NLM_article-title">Arylsulfonamides for the Treatment of CNS Diseases</span>. WO2012035123(A1), March 22,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Kolaczkowski&author=P.+Kowalski&author=J.+Jaskowska&author=M.+Marcinkowski&author=K.+Mitka&author=A.+Bucki&author=A.+Wesolowska&author=M.+Pawlowski&title=Arylsulfonamides+for+the+Treatment+of+CNS+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKolaczkowski%26aufirst%3DM.%26atitle%3DArylsulfonamides%2520for%2520the%2520Treatment%2520of%2520CNS%2520Diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">van Hes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smid, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroomer, C. N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulp, M. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heyden, J. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreary, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesselink, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">SLV310, a Novel, Potential Antipsychotic, Combining Potent Dopamine D2 Receptor Antagonism with Serotonin Reuptake Inhibition</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">408</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00996-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2FS0960-894X%2802%2900996-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=405-408&author=R.+van+Hesauthor=P.+Smidauthor=C.+N.+J.+Stroomerauthor=K.+Tipkerauthor=M.+T.+M.+Tulpauthor=J.+A.+M.+van+der+Heydenauthor=A.+C.+McCrearyauthor=M.+B.+Hesselinkauthor=C.+G.+Kruse&title=SLV310%2C+a+Novel%2C+Potential+Antipsychotic%2C+Combining+Potent+Dopamine+D2+Receptor+Antagonism+with+Serotonin+Reuptake+Inhibition&doi=10.1016%2FS0960-894X%2802%2900996-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900996-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900996-4%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BHes%26aufirst%3DR.%26aulast%3DSmid%26aufirst%3DP.%26aulast%3DStroomer%26aufirst%3DC.%2BN.%2BJ.%26aulast%3DTipker%26aufirst%3DK.%26aulast%3DTulp%26aufirst%3DM.%2BT.%2BM.%26aulast%3Dvan%2Bder%2BHeyden%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DHesselink%26aufirst%3DM.%2BB.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DSLV310%252C%2520a%2520Novel%252C%2520Potential%2520Antipsychotic%252C%2520Combining%2520Potent%2520Dopamine%2520D2%2520Receptor%2520Antagonism%2520with%2520Serotonin%2520Reuptake%2520Inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D405%26epage%3D408%26doi%3D10.1016%2FS0960-894X%2802%2900996-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Wesolowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partyka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jastrzebska-Wiesek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolarz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieńkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaczkowski, M.</span><span> </span><span class="NLM_article-title">Tail Suspension Test Does Not Detect Antidepressant-like Properties of Atypical Antipsychotics</span> <span class="citation_source-journal">Behav. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1097/FBP.0b013e3283423d6b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1097%2FFBP.0b013e3283423d6b" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=7-13&author=A.+Wesolowskaauthor=A.+Partykaauthor=M.+Jastrzebska-Wiesekauthor=A.+Kolarzauthor=P.+Mierzejewskiauthor=P.+Bie%C5%84kowskiauthor=M.+Kolaczkowski&title=Tail+Suspension+Test+Does+Not+Detect+Antidepressant-like+Properties+of+Atypical+Antipsychotics&doi=10.1097%2FFBP.0b013e3283423d6b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1097%2FFBP.0b013e3283423d6b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0b013e3283423d6b%26sid%3Dliteratum%253Aachs%26aulast%3DWesolowska%26aufirst%3DA.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DJastrzebska-Wiesek%26aufirst%3DM.%26aulast%3DKolarz%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBie%25C5%2584kowski%26aufirst%3DP.%26aulast%3DKolaczkowski%26aufirst%3DM.%26atitle%3DTail%2520Suspension%2520Test%2520Does%2520Not%2520Detect%2520Antidepressant-like%2520Properties%2520of%2520Atypical%2520Antipsychotics%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2011%26volume%3D22%26spage%3D7%26epage%3D13%26doi%3D10.1097%2FFBP.0b013e3283423d6b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Partyka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jastrzębska-Więsek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieńkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span> </span><span class="NLM_article-title">ADN-1184, a Monoaminergic Ligand with 5-HT6/7 Receptor Antagonist Action, Exhibits Activity in Animal Models of Anxiety</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">389</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1007/s00210-016-1229-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs00210-016-1229-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26979176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1WlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2016&pages=593-602&author=A.+Partykaauthor=A.+Wasikauthor=M.+Jastrz%C4%99bska-Wi%C4%99sekauthor=P.+Mierzejewskiauthor=P.+Bie%C5%84kowskiauthor=M.+Ko%C5%82aczkowskiauthor=A.+Weso%C5%82owska&title=ADN-1184%2C+a+Monoaminergic+Ligand+with+5-HT6%2F7+Receptor+Antagonist+Action%2C+Exhibits+Activity+in+Animal+Models+of+Anxiety&doi=10.1007%2Fs00210-016-1229-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety</span></div><div class="casAuthors">Partyka, Anna; Wasik, Anna; Jastrzebska-Wiesek, Magdalena; Mierzejewski, Pawel; Bienkowski, Przemyslaw; Kolaczkowski, Marcin; Wesolowska, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">593-602</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Behavioral and psychol. symptoms of dementia (BPSD) include apathy, sleep problems, irritability, wandering, elation, agitation/aggression, and mood disorders such as depression and/or anxiety.  Elderly patients are usually treated with second-generation antipsychotics; however, they present not enough efficacy against all symptoms obsd.  Hence, there still is an unmet need for novel pharmacotherapeutic agents targeted BPSD.  A novel arylsulfonamide deriv. ADN-1184 has been developed that possesses a preclin. profile of activity corresponding to criteria required for treatment of both psychosis and depressive symptoms of BPSD without exacerbating cognitive impairment or inducing motor disturbances.  To broaden its pharmacol. efficacy toward anxiety symptoms, its anxiolytic properties have been examd. in common animal preclin. models in rats and mice.  ADN-1184 significantly increased the no. of entries into open arms measured in the elevated plus-maze test; however, it simultaneously increased parameters of exploratory activity.  In the Vogel conflict drinking test, ADN-1184 dose-dependently and significantly increased the no. of shocks accepted and the no. of licks.  Moreover, in mice, it also had specific anxiolytic-like activity in the four-plate test, and only negligible one at a specific mid-range dose measured in the spontaneous marble burying test.  The obtained findings reveal that ADN-1184 displays anxiolytic-like activity in animal models of anxiety which employed punished stimuli.  In its unusual combination of some anxiolytic action with already proven antipsychotic and antidepressant properties, and lack of any disruptive impact on learning and memory processes and motor coordination, ADN-1184 displays a profile that would be desired for a novel therapeutic for BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHrAzMiwXrn7Vg90H21EOLACvtfcHk0ljPmCxl_Gyqfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1WlsL0%253D&md5=e898720612e6573efa6fa8389f7af195</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00210-016-1229-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-016-1229-3%26sid%3Dliteratum%253Aachs%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DWasik%26aufirst%3DA.%26aulast%3DJastrz%25C4%2599bska-Wi%25C4%2599sek%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBie%25C5%2584kowski%26aufirst%3DP.%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26atitle%3DADN-1184%252C%2520a%2520Monoaminergic%2520Ligand%2520with%25205-HT6%252F7%2520Receptor%2520Antagonist%2520Action%252C%2520Exhibits%2520Activity%2520in%2520Animal%2520Models%2520of%2520Anxiety%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2016%26volume%3D389%26spage%3D593%26epage%3D602%26doi%3D10.1007%2Fs00210-016-1229-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Pytka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlik, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlica-Gosiewska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witalis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkielewicz, A.</span><span> </span><span class="NLM_article-title">HBK-14 and HBK-15 with Antidepressant-like and/or Memory-Enhancing Properties Increase Serotonin Levels in the Hippocampus after Chronic Treatment in Mice</span> <span class="citation_source-journal">Metab. Brain Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span><span class="refDoi"> DOI: 10.1007/s11011-016-9932-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs11011-016-9932-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27888375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyms73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=547-556&author=K.+Pytkaauthor=K.+Gawlikauthor=D.+Pawlica-Gosiewskaauthor=J.+Witalisauthor=A.+Waszkielewicz&title=HBK-14+and+HBK-15+with+Antidepressant-like+and%2For+Memory-Enhancing+Properties+Increase+Serotonin+Levels+in+the+Hippocampus+after+Chronic+Treatment+in+Mice&doi=10.1007%2Fs11011-016-9932-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">HBK-14 and HBK-15 with antidepressant-like and/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice</span></div><div class="casAuthors">Pytka, Karolina; Gawlik, Katarzyna; Pawlica-Gosiewska, Dorota; Witalis, Jadwiga; Waszkielewicz, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Metabolic Brain Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">547-556</span>CODEN:
                <span class="NLM_cas:coden">MBDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0885-7490</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">5-HT1A and 5-HT7 receptor ligands might have antidepressant-like properties and improve cognitive function.  We previously reported significant antidepressant- and anxiolytic-like effects of two dual 5-HT1A and 5-HT7 receptor antagonists in various behavioral tests in rodents.  As a continuation of our previous expts., in this study we aimed to investigate whether chronic administration of 1-[(2,6-dimethylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-14) and 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-15) caused antidepressant-like effects and elevated serotonin levels in the murine hippocampus.  We also evaluated cholinolytic properties and the influence of acute administration of both compds. on cognitive function in mice.  To assess antidepressant-like properties and the influence on learning and memory we used forced swim test and step-through passive avoidance task in mice, resp.  Both compds. showed antidepressant-like properties and significantly elevated serotonin levels in the hippocampus after chronic treatment (HBK-14 - 2.5 mg/kg; HBK-15 - 0.625 and 1.25 mg/kg).  HBK-15 administered chronically antidepressant-like activity at lower dose (0.625 mg/kg) than the dose active after acute treatment (1.25 mg/kg).  None of the compds. affected locomotor activity of mice.  HBK-15 possessed very weak cholinolytic properties, whereas HBK-14 did not show any effect on muscarinic receptors.  Only HBK-15 (0.625 mg/kg) presented memory-enhancing properties and ameliorated cognitive impairments caused by scopolamine (1 mg/kg).  Our results indicate that 5-HT1A and 5-HT7 antagonists might have potential in the treatment of depression and possess pos. influence on cognitive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKcqgQuWut47Vg90H21EOLACvtfcHk0ljxz5uUA_2vsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyms73K&md5=594131745bf434fa2d335b728e66aa6d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs11011-016-9932-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11011-016-9932-9%26sid%3Dliteratum%253Aachs%26aulast%3DPytka%26aufirst%3DK.%26aulast%3DGawlik%26aufirst%3DK.%26aulast%3DPawlica-Gosiewska%26aufirst%3DD.%26aulast%3DWitalis%26aufirst%3DJ.%26aulast%3DWaszkielewicz%26aufirst%3DA.%26atitle%3DHBK-14%2520and%2520HBK-15%2520with%2520Antidepressant-like%2520and%252For%2520Memory-Enhancing%2520Properties%2520Increase%2520Serotonin%2520Levels%2520in%2520the%2520Hippocampus%2520after%2520Chronic%2520Treatment%2520in%2520Mice%26jtitle%3DMetab.%2520Brain%2520Dis.%26date%3D2017%26volume%3D32%26spage%3D547%26epage%3D556%26doi%3D10.1007%2Fs11011-016-9932-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">Antipsychotic, Antidepressant, and Cognitive-Impairment Properties of Antipsychotics: Rat Profile and Implications for Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span><span class="refDoi"> DOI: 10.1007/s00210-014-0966-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2Fs00210-014-0966-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=24599316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsF2isbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2014&pages=545-557&author=M.+Ko%C5%82aczkowskiauthor=P.+Mierzejewskiauthor=P.+Bienkowskiauthor=A.+Weso%C5%82owskaauthor=A.+Newman-Tancredi&title=Antipsychotic%2C+Antidepressant%2C+and+Cognitive-Impairment+Properties+of+Antipsychotics%3A+Rat+Profile+and+Implications+for+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.1007%2Fs00210-014-0966-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia</span></div><div class="casAuthors">Kolaczkowski, Marcin; Mierzejewski, Pawel; Bienkowski, Przemyslaw; Wesolowska, Anna; Newman-Tancredi, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-557</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Many dementia patients exhibit behavioral and psychol. symptoms (BPSD), including psychosis and depression.  Although antipsychotics are frequently prescribed off-label, they can have marked side effects.  In addn., comparative preclin. studies of their effects are surprisingly scarce, and strategies for discovery of novel pharmacotherapeutics are lacking.  We therefore compared eight antipsychotics in rat behavioral tests of psychosis, antidepressant-like activity, and cognitive impairment as a basis for preclin. evaluation of new drug candidates.  The methods used in this study include inhibition of MK-801-induced hyperactivity, forced swim test (FST), passive avoidance (PA), spontaneous locomotor activity, and catalepsy.  The drugs exhibited antipsychotic-like activity in the MK-801 test but with diverse profiles in the other models.  Risperidone impaired PA performance, but with some dose sepn. vs. its actions in the MK-801 test.  In contrast, clozapine, olanzapine, lurasidone, and asenapine showed little or no dose sepn. in these tests.  Aripiprazole did not impair PA performance but was poorly active in the MK-801 test.  Diverse effects were also obsd. in the FST: chlorpromazine was inactive and most other drugs reduced immobility over narrow dose ranges, whereas clozapine reduced immobility over a wider dose range, overlapping with antipsychotic activity.  Although the propensity of second-generation antipsychotics to produce catalepsy was lower, they all elicited pronounced sedation.  Consistent with clin. data, most currently available second-generation antipsychotics induced cognitive and motor side effects with little sepn. from therapeutic-like doses.  This study provides a uniform in vivo comparative basis on which to evaluate future early-stage drug candidates intended for potential pharmacotherapy of BPSD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjkNKMBogumrVg90H21EOLACvtfcHk0ljxz5uUA_2vsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsF2isbc%253D&md5=1202744b1594b23d9fa454061ef45ee6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00210-014-0966-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-014-0966-4%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3DAntipsychotic%252C%2520Antidepressant%252C%2520and%2520Cognitive-Impairment%2520Properties%2520of%2520Antipsychotics%253A%2520Rat%2520Profile%2520and%2520Implications%2520for%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2014%26volume%3D387%26spage%3D545%26epage%3D557%26doi%3D10.1007%2Fs00210-014-0966-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span> </span><span class="NLM_article-title">Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span><span class="refDoi"> DOI: 10.1021/ci300413h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300413h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1yhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=638-648&author=M.+Ko%C5%82aczkowskiauthor=A.+Buckiauthor=M.+Federauthor=M.+Paw%C5%82owski&title=Ligand-Optimized+Homology+Models+of+D1+and+D2+Dopamine+Receptors%3A+Application+for+Virtual+Screening&doi=10.1021%2Fci300413h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening</span></div><div class="casAuthors">Kolaczkowski, Marcin; Bucki, Adam; Feder, Marcin; Pawlowski, Maciej</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">638-648</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent breakthroughs in crystallog. studies of G protein-coupled receptors (GPCRs), together with continuous progress in mol. modeling methods, have opened new perspectives for structure-based drug discovery.  A crucial enhancement in this area was development of induced fit docking procedures that allow optimization of binding pocket conformation guided by the features of its active ligands.  In the course of our research program aimed at discovery of novel antipsychotic agents, our attention focused on dopaminergic D2 and D1 receptors (D2R and D1R).  Thus, we decided to investigate whether the availability of a novel structure of the closely related D3 receptor and application of induced fit docking procedures for binding pocket refinement would permit the building of models of D2R and D1R that facilitate a successful virtual screening (VS).  Here, we provide an in-depth description of the modeling procedure and the discussion of the results of a VS benchmark we performed to compare efficiency of the ligand-optimized receptors in comparison with the regular homol. models.  We obsd. that application of the ligand-optimized models significantly improved the VS performance both in terms of BEDROC (0.325 vs 0.182 for D1R and 0.383 vs 0.301 for D2R) as well as EF1% (20 vs 11 for D1R and 18 vs 10 for D2R).  In contrast, no improvement was obsd. for the performance of a D2R model built on the D3R template, when compared with that derived from the structure of the previously published and more evolutionary distant β2 adrenergic receptor.  The comparison of results for receptors built according to various protocols and templates revealed that the most significant factor for the receptor performance was a proper selection of tool ligand used in induced fit docking procedure.  Taken together, our results suggest that the described homol. modeling procedure could be a viable tool for structure-based GPCR ligand design, even for the targets for which only a relatively distant structural template is available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHGgw5lOnO9bVg90H21EOLACvtfcHk0lg5lODvbAUmoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1yhsb0%253D&md5=58f111e8132b7229898f1a44feb6199b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fci300413h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300413h%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DFeder%26aufirst%3DM.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26atitle%3DLigand-Optimized%2520Homology%2520Models%2520of%2520D1%2520and%2520D2%2520Dopamine%2520Receptors%253A%2520Application%2520for%2520Virtual%2520Screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D638%26epage%3D648%26doi%3D10.1021%2Fci300413h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Coleman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouaux, E.</span><span> </span><span class="NLM_article-title">X-Ray Structures and Mechanism of the Human Serotonin Transporter</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">532</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1038/nature17629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1038%2Fnature17629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27049939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=334-339&author=J.+A.+Colemanauthor=E.+M.+Greenauthor=E.+Gouaux&title=X-Ray+Structures+and+Mechanism+of+the+Human+Serotonin+Transporter&doi=10.1038%2Fnature17629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structures and mechanism of the human serotonin transporter</span></div><div class="casAuthors">Coleman, Jonathan A.; Green, Evan M.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7599</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The serotonin transporter (SERT) terminates serotonergic signaling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons.  SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signaling.  Here the authors report x-ray crystallog. structures of human SERT at 3.15 Å resoln. bound to the antidepressants (S)-citalopram or paroxetine.  Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helixes 1, 3, 6, 8 and 10, directly blocking serotonin binding.  The authors further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helixes 1, 6, 10 and 11.  Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand.  These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAxl5tROCorVg90H21EOLACvtfcHk0lg5lODvbAUmoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D&md5=e4fa11a1e5abdd7b39f44375506aa249</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnature17629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17629%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DGreen%26aufirst%3DE.%2BM.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DX-Ray%2520Structures%2520and%2520Mechanism%2520of%2520the%2520Human%2520Serotonin%2520Transporter%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D334%26epage%3D339%26doi%3D10.1038%2Fnature17629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Thal, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawaratne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bures, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachhawat, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Crystal Structures of the M1 and M4Muscarinic Acetylcholine Receptors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">531</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1038/nature17188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1038%2Fnature17188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=26958838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlGjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=531&publication_year=2016&pages=335-340&author=D.+M.+Thalauthor=B.+Sunauthor=D.+Fengauthor=V.+Nawaratneauthor=K.+Leachauthor=C.+C.+Felderauthor=M.+G.+Buresauthor=D.+A.+Evansauthor=W.+I.+Weisauthor=P.+Bachhawatauthor=T.+S.+Kobilkaauthor=P.+M.+Sextonauthor=B.+K.+Kobilkaauthor=A.+Christopoulos&title=Crystal+Structures+of+the+M1+and+M4Muscarinic+Acetylcholine+Receptors&doi=10.1038%2Fnature17188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the M1 and M4 muscarinic acetylcholine receptors</span></div><div class="casAuthors">Thal, David M.; Sun, Bingfa; Feng, Dan; Nawaratne, Vindhya; Leach, Katie; Felder, Christian C.; Bures, Mark G.; Evans, David A.; Weis, William I.; Bachhawat, Priti; Kobilka, Tong Sun; Sexton, Patrick M.; Kobilka, Brian K.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">531</span>
        (<span class="NLM_cas:issue">7594</span>),
    <span class="NLM_cas:pages">335-340</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Muscarinic M1-M5 acetylcholine receptors are G protein-coupled receptors (GPCRs) that regulate many vital functions of the central and peripheral nervous systems.  In particular, the M1 and M4 receptor subtypes have emerged as attractive drug targets for treatments of neurol. disorders, such as Alzheimer's disease and schizophrenia, but the high conservation of the acetylcholine-binding pocket has spurred current research into targeting allosteric sites on these receptors.  Here we report the crystal structures of the M1 and M4 muscarinic receptors bound to the inverse agonist, tiotropium.  Comparison of these structures with each other, as well as with the previously reported M2 and M3 receptor structures, reveals differences in the orthosteric and allosteric binding sites that contribute to a role in drug selectivity at this important receptor family.  We also report identification of a cluster of residues that form a network linking the orthosteric and allosteric sites of the M4 receptor, which provides new insight into how allosteric modulation may be transmitted between the two spatially distinct domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3oy2Ml852CrVg90H21EOLACvtfcHk0lg5lODvbAUmoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlGjurg%253D&md5=8ed3f453737ad0291cf5b2c088f528da</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnature17188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17188%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DNawaratne%26aufirst%3DV.%26aulast%3DLeach%26aufirst%3DK.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DBures%26aufirst%3DM.%2BG.%26aulast%3DEvans%26aufirst%3DD.%2BA.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DBachhawat%26aufirst%3DP.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520M1%2520and%2520M4Muscarinic%2520Acetylcholine%2520Receptors%26jtitle%3DNature%26date%3D2016%26volume%3D531%26spage%3D335%26epage%3D340%26doi%3D10.1038%2Fnature17188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Farid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlstein, R. A.</span><span> </span><span class="NLM_article-title">New Insights about HERG Blockade Obtained from Protein Modeling, Potential Energy Mapping, and Docking Studies</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3160</span><span class="NLM_x">–</span> <span class="NLM_lpage">3173</span><span class="refDoi"> DOI: 10.1016/j.bmc.2005.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.bmc.2005.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=16413785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1ehs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=3160-3173&author=R.+Faridauthor=T.+Dayauthor=R.+A.+Friesnerauthor=R.+A.+Pearlstein&title=New+Insights+about+HERG+Blockade+Obtained+from+Protein+Modeling%2C+Potential+Energy+Mapping%2C+and+Docking+Studies&doi=10.1016%2Fj.bmc.2005.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies</span></div><div class="casAuthors">Farid, Ramy; Day, Tyler; Friesner, Richard A.; Pearlstein, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3160-3173</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We created a homol. model of the homo-tetrameric pore domain of HERG using the crystal structure of the bacterial potassium channel, KvAP, as a template.  We docked a set of known blockers with well-characterized effects on channel function into the lumen of the pore between the selectivity filter and extracellular entrance using a novel docking and refinement procedure incorporating Glide and Prime.  Key arom. groups of the blockers are predicted to form multiple simultaneous ring stacking and hydrophobic interactions among the eight arom. residues lining the pore.  Furthermore, each blocker can achieve these interactions via multiple docking configurations.  To further interpret the docking results, we mapped hydrophobic and hydrophilic potentials within the lumen of each refined docked complex.  Hydrophilic iso-potential contours define a 'propeller-shaped' vol. at the selectivity filter entrance.  Hydrophobic contours define a hollow 'crown-shaped' vol. located above the 'propeller', whose hydrophobic 'rim' extends along the pore axis between Tyr652 and Phe656.  Blockers adopt conformations/binding orientations that closely mimic the shapes and properties of these contours.  Blocker basic groups are localized in the hydrophilic 'propeller', forming electrostatic interactions with Ser624 rather than a generally accepted π-cation interaction with Tyr652.  Terfenadine, cisapride, sertindole, ibutilide, and clofilium adopt similar docked poses, in which their N-substituents bridge radially across the hollow interior of the 'crown' (analogous to the hub and spokes of a wheel), and project arom./hydrophobic portions into the hydrophobic 'rim'.  MK-499 docks with its longitudinal axis parallel to the axis of the pore and crown', and its hydrophobic groups buried within the hydrophobic 'rim'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-1RsiljwGxrVg90H21EOLACvtfcHk0lgpqJWqLRUpPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1ehs7o%253D&md5=8df638aa78d2d35337bb82d8a94357c4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DPearlstein%26aufirst%3DR.%2BA.%26atitle%3DNew%2520Insights%2520about%2520HERG%2520Blockade%2520Obtained%2520from%2520Protein%2520Modeling%252C%2520Potential%2520Energy%2520Mapping%252C%2520and%2520Docking%2520Studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D3160%26epage%3D3173%26doi%3D10.1016%2Fj.bmc.2005.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Kurowski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bujnicki, J. M.</span><span> </span><span class="NLM_article-title">GeneSilico Protein Structure Prediction Meta-Server</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3305</span><span class="NLM_x">–</span> <span class="NLM_lpage">3307</span><span class="refDoi"> DOI: 10.1093/nar/gkg557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1093%2Fnar%2Fgkg557" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=3305-3307&author=M.+A.+Kurowskiauthor=J.+M.+Bujnicki&title=GeneSilico+Protein+Structure+Prediction+Meta-Server&doi=10.1093%2Fnar%2Fgkg557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkg557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkg557%26sid%3Dliteratum%253Aachs%26aulast%3DKurowski%26aufirst%3DM.%2BA.%26aulast%3DBujnicki%26aufirst%3DJ.%2BM.%26atitle%3DGeneSilico%2520Protein%2520Structure%2520Prediction%2520Meta-Server%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2003%26volume%3D31%26spage%3D3305%26epage%3D3307%26doi%3D10.1093%2Fnar%2Fgkg557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">High-Resolution Crystal Structure of an Engineered Human Beta2-Adrenergic G Protein-Coupled Receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1258</span><span class="NLM_x">–</span> <span class="NLM_lpage">1265</span><span class="refDoi"> DOI: 10.1126/science.1150577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1126%2Fscience.1150577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=17962520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1258-1265&author=V.+Cherezovauthor=D.+M.+Rosenbaumauthor=M.+A.+Hansonauthor=S.+G.+F.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.-J.+Choiauthor=P.+Kuhnauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=R.+C.+Stevens&title=High-Resolution+Crystal+Structure+of+an+Engineered+Human+Beta2-Adrenergic+G+Protein-Coupled+Receptor&doi=10.1126%2Fscience.1150577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor</span></div><div class="casAuthors">Cherezov, Vadim; Rosenbaum, Daniel M.; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Kuhn, Peter; Weis, William I.; Kobilka, Brian K.; Stevens, Raymond C.; Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S.; Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Lefkowitz, R. J.; Shenoy, S. K.; Rosenbaum, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Second extracellular loop, which in the β2-adrenergic receptor contains an unusual pair of disulfide bonds and an extra helix.  This loop and the absence Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane.  We report the crystal structure of a human β2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resoln.  The structure provides a high-resoln. view of a human G protein-coupled receptor bound to a diffusible ligand.  Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop.  Cholesterol, a necessary component for crystn., mediates an intriguing parallel assocn. of receptor mols. in the crystal lattice.  Although the location of carazolol in the β2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-8wZ2k2GHLVg90H21EOLACvtfcHk0lgpqJWqLRUpPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I&md5=12c5bacb8464a4b243fe9341192b5b3b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150577%26sid%3Dliteratum%253Aachs%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.-J.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHigh-Resolution%2520Crystal%2520Structure%2520of%2520an%2520Engineered%2520Human%2520Beta2-Adrenergic%2520G%2520Protein-Coupled%2520Receptor%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1258%26epage%3D1265%26doi%3D10.1126%2Fscience.1150577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Chien, E. Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">1091</span><span class="NLM_x">–</span> <span class="NLM_lpage">1095</span><span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+Human+Dopamine+D3+Receptor+in+Complex+with+a+D2%2FD3+Selective+Antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0liy4yKdGcGiog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520Human%2520Dopamine%2520D3%2520Receptor%2520in%2520Complex%2520with%2520a%2520D2%252FD3%2520Selective%2520Antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkowska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Śniecikowska, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jastrzębska-Więsek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Partyka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesołowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, P.</span><span> </span><span class="NLM_article-title">Novel 5-HT6 Receptor Antagonists/D2 Receptor Partial Agonists Targeting Behavioral and Psychological Symptoms of Dementia</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.ejmech.2014.12.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=221-235&author=M.+Ko%C5%82aczkowskiauthor=M.+Marcinkowskaauthor=A.+Buckiauthor=J.+%C5%9Aniecikowskaauthor=M.+Paw%C5%82owskiauthor=G.+Kazekauthor=A.+Siwekauthor=M.+Jastrz%C4%99bska-Wi%C4%99sekauthor=A.+Partykaauthor=A.+Wasikauthor=A.+Weso%C5%82owskaauthor=P.+Mierzejewskiauthor=P.+Bienkowski&title=Novel+5-HT6+Receptor+Antagonists%2FD2+Receptor+Partial+Agonists+Targeting+Behavioral+and+Psychological+Symptoms+of+Dementia&doi=10.1016%2Fj.ejmech.2014.12.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3D%25C5%259Aniecikowska%26aufirst%3DJ.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26aulast%3DKazek%26aufirst%3DG.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DJastrz%25C4%2599bska-Wi%25C4%2599sek%26aufirst%3DM.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DWasik%26aufirst%3DA.%26aulast%3DWeso%25C5%2582owska%26aufirst%3DA.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26atitle%3DNovel%25205-HT6%2520Receptor%2520Antagonists%252FD2%2520Receptor%2520Partial%2520Agonists%2520Targeting%2520Behavioral%2520and%2520Psychological%2520Symptoms%2520of%2520Dementia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D92%26spage%3D221%26epage%3D235%26doi%3D10.1016%2Fj.ejmech.2014.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Więckowska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kołaczkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godyń, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkowska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Więckowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaręba, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Głuch-Lutwin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mierzejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sienkiewicz-Jarosz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wichur, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobec, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malawska, B.</span><span> </span><span class="NLM_article-title">Novel Multi-Target-Directed Ligands for Alzheimer’s Disease: Combining Cholinesterase Inhibitors and 5-HT6 Receptor Antagonists. Design, Synthesis and Biological Evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2016.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.ejmech.2016.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=27560283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=63-81&author=A.+Wi%C4%99ckowskaauthor=M.+Ko%C5%82aczkowskiauthor=A.+Buckiauthor=J.+Gody%C5%84author=M.+Marcinkowskaauthor=K.+Wi%C4%99ckowskiauthor=P.+Zar%C4%99baauthor=A.+Siwekauthor=G.+Kazekauthor=M.+G%C5%82uch-Lutwinauthor=P.+Mierzejewskiauthor=P.+Bienkowskiauthor=H.+Sienkiewicz-Jaroszauthor=D.+Knezauthor=T.+Wichurauthor=S.+Gobecauthor=B.+Malawska&title=Novel+Multi-Target-Directed+Ligands+for+Alzheimer%E2%80%99s+Disease%3A+Combining+Cholinesterase+Inhibitors+and+5-HT6+Receptor+Antagonists.+Design%2C+Synthesis+and+Biological+Evaluation&doi=10.1016%2Fj.ejmech.2016.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation</span></div><div class="casAuthors">Wieckowska, Anna; Kolaczkowski, Marcin; Bucki, Adam; Godyn, Justyna; Marcinkowska, Monika; Wieckowski, Krzysztof; Zareba, Paula; Siwek, Agata; Kazek, Grzegorz; Gluch-Lutwin, Monika; Mierzejewski, Pawel; Bienkowski, Przemyslaw; Sienkiewicz-Jarosz, Halina; Knez, Damijan; Wichur, Tomasz; Gobec, Stanislav; Malawska, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-81</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluation of a novel class of multifunctional ligands that combined a 5-HT6 receptor antagonist with a cholinesterase inhibitor was reported.  Novel multi-target-directed ligands (MTDLs) were designed by combining pharmacophores directed against the 5-HT6 receptor (1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole) and cholinesterases (tacrine or N-benzylpiperidine analogs).  In-vitro evaluation led to the identification of tacrine deriv. I with well-balanced potencies against the 5-HT6 receptor (Kb = 27 nM), acetylcholinesterase and butyrylcholinesterase (IC50hAChE = 12 nM, IC50hBuChE = 29 nM).  The compd. also showed good in vitro blood-brain-barrier permeability (PAMPA-BBB assay), which was confirmed in-vivo (open field study).  Central cholinomimetic activity was confirmed in-vivo in rats using a scopolamine-induced hyperlocomotion model.  A novel class of multifunctional ligands with compd. I as the best deriv. in a series represented an excellent starting point for the further development of an effective treatment for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosefvo-I6wD7Vg90H21EOLACvtfcHk0liy4yKdGcGiog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqsrzF&md5=861844a56249e97199907c4d8a8dff7e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWi%25C4%2599ckowska%26aufirst%3DA.%26aulast%3DKo%25C5%2582aczkowski%26aufirst%3DM.%26aulast%3DBucki%26aufirst%3DA.%26aulast%3DGody%25C5%2584%26aufirst%3DJ.%26aulast%3DMarcinkowska%26aufirst%3DM.%26aulast%3DWi%25C4%2599ckowski%26aufirst%3DK.%26aulast%3DZar%25C4%2599ba%26aufirst%3DP.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DKazek%26aufirst%3DG.%26aulast%3DG%25C5%2582uch-Lutwin%26aufirst%3DM.%26aulast%3DMierzejewski%26aufirst%3DP.%26aulast%3DBienkowski%26aufirst%3DP.%26aulast%3DSienkiewicz-Jarosz%26aufirst%3DH.%26aulast%3DKnez%26aufirst%3DD.%26aulast%3DWichur%26aufirst%3DT.%26aulast%3DGobec%26aufirst%3DS.%26aulast%3DMalawska%26aufirst%3DB.%26atitle%3DNovel%2520Multi-Target-Directed%2520Ligands%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Combining%2520Cholinesterase%2520Inhibitors%2520and%25205-HT6%2520Receptor%2520Antagonists.%2520Design%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D63%26epage%3D81%26doi%3D10.1016%2Fj.ejmech.2016.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katritch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vardy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, E. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melcher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H. E.</span><span> </span><span class="NLM_article-title">Structural Basis for Molecular Recognition at Serotonin Receptors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">–</span> <span class="NLM_lpage">614</span><span class="refDoi"> DOI: 10.1126/science.1232807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1126%2Fscience.1232807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=23519210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=610-614&author=C.+Wangauthor=Y.+Jiangauthor=J.+Maauthor=H.+Wuauthor=D.+Wackerauthor=V.+Katritchauthor=G.+W.+Hanauthor=W.+Liuauthor=X.-P.+Huangauthor=E.+Vardyauthor=J.+D.+McCorvyauthor=X.+Gaoauthor=E.+X.+Zhouauthor=K.+Melcherauthor=C.+Zhangauthor=F.+Baiauthor=H.+Yangauthor=L.+Yangauthor=H.+Jiangauthor=B.+L.+Rothauthor=V.+Cherezovauthor=R.+C.+Stevensauthor=H.+E.+Xu&title=Structural+Basis+for+Molecular+Recognition+at+Serotonin+Receptors&doi=10.1126%2Fscience.1232807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Molecular Recognition at Serotonin Receptors</span></div><div class="casAuthors">Wang, Chong; Jiang, Yi; Ma, Jinming; Wu, Huixian; Wacker, Daniel; Katritch, Vsevolod; Han, Gye Won; Liu, Wei; Huang, Xi-Ping; Vardy, Eyal; McCorvy, John D.; Gao, Xiang; Zhou, X. Edward; Melcher, Karsten; Zhang, Chenghai; Bai, Fang; Yang, Huaiyu; Yang, Linlin; Jiang, Hualiang; Roth, Bryan L.; Cherezov, Vadim; Stevens, Raymond C.; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6132</span>),
    <span class="NLM_cas:pages">610-614</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Serotonin or 5-hydroxytryptamine (5-HT) regulates a wide spectrum of human physiol. through the 5-HT receptor family.  The authors report the crystal structures of the human 5-HT1B G protein-coupled receptor bound to the agonist antimigraine medications ergotamine and dihydroergotamine.  The structures reveal similar binding modes for these ligands, which occupy the orthosteric pocket and an extended binding pocket close to the extracellular loops.  The orthosteric pocket is formed by residues conserved in the 5-HT receptor family, clarifying the family-wide agonist activity of 5-HT.  Compared with the structure of the 5-HT2B receptor, the 5-HT1B receptor displays a 3 angstrom outward shift at the extracellular end of helix V, resulting in a more open extended pocket that explains subtype selectivity.  Together with docking and mutagenesis studies, these structures provide a comprehensive structural basis for understanding receptor-ligand interactions and designing subtype-selective serotonergic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLc0rOIqg_2bVg90H21EOLACvtfcHk0lies6oBCXGglg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWksbw%253D&md5=ce0773088a86f6a2c83b6cb77a63e708</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1126%2Fscience.1232807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1232807%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DE.%2BX.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DStructural%2520Basis%2520for%2520Molecular%2520Recognition%2520at%2520Serotonin%2520Receptors%26jtitle%3DScience%26date%3D2013%26volume%3D340%26spage%3D610%26epage%3D614%26doi%3D10.1126%2Fscience.1232807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Bordoli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwede, T.</span><span> </span><span class="NLM_article-title">Automated Protein Structure Modeling with SWISS-MODEL Workspace and the Protein Model Portal</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">857</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1007/978-1-61779-588-6_5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2F978-1-61779-588-6_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=857&publication_year=2011&pages=107-136&author=L.+Bordoliauthor=T.+Schwede&title=Automated+Protein+Structure+Modeling+with+SWISS-MODEL+Workspace+and+the+Protein+Model+Portal&doi=10.1007%2F978-1-61779-588-6_5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-588-6_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-588-6_5%26sid%3Dliteratum%253Aachs%26aulast%3DBordoli%26aufirst%3DL.%26aulast%3DSchwede%26aufirst%3DT.%26atitle%3DAutomated%2520Protein%2520Structure%2520Modeling%2520with%2520SWISS-MODEL%2520Workspace%2520and%2520the%2520Protein%2520Model%2520Portal%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D857%26spage%3D107%26epage%3D136%26doi%3D10.1007%2F978-1-61779-588-6_5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Bollinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hübner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinemann, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Novel Pyridylmethylamines as Highly Selective 5-HT1A Superagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7167</span><span class="NLM_x">–</span> <span class="NLM_lpage">7179</span><span class="refDoi"> DOI: 10.1021/jm100835q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100835q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7167-7179&author=S.+Bollingerauthor=H.+H%C3%BCbnerauthor=F.+W.+Heinemannauthor=K.+Meyerauthor=P.+Gmeiner&title=Novel+Pyridylmethylamines+as+Highly+Selective+5-HT1A+Superagonists&doi=10.1021%2Fjm100835q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm100835q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100835q%26sid%3Dliteratum%253Aachs%26aulast%3DBollinger%26aufirst%3DS.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DNovel%2520Pyridylmethylamines%2520as%2520Highly%2520Selective%25205-HT1A%2520Superagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7167%26epage%3D7179%26doi%3D10.1021%2Fjm100835q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Daina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michielin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoete, V.</span><span> </span><span class="NLM_article-title">SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">42717</span><span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=SwissADME%3A+A+Free+Web+Tool+to+Evaluate+Pharmacokinetics%2C+Drug-Likeness+and+Medicinal+Chemistry+Friendliness+of+Small+Molecules&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2eadpsLN0mMUzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwissADME%253A%2520A%2520Free%2520Web%2520Tool%2520to%2520Evaluate%2520Pharmacokinetics%252C%2520Drug-Likeness%2520and%2520Medicinal%2520Chemistry%2520Friendliness%2520of%2520Small%2520Molecules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lies6oBCXGglg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Dörje, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wess, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambrecht, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutschler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brann, M. R.</span><span> </span><span class="NLM_article-title">Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1994002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADyaK3M7jt1CrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1991&pages=727-733&author=F.+D%C3%B6rjeauthor=J.+Wessauthor=G.+Lambrechtauthor=R.+Tackeauthor=E.+Mutschlerauthor=M.+R.+Brann&title=Antagonist+Binding+Profiles+of+Five+Cloned+Human+Muscarinic+Receptor+Subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonist binding profiles of five cloned human muscarinic receptor subtypes</span></div><div class="casAuthors">Dorje F; Wess J; Lambrecht G; Tacke R; Mutschler E; Brann M R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">727-33</span>
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">A variety of muscarinic antagonists are currently used as tools to pharmacologically subclassify muscarinic receptors into M1, M2 and M3 subtypes.  In the present study, we have determined the affinity profiles of several of these antagonists at five cloned human muscarinic receptors (m1-m5) stably expressed in Chinese hamster ovary cells (CHO-K1).  At all five receptors, the (R)-enantiomers of trihexyphenidyl and hexbutinol displayed considerably higher affinities (up to 525-fold) than their corresponding (S)-isomers.  The stereoselectivity ratios [inhibition constant(S)/inhibition constant(R)] for both pairs of enantiomers were lowest at m2 receptors, suggesting that less stringent configurational demands are made by this receptor subtype.  The "M1-selective" antagonist (R)-trihexyphenidyl displayed high affinities for m1 and m4 receptors.  The "M2-selective" antagonists himbacine, (+-)-5,11-dihydro-11- ([(2-[(dipropylamino)methyl]-1- piperidinyl)ethyl)amino]carbonyl)-6H-pyrido(2,3-b)(1,4)benzodiazepine-6- one (AF-DX 384), 11-[4-[4-(diethylamino)butyl]-1-piperidinyl)acetyl)-5,11- dihydro-6H-pyrido(2,3-b) (1,4)benzodiazepine-6-one (AQ-RA 741) and (+)-(11-[2-[(diethylamino) methyl]-1-piperidinyl)acetyl)-5,11-di-hydro-6H-pyrido(2,3-b)(1,4) benzodiazepine-6-one [AF-DX 250; the (+)-enantiomer of AF-DX 116] exhibited high affinities for m2 and m4, intermediate affinities for m1 and m3 and low affinities for m5 receptors.  This selectivity profile was most prominent for AQ-RA 741, which displayed 195- and 129-fold higher affinities for m2 and m4 receptors than for m5 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4swN6h2ItNhKDYG3bNImrfW6udTcc2eab0dI3uTjDsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7jt1CrtQ%253D%253D&md5=24fb5162f94b5e0163c9ae9ca2a5a582</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6rje%26aufirst%3DF.%26aulast%3DWess%26aufirst%3DJ.%26aulast%3DLambrecht%26aufirst%3DG.%26aulast%3DTacke%26aufirst%3DR.%26aulast%3DMutschler%26aufirst%3DE.%26aulast%3DBrann%26aufirst%3DM.%2BR.%26atitle%3DAntagonist%2520Binding%2520Profiles%2520of%2520Five%2520Cloned%2520Human%2520Muscarinic%2520Receptor%2520Subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1991%26volume%3D256%26spage%3D727%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Payne, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, P. G.</span><span> </span><span class="NLM_article-title">Mechanisms of Ligand Binding and Efficacy at the Human D2(Short) Dopamine Receptor</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">1106</span><span class="NLM_x">–</span> <span class="NLM_lpage">1117</span><span class="refDoi"> DOI: 10.1046/j.1471-4159.2002.01046.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1046%2Fj.1471-4159.2002.01046.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=12358758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvVertLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2002&pages=1106-1117&author=S.+L.+Payneauthor=A.+M.+Johanssonauthor=P.+G.+Strange&title=Mechanisms+of+Ligand+Binding+and+Efficacy+at+the+Human+D2%28Short%29+Dopamine+Receptor&doi=10.1046%2Fj.1471-4159.2002.01046.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor</span></div><div class="casAuthors">Payne, Sarah L.; Johansson, Anette M.; Strange, Philip G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1106-1117</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Mechanisms of ligand binding and receptor activation for the human D2(short) dopamine receptor have been probed using two homologous series of monohydroxylated and dihydroxylated agonists (phenylethylamines and 2-dipropylaminotetralins).  In ligand binding studies, the majority of compds. exhibited competition curves vs. [3H]spiperone that were best fitted using a two site binding model.  The compds. had different abilities (potencies and maximal effects) to stimulate [35S]GTPγS binding and to inhibit forskolin-stimulated cAMP accumulation.  From the data it can be concluded that: (i) the ability of an agonist to stabilize receptor/G protein coupling can be used to predict agonist efficacy for some groups of compds. (2-dipropylaminotetralins) but not for others (phenylethylamines); (ii) the receptor may be activated by unhydroxylated compds.; (iii) single hydroxyl groups or pairs of hydroxyl groups on the agonist may contribute to binding affinity, potency and efficacy; and (iv) for the 2-dipropylaminotetralin series two modes of agonist/receptor interaction have been identified assocd. with different relative efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsUeXSzj0F5rVg90H21EOLACvtfcHk0liFQwpSScl7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvVertLo%253D&md5=d2772f4bee642c50bcb6f7721ad84d84</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2002.01046.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2002.01046.x%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DS.%2BL.%26aulast%3DJohansson%26aufirst%3DA.%2BM.%26aulast%3DStrange%26aufirst%3DP.%2BG.%26atitle%3DMechanisms%2520of%2520Ligand%2520Binding%2520and%2520Efficacy%2520at%2520the%2520Human%2520D2%2528Short%2529%2520Dopamine%2520Receptor%26jtitle%3DJ.%2520Neurochem.%26date%3D2002%26volume%3D82%26spage%3D1106%26epage%3D1117%26doi%3D10.1046%2Fj.1471-4159.2002.01046.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Kohen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druck, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamblin, M. W.</span><span> </span><span class="NLM_article-title">Cloning, Characterization, and Chromosomal Localization of a Human 5-HT6 Serotonin Receptor</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span><span class="refDoi"> DOI: 10.1046/j.1471-4159.1996.66010047.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1046%2Fj.1471-4159.1996.66010047.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=8522988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSns7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1996&pages=47-56&author=R.+Kohenauthor=M.+A.+Metcalfauthor=N.+Khanauthor=T.+Druckauthor=K.+Huebnerauthor=J.+E.+Lachowiczauthor=H.+Y.+Meltzerauthor=D.+R.+Sibleyauthor=B.+L.+Rothauthor=M.+W.+Hamblin&title=Cloning%2C+Characterization%2C+and+Chromosomal+Localization+of+a+Human+5-HT6+Serotonin+Receptor&doi=10.1046%2Fj.1471-4159.1996.66010047.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor</span></div><div class="casAuthors">Kohen, Ruth; Metcalf, Mark A.; Khan, Naseem; Druck, Teresa; Huebner, Kay; Lachowicz, Jean E.; Meltzer, Herbert Y.; Sibley, David R.; Roth, Bryan L.; Hamblin, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">The authors describe the cloning and characterization of a human 5-HT6 serotonin receptor.  The open reading frame is interrupted by two introns in positions corresponding to the third cytoplasmic loop and the third extracellular loop.  The human 5-HT6 cDNA encodes a 440-amino-acid polypeptide whose sequence diverges significantly from that published for the rat 5-HT6 receptor.  Resequencing of the rat cDNA revealed a sequencing error producing a frame shift within the open reading frame.  The human 5-HT6 amino acid sequence is 89% similar to the cor. rat sequence.  The recombinant human 5-HT6 receptor is pos. coupled to adenylyl cyclase and has pharmacol. properties similar to the rat receptor with high affinity for several typical and atypical antipsychotics, including clozapine.  The receptor is expressed in several human brain regions, most prominently in the caudate nucleus.  The gene for the receptor maps to the human chromosome region 1p35-p36.  This localization overlaps that established for the serotonin 5-HT1Dα receptor, suggesting that these may be closely linked.  Comparison of genomic and cDNA clones for the human 5-HT6 receptor also reveals an Rsal restriction fragment length polymorphism within the coding region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWMnEw6_ukEbVg90H21EOLACvtfcHk0liFQwpSScl7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSns7rI&md5=751bb21c3a65f2fe052a9f9d79990699</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1996.66010047.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1996.66010047.x%26sid%3Dliteratum%253Aachs%26aulast%3DKohen%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DM.%2BA.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DDruck%26aufirst%3DT.%26aulast%3DHuebner%26aufirst%3DK.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHamblin%26aufirst%3DM.%2BW.%26atitle%3DCloning%252C%2520Characterization%252C%2520and%2520Chromosomal%2520Localization%2520of%2520a%2520Human%25205-HT6%2520Serotonin%2520Receptor%26jtitle%3DJ.%2520Neurochem.%26date%3D1996%26volume%3D66%26spage%3D47%26epage%3D56%26doi%3D10.1046%2Fj.1471-4159.1996.66010047.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Adham, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zgombick, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branchek, T. A.</span><span> </span><span class="NLM_article-title">Functional Characterization of the Recombinant Human 5-Hydroxytryptamine7(a) Receptor Isoform Coupled to Adenylate Cyclase Stimulation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">508</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=9808674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVertrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1998&pages=508-514&author=N.+Adhamauthor=J.+M.+Zgombickauthor=J.+Bardauthor=T.+A.+Branchek&title=Functional+Characterization+of+the+Recombinant+Human+5-Hydroxytryptamine7%28a%29+Receptor+Isoform+Coupled+to+Adenylate+Cyclase+Stimulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation</span></div><div class="casAuthors">Adham, Nika; Zgombick, John M.; Bard, Jonathan; Branchek, Theresa A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">508-514</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Lippencott Williams & Wilkins</span>)
        </div><div class="casAbstract">Functional characterization of the recombinant human 5-hydroxytryptamine7(a) (h5-HT7(a)) receptor isoform was performed using stably transfected LM(tk-) cells.  Expression levels of the h5-HT7(a) receptor detd. from satn. studies using either a labeled agonist ([3H]5-HT) or antagonist ([3H]LSD) were very similar (Bmax = 160-190 fmol/mg protein), suggesting that all receptors may exist in the high affinity (G protein-coupled) state.  In intact cells, 5-HT produced a concn.-dependent elevation of intracellular cAMP levels ([cAMP]i) with an EC50 value of 80 nM and a maximal response of 5-fold increase above basal levels.  The rank order of agonist potencies in the second messenger assay paralleled their rank order of binding affinities: 5-carboxamidotryptamine > 5-hydroxytryptamine ≥ 5-methoxytryptamine > 8-hydroxy N,N-di-Pr aminotetralin > sumatriptan.  Agonist potencies (EC50 values) to stimulate [cAMP]i were more than 25-fold lower relative to their resp. binding affinities (Ki values) obtained in [3H]5-HT competition assays.  In contrast, antagonist potencies (Kb values) to block 5-HT-stimulated [cAMP]i were in close agreement with their corresponding Ki values.  These data may indicate low efficiency of receptor-effector coupling to adenylate cyclase stimulation.  Pretreatment of stably transfected cells with cholera toxin abolished the 5-HT-mediated elevation of [cAMP]i, indicating that the 5-HT7(a) subtype directly interacts with Gαs protein(s) to activate adenylate cyclase(s).  Clonal cell lines stably expressing h5-HT7 receptor isoforms will serve as valuable cellular models to study their function and regulation, as well as assist in the development of selective 5-HT7 receptor agents to uncover the biol. roles and potential therapeutic applications of this novel receptor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBBA4yPrxxArVg90H21EOLACvtfcHk0ljmY_dac1yuMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVertrc%253D&md5=d5f48b703c9e8c82ea0692f623052b94</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdham%26aufirst%3DN.%26aulast%3DZgombick%26aufirst%3DJ.%2BM.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DBranchek%26aufirst%3DT.%2BA.%26atitle%3DFunctional%2520Characterization%2520of%2520the%2520Recombinant%2520Human%25205-Hydroxytryptamine7%2528a%2529%2520Receptor%2520Isoform%2520Coupled%2520to%2520Adenylate%2520Cyclase%2520Stimulation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D287%26spage%3D508%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Martel, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assié, M.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depoortère, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cussac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span> </span><span class="NLM_article-title">5-HT1A Receptors Are Involved in the Effects of Xaliproden on G-Protein Activation, Neurotransmitter Release and Nociception</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00249.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1111%2Fj.1476-5381.2009.00249.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=19508400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=232-242&author=J.-C.+Martelauthor=M.-B.+Assi%C3%A9author=L.+Bardinauthor=R.+Depoort%C3%A8reauthor=D.+Cussacauthor=A.+Newman-Tancredi&title=5-HT1A+Receptors+Are+Involved+in+the+Effects+of+Xaliproden+on+G-Protein+Activation%2C+Neurotransmitter+Release+and+Nociception&doi=10.1111%2Fj.1476-5381.2009.00249.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception</span></div><div class="casAuthors">Martel, J-C.; Assie, M.-B.; Bardin, L.; Depoortere, R.; Cussac, D.; Newman-Tancredi, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">232-242</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Xaliproden (SR57746A) is a 5-HT1A receptor agonist and neurotrophic agent that reduces oxaliplatin-mediated neuropathy in clin. trials.  The present study investigated its profile on in vitro transduction, neurochem. responses and acute nociceptive pain tests in rats.  Xaliproden was tested on models assocd. with 5-HT1A receptor activation including G-protein activation, extracellular dopamine and 5-HT levels measured by microdialysis and formalin-induced pain.  Activation of 5-HT1A receptors was confirmed by antagonism with WAY100635.  Xaliproden exhibited high affinity for rat (r) and human (h) 5-HT1A receptors (pKi = 8.84 and 9.00).  In [35S]GTPγS (guanosine 5'-O-(3-[35S]thio)triphosphate) assays it activated both hippocampal r5-HT1A [pEC50/EMAX of 7.58/61% (%5-HT)] and recombinant h5-HT1A receptors (glioma C6-h5-HT1A: 7.39/62%; HeLa-h5-HT1A: 7.24/93%).  In functional [35S]GTPγS autoradiog., xaliproden induced labeling in structures enriched with 5-HT1A receptors (hippocampus, lateral septum, prefrontal and entorhinal cortices).  Xaliproden inhibited in vivo binding of [3H]WAY100635 to 5-HT1A receptors in mouse frontal cortex and hippocampus (ID50: 3.5 and 3.3 mg/kg-1, p.o. resp.).  In rat, it increased extracellular dopamine levels in frontal cortex and reduced hippocampal 5-HT levels (ED50: 1.2 and 0.7 mg/kg-1, i.p. resp.).  In a rat pain model, xaliproden inhibited paw licking and elevation (ED50: 1 and 3 mg/kg-1, i.p. resp.) following formalin injection in the paw.  All effects were reversed by pretreatment with WAY100635.  These results indicate that activation of 5-HT1A receptors is the principal mechanism of action of xaliproden and provide further support for the utility of 5-HT1A receptor activation as an anti-nociceptive strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYZSCqUkhYYrVg90H21EOLACvtfcHk0ljmY_dac1yuMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsr%252FO&md5=26321f915552dbbda3285c0b3603a8c4</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00249.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00249.x%26sid%3Dliteratum%253Aachs%26aulast%3DMartel%26aufirst%3DJ.-C.%26aulast%3DAssi%25C3%25A9%26aufirst%3DM.-B.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DDepoort%25C3%25A8re%26aufirst%3DR.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26atitle%3D5-HT1A%2520Receptors%2520Are%2520Involved%2520in%2520the%2520Effects%2520of%2520Xaliproden%2520on%2520G-Protein%2520Activation%252C%2520Neurotransmitter%2520Release%2520and%2520Nociception%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D232%26epage%3D242%26doi%3D10.1111%2Fj.1476-5381.2009.00249.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Perovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, W. E.</span><span> </span><span class="NLM_article-title">Pharmacological Profile of Hypericum Extract. Effect on Serotonin Uptake by Postsynaptic Receptors</span> <span class="citation_source-journal">Arzneim.-Forsch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1145</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=8929227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSmt77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1995&pages=1145-1148&author=S.+Perovicauthor=W.+E.+M%C3%BCller&title=Pharmacological+Profile+of+Hypericum+Extract.+Effect+on+Serotonin+Uptake+by+Postsynaptic+Receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of Hypericum extract: effect on serotonin uptake by postsynaptic receptors</span></div><div class="casAuthors">Perovic, S.; Mueller, W. E. G.</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1145-8</span>CODEN:
                <span class="NLM_cas:coden">ARZNAD</span>;
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    
            (<span class="NLM_cas:orgname">Cantor</span>)
        </div><div class="casAbstract">In the present study it is reported that the methanolic Hypericum ext. LI 160 (Jarsin 300) exerts no protective effect against NMDA- or gpl120- (from the HIV virus)-induced cytotoxicity.  Moreover, it is established that Hypericum ext. causes no activation of arachidonic acid release from neurons activated by gp120; hence it displays no sensitization effect on the NMDA receptor channel.  The main outcome of this study is the finding that Hypericum ext. causes a 50% inhibition (IC50 value) of serotonin uptake by rat synaptosomes at a concn. of 6.2 μg/mL.  Therefore it is concluded, that the antidepressant activity of Hypericum ext. is due to an inhibition of serotonin uptake by postsynaptic receptors.  Future studies might focus on the effect of Hypericum ext. on serotonin binding to neurons, serotonin storage in granules, the rate of synthesis of serotonin, and on the activity of monoamine oxidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPyzkv5O0PhLVg90H21EOLACvtfcHk0ljmY_dac1yuMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSmt77N&md5=b28ebd2a2e70560f4f90a25670cb82e2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerovic%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DW.%2BE.%26atitle%3DPharmacological%2520Profile%2520of%2520Hypericum%2520Extract.%2520Effect%2520on%2520Serotonin%2520Uptake%2520by%2520Postsynaptic%2520Receptors%26jtitle%3DArzneim.-Forsch.%26date%3D1995%26volume%3D45%26spage%3D1145%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Porsolt, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalfre, M.</span><span> </span><span class="NLM_article-title">Behavioral Despair in Mice: A Primary Screening Test for Antidepressants</span> <span class="citation_source-journal">Arch. Int. Pharmacodyn. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">229</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=596982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A528%3ADyaE1cXktlKgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=1977&pages=327-336&author=R.+D.+Porsoltauthor=A.+Bertinauthor=M.+Jalfre&title=Behavioral+Despair+in+Mice%3A+A+Primary+Screening+Test+for+Antidepressants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral despair in mice:  a primary screening test for antidepressants</span></div><div class="casAuthors">Porsolt, R. D.; Bertin, A.; Jalfre, M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives Internationales de Pharmacodynamie et de Therapie</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-36</span>CODEN:
                <span class="NLM_cas:coden">AIPTAK</span>;
        ISSN:<span class="NLM_cas:issn">0003-9780</span>.
    </div><div class="casAbstract">A depressed state can be induced in mice by forcing them to swim in a narrow cylinder from which they cannot escape.  After a brief period of vigorous activity the mice adopt a characteristic immobile posture which is readily identifiable.  Immobility was reduced by tricyclic antidepressants, monoamine oxidase inhibitors and atypical antidepressants, as well as by electroconvulsive shock.  Psychostimulants also reduced immobility but in contrast to antidepressants caused marked motor stimulation.  Immobility was not affected by minor or major tranquilizers.  These findings, closely parallel to those previously reported in rats, suggest that the procedure is selectively senstitive to antidepressant treatments.  The mouse procedure is, however, more rapid and less costly than that with rats and is thus more suitable for the primary screening of antidepressant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3THea0LRwE7Vg90H21EOLACvtfcHk0lic1tQ5oaqLag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXktlKgsbs%253D&md5=70dd5706992ee8151a9801a2aeb42961</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPorsolt%26aufirst%3DR.%2BD.%26aulast%3DBertin%26aufirst%3DA.%26aulast%3DJalfre%26aufirst%3DM.%26atitle%3DBehavioral%2520Despair%2520in%2520Mice%253A%2520A%2520Primary%2520Screening%2520Test%2520for%2520Antidepressants%26jtitle%3DArch.%2520Int.%2520Pharmacodyn.%2520Ther.%26date%3D1977%26volume%3D229%26spage%3D327%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Aron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larousse, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boissier, J. R.</span><span> </span><span class="NLM_article-title">Evaluation of a Rapid Technique for Detecting Minor Tranquilizers</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span><span class="refDoi"> DOI: 10.1016/0028-3908(71)90074-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2F0028-3908%2871%2990074-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1971&pages=459-469&author=C.+Aronauthor=P.+Simonauthor=C.+Larousseauthor=J.+R.+Boissier&title=Evaluation+of+a+Rapid+Technique+for+Detecting+Minor+Tranquilizers&doi=10.1016%2F0028-3908%2871%2990074-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0028-3908%2871%2990074-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0028-3908%252871%252990074-8%26sid%3Dliteratum%253Aachs%26aulast%3DAron%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DP.%26aulast%3DLarousse%26aufirst%3DC.%26aulast%3DBoissier%26aufirst%3DJ.%2BR.%26atitle%3DEvaluation%2520of%2520a%2520Rapid%2520Technique%2520for%2520Detecting%2520Minor%2520Tranquilizers%26jtitle%3DNeuropharmacology%26date%3D1971%26volume%3D10%26spage%3D459%26epage%3D469%26doi%3D10.1016%2F0028-3908%2871%2990074-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Ogren, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köhler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjöstrand, S. E.</span><span> </span><span class="NLM_article-title">The Selective Dopamine D2 Receptor Antagonist Raclopride Discriminates between Dopamine-Mediated Motor Functions</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1007/BF00179179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1007%2FBF00179179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=2947255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=1%3ACAS%3A280%3ADyaL2s%252FmvVWmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1986&pages=287-294&author=S.+O.+Ogrenauthor=H.+Hallauthor=C.+K%C3%B6hlerauthor=O.+Magnussonauthor=S.+E.+Sj%C3%B6strand&title=The+Selective+Dopamine+D2+Receptor+Antagonist+Raclopride+Discriminates+between+Dopamine-Mediated+Motor+Functions&doi=10.1007%2FBF00179179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions</span></div><div class="casAuthors">Ogren S O; Hall H; Kohler C; Magnusson O; Sjostrand S E</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-94</span>
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">The actions on central dopamine (DA) mechanisms of raclopride, a new substituted benzamide, were studied by means of behavioural and biochemical methods in the rat.  Raclopride blocked the in vitro binding of the dopamine D2 antagonist 3H-spiperone (IC50 = 32 nM), but not of the unselective D1 antagonist 3H-flupenthixol (IC50 greater than 100,000 nM) in rat striatum, and failed to inhibit striatal DA-sensitive adenylate cyclase in vitro (IC50 greater than 100,000 nM).  Raclopride caused a dose-dependent increase in the DA metabolites HVA and DOPAC in the striatum and olfactory tubercle.  Behavioural studies showed that raclopride discriminates between the motor behaviours induced by the DA agonist apomorphine.  Thus, unlike haloperidol, raclopride blocked apomorphine-induced hyperactivity at considerably lower doses than those inhibiting oral stereotypies.  Moreover, raclopride showed a high separation between the doses for blockade of apomorphine-induced hyperactivity and those inducing catalepsy in rats.  Raclopride caused a dose-dependent blockade of the specific binding of 3H-spiperone and 3H-N-n-propylnorapomorphine (3H-NPA) in vivo at doses similar to those blocking the behavioural effects of apomorphine.  The maximal blockade of 3H-spiperone binding in vivo was lower for raclopride than for haloperidol.  Raclopride caused a greater inhibition of 3H-NPA than of 3H-spiperone in vivo binding in the striatum.  It is suggested that the ability of raclopride to discriminate between different DA-mediated functions may be attributed to a preferential blockade of a subclass of functionally coupled dopamine D2 receptors in striatal as well as in extrastriatal brain regions in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp_jirgeZI142y4bB4mnvYfW6udTcc2ebpunSonGso6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FmvVWmtA%253D%253D&md5=2f4f6d142c66252853dac308966f18d9</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2FBF00179179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00179179%26sid%3Dliteratum%253Aachs%26aulast%3DOgren%26aufirst%3DS.%2BO.%26aulast%3DHall%26aufirst%3DH.%26aulast%3DK%25C3%25B6hler%26aufirst%3DC.%26aulast%3DMagnusson%26aufirst%3DO.%26aulast%3DSj%25C3%25B6strand%26aufirst%3DS.%2BE.%26atitle%3DThe%2520Selective%2520Dopamine%2520D2%2520Receptor%2520Antagonist%2520Raclopride%2520Discriminates%2520between%2520Dopamine-Mediated%2520Motor%2520Functions%26jtitle%3DPsychopharmacology%26date%3D1986%26volume%3D90%26spage%3D287%26epage%3D294%26doi%3D10.1007%2FBF00179179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Pytka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazek, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwek, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mordyl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Głuch-Lutwin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapacz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gałuszka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkielewicz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marona, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zygmunt, M.</span><span> </span><span class="NLM_article-title">HBK-7 - A New Xanthone Derivative and a 5-HT1A Receptor Antagonist with Antidepressant-like Properties</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">146–147</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1016/j.pbb.2016.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;key=10.1016%2Fj.pbb.2016.04.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146%E2%80%93147&publication_year=2016&pages=35-43&author=K.+Pytkaauthor=G.+Kazekauthor=A.+Siwekauthor=B.+Mordylauthor=M.+G%C5%82uch-Lutwinauthor=A.+Rapaczauthor=A.+Olczykauthor=A.+Ga%C5%82uszkaauthor=A.+Waszkielewiczauthor=H.+Maronaauthor=J.+Sapaauthor=B.+Filipekauthor=M.+Zygmunt&title=HBK-7+-+A+New+Xanthone+Derivative+and+a+5-HT1A+Receptor+Antagonist+with+Antidepressant-like+Properties&doi=10.1016%2Fj.pbb.2016.04.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2016.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2016.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DPytka%26aufirst%3DK.%26aulast%3DKazek%26aufirst%3DG.%26aulast%3DSiwek%26aufirst%3DA.%26aulast%3DMordyl%26aufirst%3DB.%26aulast%3DG%25C5%2582uch-Lutwin%26aufirst%3DM.%26aulast%3DRapacz%26aufirst%3DA.%26aulast%3DOlczyk%26aufirst%3DA.%26aulast%3DGa%25C5%2582uszka%26aufirst%3DA.%26aulast%3DWaszkielewicz%26aufirst%3DA.%26aulast%3DMarona%26aufirst%3DH.%26aulast%3DSapa%26aufirst%3DJ.%26aulast%3DFilipek%26aufirst%3DB.%26aulast%3DZygmunt%26aufirst%3DM.%26atitle%3DHBK-7%2520-%2520A%2520New%2520Xanthone%2520Derivative%2520and%2520a%25205-HT1A%2520Receptor%2520Antagonist%2520with%2520Antidepressant-like%2520Properties%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2016%26volume%3D146%25E2%2580%2593147%26spage%3D35%26epage%3D43%26doi%3D10.1016%2Fj.pbb.2016.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I73" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I73','PDB','5I73'); return false;">PDB: 5I73</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CXV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CXV','PDB','5CXV'); return false;">PDB: 5CXV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RH1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RH1','PDB','2RH1'); return false;">PDB: 2RH1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL','PDB','3PBL'); return false;">PDB: 3PBL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4IAR','PDB','4IAR'); return false;">PDB: 4IAR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00839">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_03714"></div></div></div></div></div><hr /></hr><p class="last">This material is available free of charge on the ACS Publications Web site at The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00839">10.1021/acs.jmedchem.7b00839</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional ligand binding mode descriptions (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_002.csv">CSV</a>)</p></li><li><p class="inline">Coordinates for homology model of D<sub>2</sub> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates for homology model of 5-HT<sub>1A</sub> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates for homology model of 5-HT<sub>6</sub> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Coordinates for homology model of 5-HT<sub>7</sub> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_006.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_001.pdf">jm7b00839_si_001.pdf (931.64 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_002.csv">jm7b00839_si_002.csv (4.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_003.pdb">jm7b00839_si_003.pdb (173.21 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_004.pdb">jm7b00839_si_004.pdb (163.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_005.pdb">jm7b00839_si_005.pdb (170.99 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00839/suppl_file/jm7b00839_si_006.pdb">jm7b00839_si_006.pdb (165.42 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00839&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00839%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-17%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00839" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679910e56e7d238c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
